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Definitions list 
Pharmacist intervention: any action by a clinical pharmacist that directly results in a change 
in patient management or therapy 
Medication review: a structured, critical examination of a patient’s medications with the 
objectives of reaching an agreement with the patient about their treatment and optimizing the 
impact of medications on patient’s health outcomes. 
Drug-related problem: an event or circumstance involving drug treatment that actually or 
potentially interferes with the patient experiencing an optimum outcome of medical care. 
Medication error: the failure of a planned action to be completed as intended or use of a 
wrong plan to achieve an aim. 
"Actual" or "potential" impact/consequence/significance: Term “actual” is understood as 
meaning the entity that has appeared in the patient, while the term “potential” referred to the 
situation in which the possibility that the entity could appear in the patient existed. 
A tool for assessing the impacts of a pharmacist intervention: an explicit description of a 
method for rating the impacts of a pharmacist intervention. 
Quality: quality can have two meanings: 1. the characteristics of a product or service that 
bear on its ability to satisfy stated or implied needs; 2. a product or service free of 
deficiencies. (ISO 9000) 
Structure of care: context in which care is delivered, including hospital buildings, staff, 
financing, and equipment... 
Process of care: transactions between patients and providers throughout the delivery of 
healthcare 
Costs: Costs can be thought of as “inputs” or resources required to provide the service. In the 
case of clinical pharmacy services, inputs are primarily comprised of the labor costs 
associated with the personnel who provide the care or services. 
Outcomes: outcomes can be thought of as “outputs” of the service or program. Outcomes can 
be in the form of clinical outcomes, humanistic outcomes, or economic outcomes. 
Clinical outcome: medical events occur as a result of disease or treatment. 
Humanistic outcome: consequences of disease or treatment on patient functional status, or 
quality of life.  
Economic outcome: direct, indirect, and intangible costs, compared with the consequences of 
medical treatment alternatives.  
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Cost savings of a PI: The difference between the cost of the original therapy and the new 
therapy gives the cost savings (or the increase in the cost of therapy).  
Cost avoidance of a PI: Cost avoidance refers to the prevention of additional health 
resources which are required to treat drug adverse events if a pharmacist has not intervened 
such as a hospitalization or a medical visit.  
Cost of implementation of a PI: cost refers to the expenses of providing the PI such as cost 
of pharmacist’s time, phone calls.  
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INTRODUCTION 
Prescription medication use is widespread, complex, and increasingly risky. For example, 
clinicians have access to more than 10,000 prescription medications, and nearly one-third of 
adults take 5 or more medications in the United States of America (USA)  (1). Advances in 
pharmaceutical treatments have undoubtedly resulted in major improvements in health for 
patients with many diseases, but these treatments have also been accompanied by increased 
risks.  
Drug-related problems (DRPs) are one of the significant causes of morbidity and mortality in 
developed countries (2). The rate of drug-related admission have ranged from 2.3% (3) to 
27.3% (4) in different studies in USA. In France, the serious adverse drug events are 
responsible for 1.5% of the hospital admissions (5). The cost of adverse drug events admitted 
to urgent care services was estimated at 636 million EUR in France in 2002 (6). In both USA 
and France, approximately 50% of these drug-related hospital admission were potentially 
preventable (5, 7).   
A major report by the Institute of Medicine in USA on medication errors suggests that, 
despite all the progress in patient safety, medication errors remain extremely common, and the 
health care system can do much more to prevent them. The report emphasizes actions that 
health care systems, providers, funders, and regulators can take to improve medication safety 
(7).  
Clinical pharmacists are experts in the therapeutic use of medications and, thus, are an 
essential part of promotion of the patient safety and optimization of patient outcomes (8). The 
nature and extent of clinical pharmacy services (CPSs) provided appear to be highly variable. 
Of which, medication review (MR) is one of the major contribution of pharmacists, defined as 
"as a structured, critical examination of a patient’s medications with the objectives of reaching 
an agreement with the patient about their treatment and optimizing the impact of medications 
on patient’s health outcomes (9)."  
 
One of the major outputs of MR is the generation of pharmacist interventions (PIs) described 
as "any action by a clinical pharmacist that directly results in a change in patient management 
or therapy" (10). Within the system of health care, pharmacists routinely provide medication 
therapy evaluations and recommendations to patients and health care professionals (8).  
 
While the pharmaceutical care has undergone dramatic changes since 30 years, pharmacists 
still need to demonstrate the benefits or added value of services. Clinical pharmacy services in 
general and PIs in particular add quality and value to health care outcomes, but the magnitude 
and value of these effects have not been adequately established. Anecdotal reports of CPSs’ 
impact on outcomes are more common than empirical evidence. In times of limited resources 
allocation, it is necessary for pharmacists to justify the added value of CPSs and PIs (11).  
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Methods and tools assessing the significance of PIs are diverse and their valid, reliable, 
comprehensive and practical properties are questionable. The only literature review of tools of 
rating of pharmacist interventions was reported in 1999 by Overhage and Lakes (12). The 
paper noted that among 51 identified articles, only 10 included an explicit description of the 
rating tool used. Thus, the authors developed a two-dimensional tool that could characterize 
the severity of the DRP inspired from the tool of Folli et al. (13) and the value of that 
intervention inspired from the tool of Hatoum et al. (14). A broad adoption of this validated 
tool has been used for characterizing clinical activities in different settings. This tool was 
demonstrated to be valid, comprehensive and practical in the original study. However, others 
adopted this tool and many found poor agreement of ratings. There were some risks of bias 
which were likely to explain high agreement in the study of Overhage and Lakes but not 
repeatable in other studies. To our knowledge, there is no other up-to-date literature review of 
existing tool for assessing potential impacts of PIs. Furthermore, since then, with economic 
constraints growing, aging, burden of chronic disease, patient’s lack of compliance, the 
assessment of quality of PIs is shifting from only clinical to economic and humanistic impacts 
(e.g., patient’s quality of life, compliance, and satisfaction). This trend requires new 
properties of tools. Therefore, the purpose of this thesis work is to research on methodologies 
of evaluation of value of PIs as well as development and validation of a new tool for assessing 
potential impacts of PIs in hospitals.  
The Part 1 presents the global picture of MR with three main sub-parties: (i) context in which 
medication review locates, (ii) characteristics of practice of MR, and (iii) methodologies of 
evaluation of impacts of MR/PIs.  
In the Part 2, we review tools for assessing potential significance of PIs in literature and 
present some important tools in detail. 
The Part 3 presents the process of development and validation of a new tool - CLEO for 
assessing potential impacts of PIs in hospital.  
Then in the Part 4, we discuss on findings of the work and perspectives from results of the 
studies.   
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PART 1.  
MEDICATION REVIEW: CONTEXT, PRACTICE AND 
EVALUATION OF IMPACTS 
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In this Part 1, firstly, we present why drug safety has become a major problem of health care 
system and how clinical pharmacy services can contribute to resolve this problem. MR is 
considered as a core and integrated practice of other CPSs, therefore, practice of MR in 
literature is described in detail. We finish this part by review of methodologies of evaluation 
of impacts of MR, which is useful to development a new tool for assessing PIs in the Part 2.   
1. Context: drug safety and clinical pharmacy services   
1.1. Drug safety 
Although there is a growing interest in drug safety, there remains much confusion about the 
terminology used to describe the problem. The inconsistencies in the definitions of commonly 
used terms may have an adverse impact on the accuracy of event rates, the establishment of 
medication safety priorities and on the validity of cross-study comparisons. It is imperative 
that standardized terminology be adopted and used consistently (15).  
1.1.1. Types of problems associated with drug use 
Ackroyd-Stolarz et al. (15) performed a review of the drug safety literature. The differences 
between the main types of problems associated with medication use are substantial: some are 
preventable events and some are not, some result in injury and some do not. A description of 
commonly used terms is provided.  
 
First, the terminology will be defined broadly to include drug-related (therapy) problems 
(DRPs). Subsets of DRPs include drug-related morbidity (DRM) and medication 
misadventures. The latter term includes medication errors, adverse drug reactions (ADRs), 
and adverse drug events (ADEs). Figure 1 provides a visual depiction of the relationships 
between these terms. The authors have classified events into those that result in injury and 
those that do not. 
 
Figure 1. Relationships between the different types of problems associated with medication 
use 
ADE: adverse drug event. ADR: adverse drug reaction 
Source: Duplicated from Ackroyd-Stolarz S, Hartnell N, Mackinnon NJ. Demystifying medication safety: 
making sense of the terminology. Res Social Adm Pharm. 2006 Jun;2(2):280-9. 
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1.1.1.1. Drug-related problems 
A DRP can be defined as "an event or circumstance involving drug treatment that actually or 
potentially interferes with the patient experiencing an optimum outcome of medical care" by 
Hepler and Strand (16).  
1.1.1.2. Drug-related morbidity 
Drug-related morbidity (DRM) is defined as "the failure of a therapeutic agent to produce the 
intended therapeutic outcome, or the clinical or biosocial manifestation of unresolved DRPs" 
(16). In helping to distinguish between DRPs and DRMs, Hepler (17) states that the patient 
injury that occurs as part of a DRM is a ‘‘severe, dangerous, injurious, or disabling clinical 
outcome that was not correctable or required significant additional medical care to correct, 
e.g., emergency treatment or hospitalization.’’ Thus, all DRMs result in injury whereas only a 
small percentage of DRPs result in injury, and those injuries would not be serious. 
 
It is estimated that approximately 50% of DRMs are preventable (18). To claim that a 
particular DRM is preventable, Hepler and Strand state that the following 4 characteristics 
must be met: a preexisting DRP must have been recognizable: the adverse outcome or 
treatment failure must have been foreseeable; the causes of the DRP and the outcome must 
have been both identifiable and controllable (16). 
1.1.1.3. Medication misadventures 
Another ‘‘broad’’ term that captures several different types of adverse outcomes from 
pharmaceuticals is medication misadventure. According to the American Society of Health-
System Pharmacists, medication misadventures consist of the sum of (1) medication errors, 
(2) ADRs, and (3) ADEs. Medication misadventures encompass more events than DRM in 
that DRM only includes events that result in serious injury while a medication misadventure 
does not necessitate a serious injury to the patient (e.g., may result in discomfort only) (19). 
1.1.1.4. Adverse drug events 
An ADE is any injury that is caused by a medication (or lack of an intended medicine) (20). A 
subset of ADEs can happen despite proper use of the medication by the patient, and these 
would be considered ADRs. Not all ADEs are caused by error. But, most of the ADEs that are 
caused by errors are usually predictable and preventable (e.g., excessive dose) (15). 
1.1.1.5. Medication errors 
Medication error (ME) is defined  as "the failure of a planned action to be completed as 
intended or use of a wrong plan to achieve an aim" (7). Medication errors are preventable. 
Events that can occur at any stage in the medication use process that lead to patient harm or 
inappropriate medication use. Only a very small percentage of medication errors actually 
result in injury. All of those that do result in an injury would also be classified as ADEs. 
However, not all ADEs are classified as medication errors, such as ADRs that do not occur as 
a result of error (15). According to James Reason, errors depend in two kinds of failures: 
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either the correct action does not proceed as intended (an error of execution) or the original 
action is not correct (an error of planning) (21).  
1.1.1.6. Adverse drug reactions 
The World Health Organization has defined an ADR as a "response to a drug that is noxious 
and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or 
therapy of a disease, or for modification of physiologic function." This definition does not 
include therapeutic failures, drug abuse, errors in drug administration, noncompliance with 
directions for drug use, or intentional and accidental poisonings. Some ADRs do result from 
medication errors (also known as preventable ADRs). ADRs can also be thought as a subset 
of ADEs. All ADRs result in injury, although the injury can be temporary or permanent (15). 
 
1.1.2. Epidemiology of drug safety 
1.1.2.1. Incidence 
The Harvard Medical Practice Study (22) is probably the most well-known retrospective 
study of ADEs, suggested that ADEs occurred in 0.7% of inpatients. A more recent US study 
suggested a similar figure of 0.6% (23). From Australian and UK studies, it can be estimated 
that preventable medication-related harm (harm due to MEs) occurred in 0.8% of admissions 
(24). In France, a frequency of ADEs was of 6.7-10.4% of inpatients (6).  
 
ME rates reported in the literature vary widely. Studies suggest that MEs occur in 0.3–9.1% 
of medication orders written for hospital inpatients (24). Not all errors have equal propensity 
for harm; one study estimated that only 0.9% of errors resulted in harm (20). Medication 
errors can happen in all stages in the drug use process, most frequently at the prescribing and 
administration stages:  
- prescription (37%(25); 56%(26)) 
- transcription of prescription (18%(25); 6%(26)) 
- dispensing (22%(25); 4%(26)) 
- administration (23%(25); 34%(26)).  
 
The incidence of DRPs will be presented in 2.2. Epidemiology of medication review. 
1.1.2.2. Morbidity/Mortality 
ADEs are one of the significant causes of morbidity and mortality in developed countries (2). 
Incidence estimates suggest that more than 1.5 million preventable ADEs occur each year in 
the United States, responsible for approximately 3-16% of the hospital admissions. In 1983, 
2876 people died from ME in USA. ME deaths increased 2.57-fold between 1983 and 1993 
(27). It caused a significant impact on their health care system, estimated at $76 and $177 
billions in the years 1995 and 2000, respectively (28).  
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In France, the serious adverse drug events were responsible for 1.5% of the hospital 
admissions (5) and the cost of ADEs admitted to urgent care services was estimated at 636 
million EUR (6). In both the USA and France, approximately 50% of these drug-related 
hospital admission are potentially preventable (5, 7).   
1.2. Management of medication errors  
1.2.1. System Approach of management of medication errors 
The problem of ME can be viewed in 2 ways: the person approach and the system approach. 
Each has its model of error causation, and each model gives rise to different philosophies of 
error management which are described in Table 1(29).  
Table 1. Approach of management of medication errors 
 Person approach System approach 
Philosophy It focuses on the unsafe acts—errors 
and procedural violations—of people on 
the front line: nurses, physicians, 
surgeons, anesthetists, pharmacists, and 
the like.  
Errors are seen as consequences 
rather than causes, having their 
origins not so much in the 
perversity of human nature as in 
“upstream” systemic factors.  
Causes Errors of individuals include 
forgetfulness, inattention, or moral 
weakness.  
Defenses, barriers and safeguards 
failed to prevent errors.  
Corrective 
strategies 
Reducing unwanted variability in 
human behavior (campaigns that appeal 
to people's fear, writing another 
procedure, disciplinary measures, threat 
of litigation, retraining, naming, 
blaming, and shaming 
We can change the conditions 
under which humans work = 
system defenses 
Source: Adapted from Reason J. Human error: models and management. BMJ. 2000 Mar 18;320(7237):768-70. 
 
The person approach has serious shortcomings and is ill-suited to management of ME. Indeed, 
continued adherence to this approach is likely to prevent the development of safer health care 
institutions. Preventing errors means designing the health care system at all levels to make it 
safer by using the system approach (7).  
 
The "Swiss Cheese"model of system accidents 
According to the "Swiss Cheese" model of system accidents, defenses, barriers, and 
safeguards occupy a key position in the system approach (29). Their function is to protect 
potential victims and assets from local hazards. They are more like slices of Swiss cheese, 
having many holes—although, unlike in the cheese, these holes are continually opening, 
shutting, and shifting their location. The presence of holes in any one “slice” does not 
normally cause a bad outcome. Usually this can happen only when the holes in many layers 
momentarily line up to permit a trajectory of accident opportunity—bringing hazards into 
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damaging contact with victims (Figure 2). The holes in the defenses arise for 2 reasons: 
active failures and latent conditions. 
 Active failures: are the unsafe acts committed by people who are in direct contact with 
the patient or system. They take a variety of forms: slips, lapses, fumbles, mistakes, 
and procedural violations. 
 Latent conditions: are the inevitable “resident pathogens” within a system. They arise 
from decisions made by designers, builders, procedure writers, and top-level 
management.  
 
Figure 2. The Swiss cheese model of how defenses, barriers, and safeguards may be 
penetrated by a patient safety incident 
Source: Duplicated from Reason J. Human error: models and management. BMJ. 2000 Mar 18;320(7237):768-
70. 
 
Latent conditions—as the term suggests—may lie dormant within the system for many years 
before they combine with active failures and local triggers to create an accident opportunity. 
Unlike active failures, whose specific forms are often hard to foresee, latent conditions can be 
identified and remedied before an adverse event occurs. Understanding this leads to proactive 
rather than reactive risk management (29).  
For example, Leape et al. have taken the analysis of ADEs (30). They defined a system as “an 
interdependent group of items, people or processes with a common purpose” and recognized 
that a medicines use system would involve external systems, e.g., professional education and 
information dissemination, and would include subsystems of various complexities. They first 
classified errors into 15 types and cross-tabulated them by the stage in order processing where 
they had occurred. Then they searched for proximal causes, defined as the apparent reason the 
error was made. They found 13 proximal causes and 16 system failures. The usefulness of the 
system view was demonstrated powerfully by the fact that there was not a one-to-one 
relationship between proximal causes and errors. Some proximal causes contributed to many 
error types. Likewise, an error could result from more than one proximal cause. The 
identification of system failures led the investigators to recommend four specific system 
changes: computerized order entry, adding a clinical pharmacist to the patient care team, 
providing electronic drug information, and standardizing doses and administration times. 
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1.2.2. Strategies for improvement of drug safety 
In a study, physician raters identified three strategies that might be most effective in 
preventing errors: computerized physician order entry with clinical decision support systems 
(76%); ward-based clinical pharmacists (81%); and improved communication among 
physicians, nurses, and pharmacists (86%) (31). 
 
Single methods of optimizing medication outcomes have not been shown to be as effective as 
multifaceted approaches (32). Recent analyses have shown that there is a higher likelihood of 
achieving improved outcomes of care when three or more of the following aspects of 
healthcare are impacted: patient self-management, clinical information availability, redesign 
of the way care is delivered, decision support strategies, the healthcare system, and the 
provider organization. In a review of interventions designed to improve the care of patients 
with chronic illnesses, process variables were improved when one or two of the aspects were 
improved. Outcome variables were improved when three or four of the aspects were impacted 
(32). 
 
A comprehensive approach to improving patient safety is needed. Consistent with 
recommendations from the Institute of Medicine in USA  this will mean (7):  
1. Creation of leadership and research to enhance the knowledge base about safety (eg, 
tools for identifying and analyzing errors and evaluate approaches taken; tools and 
methods for educating consumers about patient safety; standardizing and simplifying 
equipment, supplies, and processes). 
2. Identifying and learning from errors through immediate and strong mandatory 
reporting efforts, as well as the encouragement of voluntary efforts.  
3. Raising standards and expectations for improvements in safety (such as licensing, 
certification, and accreditation) through the actions of organizations, group purchasers, 
and professional groups 
4. Improvement of provider-patient and inter-provider communications 
5. Development of effective multidisciplinary teams with good cooperation among 
patients, physicians, and pharmacists 
6. Establish interdisciplinary team training programs for providers that incorporate 
proven methods of team training, such as simulation. 
7. Information technology in planning care and in evaluating quality: e.g., computerized 
prescription order entry and computerized decision support systems, bar coding and 
smart intravenous (IV) pumps. 
8. Coordination of care across patient conditions, and type and location of service 
9. Development of clinical pharmacy services (e.g., patient education, medication 
review, pharmacist participation on hospital rounds). 
1.3. Clinical pharmacy and clinical pharmacy services 
1.3.1. Clinical pharmacy: definition and history 
Clinical pharmacy is a health science discipline in which pharmacists provide patient care that 
optimizes medication therapy and promotes health, wellness, and disease prevention (8). The 
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practice of clinical pharmacy embraces the philosophy of pharmaceutical care as "the 
responsible provision of drug therapy for the purpose of achieving definite outcomes that 
improve a patient’s quality of life" (16). Within the system of health care, clinical pharmacists 
are experts in the therapeutic use of medications. They routinely provide medication therapy 
evaluations and recommendations to patients and health care professionals. Clinical 
pharmacists are a primary source of scientifically valid information and advice regarding the 
safe, appropriate, and cost-effective use of medications(8). 
 
The strategic framework for optimizing drug therapy outcomes has evolved over time (Table 
1). Since 2000, the focus shifted to population-based approaches of reducing cost and 
maintaining quality care for patients with chronic illnesses and disease prevention (32).  
 
Table 2. Evolution of strategic framework for optimizing drug therapy outcomes 
Period Strategy Features 
1980-1990 Drug focus Choices of medications within drug classes; drugs 
blamed for poor outcome 
1990-2000 Disease focus High-cost, prevalent diseases; drug classes 
involved in disease treatment; disease or physician 
blamed for poor outcome 
1995-present Patient focus High-cost, complex-care patients; patient or 
physician blamed for poor outcome 
2000-present Chronic care focus; 
disease prevention 
System of providing care; blameless culture 
Source: Czubak R, Tucker J, Zarowitz BJ. Optimizing drug prescribing in managed care populations - 
Improving clinical and economic outcomes. Dis Manage Health Outcomes 2004;12(3):147-67. 
 
1.3.2. Clinical pharmacy services 
For optimizing drug therapy outcomes, there are various types of clinical pharmacy services 
(CPSs) which pharmacists participate actively in patient care. Bond et al. (33) gave a 
definition of 15 CPSs in hospitals which were divided into 2 groups: central and patient-
specific CPSs (Table 3) while Harrison et al. (34) described 7 types of CPSs in ambulatory 
settings (Table 4).  
Table 3. Definitions of Clinical Pharmacy Services in hospitals 
Service Definition 
Central Clinical Services 
1. Drug-Use 
evaluation 
check if at minimum, drug-use patterns are analyzed and results are 
reported to a hospital committee. 
2. In-service 
education 
pharmacist presents continuing education to fellow employees 
(physicians, nurses, pharmacists, etc.) on a scheduled basis at least 4 
times/year. 
3. Drug provided only if a formal drug information service with specifically 
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information assigned pharmacist is available for questions. Does not required a 
physical location called drug information center.   
4. Poison 
information 
provided only if a pharmacist is available to answer toxicity and 
overdose questions on a routine basis with appropriate resources.  
5. Clinical 
research 
performed by pharmacist either as a principal investigator or 
coinvestigator. Pharmacist is likely to be (co-) author on a published 
paper. Do not check if activity is limited to investigational drug 
distribution or record keeping.  
6. Drug safety 
officer 
pharmacist(s) has specific time set aside each week to work on 
improving drug safety in the hospital.  
Patient-Specific Clinical Pharmacy Services 
7. ADR 
management 
pharmacist evaluates potential ADR while the patient is hospitalized 
and appropriately follows through with physicians. 
8. 
Pharmacokinetic 
consultation 
provided only if at a minimum, the drug regimen, serum level, and 
patient's medical record is reviewed, and verbal or written follow-up is 
provided when necessary.  
9. Drug therapy 
monitoring 
provided only if a patient's medical record is reviewed, and verbal or 
written follow-up is provided when needed. Monitoring is ongoing and 
repeated, often on a daily basis. Do not check if drug orders are 
reviewed. Does not include pharmacokinetic consults, total parenteral 
nutrition (TPN) team, rounds, ADR management, or drug therapy 
protocol management.  
10. Drug 
protocol 
management 
pharmacist, under the order of a prescriber, requests laboratory tests if 
needed and initiates or adjusts drug dosage to obtain the desired 
therapeutic outcome (e.g., aminoglycoside or heparin dosing per 
pharmacy). 
11. TPN team 
participation 
pharmacist, at a minimum, reviews patient's medical records and/or 
provides written or verbal follow-up if needed. 
12. Drug 
counseling 
pharmacist provides counseling on drugs either during hospitalization 
or at time of discharge. Do not check if counseling involves solely 
review of label direction.  
13. 
Cardiopulmonary 
resuscitation 
team 
participation 
pharmacist is an active member of the CPR team attending most cardiac 
arrests when the pharmacist is present in the hospital. 
14. Medical 
rounds 
participation 
pharmacist rounds with a medical team at least 3 days/week, actively 
providing specific input. 
15. Admission 
drug histories 
pharmacist provides admission histories.  
ADR: adverse drug reaction. TPN: total parenteral nutrition. CRP: Cardiopulmonary resuscitation team 
Source: Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication 
errors in United States hospitals. Pharmacotherapy. 2002 Feb;22(2):134-47. 
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Table 4. Types of clinical pharmacy services in ambulatory settings 
Service Description 
1. Primary 
pharmaceutical 
care intervention 
Comprehensive patient assessment with review of drug therapy regimen 
for indication, efficacy and safety  
Identification of actual and potential drug therapy problems, preparation 
of care plans and therapeutic recommendations 
2. Patient 
teaching 
Medication teaching and review of drug therapy regimens 
Providing updated medication schedule to patient 
3. Medication 
reconciliation 
Performing a comprehensive medication history including all 
prescription, non-prescription and complementary and alternative 
medication use 
Documentation of full medication history in outpatient electronic chart 
Communicating medication changes to patients, other health care 
providers and community pharmacies 
4. Referral of 
issue for 
team follow-up 
Re-directing and communicating patient care issues as appropriate 
to other members of the inter-professional team; may involve verbal 
and/or written communication 
5. Optimizing 
medication 
adherence 
Optimizing medication schedules to promote patient adherence taking 
into account cultural/lifestyle factors and medication-taking behavior 
Developing and implementing patient-specific adherence strategies and 
tools 
6. Medical/drug 
information 
and advice 
Responding to drug information queries from patients and the inter-
professional team 
Providing medical advice where appropriate, in collaboration with the 
inter-professional team 
7. Other Assisting with drug coverage and reimbursement issues 
Assisting with preparation of prescriptions 
Updating community pharmacies with changes to drug therapy regimens 
Collaborating with community pharmacist to manage adherence 
issues (e.g., blister packing) 
Source: Harrison JJ, Wang J, Cervenko J, Jackson L, Munyal D, Hamandi B, et al. Pilot study of a 
pharmaceutical care intervention in an outpatient lung transplant clinic. Clin Transplant. 2012;26(2):E149-57. 
 
The provision of CPSs to individual patients consists of a range of overlapping CPSs, many 
which are performed concurrently. These CPSs contribute to the patient's medication view 
with the goal of optimizing the drug use (10).  Medication review will be introduced in detail 
in the Section "Practice of medication review".  
1.3.3. Impacts of clinical pharmacy services 
1.3.3.1. Clinical impacts 
Clinical pharmacists provide a unique set of knowledge and skills to the health care team by 
assuming the role of drug therapy expert to proactively advance rational drug therapy (1). 
There is a growing body of literature demonstrating the beneficial effects of clinical 
20 
 
pharmacist care on important outcomes for both hospitalized (35, 36) and ambulatory patients 
(37, 38). 
A recent systematic review of 36 controlled trials (35) found that "interacting with the health 
care team on patient rounds, interviewing patients, reconciling medications, and providing 
patient discharge teaching and follow-up" led to reductions in MEs, ADEs, ADRs, and length 
of hospital stay (LOS), with no evidence of harm. A retrospective analysis of data from nearly 
3 million patients in 885 US hospitals (36) showed that CPSs were associated with 
improvements in mortality and LOS. Favorable results were also found in  hemoglobin A1c, 
LDL cholesterol, blood pressure, and adverse drug events with pharmacists' direct patient care 
over comparative services (39). 
Where it may be appropriate to anticipate that pharmacists can positively impact in deaths or 
hospital admissions, given the types of PIs make, the outcome achieved are likely to be more 
limited. For example, hospital admissions that are related to drug therapy and are preventable 
occur at a rate of 4.5% of all admissions. However, only approximately 13% of patients who 
receive pharmaceutical care will be admitted to hospital; hence, the proportion in whom a PI 
could prevent an admission is likely to be around 0.6%. Using admissions as primary outcome 
measure would thus seem to be limited in its sensitivity to PIs, requiring large patient 
numbers to detect benefit (40). Many studies have involved patient groups at high risk of 
drug-related hospital admissions, yet researchers often fail to detect a benefit (41). In heart 
failure, for example, meta-analysis, has shown that there may be benefits, but only if 
pharmacists are part of a multi-disciplinary team (42). In addition, there are occasions when 
hospital admission is a beneficial outcome of a PI (40).   
1.3.3.2. Economic impacts 
A study of 1016 hospitals in USA found that CPSs were associated with lower total cost of 
care (43). Another review of economic evaluations of CPSs found that a positive economic 
benefit associated with CPSs was noted in 69% of studies and the pooled median value was 
4.81:1- meaning that for every $1 invested in CPS, $4.81 was achieved in reduced costs or 
other economic benefits (44). Another systematic review found 16% of studies indicated 
positive economic benefits as a result of CPSs.   
 
1.3.3.3. Humanistic impacts 
Humanistic impacts, also called as patient-related outcome measures are increasingly 
recognized as important. Results for humanistic outcomes varied across studies. A meta-
analyses found that medication adherence, patient knowledge, and quality of life-general 
health were favorable with pharmacists' direct patient care (35, 39). In contrary, many studies 
assessing the potential benefits of PIs have measured quality of life, using generic measures, 
such as the 36-Item Short Form Health Survey (SF-36) or the EG-5D (a standardized measure 
of health status), which generally have shown no impact. Studies using disease-specific 
quality-of-life measure have been more successful (45).  
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In conclusion, drug safety is a major problem of public health because of its morbidity and 
mortality. System approach rather than personal approach is effective to manage drug safety 
and quality improvement. In fact, combination and cooperation of many strategies at different 
levels is necessary to deal with this problem. Of that, clinical pharmacy and pharmaceutical 
care in a form of many different clinical pharmacy services were proved as promising 
solutions to improve rational drug use and improve patient outcomes.      
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2. Practice of medication review 
The provision of CPSs to individual patients consists of a range of overlapping CPSs, many 
which are performed concurrently. These CPSs contribute to the patient's medication view 
with the goal of optimizing the drug use (10). Medication review is one of the major 
contributions of pharmacists to detect, resolve and prevent DRPs for patients. In this section, 
we will describe how MR is practiced in literature.  
2.1. Process of Medication Review  
2.1.1. Definitions 
2.1.1.1. Medication review 
Medication review is one of daily main activities of pharmacists in clinical settings. 
"Medication review can be defined as a structured, critical examination of a patient’s 
medications with the objectives of reaching an agreement with the patient about their 
treatment and optimizing the impact of medications on patient’s health outcomes (9)." 
 
Medication review is available in many countries in different names and characteristics such 
as Medicines Use Review in UK (46), Medication Therapy Management in United States of 
America (47), Home Medication Review in Australia (48), MedsCheck in Canada (49) and 
Medicines Use Review in New Zealand (50) and Pharmaceutical Analysis in France (51).  
 
2.1.1.2. Pharmacist Interventions  
One of the major outputs of medication review is the generation of PIs. Within the system of 
health care, pharmacists routinely provide MR and recommendations to patients and health 
care professionals (8). Definitions of pharmacist interventions vary across studies. Some 
typical definitions are summarized in Table 5. Among them, a PI is commonly defined as 
"any action by a pharmacist that directly resulted in a change in patient management or 
therapy" by the Society of Hospital Pharmacists of Australia (52). In this thesis, we used this 
definition of a PI.  
Table 5. Definitions of pharmacist intervention 
Terms Definition  Author(s), published year 
Pharmacist 
intervention 
"discrete activities by pharmacists related to 
patient care"  
Rothschild et al., 2010 (53) 
Pharmacists' 
Clinical 
Intervention  
 
"any reactive (in response to an erroneous 
medication order) activity undertaken to 
suggest changes in one medication order that 
might involve contacting medical staff"  
Abdel-Qader et al., 2010 
(54) 
Clinical 
Pharmacy 
Intervention 
"any action by a pharmacist that directly 
resulted in a change in patient management or 
therapy" 
Society of Hospital 
Pharmacists of Australia, 
2005 (55) 
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2.1.2. Process of medication review 
Medication review by pharmacists is a systematic process of collecting patient-specific 
information, assessing drug therapy to identify medication related problems, prioritizing such 
problems, and creating a care plan to resolve them (16). The Review Process consists of 4 
steps (46): 
1. Identify patients 
2. Carry out the review 
3. Record review outcomes/Feedback results 
4. Audit/Quality assurance 
 
2.1.2.1. Identifying patients 
Patients with a potential need for MR can be identified by the pharmacist, the physician or 
other healthcare professionals, or the patients themselves when DRPs are suspected (47). 
Starting to carry out MRs can be quite daunting particularly where there are large numbers of 
patients involved. Therefore, MR initially needs to be prioritized to patients who are at risk of 
DRPs.  Some screening tools for the patient at risk were developed. For example, according to 
"A Guide to Patient Medication Review" of  the Northern Health and Social Services Board in 
UK (46), these risk groups fall into 5 main categories that often overlap as shown in Table 6. 
 
Table 6. High risk group of drug-related problems 
High Risk 
Group  
Examples of reasons for high risk 
Elderly 
(>75 
years) 
• Complex medication regimen 
• Polypharmacy 
• Multiple pathologies 
• Compliance issues 
• Physical problems (e.g., swallowing, arthritis) 
• Resident in care home 
• Mental states (e.g., confusion, dementia, depression, anxiety) 
Chronic 
diseases 
• Polypharmacy 
• Recent discharge from hospital 
• Medicines from more than one source 
• Adverse effects/drug interactions 
• Taking drugs requiring special monitoring 
• Current management plan is outdated due to the availability of new evidence 
Specialist 
drugs** 
Drugs with narrow therapeutic range (e.g., digoxin, warfarin) 
• Drugs on red/amber lists 
• Drugs which require special monitoring (e.g., lithium) 
Nursing/ 
Residentia
l Homes 
• • Use of commercial sip feeds as an ‘easy’ alternative to 
liquidized or pureed foods 
• Polypharmacy 
• Poor utilization of "Home Remedies" 
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• Reordering systems can be time-consuming 
• Overuse of antipsychotics/sedatives 
Polypharm
acy 
 
• Taking four or more regular medicines daily 
• Complex regimes 
• Compliance problems 
• Adverse effects or drug interactions 
• Current management plan is outdated due to the availability of new evidence 
Source: Clyne W, Blenkinsopp A, Seal R. A Guide to Medication Review. 2008. Available at 
http://www.npc.nhs.uk/review_medicines/intro/resources/agtmr_web1.pdf (last accessed November 2011). 2008. 
 
The descriptions of other screening tools are summarized in Table 7.  
Table 7. Screening Tools for patients at risk of DRPs 
Tools  Description 
Indicators for the 
selection of 
ambulatory 
patients (56) 
An eight-member panel of ambulatory-care pharmacists choose and 
tested 6 prognostic indicators: (1) five or more medications in present 
drug regimen, (2) 12 or more medication doses per day, (3) medication 
regimen changed four or more times during the past 12 months, (4) 
more than three concurrent disease states present, (5) history of 
noncompliance, and (6) presence of drugs that require therapeutic drug 
monitoring 
A computer-based 
program to 
identify patients 
at high risk for 
DRPs (57) 
The program used 6 criteria regarding medication use: (1) five or more 
medications, (2) > or = 12 doses per day, (3) four or more changes to 
the medication regimen, (4) three or more chronic diseases, (5) history 
of noncompliance, and (6) presence of a drug requiring therapeutic 
drug monitoring 
A self-
administered 
medication-risk 
questionnaire in 
an elderly 
population (58) 
10-item self-administered questionnaire for use by elderly patients to 
identify who is at increased risk of potentially experiencing a DRP 
A screening tool 
for the 
identification of 
patients 
experiencing 
DRPs (59) 
A semi-structured tool 
Using the costs of 
drug therapy (60) 
 
Using the cost of drug therapy (threshold = 2000 Swiss francs [CHF], 
1440 USD, 1360 EUR) as a screening criterion for identifying patients 
who may benefit from community pharmacy-based MR. 
Considerations 
for identification 
of patients who 
Providing 12 factors needed to take into account for prioritizing who 
may benefit most from Medication Therapy Management: experienced 
a transition of care, receiving care from more than one prescriber, has 
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may benefit from 
Medication 
Therapy 
Management 
Services (47) 
at least one chronic disease or chronic health condition... 
 
Medication 
Regimen 
Complexity Index 
(61) 
A 65–item Medication Regimen Complexity Index was developed, 
including the number of drugs, dosage frequency, administration 
instructions, and the prescribed dosage forms. 
Electronic 
screening of 
medical records 
to detect 
inpatients at risk 
of DRPs (62) 
A screening tool consists of electronic queries: patients receiving drugs 
such as cytochrome P450 inducers, inhibitors or high-risk medications, 
those with renal impairment, those on digoxin with low serum 
potassium, those with intravenous anti-infectives or intravenous 
acetaminophen for more than 3 days, and elderly patients with poly-
medication (>or=80 years and >10 drugs). 
A new set of 
explicit 
medication 
assessment 
criteria and 
prioritization of 
topics for 
improvement (63) 
Fifty-two final "quality" assessment criteria target patients with unmet 
indications, sub-optimal selection or intensity of beneficial drug 
treatments. A total of 124 "safety" assessment criteria target patients 
with unmet needs for risk-mitigating agents, high-risk drug selection, 
excessive dose or duration, inconsistent monitoring or dosing 
instructions. 
A method of 
targeting CPSs at 
high-risk patients 
through the use of 
an electronic 
prescribing 
system (64) 
A scoring system assigned patients into a low, medium or high risk 
category. The results were then emailed to all members of the clinical 
pharmacy team automatically for use and evaluation.  
An electronic 
patient 
prioritization tool 
for clinical 
pharmacist 
interventions (65) 
Developed the Assessment of Risk Tool (ART), an application for 
monitoring pre-specified clinical "flags" for high-risk medication use 
and other ADE risk factors. The ART permits ADE risk assessment in 
virtual real time (e.g., medication-use data and other clinical 
information are updated multiple times daily). Each of the 38 flags 
captured by the ART is assigned a weighted score; the item scores are 
summed to provide a total ART score indicating low, medium, or high 
ADE risk, and patients are prioritized by the ART score for PIs such as 
clinical review and discharge coordination. 
DRP: drug-related problem. MR: medication review. ART: assessment of risk tool. ADE: adverse drug event. PI: 
pharmacist intervention 
 
 
26 
 
2.1.2.2. Carrying out the review 
Depending on its scope, the MR may include the following (47): 
- Gather all relevant clinical information of the patient, including demographic information, 
general health and activity status, medical history, medication history, immunization history, 
and patients’ thoughts or feelings about their conditions and medication use 
- Assessing the patient’s physical and overall health status, including current and previous 
diseases or conditions 
- Assessing the patient’s values, preferences, quality of life, and goals of therapy 
- Assessing cultural issues, education level, language barriers, literacy level, and other 
characteristics of the patient’s communication abilities that could affect outcomes 
- Evaluating the patient to detect symptoms that could be attributed to adverse events caused 
by any of his or her current medications 
- Interpreting, monitoring, and assessing patient’s laboratory results 
- Assessing, identifying, and prioritizing DRPs related to: 
 The clinical appropriateness of each medication being taken by the patient, including 
benefit versus risk 
 The appropriateness of the dose and dosing regimen of each medication, including 
consideration of indications, contraindications, potential adverse effects, and potential 
problems with concomitant medications 
 Therapeutic duplication or other unnecessary medications 
 Adherence to the therapy 
 Untreated diseases or conditions 
 Medication cost considerations 
 Healthcare/medication access considerations 
- Developing a plan for resolving each DRP identified 
- Providing education and training on the appropriate use of medications and monitoring 
devices and the importance of medication adherence and understanding treatment goals 
- Coaching patients to be empowered to manage their medications 
- Monitoring and evaluating the patient’s response to therapy, including safety and 
effectiveness 
- Communicating appropriate information to the physician or other healthcare professionals  
 
The useful of systematic procedure to conduct MR has been demonstrated, comparing them to 
traditional procedures (66). Many methods have been suggested for standardization of process 
of MR and enhancement of DRP detection.  
The simplest tool is perhaps a checklist which could be used as a prompt to verify that all 
critical checks have been performed and to ensure that optional check items are not forgotten. 
For example, a checklist developed by Meyler et al. (67) contained items related to order 
urgency, verification of patients’ identity, therapeutic review (for safety and efficacy), and 
actionable items, and was designed for general purpose use on all wards for all types of 
patients. The French Society of Clinical Pharmacy (SFPC) developed also a comprehensive 
checklist as recommendations for a good practice of MR (51).  
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Different methods of MR in community pharmacy in France were introduced. Of them, Calop 
proposed a step-by-step process through an algorithm (68); Dupin-Spriet presented the ALAC 
pocket card (69) of 4 simple steps  "Accueillir, Lire, Analyser, Commenter" (means 
"welcome, read, analyze, comment"); and the ADAPCO association (70) developed 6 specific 
evaluation grids to facilitate and standardize MR in community pharmacy. Kassam et al. in 
Canada (1999) (71) developed also tools used to help community pharmacists implement 
comprehensive pharmaceutical care.  
In other study, Rovers et al. (66) developed the guided interview tool (a paper form) for 
pharmacy students in a hospital to gather a medication history, perform a review of general 
medication safety, and determine the need for additional therapy. The Northern Health and 
Social Services Board in UK (72) provided "A Guide to Patient Medication Review" with 
examples of forms and prompts that may be used during the review.   
Many methods of documentation of MR also assisted pharmacists in completing the MR. 
Many acronyms have been coined that suggest the proper steps to follow when writing-up a 
patient (73). For example, the well-known SOAP (subjective, objective, analysis, plan) (74), 
an expanded-SOAP (adds goals, monitoring and education) (75), HOAP (replaces subjective 
and objective with history and observations) (76), FARM (findings, assessment, resolution, 
monitoring) (77), PWDT (pharmacist’s workup of drug therapy) (78), PMDRP (Pharmacist’s 
Management of Drug- Related Problems) (79), or SMPC (Standardized Method for 
Pharmaceutical Care) (80), PH-MD-ROME (Patient Introduction, Health Problems, 
Medications, Pharmaceutical Diagnoses, Recommended Orders, Desired Outcomes, 
Monitoring, Patient Counseling and Education) (73). 
 
These various approaches all contain important elements of MR, but they all have advantages 
and disadvantages. The checklists, pocket card are simple but they are not complete and 
maybe difficult for initial stages of learning/practicing. The original SOAP concentrates on 
development of a medical diagnosis rather than DRPs or pharmacotherapeutic assessment. 
The expanded SOAP and FARM emphasize therapeutic problems, but continue to be 
organized around medical diagnoses (73). The PWDT, PMDRP, SMPC and PH-MD-ROME 
provided a structure which explicitly guided pharmacists through the pharmaceutical care 
process, assist pharmacists and students in the initial stages of learning and they can modify it 
into various shorter specialized tools according to practice requirement (79). In conclusion, 
during the initial training of pharmacy students, very detailed methods such as the PMDRP, 
PMDRP, SMPC can help inexperienced students more fully internalize aspects of the 
pharmaceutical care process. However, as students progress and develop a basic knowledge of 
therapeutic principles, these methods become cumbersome and checklists, post cards, 
algorithms are more efficient.  
 
Coding instruments for recoding of PIs (16, 81-83) also assisted pharmacists in completing 
the MR. Other explicit/implicit tools have been developed to guide healthcare professionals in 
reviewing the medication patterns of general patients (84, 85), elderly patients (86, 87) or 
patients with chronic kidney disease (88). 
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Although MR and the needs of individual patients may vary, the use of consistent and 
standardized tools for MR, as described above, will enhance their efficient delivery and 
effective quality measurement (34). 
 
2.1.3.3. Documentation and Follow-up 
 Documentation 
Documentation of MR and PIs has recognized as essential for demonstrating the added value 
of pharmacists to the healthcare system and justification for obtaining additional resources in 
clinical pharmacy practice. This assessment is also used as indicators of pharmacist’s 
performance and the continuing quality improvement, research and education (89).  There are 
many guidelines for the documentation of pharmacist-provided care (90), (91). 
Documentation elements for the patient record may include, but are not limited to, the 
following (47): 
 
Table 8. Documentation elements for the patient record 
Documentation 
category 
Examples 
Patient 
demographics 
Basic information: address, phone, e-mail, gender, age, ethnicity, 
education status, patient’s special needs, health plan benefit/insurance 
coverage 
Subjective 
observations 
Pertinent patient-reported information: previous medical history, family 
history, social history, chief complaints, allergies, previous adverse drug 
reactions 
Objective 
observations 
Known allergies, diseases, conditions, laboratory results, vital signs, 
diagnostic signs, physical exam results, review of systems 
Assessment Problem list, assessment of DRPs 
Plan A care plan is the healthcare professional’s course of action for helping a 
patient achieve specific health goals 
Education Goal setting and instruction provided to the patient with verification of 
understanding 
Collaboration Communication with other healthcare professionals: recommendations, 
referrals, and correspondence with other professionals (cover letter, 
SOAP note) 
Personal 
Medication 
Record 
A record of all medications, including prescription and nonprescription 
medications, herbal products, and other dietary supplements 
Medication-
related action 
plan 
Patient-centric document containing a list of actions to use in tracking 
progress for self-management 
Follow-up Transition plan or scheduling of next follow-up visit 
Billing Amount of time spent on patient care, level of complexity, amount 
charged 
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DRP: drug-related problem. SOAP note: an acronym for Subjective, Objective, Assessment, and Plan which is a 
method of documentation.  
Source: American Pharmacist Association and National Association of Chain Drug Stores Foundation. 
Medication therapy management in pharmacy practice: core elements of an MTM service model. 2008. 
 
MR documentation includes creating and maintaining an ongoing patient-specific record that 
contains, in chronological order, a record of all provided care in an established standard. 
Ideally, documentation will be completed electronically or alternatively on paper (47). 
A variety of coding instruments has been reported for recoding of intervention. For example, 
Classification of Helper and Strand (16), a comprehensive classification tool for treatment-
related problems (92), PCNE Classification for DRPs (81), PI-Doc (82), APS-Doc (93), CPR 
taxonomy (94), systems developed by Westerlund (95), DOCUMENT system (96), Act-IP 
(97).  
A computerized system for documenting PIs compared favorably with a manual system in 
terms of ease of use, accessibility, time efficiency, and acceptability (98) and facilitate 
integration with other clinicians, payer records, and healthcare systems (99).  
Under-reporting of PIs is a known phenomenon that has been observed. Boardman et al. (100) 
found that under one-third (31%) of PIs were actually documented. The interventions that 
were documented tended to be those of highest clinical importance and those that were time-
consuming to the pharmacist, interventions accepted by the attending physician. This high 
patient burden may contribute to under-reporting of PIs, as there is often not adequate time 
during clinic to document each PI. A survey of documentation practices was conducted in 106 
community pharmacists in North Carolina in 2003(101) found that pharmacists spent an 
average of 14.9 hours per week providing patient care, with an average of 3.9 of these hours 
(approximately one fourth of patient care time) devoted to documentation. If recorded PIs 
continue to be used the main source of evidence of outputs of CPS, a better way of capturing 
this data needs to be developed (100).  
 Follow-up 
When a patient’s care setting changes (e.g., hospital admission, hospital to home, hospital to 
long-term care facility, home to long-term care facility), the pharmacist transitions the patient 
to another pharmacist in the patient’s new care setting. In these situations, the initial 
pharmacist participates cooperatively with the patient’s new pharmacist to facilitate the 
coordinated transition of the patient, including the transfer of relevant medication and other 
health-related information. 
 
If the patient will be remaining in the same care setting, the pharmacist should arrange for 
consistent follow-up in accordance with the patient’s unique medication-related needs. All 
follow-up evaluations and interactions with the patient and his or her other healthcare 
professional(s) should be documented (47). 
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Figure 3. Flow Chart of a Medication Therapy Management Service Model 
Source: American Pharmacist Association and National Association of Chain Drug Stores Foundation. 
Medication therapy management in pharmacy practice: core elements of an MTM service model. Version 2.0. 
2008. 
 
2.1.3.4. Quality Assurance/Audit  
Pharmacists have a responsibility to develop and participate in a continuous quality 
improvement program. Quality assurance and audit should be part of the continuous quality 
improvement program of MR process (72). 
 Quality Assurance 
One method of assessing the quality of the review system is by evaluating the feedback from 
patients or their careers who have participated in the MR process. This might include an 
evaluation of their experience of the review and the level of satisfaction with its outcome. 
 Audit 
Medication review is an integral part of the repeat prescribing process and many practices 
undertake regular audits of their repeat prescribing system. 
 Measuring Progress 
It is important to identify the baseline before audit is undertaken. The practice should agree an 
achievable target for increasing their MR rate. Regular feedback is essential to enable 
evaluation of the progress being made and to ensure that the practice is on target to achieve 
their objectives. 
The utilization of documentation system of PIs to quantify the pharmacy productivity has 
been conducted in many settings. Some pharmacy productivity models have been developed 
(102-105). A survey found that 79% of hospitals identified the inability to account for CPSs 
as the single biggest limitation of productivity monitoring (106). In order to solve this 
problem, Pawloski et al.(104) developed an automated tool to quantify decentralized clinical 
pharmacists’ productivity by extracting these data from the electronic medical record. 
Decentralized pharmacists were asked to weigh each activity relative to other activities on the 
basis of the average time and cognitive skill required to complete a specific intervention. 
Reports were generated and extracted into a database for data analysis, data graphing, and 
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final report generation. This report assists in the determination of staffing levels and 
assignment constructs and identifies pharmacists who need additional training in a particular 
assignment area. 
 
2.1.3. Types of medication review 
2.1.3.1. Comprehensive and target medication review  
In a comprehensive MR, ideally the patient presents all current medications to the pharmacist, 
including all prescription and nonprescription medications, herbal products, and other dietary 
supplements. The pharmacist then assesses the patient’s medications for the presence of any 
DRPs, including adherence, and works with the patient, the physician, or other healthcare 
professionals to determine appropriate options for resolving identified problems. In addition, 
the pharmacist supplies the patient with education and information to improve the patient’s 
self-management of his or her medications. 
Targeted MRs are used to address an specific DRP. Ideally, targeted MRs are performed for 
patients who have received a comprehensive MR. Whether for a new problem or subsequent 
monitoring, the pharmacist assesses the specific DRP in the context of the patient’s complete 
medical and medication history. Following assessment, the pharmacist intervenes and 
provides education and information to the patient, the physician or other healthcare 
professionals, or both, as appropriate (47). 
2.1.3.2. Levels of medication review 
 
Medication review can be classified differently according to authors/associations. "Room for 
Review" in 2002 in UK (46) described 4 levels of MR depending on whether a patient is 
presented and whether access to the patient's clinical record is possible.  
Table 9. Levels of medication review in UK 
Level  Definitions  
Level 0 Ad hoc: an unstructured opportunistic review 
Level 1 
 
Prescription review: a technical review of a list of patient's medicines (paper-
based) 
Level 2 Treatment review: a review of medicines with patient's full notes (not necessarily 
with the patient present) 
Level 3 Clinical medication review: face-to-face review of medicines and condition with 
the patient 
Source: Clyne W, Blenkinsopp A, Seal R. A Guide to Medication Review. 2008.  
 
The French Society of Clinical Pharmacy(107) groups MR into 3 levels: (1) prescription 
review, (2) therapeutic review, (3) pharmaceutical care review, depending on  context, 
content, and required elements of MR (Table 10). The SFPC recommends medication review 
level 3 for all patients. Levels 1 and 2 may be required for patients already known, not 
justifying more comprehensive review.  
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A new classification of MR (46) focuses on the purpose of MR rather than a hierarchy of MR. 
MR can be classified into three types: prescription review, adherence support review, and 
clinical MR. In some countries, an extension of type 3 exists and includes the authority for 
prescribing. Therefore, Hatah et al. (9), added the fourth type of MR - clinical MR with 
prescribing (as in type 3 but pharmacist had the ability to prescribe or adjust the medication 
dose, either in a supplementary or fully independent role). A subgroup meta-analysis of 36 
studies found that clinical MR but not adherence support review reduced hospitalization (9). 
Table 10. Levels of medication review according to the SFPC 
Type  Context Content Required elements 
Level 1:  
Prescription 
review  
Patient known, 
without new 
clinical 
information 
 
- Choice and availability of 
health products, dosages, 
contraindications, and major 
interactions 
All prescriptions, 
basic patient 
information 
 
Level 2:  
Therapeutic 
review 
  
Patient known, 
with evolving 
situation 
- Choice and availability of 
health products, dosages, 
contraindications, and major 
interactions. 
- Dose adjustments in 
relationship with biological 
results, markers of effect 
All prescriptions, 
basic patient 
information, 
biological data 
Level 3:  
Pharmaceutical 
care review 
New 
admission of a 
patient, current 
evolution and 
issues not 
established 
- Choice and availability of 
health products, dosages, 
contraindications, and major 
interactions 
- Dose adjustments in 
relationship with biological 
results, markers of effect 
- Compliance with therapeutic 
goals, therapeutic drug 
monitoring, compliance. Links 
to conciliation, patient
counseling and patient education 
All prescriptions, 
basic patient 
information, 
biological data, drug 
history, therapeutic 
goals 
Source: Société français de pharmacie clinique. Recommandation de Bonne Pratique de  Pharmacie Clinique - 
Niveaux Analyse Pharmaceutique. 2012. 
2.1.4. The factor affecting the quality of medication review 
There are many factors which affect the quality of MR such as quality of patient information 
(exact, sufficient, updated), relevance and validity), involvement of patient in decision, 
collaboration between health care providers, and competence and training of pharmacists.  
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2.1.5.1. Quality of patient information 
Collection of patient information should be as much as possible from prescriptions, clinical 
records, interview with the patient (e.g., medication history). To perform the most 
comprehensive assessment of a patient, personal interaction with direct contact between a 
healthcare professional and a patient is optimal (47). A face-to-face interaction optimizes the 
pharmacist’s ability to observe signs of and visual cues to the patient’s health problems (e.g., 
ADRs to medications) and can enhance the patient–pharmacist relationship. It is useful to 
construct a guide on interview with patients (66). It is recognized, however, that alternative 
methods of patient contact and interaction such as telephonic may be necessary for those 
patients for whom a face-to-face interaction is not possible or not desired (e.g., patients at 
home) or in pharmacy practice settings in which the pharmacist serves in a consultative role 
on the healthcare team (47). Pharmacists have been shown to obtain accurate and efficient 
medication related information from patients rather than other health care professionals (108, 
109). 
A study of Kwint et al. (110) found that 27% of all DRPs were identified during patient 
interviews and 74% from medication and clinical records. Compared to DRPs identified from 
medication and clinical records, DRPs identified during patient interviews were more 
frequently assigned a higher clinical relevance. Of all the interventions performed in a study 
on pharmacotherapy consultations in ambulatory care patients receiving polypharmacy, 73% 
of the original problems were recognized only through a patient interview, suggesting that an 
interpersonal relationship remains critical to the provision of pharmaceutical care (111). 
Another study evaluated the activities and interventions provided by ambulatory care clinical 
pharmacists in US found that more drug-related problems were addressed and resolved when 
visits were 15 minutes or longer (p=0.001) and when the contact was in person (p=0.001) 
rather than telephone contact (112). 
2.1.5.2. Involvement of patient in decision 
PI is only implemented by “reaching an agreement with the patient”. Therefore, PIs should be 
based on not only evidence from clinical and pharmacological research, also evidence about 
the medicines that the patient is actually taking, about the patient’s capacity and motivation to 
take the medicines, and about the patient’s priorities and beliefs about medicine taking 
(patient compliance) (113). 
Motivational interviewing with patients has been shown to improve treatment adherence and 
outcomes, promote behavior change, and improve patient satisfaction with care. Therefore, 
pharmacists should use behavioral interventions such as “a coaching approach to improving 
concordance”. A coaching approach focuses the four elements in concordant consultations: 
 Explore what the patient wants to know and follow their agenda (patient engagement: 
they’ll stay interested). 
 Educate them on what they want to know (patient education: benefits, concerns). 
 Empower patients to take responsibility for medicines taking (patient motivation: they 
take responsibility). 
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 Enable behavioral change for patients to achieve their aims (patient action: identify 
and implement their way) (114). 
2.1.5.3. Collaboration 
Knez et al. found that pharmacists were more likely to independently solve problems of minor 
significance, whereas they worked with clinicians and nurses to implement interventions of 
higher significance (115).  
 
A systematic review of Kwint et al. 2013(116) found that the more intense collaboration 
between the general practitioners (CP) and pharmacists in MR leaded to a higher rate of 
implementation of recommendations arising from medication review. The following key 
elements reflecting collaborative aspects between a general practitioner and a pharmacist were 
assessed:  
 "pharmacist with clinical experience" means that the pharmacist had adequate clinical 
training and expertise to perform MRs 
 "own pharmacist involved" means that the pharmacist is the patient’s regular 
pharmacist who has a longer lasting therapeutic relationship with his or her patient 
 "sharing of medical records" describes full access for the care provider performing the 
medication review to GP data on diseases of the patient and clinical values 
 "patient interview by pharmacist" means a face-to-face consultation between a 
pharmacist and a patient—this pharmacist must have a relationship with the GP 
 "invitation of the patients by GP" means that the patient is invited to the study or 
referred for MR by the GP 
 "case conference GP and pharmacist" indicates a face-to-face meeting between at least 
the GP and the pharmacist to discuss the DRPs and recommendations for specific 
patients 
 "action plan" means that the study investigators reported that the agreed 
recommendations were formulated as an action plan and that there were designated 
persons responsible for implementation of this plan 
 "follow-up" has taken place to assess whether the actions have been implemented, and 
to assess the patient’s experience with these actions.  
2.1.5.4. Competence and training of Pharmacists 
A study of Currie et al.(117) showed that the training program proved to be an effective way 
to increase the number of DRPs identified and addressed by pharmacists. A 40-hour 
pharmaceutical care training program was developed and presented to pharmacists who 
provide pharmaceutical care in a community pharmacy; and 1 078 patients were randomly 
assigned to receive either (1) traditional pharmacy services or (2) pharmaceutical care. 
Patients receiving pharmaceutical care were more than seven times as likely to have any 
problems identified, more than eight times as likely to have an intervention performed. 
Another study suggested also that community pharmacists with limited experience in MR 
may need more intensive post-graduate training (118).  
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2.1.5. Remuneration 
Several countries such as the UK, the US, Denmark, Germany, the Netherlands, Chile, 
Belgium, Canada, Australia, New Zealand pay pharmacists for providing MRs for patients(9). 
These can be termed "fee-for-service" MRs because pharmacists are remunerated by the 
government or a health provider for each item of service; or under capitation models.  
 
2.2. Epidemiology of medication review 
2.2.1. Place where medication review were conducted  
MR are currently being delivered in both the public and private sectors (47). MR can be 
conducted in clinical departments or central pharmacy department at hospitals, community 
pharmacies, medical centers in community, patients' home, nursing home care, acute care, 
long-term care, home care (9, 46, 47). A study (119) found that 2 of the 23 DRP domains 
differed significantly when comparing MRs conducted in the patient's home to those 
conducted in the medical centre. 
2.2.2. Who should carry out medication review 
Pharmacists who are considered as experts on pharmacotherapy should be play a key role in 
MR. Many studies showed that types of health care professionals influence performance of 
MR. A study of Rovers at al. (66) found that clinical pharmacists reported a higher median 
number of DRPs (3; range 0-6 versus 2; range 0-5) compared to student pharmacists. 
Compared to the clinical pharmacists, student pharmacists were more likely to report wrong 
drug, adverse drug reaction, and inappropriate compliance. Clinical pharmacists were more 
likely than the student pharmacists to report unnecessary drug therapy, dosage too low, 
dosage too high, and the need for additional therapy. Similarly, another study (120) showed 
that PIs done by faculty clinical pharmacists, and student pharmacists were very different than 
those performed by the hospital staff pharmacists. The authors concluded that the different 
interventions performed by the three groups may suggest a multi-interdisciplinary approach to 
patient care where different types of PIs may result in improved outcomes. 
2.2.3. Number/rate of DRPs and PIs and time spent on PIs 
The rate of PIs (number of PIs/number of prescription reviewed) ranged from 1 to 37% (121, 
122). Analysis of the time spent on interventions can be used for quality improvement 
initiatives and can be used to estimate clinical pharmacist workload. The mean time spent on 
an intervention was 7.0-9.6 minutes (52, 123, 124).  
2.2.4. Which medications most involved 
A high-risk medication was defined as a medication that, if involved in an erroneous 
medication order, carried a greater risk of significant harm or death. Although errors 
involving these drugs are not more frequent than with other products, the consequences can be 
devastating for patients. For this reason, high-risk drugs must be handled differently from 
others, whether at the time of packaging, storage, prescription or administration. In 2014, the 
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Institute for Safe Medication Practices Canada suggested two lists of "High Alert 
Medications" - one in ambulatory care (125) and one in intensive care (126). In the US, the 
campaign 5 Million Lives, launched in December 2006 by the Institute for Healthcare 
Improvement chose to target four drug groups with higher risks: anticoagulants, narcotics and 
opiates, insulins and sedatives (127). A review in 2003 found that five drug groups which 
were most frequently associated with preventable ADEs were cardiovascular drugs, 
psychoactive and other central nervous system drugs, analgesic drugs, anticoagulants, and 
anti-infectives. In an another systematic review in 2007, Howard et al.(128) found that four 
groups of drugs accounted for more than 50% of the drug groups associated with preventable 
drug-related hospital admissions. These were anti-platelets, diuretics, non-steroidal anti-
inflammatory drugs and anticoagulants.  
2.2.5. Which DRPs detected and PIs proposed 
In a prospective study of  PIs (129) conducted in 6 French hospitals, the most commonly 
identified DRPs were nonconformity to guidelines or contraindication (21.3%), followed by 
improper administration (20.6%), supra-therapeutic dose (19.2%), and drug interaction 
(12.6%). Another study of Bedouch et al. (130) reviewed PIs documented into Act-IP© - a 
French database of PIs over a 30-month period. A total of 34 522 PIs were registered by 201 
pharmacists working in 59 hospitals. The most common type of DRP identified was similar to 
the former study, including "supra-therapeutic dosage" (20.6%), followed by "improper 
administration" (20.1%) and "non-conformity to guidelines/contra-indication" (17.6%). PIs 
were mainly proposals for "dose adjustment" (24.5%), followed by "drug discontinuation" 
(20.0%) and "drug switch" (19.0%). 
2.2.6. Acceptance and Implementation of pharmacist interventions  
In order for the pharmacist to impact upon the quality of patient care or drug costs, the 
prescriber must accept the suggestions. A review of 23 studies conducted in 1990 (131) found 
that the average rate of acceptance was 85.5%. Factors affecting acceptance included time, 
communication, solicited versus unsolicited recommendations, type of prescriber, and type of 
pharmacist. Factors leading to non-acceptance included lack of physician awareness of 
pharmacokinetic parameters, quality of suggestions, prescribers' exercise of caution with 
respect to patient safety and well-being, and negative attitude toward clinical pharmacy.  
 
The factors that affected the rate of physician-accepted PIs in acute care hospitals in the 
United Kingdom found that ward type, pharmacist grade, and total time spent on the ward by 
the pharmacist were significant predictors of the intervention rate (132, 133). A higher 
acceptance rate was achieved if the recommendations from the pharmacist were 
communicated directly to the prescriber. Barber et al.  (132) also found that on pediatric 
wards, the number of physician-accepted interventions was 1.7 times greater than on other 
types of wards.   
 
Anderegg et al.(134) found that recommendations to reconcile medications or address actual 
drug allergies or medication errors were frequently accepted. Physicians were less likely to 
accept recommendations related to drug indications (p<0.001), drug efficacy (p=0.041), and 
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therapeutic drug and disease state monitoring (p=0.011) than the “other” category which were 
typically more procedural such as clarify duration, provide dietician consultation, or restart a 
drug when at home. Recommendations made for patients with a relatively greater number of 
drugs were also less likely to be accepted (p=0.003). The study also determined whether 
recommendations made by pharmacists and accepted by hospital physicians resulted in fewer 
post-discharge readmissions and urgent care visits compared with recommendations that were 
not implemented. Data on readmissions, emergency department use, urgent care visits, and 
death of 192 patients were collected for 90 days after discharge. The acceptance rate was 
lower for those who had an urgent care visit compared with all other patients (33.6% vs 
52.2%, p=0.033). No significant association was noted between recommendation acceptance 
rates and readmission, emergency department visit, or death. Because only 48% of all 
recommendations were accepted by inpatient physicians, and there was no impact on health 
care use 90 days after discharge. This study suggests that recommendations by pharmacy case 
managers were underused, and the low acceptance rate may have reduced the potential to 
avoid readmissions. Other studies of PIs to hospitalized patients reported positive clinical and 
economic outcomes associated with acceptance rate of IPs over 90% (135-137).  
 
The medical literature also supports the notion that valid PIs are not always accepted. The 
well-established theory of psychological reactance might at least partially explain instances 
when physicians do not act upon such recommendations. Reactance theory suggests that when 
recommended to take a certain action, a motivational state compels us to react in a way that 
affirms our freedom to choose. Often we choose to do the opposite of what the 
recommendation is proposing that we do or we just become entrenched in our initial position. 
Making recommendations regarding clinical care, including pharmacotherapy, may carry with 
it implied threats, as it can be perceived as an attempt to restrict one’s freedom of choice 
potentially generating reactance and efforts to avoid them. By identifying and taking into 
account factors likely to promote reactance, physician-oriented interventions could become 
more effective (138).  
2.2.7. Risk factors of medication errors   
Due to the variability between health care facilities, so the trans-validity of predictors of 
DRPs is not always valid. Therefore, hospitals could use an epidemiological framework to 
identify their own error predlictors in order to target interventions. For example, a 
retrospective case-control study of Fijn et al. (139), comparing prescriptions with and without 
MEs, found that only prescriber and drug characteristics were associated with errors. 
Prescriber characteristics were medical specialty (e.g. orthopaedics) and prescriber status (e.g. 
verbal orders transcribed by nursing staff). Drug characteristics were dosage form (e.g. 
inhalation devices), therapeutic area (e.g. gastrointestinal tract) and continuation of 
preadmission treatment (Yes). In a retrospective cross-sectional study conducted at an acute-
care hospital in Singapore, Koh et al. (140) found that age and gender were less important 
than the number of drugs prescribed as predictors for experiencing a DRP for patients with 
polypharmacy. Errors were much more likely to be intercepted if the error occurred in the 
earlier process (26).  
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Some studies showed that medical residents (141), doctors of having less years of experience 
(54), or with less training(13, 142) were also more likely to make MEs; specialists prescribed 
fewer abnormalities than generalists (22% against 41%). The best performances seem to see 
by physicians with between 15 and 30 years of practice (143). However, another study in the 
Netherlands where it was shown that specialists had a higher rate of errors than the GP (144) 
and the frequency of prescribing errors in prescriptions from hospital physicians is higher than 
on prescriptions from GPs (145). It has been shown that prescribers with a high rate of trivial 
prescribing errors also make more serious errors (146). 
2.2.8. Factors influencing pharmacist interventions   
According to a study performed in a pediatric intensive care setting, a full-time unit-
based clinical pharmacist substantially decreased the serious medication error rate, but a part-
time pharmacist was not as effective (147). In another study, the total cost avoidance to the 
institution over a 4.5-month period with the ICU pharmacist would have been $209,000–
$280,000. The majority of interventions were initiated during chart review (40%) and patient 
care rounds (39%) (148). Most of the costs avoided were generated from interventions made 
during patient care rounds and chart-review activities, each of which ranged from 
approximately $80,000 to $110,000. These results suggest that systems changes (e.g., CPOE, 
technician support for routine order entry) that minimize the time spent verifying orders and 
maximize the time spent on these activities are most likely to improve patient outcomes. 
 
There is considerable evidence that clinical pharmacists providing medication reviews can 
decrease the occurrence of DRPs. Successful interventions require that clinical pharmacists 
work in close liaison with the prescriber, and have access to the full clinical record of the 
patient (149). Several studies that did not meet these conditions reported only weak impact or 
even detrimental effects (150, 151). 
 
In conclusion, practice of medication review varies across individuals, settings and countries. 
There is a variety of factors that influence quality and impacts of medication review. Research 
on relationships between the characteristics of practice of MR and its impacts is necessary to 
optimize its outcomes. Standardization and continuous quality improvement are also the two 
key strategies to improve impacts of MR. 
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3. Evaluation of impacts of medication review/pharmacist 
interventions 
In this section, we will present some models or conceptual frameworks that can be applied to 
assess impacts of MR/PIs. Then, we combined these existing models into an integrated model 
for assessment of MR/PIs.  
3.1. Quality of medical care - The Structure-Process-Outcome model of 
Donabedian 
The Donabedian's Model (152, 153) is a conceptual model that provides a framework for 
evaluating quality of medical care. According to the model, information about quality of care 
can be drawn from three categories abbreviated SPO: Structure (context in which care is 
delivered, including hospital buildings, staff, financing, and equipment...), Process 
(transactions between patients and providers throughout the delivery of healthcare), and 
Outcomes (effects of healthcare on the health status of patients and populations).  
The outcome has been frequently used as an indicator of the quality of medical care. 
Examples are studies of death, event (hospitalization, medical consultation), and quality of 
life (52, 154). To be complete, outcome assessment should include all factors that contribute 
to the outcomes such as functional status; symptomatology; and psychologic, economic, 
social factors, and quality of life (155). Its advantages includes a validity and a fairly concrete 
and precise measurement in many situations (153). However, the use of outcomes as measures 
of quality is associated with some main difficulties: criteria/technology of follow-up, time, 
determination of causal relationships between medical care and outcomes (136, 156-158). 
Furthermore, sometimes a particular outcome may be irrelevant, as when survival is chosen as 
a criterion of success in a situation which is not fatal but is likely to produce suboptimal 
health. Some outcomes, not so clearly defined, can be difficult to measure, for example 
patient attitudes and satisfactions, social restoration and physical disability and rehabilitation. 
However, outcomes remain the ultimate validators of the effectiveness and quality of medical 
care (153).  
Another approach to assessment is to examine the process of care itself rather than its 
outcomes. Par example, a number and type of DRPs, consistence of PIs to practice standards, 
acceptance by physicians and health care providers in case of MR. Process evaluation are 
often preferred by providers because they are generally simple to understand and interpret and 
they related directly to practice. However, process measures may be of little value if standard 
practice cannot be agreed upon or if process and outcome are not causally related (155). They 
may, however, be more relevant to the question at hand: whether pharmacists is properly 
practiced (153). Process criteria of quality assessment usually are categorized as either 
technical or interpersonal. Technical care in pharmacy represents the 
procedures/knowledge/skills pharmacists employ to provide the optimal drug therapy. The 
interpersonal component of process addresses the characteristics of the interaction between 
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patients and pharmacists such as concerned, polite, respectful, friendly, and honest (or their 
opposites).  
A third approach to assessment is to study not the process of care itself, but the settings in 
which it takes place (structure). It is concerned with such things as the adequacy of facilities 
and equipment; the qualifications of pharmacy staff; the administrative structure and 
operations of programs. This approach offers the advantage of dealing, at least in part, with 
fairly concrete and accessible information. It has the major limitation that assessment of the 
relationship between structure and process or structure and outcome, is often not well 
established (153). Structure represents the stable, physical structure and capacities of a 
healthcare setting. Therefore, an individual PI rarely has impacts on structure outcomes.   
 
According to the Donabedian's Model, measures of structure, process, and outcome (SPO 
framework) are all useful for assessing health care quality. For example, a SPO framework for 
quality assessment of pharmaceutical care in a community pharmacy was described in Figure 
4. Each element of quality is dependent on the other, like links in a chain. However, as one 
moves down the chain from structure to process to outcome, measures become harder to 
capture and more subject to questions of validity and reliability(11).   
 
Figure 4. Structure-process-outcome: a framework for quality assessment of pharmaceutical 
care in community pharmacies 
Source: Adapted from the figure in an article by Farris KB, Kirking DM. Assessing the quality of 
pharmaceutical care. II. Application of concepts of quality assessment from medical care. Ann Pharmacother. 
1993;27(2):215-23. 
 
3.2. The Model of Systems Engineering Initiative for Patient Safety  
The Systems Engineering Initiative for Patient Safety (SEIPS) model was adopted to study 
pharmacy work systems (Figure 5). According to the SEIPS model, a person (the person 
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•... 
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Outcome 
•PHYSICAL STATUS AND 
FUNCTIONAL ABILITY 
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could be a care provider, another employee of a healthcare institution such as a biomedical 
engineer, a unit clerk, or the patient) performs a range of tasks using various tools and 
technologies. The performance of these tasks occurs within a certain physical environment 
and under specific organizational conditions. The five components of the work system 
(person, tasks, tools and technologies, physical environment, organizational conditions) 
interact with each other and influence each other. Overall, the work system in which care is 
provided affects both the work and clinical processes, which in turn influence the patient, 
employee, and organizational outcomes of care (159). 
 
 
Figure 5. The SEIPS model of work system and patient safety  
Source: Duplicated from Carayon P, Schoofs Hundt A, Karsh BT, Gurses AP, Alvarado CJ, Smith M, et al. 
Work system design for patient safety: the SEIPS model. Qual Saf Health Care. 2006 Dec;15 Suppl 1:i50-8. 
 
The model was used to study how the relationship between the structural components of the 
work system interact to influence the various working system processes and ultimately 
influence the outcomes of the work system. The model SEIPS could offer an improvement 
over the Donabedian's SPO model, which tends to focus only on components, while the 
SEIPS model focuses on the different components of a working system and the interactions 
between the components and how the components can influence the process and outcomes of 
care (159, 160). Table 11 displays elements of the various SEIPS model components. 
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Table 11. Components and elements of the SEIPS model 
 Components Elements (examples) 
Work 
system or 
structure 
Person Education, skill and knowledge 
Motivation and needs
Physical characteristics 
Psychological characteristics 
Organization Teamwork 
Coordination, collaboration and communication 
Organizational culture and patient safety culture 
Work schedules 
Social relationships 
Supervisory and management style 
Performance evaluation, rewards and incentives 
Technologies 
and tools 
Various information technologies: electronic health record, 
computerized provider order entry and bar coding 
medication administration 
Medical devices 
Other technologies and tools 
Human factors characteristics of technologies and tools 
(e.g., usability)  
Tasks Variety of tasks 
Job content, challenge and utilization of skills 
Autonomy, job control and participation 
Job demands (e.g., workload, time pressure, cognitive 
load, need for attention) 
Environment Layout 
Noise 
Lighting 
Temperature, humidity and air quality 
Work station design 
Process Care processes 
and other 
processes 
Care processes 
Other processes: information flow, purchasing, 
maintenance, cleaning 
Process improvement activities
Outcomes Employee and 
or 
organizational 
outcomes 
Job satisfaction and other attitudes  
Job stress and burnout 
Turnover 
Organizational health (e.g. profitability) 
Patient 
outcomes 
Patient safety 
Quality of care 
Source: Carayon P, Schoofs Hundt A, Karsh BT, Gurses AP, Alvarado CJ, Smith M, et al. Work system design 
for patient safety: the SEIPS model. Qual Saf Health Care. 2006 Dec;15 Suppl 1:i50-8. 
 
3.3. Quality of medication review - The model of Martini   
The first time in literature, Martini M. (161) suggested a definition of the quality of 
medication review. The author stated that the quality of MR in a given case depends on (1) 
the accuracy (trueness and precision) of MR, (2) the acceptance and implementation by 
health care providers and the patient, and (3) the benefits on the patient (clinical, economic 
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and humanistic impacts) and the society (economic impacts) (see Figure 6). Medication 
review consists of two main steps: detection of DRPs and proposition of PIs to solve DRPs. 
Therefore, the trueness of MR includes detection of right DRPs (consistency to a reference) 
and a right number of DRPs (exhaustiveness) and proposition of right PIs (trueness) and 
relevant PIs (pertinence) by a pharmacist. The precision of MR is the concordance between 
results of MR conducted by different pharmacists. And the expected MR is the one that has all 
above characteristics.  
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Many 
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Implementation 
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Figure 6. Quality of medication review 
DRP: drug-related problem. PI: pharmacist intervention. Source: Adapted from a figure in a thesis by Martini M. 
La qualité de l'analyse pharmaceutique des traitements médicamenteux au centre hospitalier de Luneville Nancy: 
Université Henri Poincare - Nancy 1; 2010. 
 
3.4. The Economic-Clinical-Humanistic Outcome Model 
The model provided by Kozma et al. (162) describes the proposed relationships of causality 
between the disease, medical interventions (e.g., drug treatment or CPSs) and outcomes 
(Figure 7). The authors argued that the evaluation of outcomes related CPSs should include 
an assessment of Economic, Clinical, and Humanistic Outcomes (ECHO model).  
Clinical outcomes are defined as medical event that occur as a result of disease or medical 
intervention. Economic outcomes are defined as direct, indirect, and intangible costs, 
compared with the consequences of intervention alternatives. Humanistic outcomes are 
defined as the consequences of disease or treatment on patient functional status, or quality of 
life.  
Trueness Precision 
Accuracy Acceptance Benefits 
Expected medication review 
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Many variables exist within each type of outcomes. Some of these variables are intermediate 
outcomes, or intermediaries. For example: 
 A patient's physical and biomedical status are intermediaries of clinical outcomes. 
 Humanistic outcomes have other humanistic intermediaries, such as the patients' 
willingness or ability to pay, patient compliance, patient knowledge, patient 
satisfaction.  
 The economic outcomes have intermediaries introduced from both the clinical and 
humanistic outcomes. The clinical outcomes have intermediaries introduced from the 
direct costs of medical care, including direct medical costs (the cost of laboratory 
testing, emergency department visit and hospitalization, and costs of retreatment from 
product failures) and direct nonmedical costs (costs for transportation to the hospital 
or physician's office). Humanistic outcomes have intermediaries, including indirect 
costs such as time lost from work (163).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The conceptual model: Economic, Clinical, and Humanistic Outcomes (ECHO) 
Model 
Source: Adaption of a figure in an article by Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and 
humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther. 1993;15(6):1121-32. 
 
Kozma et al. also suggest that pharmacists generally influence the outcomes of treatment 
alternatives through the use of external controls and treatment modifiers.  
Clinical Endpoints 
Measurements of a patient's physical 
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degree of disease 
Clinical Outcomes 
Medical events that occur as 
a result of disease or 
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Disease  Humanistic Mediators Effects of disease or treatment 
that affect humanistic outcomes 
Humanistic Outcomes 
Functional status, health 
status, or quality of life 
Interventions 
Alternatives (eg, drug 
treatment or  
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Treatment Modifiers  
Factors that alter outcome 
associated with treatment 
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Economic Outcomes 
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Economic Costs 
Medical, non­medical, and indirect 
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 External controls are defined as non-clinical factors, par example, formulary and 
clinical guidelines, that affect the availability or use of alternative treatment. 
 Treatment modifiers are defined as factors that affect the outcomes associated with 
treatment alternatives, for example, pharmacists affect patient compliance or act of 
prescription by the physician (162).   
 
Medication review is one of CPSs and a pharmacist intervention is an action by a pharmacist 
to change patient management or therapy. Therefore, the ECHO model can be applied for 
each individual PI to evaluate value of a PI. That means that the value of the PI consists of the 
total of value of economic, clinical, humanistic outcomes, compared to the case in absence of 
the PI.    
 
Measures used to evaluate the impacts of CPSs were grouped according to the models of 
Donabedian and Kozma et al. as shown in Table 12 (11). 
Table 12. Measures used to assess the impact of clinical pharmacy services 
Outcomes Clinical outcomes (the end physiologic result of antecedent health care): 
events (emergency room visits, hospitalizations) or cases prevented, 
improvement or resolution of disease, days hospitalized after start of 
medication, length of stay, mortality, morbidity, complications, decrease 
in disease symptoms, adverse drug reactions, absence of disease, 
readmission rates, drug resistance 
Economic outcomes (ratios of cost to some desirable outcome): cost-
effectiveness, cost minimization 
Humanistic outcomes (measures of non-physiologic patient outcomes): 
patient satisfaction, compliance with medication, quality of life 
Intermediaries Clinical intermediaries (risk and effectiveness markers) 
 Risk markers: wheezing, exercise tolerance, forced expiratory 
volume, blood cholesterol, white blood cell count, temperature 
 Effectiveness markers: drug concentration, mean daily dosage 
required for effect, drug interactions 
Cost intermediaries (financial measures of impact): increased revenues, 
costs, charges, wastage, inventory level, expenditures, cost avoidance 
Process intermediaries (processes associated with patient outcomes): 
communication, documentation errors, number of interventions, accepted 
recommendations, prescribing changes, decreased use of targeted drugs, 
adherence to guidelines, prescribing within accepted limits, improved 
record keeping, improved narcotic control, relative use of drugs) 
Source: Adaption from Holdford DA, Smith S. Improving the quality of outcomes research involving 
pharmaceutical services. Am J Health Syst Pharm. 1997;54(12):1434-42. 
3.5. Matrix of evaluation of risk 
According to matrix of risk assessment (164), risks are analyzed by combining severity of 
consequences and their probabilities in the context of existing situation. A risk matrix is used 
predominantly in safety risk management such as National Patient Safety Risk Matrix in UK 
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(164), Safety Assessment Code Matrix in USA (165), Standard for risk management in 
Australia (10). Below is the National Patient Safety Risk Matrix (164), assessing a broad 
range of risks including clinical, financial risks, risk related to reputation, business process, 
and system, etc. 
 Model matrix of the National Patient Safety  
Instructions for use 
 Define the risk(s) explicitly in terms of the adverse consequence(s) that might arise 
from the risk. 
 Use table 1 to determine the consequence score(s) (C) for the potential adverse 
outcome(s) relevant to the risk being evaluated.  
 Use table 2 to determine the likelihood score(s) (L) for those adverse outcomes. 
 Calculate the risk score by multiplying the consequence by the likelihood:  
C (consequence) x L (likelihood) = R (risk score) 
 Identify the level at which the risk will be managed in the organization, assign 
priorities for remedial action, and determine whether risks are to be accepted on the 
basis of the color bandings and risk ratings, and the organization's risk management 
system.  
Table 1. Consequence scores  
Choose the most appropriate domain for the identified risk from the left hand side of the table 
Then work along the columns in same row to assess the severity of the risk on the scale of 1 
to 5 to determine the consequence score, which is the number given at the top of the column.  
 
Consequence score (severity levels) and examples of descriptors  
1  2  3  4  5  
Domains  Negligible  Minor  Moderate  Major  Catastrophic  
Impact on the 
safety of patients, 
staff or public 
(physical/psycholog
ical harm)  
- Minimal injury 
requiring 
no/minimal 
intervention or 
treatment.  
- No time off 
work 
- Minor injury or illness, 
requiring minor 
intervention  
- Requiring time off 
work for >3 days  
- Increase in length of 
hospital stay by 1-3 days  
- Moderate injury  
requiring professional 
intervention  
- Requiring time off 
work for 4-14 days  
- Increase in length of 
hospital stay by 4-15 
days 
- RIDDOR/agency 
reportable incident  
- An event which 
impacts on a small 
number of patients  
- Major injury leading to 
long-term 
incapacity/disability  
- Requiring time off work 
for >14 days  
- Increase in length of 
hospital stay by >15 days  
 
- Mismanagement of 
patient care with long-term 
effects  
- Incident leading  to 
death  
 
- Multiple permanent 
injuries or irreversible 
health effects 
  
 
- An event which 
impacts on a large 
number of patients  
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Quality/complaints
/audit  
Peripheral 
element of 
treatment or 
service 
suboptimal  
 
Informal 
complaint/inquiry  
- Overall treatment or 
service suboptimal  
- Formal complaint 
(stage 1)  
- Local resolution  
- Single failure to meet 
internal standards  
- Minor implications for 
patient safety if 
unresolved  
- Reduced performance 
rating if unresolved  
- Treatment or service 
has significantly reduced 
effectiveness  
- Formal complaint 
(stage 2) complaint  
- Local resolution (with 
potential to go to 
independent review)  
- Repeated failure to 
meet internal standards  
- Major patient safety 
implications if findings 
are not acted on  
- Non-compliance with 
national standards with 
significant risk to patients 
if unresolved  
- Multiple complaints/ 
independent review  
- Low performance rating  
- Critical report  
- Totally unacceptable 
level or quality of 
treatment/service  
- Gross failure of 
patient safety if 
findings not acted on  
- Inquest/ombudsman 
inquiry  
- Gross failure to meet 
national standards  
Human resources/ 
organisational 
development/staffi
ng/ competence  
Short-term low 
staffing level that 
temporarily 
reduces service 
quality (< 1 day)  
- Low staffing level that 
reduces the service 
quality  
- Late delivery of key 
objective/ service due to 
lack of staff  
- Unsafe staffing level or 
competence (>1 day)  
- Low staff morale  
- Poor staff attendance 
for mandatory/key 
training  
- Uncertain delivery of key 
objective/service due to 
lack of staff  
- Unsafe staffing level or 
competence (>5 days)  
- Loss of key staff  
- Very low staff morale  
- No staff attending 
mandatory/ key training  
- Non-delivery of key 
objective/service due 
to lack of staff  
- Ongoing unsafe 
staffing levels or 
competence  
- Loss of several key 
staff  
- No staff attending 
mandatory training 
/key training on an 
ongoing basis  
Statutory duty/ 
inspections  
No or minimal 
impact or breech 
of guidance/ 
statutory duty  
- Breech of statutory 
legislation  
- Reduced performance 
rating if unresolved  
- Single breech in 
statutory duty  
- Challenging external 
recommendations/ 
improvement notice  
- Enforcement action  
- Multiple breeches in 
statutory duty  
- Improvement notices  
- Low performance rating  
- Critical report  
- Multiple breeches in 
statutory duty  
- Prosecution  
- Complete systems 
change required  
- Zero performance 
rating  
- Severely critical 
report  
Adverse publicity/ 
reputation  
Rumours  
Potential for 
public concern  
- Local media coverage –  
short-term reduction in 
public confidence  
- Elements of public 
expectation not being 
met  
Local media coverage – 
long-term reduction in 
public confidence  
National media coverage 
with <3 days service well 
below reasonable public 
expectation  
- National media 
coverage with >3 days 
service well below 
reasonable public 
expectation. MP 
concerned (questions 
in the House)  
- Total loss of public 
confidence  
Business 
objectives/ projects  
Insignificant cost 
increase/ schedule 
slippage  
- <5 per cent over project 
budget  
- Schedule slippage  
- 5–10 per cent over 
project budget  
- Schedule slippage  
- Non-compliance with 
national 10–25 per cent 
over project budget  
- Schedule slippage  
- Key objectives not met  
- Incident leading >25 
per cent over project 
budget  
- Schedule slippage  
- Key objectives not 
met  
Finance including 
claims  
Small loss Risk of 
claim remote  
- Loss of 0.1–0.25 per 
cent of budget  
- Claim less than 
£10,000  
- Loss of 0.25–0.5 per 
cent of budget  
- Claim(s) between 
£10,000 and £100,000  
- Uncertain delivery of key 
objective/Loss of 0.5–1.0 
per cent of budget  
- Claim(s) between 
£100,000 and £1 million 
- Purchasers failing to pay 
on time  
- Non-delivery of key 
objective/ Loss of >1 
per cent of budget  
- Failure to meet 
specification/ slippage  
- Loss of contract / 
payment by results  
- Claim(s) >£1 million  
Service/business 
interruption 
Environmental 
impact  
- Loss/interruption 
of >1 hour  
- Minimal or no 
impact on the 
environment  
- Loss/interruption of >8 
hours 
- Minor impact on 
environment  
- Loss/interruption of >1 
day  
- Moderate impact on 
environment  
- Loss/interruption of >1 
week  
- Major impact on 
environment  
- Permanent loss of 
service or facility  
- Catastrophic impact 
on environment  
Source: National Patient Safety Agency. A risk matrix for risk managers.  London; 2008. 
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Table 2. Likelihood score (L)  
What is the likelihood of the consequence occurring?  
The frequency-based score is appropriate in most circumstances and is easier to identify. It 
should be used whenever it is possible to identify a frequency.  
Likelihood 
score  
1  2  3  4  5  
Descriptor  Rare  Unlikely  Possible  Likely  
Almost 
certain  
Frequency 
How often 
might it/does 
it happen  
This will 
probably 
never 
happen/recur  
Do not 
expect it to 
happen/recur 
but it is
possible it
may do so 
Might 
happen or 
recur 
occasionally 
 
Will probably 
happen/recur
but it is not a 
persisting 
issue 
Will 
undoubtedly 
happen/recur,
possibly 
frequently 
Source: National Patient Safety Agency. A risk matrix for risk managers.  London; 2008. 
 
Table 3. Risk scoring = consequence x likelihood (C x L)  
 Likelihood  
Likelihood 
score  
1  2  3  4  5  
 
Rare  Unlikely  Possible  Likely  
Almost 
certain  
5-Catastrophic  5  10  15  20  25  
4-Major  4  8  12  16  20  
3-Moderate  3  6  9  12  15  
2-Minor  2  4  6  8  10  
1-Negligible  1  2  3  4  5  
Source: National Patient Safety Agency. A risk matrix for risk managers.  London; 2008. 
 
For grading risk, the scores obtained from the risk matrix are assigned grades as follows: 
    1 - 3  Low risk 
    4 - 6 Moderate risk 
    8 - 12 High risk  
    15 - 25 Extreme risk  
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3.6. The model of pharmacoeconomic analysis 
Theory about the model of pharmacoeconomic analysis is so useful to evaluate the value of 
PIs. Firstly, we will introduce about pharmacoeconomics as a method of analysis of value of 
drugs or pharmaceutical services in general. Then, we will demonstrate how this model can be 
applied to evaluate the value of PIs from typical examples of studies in literature.   
3.6.1. Pharmacoeconomics 
Pharmacoeconomics typically is defined as the description and analysis of the costs and 
consequences of drugs or pharmaceutical services, and its impact in individuals, health care 
systems, and society (163).  
The basic model of an economic evaluation includes measurement of both costs and 
consequences (outcomes) of a service and of an alternative for comparison (166). Costs can 
be thought of as “inputs” or resources required to provide the service. In the case of CPSs, 
inputs are primarily comprised of the labor costs associated with the personnel who provide 
the care or services. Outcomes can be thought of as “outputs” of the service or program. 
Outcomes can be in the form of clinical outcomes, humanistic outcomes, or economic 
outcomes. The key element of this model is the inclusion of a comparison or alternative to the 
service in question. An alternative might be, for example, the absence of service (control) 
(166). 
 
 
 
 
 
 
 
Figure 8. Model of pharmacoeconomic analysis 
Source: Schumock GT. Methods to assess the economic outcomes of clinical pharmacy services. 
Pharmacotherapy. 2000;20(10 Pt 2):243S-52S. 
3.6.1.1. Costs 
Cost categories that need to be considered included direct, indirect, and intangible costs 
(Figure 9).   
- Direct costs: Direct costs are the resources consumed in the prevention, detection, or 
treatment of a disease or illness. These costs can be divided into direct medical costs (eg, 
costs associated directly with health care interventions include hospitalizations, drugs, 
laboratory testing, and physician visits) and direct nonmedical costs (resource expenditure 
Inputs 1 
Inputs 2 
Program 1 
Program 2 
Outputs 1 
Outputs 2 
Costs (resources consumed) 
Cost providing service 
- direct 
- indirect 
Units of measurement = currency (e.g., 
dollars) 
Consequences (outcomes)  
 Effect (clinical outcome) 
 Utility (humanistic outcome)  
 Benefit (economic outcome)  
Units of measurement = depends on 
outcome 
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born by patients in seeking care, for example, transportation to and from health settings, 
family care expenses, special diets or clothes).  
- Indirect cost: Indirect costs are those costs that result from morbidity and mortality. These 
costs are related to changes in production capacities that result from disease or health care 
interventions. To estimate indirect costs, two techniques typically used are the human capital 
method, and the "willingness-to-pay" method. Each method attempts to estimate different 
types of costs. The human capital approach attempts to value morbidity and mortality losses 
based on an individual's earning capacity. In the willingness-to-pay approach, patients are 
explicitly asked how much money they would be willing to spend to reduce the likelihood of 
illness. While the willing-to-pay approach incorporates indirect and intangible costs, the 
human capacity approach considers only changes in work loss and productivity due to 
morbidity and mortality.   
- Intangible costs: Intangible costs are probably the most difficult costs to measure. 
Intangible costs are those costs incurred that represent nonfinancial outcomes of disease and 
medical care, and which are not properly expressed in monetary terms. Examples of 
intangible costs include pain, suffering, inconvenience and grief. These costs can either be 
presented as a caveat in the discussion of the result of an economic evaluation or converted 
into a common unit - a quality-adjusted life-year.  
 
Figure 9. Types of costs in pharmacoeconomic analysis 
DC: direct cost 
3.6.1.2. Outcomes 
Outcomes include clinical, economic and humanistic outcomes. How to consider both costs 
and outcomes to evaluate economic value of a service was described in the ECHO model  
(162) and in the next section "Types of pharmacoeconomic evaluation".  
There are two considerations concerning the choice of consequences to evaluate:  
Costs 
Direct costs 
Medical DC 
hospitalizations, 
drugs, laboratory 
testing, and physician 
visits 
Non­medical DC 
transportation to and 
from health settings, 
family care expenses, 
special diets or clothes 
Indirect costs 
missing working, lost 
productivity, 
premature death 
Intangible costs 
costs include pain, 
suffering, 
inconvenience and 
grief 
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- Positive versus negative outcomes: A comprehensive assessment of benefits of drug 
therapy will address both positive and negative effects of competing alternatives. Positive 
consequences may translate into life-years gained, improved functional status and well-being. 
Negative consequences can include harmful effects, drug toxicity, or even death.  
- Intermediate versus final outcomes: Intermediate consequences are commonly used in 
clinical trials to demonstrate clinical efficacy of drug therapy because of cost and time 
savings, practicality (167). For example, a decrease in low-density lipoprotein cholesterol 
levels serves as an intermediate outcome for more relevant final outcomes, expressed as a 
decrease in myocardial infarction rate and an increase in lives saved. But the challenges lies in 
finding intermediate outcome indicators that can reliably predict long-term effects.  
3.6.1.3. Perspectives  
Perspective refers to the point of view from which the economic is performed. These 
perspectives will influence the costs and consequences identified and measured. An economic 
evaluation can be conducted from a single perspective, or multiple perspectives. Common 
perspectives include those of the patient, provider, payer, and society (163).  
- Patient perspective: Costs from the perspective of patients are essentially what they pay for 
a product or service, that is, the portion not covered by insurance.  
- Provider perspective: Costs from the provider's perspective are the true expense of 
providing a product or service, regardless of the charge. Charge data may be more readily 
available, but are usually not reflective of the true costs of health care. Providers can be 
hospitals, health care organization, or private physicians.  
- Payer perspective: Payers include insurance companies, the government, or employers. The 
costs to the payer are those charges for health care products and services allowed, or 
reimbursed, by the payer.  
- Societal perspective: This perspective is the broadest of all perspectives because it is the 
only one that considers the benefit to society as a whole. In general, all direct and indirect 
costs are included in an economic evaluation performed from a societal perspective(163).  
The perspective of most of the study was unclear. It was obvious in many studies that the 
payer was the primary focus, because cost savings were a common measure of outcome. 
However, it was unclear whether the payer was the institution, the insurer or the patient (11). 
Because of differences in the healthcare systems of each country, the payer varied between 
studies. Hence, the differing health-care systems lake it unfeasible to compare the studies 
(168).  
3.6.1.4. Types of pharmacoeconomic evaluation 
There are several types of pharmacoeconomic analysis. Based on the elements of the model 
that are incorporated into an evaluation, analyses of CPSs can be characterized as shown in 
Table 13 (169).  
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Table 13. Types of pharmacoeconomic evaluation 
 Were both cost and outcomes considered? 
No Yes 
Were two or 
more 
alternatives 
considered? 
No Cost description or 
outcome description 
Cost and outcome description 
Yes Cost analysis or 
outcome analysis 
True clinical economic analysis 
Cost-minimization analysis (CMA) 
Cost-benefit analysis (CBA) 
Cost-effectiveness analysis (CEA) 
Cost-utility analysis (CUA) 
Source: Drummond M, Stoddart G, Torrance G, editors. Methods for the economic evaluation of health care 
programmes. Oxford, UK: Oxford Medical Publications; 1997. 
 
The four most commonly used analysis methods (CMA, CBA, CEA, CUA) are shown in 
Table 14. For all four types, costs are measured in currency (e.g., dollars). The unit of 
measure of the consequences differentiates each type of analysis, and each analysis serves a 
different purpose. 
Table 14. Comparison of types of pharmacoeconomic analysis 
Method Unit of 
measure of 
costs 
Unit of measure of 
consequences 
Use 
Cost-
minimization 
analysis 
Currency  
(e.g., dollars) 
None, assumed equivalent Compare efficiency of 
alternatives 
Cost-
effectiveness 
analysis 
Currency  
(e.g., dollars) 
Natural units (e.g., lives 
saved) 
Least costly way to 
achieve clinical objective 
Cost-utility 
analysis 
Currency  
(e.g., dollars) 
Natural units adjusted for 
quality Least costly way to 
achieve quality of life (e.g. 
QALYs gained) 
Least costly way to 
achieve quality of life 
Cost-benefit 
analysis 
Currency  
(e.g., dollars) 
Currency (e.g., dollars) Best investment 
QALYs: Quality-adjusted life years. Source: Drummond M, Stoddart G, Torrance G, editors. Methods for the 
economic evaluation of health care programmes. Oxford, UK: Oxford Medical Publications; 1997. 
3.6.1.5. Strategies of pharmacoeconomic evaluation 
As a practical approach to documenting the value of, and gaining approval for, CPS, three 
methodological strategies can be considered: literature generalization, modeling, and local 
assessment (166).  
- Literature generalization: Literature generalization is the application of data from 
published studies of services or practice sites similar to one’s own environment. For example, 
a pharmacy department in a community hospital proposed and gained approval for 
implementation of CPS as a cost savings measure  (170). Published articles that described 
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CPSs in community hospitals were reviewed to identify those that described patient mix, drug 
utilization patterns, and types of services similar to those proposed. Drug cost savings or cost 
avoided, and the number of clinical pharmacists man-hours associated with those costs were 
abstracted from each article. By combining the results of applicable articles, the authors 
estimated that implementing CPS would require 3.5 full-time equivalents in clinical 
pharmacists and would save about $500,000 (gross) in drug expenses in their hospital. Costs 
were determined based on the average pharmacist salary. Net benefits were projected to 
exceed $250,000 with a B:C ratio of > 2:1.  
- Economic modeling: Economic modeling may also use previously published literature 
and/or may use locally collected data, and more effectively defines costs and consequences by 
use of a decision analysis model. For example, a study (171) compared outcomes of patients 
who received consultant pharmacist services versus those who did not. Probabilities for each 
outcome were determined by an expert panel. The cost to provide the service, based on 
pharmacist time, was estimated to be $10 per encounter. The authors determined that for each 
optimal outcome achieved with a consultant pharmacist, $1,034 was saved by prevention of 
costly DRPs. The B:C ratio for this service based on the data provided was approximately 
12:1. 
- Local evaluation: The last strategy is to measure and analyze the actual costs and 
consequences of existing CPS in one’s own local practice site. In a recent article, Lai 
evaluated CPS provided in an ambulatory practice site (172). The implemented CPS provided 
intensive monitoring and intervention on DRPs for Medicaid patients at an ambulatory clinic. 
The goal was to determine the ability of the CPS to reduce health care utilization and 
associated expenses by comparing outcomes with a control group that did not receive the 
monitoring. The costs to provide the service for 1 year were $84,363 and primarily 
represented personnel costs. Overall health utilization was reduced by $173,651 in the 
intervention group. The B:C ratio was just over 2:1.  
3.6.2. Economic studies of pharmacist interventions  
3.6.2.1. Key methodological issues 
The intervention process begins with the detection and recognition of a DRP by the 
pharmacist, followed by a recommendation for the resolution of the problem. In considering 
the value of the intervention process, a number of issues raised at each step of the process (see 
Figure 1), including: 
 Three scenarios may occur when a DRP is present:  
 The DRP is not identified by the pharmacist nor anyone else involved in 
managing the patient. 
 The DRP is not identified by the pharmacist but is identified and addressed by 
another person involved in managing the patient  
 The DRP is identified and addressed by the pharmacist.  
 Multiple consequences are possible for each situation. However, most previous studies 
have asked experts to predict only the most likely consequence of the PI.   
 Each consequence may have a different probability of occurring.
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 The value of a PI depends on both probability and severity of consequences without 
and with a PI.  
 The value cannot be attributed to the pharmacist if someone else carries out the 
intervention. 
 Compliance with the recommendation by the physician and/or the patient will affect 
actual but not potential value of the intervention. 
 To gain more confidence in the robustness of the estimate, it is prudent to use 
uncertainty analysis.  
 Consider utilizing actual economic costs where possible, rather than charges or 
government-established fees.  
 Develop a common framework for resource costs, as recommended by Schulman et al. 
(173) that will facilitate cost comparisons across healthcare systems and countries.  
 The generalizability of economic evaluations to other countries is questionable 
because of unique national data collection systems and disparities between different 
healthcare systems. 
 Develop an instrument to promote standardized economic data collection in 
pharmaceutical care research.    
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Figure 10. Issues to be considered in determining value of the intervention process 
Source: Peterson G et al. PROMISe Intervention Study - Final report to the Pharmacy Guild of Australia. 2003. 
Available from: http://goo.gl/hUI1Mi. 
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3.6.2.2. Economic model for estimation of the value of a pharmacist Intervention 
Applying the basic model of pharmacoeconomic analysis to evaluate the value of each PI, the 
value of a PI is the sum of the savings of inputs and the added outputs of the recommended 
drug therapy (with a PI) compared to the original drug therapy (without a PI) (see Formula 1 
in Figure 11).  
In most studies (38, 44, 174-178), the economic value of a PI is estimated through cost 
savings plus cost avoidance less cost of implementation of a PI (Formula 2).  The difference 
between the cost of the original therapy and the new therapy gives the cost savings (or the 
increase in the cost of therapy). Cost avoidance refers to the prevention of additional health 
resources which are required to treat drug adverse events if a pharmacist has not intervened 
such as a hospitalization or a medical visit. Cost of implementation of a PI refers to the 
expenses of providing the PI such as cost of pharmacist’s time, phone calls. These value 
estimations made were limited to the medical direct costs, and did not include the non-
medical direct costs, the indirect (lost productivity) and intangible costs (quality of life). 
Overall, the indirect costs exceed the direct costs(168). Therefore, these value estimations will 
underestimate the value of PIs.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Economic model for estimation of the value of a PI 
 
Inputs 1 
Inputs 2 
Original drug therapy  
(without a PI) 
Recommended drug therapy 
(with a PI) 
Outputs 
1 
Outputs 
2 
Costs (resources consumed) 
* Medical direct costs 
 Drug 
 Drug therapy monitoring  
...  
 Pharmacist’s time 
 Phone 
 … 
Consequences 
(Outcomes)  
 Clinical 
outcomes  
 Humanistic 
outcomes 
 Economic 
outcomes 
Value of a PI = ([Inputs 1] – [Inputs 2]) + ([Outputs 2] – [Outputs 1])    (Formula 1) 
Cost of the 
implement of 
a PI 
Cost 
savings 
* Medical direct costs  
Cost avoidance 
* Non-medical direct costs 
* Indirect costs 
* Intangible costs 
Economic value of a PI = cost savings + cost avoidance related to adverse drug 
events – cost of the implement of a PI                                  (Formula 2 
Where 
Cost savings = cost of recommended drug therapy less cost of previous drug therapy 
Cost avoidance = cost of health care resources needed to treat harm which a PI 
prevented or cause 
Cost of the implement of a PI = cost of pharmacist’s time + cost of phone... calls… 
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3.6.2.3. Methods for estimation of cost of implementation of pharmacist interventions 
It is difficult to estimate the cost of implementation of each PI. Clinical activities of 
pharmacists included professional communication, medication chart review, medication 
history interview, clinical review, providing information to patients/caregivers, ascertaining 
discharge drugs required, and obtaining drug information, etc. (179). A PI is often a result of 
complex multi-activities. Therefore, attribution of time that a pharmacist spent to propose a PI 
was not clear. Costs for training and mentoring pharmacists should be considered also(175).  
Most studies include the cost of the intervention, based on the time required to propose the IP 
and labor costs (salaries plus benefits of the pharmacists) (175, 180). Working time spent on 
this activity is variable depending on the study. The mean time spent on an intervention was 
7.0-9.6 minutes (52, 123, 124). Nerich et al. found that one minute was sufficient for 
prescription without IP against 8.7 to 14.7 minutes for a prescription with IP (181). In France, 
the same activity would take between 1 and 5 minutes (182). On this basis, Rose et al. 
estimated 5 minutes as time spent on each PI related to IV/PO change (183). 
Some authors considered the total time spent in prescription analysis and not only one 
dedicated to the realization of a single PI (52, 184, 185). Finally, in some studies, the time 
spent by pharmacists in health care services (participation in medical rounds) was also 
recorded in the cost involved (184, 186). Other costs of implementation of PIs included the 
cost of the equipment used to record PIs (175), expert panel's time for assessment (185), 
phone call (178) or materials necessary to provide PIs (176).    
Development of an instrument to promote standardized economic collection is useful. In the 
IMPROVE study - a multicenter randomized pharmaceutical care study of patients at high 
risk for DRPs, cost of clinical PIs was based on standard costs assigned by the decision 
support system that accounted for time and intensity of intervention (low, medium or high) 
(187).   
3.6.2.4. Methods for estimation of cost savings related to pharmacist interventions 
The difference between the cost of the original therapy and the new therapy recommended by 
a PI gives the cost savings (or the increase in the cost of therapy). For example, in the case of 
conversion from IV to oral dosage forms, drug discontinuation, the IP gives the cost savings 
while the PI as indication of additional drugs, switch to more expensive drugs increase the 
cost of therapy.  
Methods for estimation of cost savings related to the PI varied across studies (180). However, 
a common major component contributed to cost savings in all studies was drug cost. In some 
studies (184, 188), other components were taken into consideration such as cost savings on 
medical devices and working time of nurses for preparation and administration of drug 
prescribed. Indeed, in the case of an injectable treatment, some solutions or medical devices 
must be used (e.g., catheter, syringe, needle) for reconstitution, dilution and administration. 
All these steps require additional work to the nurse, which has a cost.  
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Cost savings can be also calculated relative to a more cost-effective method for drug therapy 
monitoring, e.g., use of appropriate monitoring variables, cancellation of unnecessary 
laboratory orders, and identification of therapeutic agents requiring fewer monitoring and/or 
fewer costly laboratory tests (14, 189). 
The formula of cost saving is as follows:  
 
 
Methods used to determine the number days affected by the PI differ across studies, including 
the whole rest of hospitalization length (175), the number of anticipated treatment (136, 175), 
a mean estimated by an expert panel (with a minimum and maximum)(190), or a fixed 
number of days (for example, 1.5 days (175) or 2 days (191) for witch IV/PO). Rose et al. 
used many hypotheses: the first one was the PI affects only 1 day, the second was the half of a 
rest of hospital stay and the final was the whole rest of hospital stay (192). Lee at al. also 
provided guidelines for determining duration of therapy when calculating cost of original and 
recommended therapy (136).     
3.6.2.5. Methods for estimation of cost avoidance related to pharmacist interventions 
Cost avoidance refers to the prevention of additional health resources which are required to 
treat ADEs if a pharmacist has not intervened such as a hospitalization or a medical visit. 
These methods are similar to the conceptual model for estimation of the cost-of-illness of 
drug-related morbidity (168, 193). In contrary, harm could have resulted from the PI if the PI 
was not appropriate, and in these cases, the PI could induce costs (136).  
 
Many methods for estimation of cost avoidance were available. For example, cost avoidance 
focused on: 
 only avoided LOS in the study of Bayliff et al. (194);  
 avoided primary care visit and avoided LOS in the study of Westerlund et al. (195),  
 probability of an ADE in the study of Nesbit et al. (175) 
 both probability of ADEs prevented and different levels of care avoided in the study of 
Rupp et al. (196) and in the study of Lee et al. (136) 
 probability of change in readmission and LOS with and without the PI in the study of 
Dooley et al. (52) 
 difference in probability of different consequences before and after the PI and 
attribution the PI to the pharmacist in the study of Stafford et al. (154) and Peterson et 
al. (178)  
Economic methodologies for estimation of the value of PIs were summarized in Table 15. 
Some studies estimated partly either cost savings, cost avoidance, or cost of implementation 
of PIs while others considered all. However, overall, the value of the PI considered only 
medical direct costs and did not consider non-medical direct, indirect and intangible costs 
which were difficult to estimate.  
Table 15. Economic methodologies for estimation of the value of PIs 
[cost saving] = [cost of the previous drug therapy] - [cost of the recommended drug therapy] 
= [daily cost saving] X [number of days of modified treatment] 
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A. Only cost avoidance 
2. Bayliff (1990) (194) - Hospital  
a. The objective of the study was: to assess the impact of PIs by physicians. 
b. Value of PI: 
[Cost avoidance] = [number of days of hospitalization avoided] x [cost per day] 
c. The result was expressed as: 
- The number of PIs judged to have a prolonged hospital stay 
- The mean days of hospitalization avoided per intervention 
- The total cost avoidance   
2. Rupp (1992) (196) - Community pharmacy 
a. The objective of the study was: to estimate the impact on patient health status of the 
PIs. 
b. Value of PI:  
[Expected medical cost avoidance] = [Probability of the most likely harmful outcome 
would have occurred] x [cost of medical care associate with that outcome] 
 Probability: 0 (zero), 0.1 (very unlikely), 0.3 (somewhat unlikely), 0.5 (neither 
likely nor unlikely), 0.7 (somewhat likely), 0.9 (very likely) or 1.0 
 Medical care: emergency medical attention with hospitalization ($2001), emergency 
medical attention without hospitalization ($110), unscheduled physician contact 
($60), scheduled physician contact ($40), or self-care ($0). 
c. The result was expressed as: 
- % PIs where was a potential for harm, had the pharmacist not intervened. 
- % PIs prevented different medical care 
- The expected medical cost avoidance per intervention 
B. Cost avoidance and cost of implementation 
5. Westerlund (2005) (195) - Community pharmacy 
a. The objective of the study: to assess the clinical and economic outcomes of community 
pharmacy interventions in patient DRPs. 
b. Value of PI:  
Ratio = [cost avoidance]/[cost of implementation]  
 [Cost avoidance] = [cost of avoided primary care visit] OR [number of avoided 
hospitalization days] x [cost per day] 
 Cost of implementation of PIs = personal cost (salaries of pharmacists) 
c. The result was expressed as: 
- The total cost avoidance  
- The total cost implementation 
- The ratio between the total cost avoidance and the cost of implementation of PIs 
C. Studies estimated both cost savings and cost avoidance 
5. Dooley 2003 (52) - Hospital  
a. The objective of the study was: to determine the financial value of pharmacist initiated 
changes to hospitalized patients' drug therapy at hospitals 
b. Value of PI: 
[Financial value] = [cost avoidance of readmission] + [cost avoidance of LOS] + [cost 
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savings of medical procedures or laboratory monitoring] + [cost savings of drug therapy] 
 [Cost avoidance of readmission] = ([Probability of readmission without the PI] - 
[Probability of readmission with the PI]) x [cost per relevant Diagnostic-Related 
Group] 
 [Cost avoidance of LOS] = [Probability of change in LOS] x ([LOS without the PI] 
- [LOS with the PI]) x [cost per day] 
 [Cost savings of medical procedures  or laboratory monitoring] = [Probability of 
change in medical procedures or laboratory monitoring] x [local costs of that 
procedure or laboratory test] 
 [Cost savings of drug therapy] = [cost of previous drug therapy] - [cost of 
recommended drug therapy]  
c. The result was expressed as: 
- The value by type of PIs 
- The annual value  
D. Studies estimated cost savings, cost avoidance and cost of implementation of  a PI 
1. Hatoum (1988) (14) - Hospital  
a. The objective of the study was: to evaluate value of PIs in a hospital 
b. Value of PI:  
V = D + M + U + L - C 
In this formula, it is possible for any one the four variables to be positive, negative, or zero.  
 V: [Value] 
 D: [Cost saving of drug therapy]: e.g., use of less expensive drugs, discontinuance 
of a drug, conversion to a less expensive drugs (including change of dose, dose 
interval, route, duration, or form of medication).  
 M: [Cost savings of drug therapy monitoring]: e.g., use of appropriate monitoring 
variables, cancellation of unnecessary laboratory orders, and identification of 
therapeutic agents requiring fewer monitoring and/or fewer costly laboratory tests. 
 U: [Cost avoidance of complications of drug therapy]: e.g., costs related to the 
detection and management of such untoward effects as toxic side effects, adverse 
drug reactions, and therapeutic failures.  
 L: [Cost avoidance related to LOS]: e.g., more effective drug therapy resulting in 
improved therapy and more efficient management of patient care, thus reducing the 
length of stay and/or avoiding predictable complications that might increase the 
hospital stay (e.g.;, preventing an allergic reaction in a patient for whom a known 
allergy is documented).  
 C: [Cost of CPSs] = [personnel cost (salaries)] + [indirect personnel cost (fringe and 
other employer-paid benefits)].   
c. The result was expressed as: 
- the average value for interventions implemented 
- the average value for interventions not implemented 
- the annual realized value for intervention implemented  
- the annual potential value for interventions not implemented 
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3. Lee (2002) (136) - Hospital  
a. The objective of the study was:  
To estimate the level of benefit or harm that would have occurred with and without PIs, as 
well as the economic and clinical consequences. 
b. Value of PI: 
[Value] = [cost savings] + [cost avoidance]  
 [Cost savings] = [cost of the original therapy] - [cost of recommended therapy]  
 [Cost of original therapy] = [daily drug acquisition cost] x [duration of 
therapy] + [labor cost for filling and processing order by pharmacist] 
 [Cost of the recommended therapy] = [drug acquisition cost] x [duration of 
therapy] + [labor cost] + [average cost of making recommendation] 
 [Cost avoidance] = [probability of harm which a PI prevented or caused] x [cost of 
care] 
 [Probability of harm]: estimated by a scale from 0 to 1.0 
 Type of health care resources need to treat the harmful event: included 
medication, laboratory and diagnostic procedures, clinical visits, telephone 
care, emergency-room visits, self-care and hospitalization 
- If hospitalization, [Cost of care] = [number of hospital days] x 
[International Classification of Disease-specific bed-cost per day] 
- If other, [Cost of care] = [local cost]  
c. The result was expressed as: 
- The average probability of harm prevented or caused 
- The mean cost savings per recommendation  
- The minimum, maximum and mean cost avoidance per recommendation 
- The total minimum, maximum and mean cost avoidance  
* [Cost of implementation of the PI] was integrated into [the cost of the recommended 
therapy]  
4. Nesbit (2001) (175) - Hospital 
a. The objective of the study was: to estimate the value of the CSP practice model to the 
institution.  
b. Value of PI:  
[Net economic value] = [cost savings] + [cost avoidance related to averted ADEs] - [the 
costs of the CSP model]  
 [Cost savings] = [cost of the previous drug therapy] - [cost of the recommended 
drug therapy] 
 [Cost avoidance] = [Probability of  an ADE in absence of intervention] x [Average 
cost of an ADE] 
 [Probability of an ADE]: 0 (zero), 0.01 (very low), 0.1 (low), 0.4 (medium) 
or 0.6 (high) 
 [Average cost of an ADE] = $5,006 
 [Costs of the CSP model] = [personnel cost (salaries + benefits of pharmacists)] + 
[equipment used to record PIs]  
c. The result was expressed as:  
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- Cost avoidance, cost savings per intervention, per intervention type per 12 months 
- Net economic value to institution 
5. Stafford (2011) 
a. The objective of the study was:  
To develop a methodological framework for estimating health resource savings and quality 
of life effects resulting from PIs by community pharmacists 
b. Value of PI:  
Value of PI attributed to the pharmacist = [value] x [% attribution to the pharmacist]  
 Value = [difference in probability of Severe consequence A] x [parameters 
describing Severe consequence A] + [difference in probability of Moderate 
consequence A] x [parameters describing Moderate consequence A] + [difference in 
probability of Mild consequence A] x [parameters describing Mild consequence A] 
+...[difference in probability of Severe, Moderate & Mild consequence B, C, D etc.] 
x [parameters describing Severe, Moderate & Mild consequence B, C, D etc.]  
 [Difference in probability of Severe Consequence A] = [Probability of 
Severe consequence A before PI] - [Probability of Severe consequence A 
after PI]  
 [Difference in probability of Moderate Consequence A] = [Probability of 
Moderate consequence A before PI] - [Probability of Moderate consequence 
A after PI]  
 [Difference in probability of Mild Consequence A] = [Probability of Mild 
consequence A before PI] - [Probability of Mild consequence A after PI]  
 ... 
 [% Attribution to the pharmacist] = 1 - [likelihood of someone other than the 
pharmacist performing the PI] 
* Consequences: such as hospitalization admission, emergency department visits, 
ambulance/patient transport costs, general practitioner or specialist consultations, allied 
health professional consultations, medications commenced and ceased, and 
pathology/laboratory investigation.  
PI: pharmacist intervention. DRP: drug-related problem. LOS: length of stay. CPS: clinical pharmacy service. 
ADE: adverse drug event  
3.7. The integrated model for evaluation of impacts of PIs 
We synthetized five models: the SPO model, the ECHO model, the SEIPS model, the model of 
Martini, the economic model, and the risk assessment matrix into an integrated model for 
evaluation of impacts of PIs, named the SP(ECH)O-P ( 
Figure 12).  
According to the SP(ECH)O-P model, the PI can have impacts on structure, process of care 
and outcomes on the patient (similar to the SPO model). The outcomes can include economic, 
clinical, and humanistic outcomes (similar to the ECHO model). Not all impacts of the PI is 
obvious and certain but a potential to occur (probability). Therefore, it should combine 
probability of each impact and severity/importance of each impact into risk matrix (similar to 
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the risk matrix). The value of each PI is the sum of differences of value of the scenario with 
and without the PI (similar to the economic model).        
 
Figure 12. The SP(ECH)O-P integrated model for evaluation of impacts of PIs 
IT: information techonolgy. DRP: drug-related problem. PI: pharmacist intervention. CMA: cost-minimization 
analysis. CBA: cost-benefit analysis. CEA: cost-effectiveness analysis. CUA: cost-utility analysis 
In conclusion, understanding of theoretical models or conceptual frameworks that can be 
applied to assess impacts of MR/PIs helps pharmacists and researchers to have a broad 
picture of possible impacts of MR. Firstly, the Structure-Process-Outcome model emphasizes 
that the quality of health care interventions depends on structure, process and outcomes-
related indicators. The model of Martini evaluates specifically the quality of MR based on 
quality of detection of DRPs and proposition of PIs; and from perspectives of intervening 
pharmacists, other pharmacists, the physician, the patient and society. Meanwhile, the 
Systems Engineering Initiative for Patient Safety (SEIPS) model considers MR as "pharmacy 
work systems" with the various components (five components of the work system: person, 
tasks, tools and technologies, physical environment, organizational conditions; process and 
outcomes) and their interactions. Next, the ECHO model described in detail three type 
outcomes (economic, clinical and humanistic outcomes) and their relationships while the risk 
assessment matrix considers probability of impacts into risk classification. Then, the 
pharmacoeconomic model is applied to estimate exactly the economic value of a pharmacist 
intervention. Finally, we tried to summarize the five models into an integrated model, named 
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SP(ECH)O-P which requires to consider impacts of PIs on indicators related to Structure, 
Process, Economic, Clinical, and Humanistic Outcomes and Probabilities of their impacts. 
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SYSTEMATIC REVIEW OF TOOLS FOR 
ASSESSMENT OF POTENTIAL SIGNIFICANCE OF 
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In this Part 2, we will present a systematic review of tools for assessing potential significance 
of PIs. Then, some important tools will be introduced more in details.    
1. A systematic review of tools for assessing potential 
significance of pharmacist interventions  
Assessment of potential significance of PIs are common in literature by using various 
methods and tools. However, few information on summarization and discussion of these tools 
has been found. The only literature review of tools of rating of pharmacist interventions was 
reported in 1999 by Overhage et al. (12). The paper noted that among 51 identified articles, 
only 10 included an explicit description of the rating tool used. However, to our knowledge, 
there is no other up-to-date literature review on this topic. Recently, a systematic review of 
tools for measuring the severity of prescribing errors was reported in 2013 by Garfield et al. 
(197). Forty tools were identified that assessed severity, only two of which had acceptable 
reliability and validity. Tools for measuring errors may be used to evaluate the effectiveness 
of interventions designed to reduce them. However, in general, tools for assessing potential 
impacts of PIs have specific properties. Furthermore, since then, with economic constraints 
growing, aging, burden of chronic disease, patient’s lack of compliance, the assessment of 
quality of PIs is shifting from only clinical to economic and humanistic impacts (e.g., 
patient’s quality of life, compliance, and satisfaction)(11). Therefore, the purpose of this
systematic review is to update available tools for assessment of potential significance of a PI 
and to propose the pragmatic, psychometric and theoretical properties of ideal tools.  
We searched English and French-language publications (from 1986 to 2013) were conducted 
in PubMed, PsycINFO, PASCAL, and CINAHL. Of 873 citations screened, 82 distinct tools 
were identified from 133 studies. While clinical aspect was often defined quite clearly, 
terminology of humanistic and economic, and process-related aspects of PIs was often 
omitted, incomplete or ambiguous in most tools. Few tools measured simultaneously 
economic, clinical, humanistic, and process-related variables. Of 133 identified studies, there 
was limited evidence for the validity (8/133, 6.0%), inter-rater reliability (49/133, 36.8%), 
and intra-rater reliability (2/133, 1.5%).  
Currently, there are no formal guidelines or any standardization of methodology concerning 
methods of assessment of the potential significance of PIs. Researchers and clinicians may 
have different needs in relation to a tool for assessing the potential significance of PIs. 
However, in general, an ideal tool should be specific to PIs' potential significance, relatively 
easy and not too time consuming to use, reliable, and validated in different healthcare 
systems. Taking into account the results of this review, we suggest some desirable pragmatic, 
psychometric and theoretical properties of idea tools for assessing of potential significance of 
PIs. Furthermore, due to the wide range of tools used in the literature, this review article is 
useful for researchers who want compare tools to assist in comparing findings across studies 
or to develop a new tools for local use.  
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Abstract 
 
Introduction 
Assessment of significance of pharmacist interventions (PIs) is essential to demonstrate added 
value of pharmacists. Methods and tools assessing potential significance of PIs are diverse 
and their properties are questionable.  
Objectives 
We aimed to review systematically on tools for assessing potential significance of PIs. 
Methods 
Systematic searches for English and French-language publications (from 1986 to 2013) were 
conducted in PubMed, PsycINFO, PASCAL, and CINAHL. Studies were screened by two 
independent reviewers based on inclusion/exclusion criteria and were abstracted for content, 
structure of tools and validation process.  
Results 
Of 873 citations screened, 82 distinct tools were identified from 133 studies. While clinical 
aspect was often defined quite clearly, terminology of humanistic and economic, and process-
related aspects of PIs was often omitted, incomplete or ambiguous in most tools. Probabilities 
of consequences of PIs/drug-related problems were evaluated in 20/82 tools. Few tools 
measured simultaneously economic, clinical, humanistic, and process-related variables. Tools' 
structure varied from an implicit, mono-dimension tool to an explicit, multi-dimensional 
algorithm. Validation processes were diverse in term of quantification and number of raters, 
rating method, and psychometric parameters. Of 133 identified studies, there was limited 
evidence for the validity (8/133, 6.0%), inter-rater reliability (49/133, 36.8%), and intra-rater 
reliability (2/133, 1.5%).   
Conclusions 
The majority of tools focused primarily on assessing clinical aspect and failed to detect 
comprehensive impacts. Heterogeneity of tools and assessment process hindered our ability to 
synthetize the results of evaluations. Limited results for their validity and reliability 
questioned credibility of this methodology for justification of value of PIs. Recommendations 
for development of tools with optimal theoretical, pragmatic and psychometric properties are 
proposed.  
Key messages 
- The role of pharmacists should be to determine the value of PIs and target PIs which have 
most value.  
- The majority of tools for assessing potential significance of PIs were used in literature. 
However, an optimal tool has not found.  
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- Recommendations for development of new tools with optimal theoretical, pragmatic and 
psychometric properties are proposed.  
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1. INTRODUCTION 
Adverse drug events (ADEs) are one of the major problems relating to patient safety. 
They are associated with increased morbidity and mortality, prolonged hospitalizations, and 
higher costs of care [1, 2]. The ADEs are considered preventable in nearly half of the cases 
[1]. Therefore, detection, resolution and prevention of actual or potential drug-related 
problems (DRPs) through pharmacist interventions (PIs) are considered as a key strategy to 
reduce ADEs [1]. In this article, a DRP is commonly defined as “an event or circumstance 
involving drug treatment that actually or potentially interferes with the patient experiencing 
an optimum outcome of medical care” [2], and PIs as “discrete activities by pharmacists 
related to patient care” [3]. 
Assessment of significance of a PI is now recognized as essential for demonstrating the 
added value of pharmacists to the healthcare system and justification for obtaining additional 
resources in clinical pharmacy practice. This assessment is also used as indicators of 
pharmacist’s performance and the continuing quality improvement, research and education 
[1].  
Through studies in the literature, it is possible to classify the approaches of assessing the 
significance of an individual PI into 3 main types: Approach 1 - the evaluation of actual 
consequences of DRPs (e.g., actual severity of harm); Approach 2 - the evaluation of actual 
consequences after performing a PI and following-up the patient (e.g., actual clinical 
outcomes); or Approach 3 - the estimation of potential significance of a PI (Fig.1). Term 
“actual” is understood as meaning the entity that has appeared in the patient, while the term 
“potential” referred to the situation in which the possibility that the entity could appear in the 
patient existed [4].   
 
 
 
 
 
 
 
 
Fig.1 Different approaches to evaluate the significance of a pharmacist intervention.  
DRP: drug-related problem. PI: pharmacist intervention 
According to the approach 1, the earlier the pharmacist intervenes to prevent harm to the 
patient, the more significant a PI is likely to be. In fact, harm due to DRPs in the patient rarely 
occurs. For example, Vessal et al. found that about 90% of the prescription errors resulted in 
no harm in patients because a great majority of errors were corrected early by pharmacists [5]. 
Two limitations of this approach are to offer little guidance for improving quality of a PI in 
Inputs 
1 
Inputs 
2 
Original drug therapy  
(without a PI) 
Recommended drug 
therapy (with a PI) 
Outputs 
1 
Outputs 
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Actual consequences of a DRP 
(Approach 1) 
Potential consequences of a DRP 
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Actual consequences of a PI 
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Potential consequences of a PI 
(Approach 3B) 
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the future and reflect the quality of the whole system of patient care rather than the only 
contribution of a PI [6]. 
According to the approach 2, the assessment of actual consequences, commonly clinical 
outcomes, in the patient after performing a PI and following-up the patient is the only valid 
indicators of the quality of a PI. It is helpful to assist in decision making on a daily basis for 
physicians and pharmacists [1]. However, the assessment of actual clinical outcome in the 
patient is associated with some main difficulties: criteria/technology of follow-up, timeframe, 
determination of causal relationships between PIs and health outcomes [7-10]. 
According to the approach 3, the assessment of potential significance of PIs may be done 
through two sub-types: approach 3A – prediction of the potential consequences of DRPs in 
absence of a PI; approach 3B - prediction of the potential consequences of an implemented PI 
[11, 12]. The assessment of the potential significance of a PI is associated with metrological 
problems such as subjectivity, validity and reliability of predictions. However, this method is 
frequently used as a means of commenting in the significance and quality of a PI because of 
its practicability when the lack of data of evaluation of actual consequences, its usefulness in 
guidance for improving quality of a PI (e.g., hierarchy of potential significance of a PI and 
target the most potential significant PIs). Therefore, the review in this article only synthetized 
the tools for assessment of potential significance of PIs – Approach 3. 
Methods and tools assessing the significance of PIs are diverse and their pragmatic, 
psychometric and theoretical properties are questionable. The only literature review of tools 
of rating of pharmacist interventions was reported in 1999 by Overhage et al. [12]. The paper 
noted that among 51 identified articles, only 10 included an explicit description of the rating 
tool used. Thus, the authors developed a two-dimensional tool that could characterize a 
hospital pharmacist’s recommendations based on the severity of the DRP and the value of that 
intervention. A broad adoption of this validated tool has been used for characterizing clinical 
activities in different settings. However, to our knowledge, there is no other up-to-date 
literature review. Furthermore, since then, with economic constraints growing, aging, burden 
of chronic disease, patient’s lack of compliance, the assessment of quality of PIs is shifting 
from only clinical to economic and humanistic impacts (e.g., patient’s quality of life, 
compliance, and satisfaction) [13]. Therefore, the purpose of this systematic review is to 
summarize available tools for assessment of potential significance of a PI and to propose the 
pragmatic, psychometric and theoretical properties of ideal tools.  
 
 
2. METHODS 
2.1. Research Strategy  
A systematic review was performed in the databases MEDLINE (Pubmed) (1986 – 
February 2013), PASCAL (1997 - February 2013), PsycINFO (1999 - February 2013), 
CINAHL with full-text (1993 - February 2013), in order to collect studies using tools for 
assessment of potential significance of an individual PI.  
We combined two groups of keywords as the equation search: drug-related problems 
AND pharmacist interventions ("drug related problems" OR "drug therapy problems" OR 
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"medication therapy problems" OR "medication inappropriateness" OR "pharmaceutical care 
issues" OR "medicine related problems" OR "medication related problems" OR "medication 
errors") AND ("pharmaceutical care" OR "pharmaceutical services" OR "medication order 
review" OR "medication review" OR "pharmacotherapy interventions" OR "pharmacy 
interventions" OR "drug utilization review" OR "pharmacist recommendations" OR 
"pharmacist interventions").  
 
2.2. Inclusion and exclusion criteria 
The inclusion criteria were as follow: (1) original articles published in English or 
French; (2) abstract available; (3) published in peer review journals; (4) a study involving 
pharmacists alone or in cooperation with other healthcare professionals; and (5) having an 
explicit description of a method for rating the impacts of a PI, called a tool in this review. 
The exclusion criteria for articles include: (1) literature reviews; (2) studies related to 
one specific type of DRPs/PIs (e.g., administration errors, drug information service); (3) tools 
only assessing the actual consequences of DRPs (e.g., ADEs/adverse drug reactions (ADRs)); 
(4) tools only assessing the actual consequences of a PI; and (5) studies assessing economic 
impact only; and (6) non-accessible articles. In addition, references listed of articles that met 
our inclusion criteria, of systematic reviews, and review articles were assessed and, if 
relevant, were retrieved. Eleven additional articles were also retrieved from a thesis of 
Quélennec [14] which performed a literature review of tools for evaluation of potential 
clinical impacts of medication errors (MEs) intercepted through medication conciliation. 
Finally, hand-search was done to identify articles that were not captured in the electronic 
database search. 
 
2.3. Screening and data extraction 
 One author screened (THV) all titles, abstracts and then full-text articles for the first 
time in February 2013. Another author (CC) independently screened with the same strategies. 
Additional articles retrieved by the second reviewer were added to the final results. The 
second reviewer also verified the extraction of relevant data from included articles conducted 
by the first reviewer. We resolved any disagreement through discussion until consensus was 
reached.  
2.3.1. Content of tools  
In order to identify the indicators used in existing tools, theoretical models which are 
possible to be applied to assess PIs were reviewed. The conceptual models “structure-process-
outcome model” by Donabedian [15] suggested that the quality of healthcare interventions 
was assessed through three types of indicators related to “structural features”- appropriate 
resources and system design; “process of care”- the method by which health care is provided; 
and “outcome”- the consequence of the health care provided. The model provided by Kozma 
et al. [16], placing outcomes into three categories - Economic, Clinical, and Humanistic 
Outcomes (ECHO model) depict the value of pharmaceutical services. The Fig. 2 
demonstrates the combination of the above two models.  
 
 
 
74 
 
 
 
 
 
 
 
Fig. 2 Evaluation model of PIs based on the Donabedian’s and Kozma et al.’s models 
According to risk model [17], risks are analyzed by combining severity of 
consequences and probability in the context of existing situation. Risk matrix are used 
predominantly in safety risk management of MEs such as National Patient Safety Risk Matrix 
in UK [17], Safety Assessment Code Matrix in USA [18], Standard for risk management in 
Australia [19]. An original safety risk matrix assesses a broad range of risks including 
clinical, financial risks, risks related to reputation, business process, and system, etc. The 
matrix of clinical risk was simplified to develop some tools assessing the potential 
significance of a PI [20-24].  
According to the basic model of pharmacoeconomics [25], the value of a PI considers 
both inputs and outputs of a PI compared to the absence of a PI (Fig. 3). Inputs can be thought 
of as resources required implementing the PI. Outputs can be thought of as consequences of a 
PI, in form of clinical, humanistic, or process-related consequences. The difference between 
the cost of the original therapy and the new therapy gives the cost savings (or the increase in 
the cost of therapy). Cost avoidance refers to the prevention of additional health resources 
which are required to treat drug adverse events if a pharmacist has not intervened such as a 
hospitalization or a medical visit. Cost of implementation of a PI refers to the expenses of 
providing the PI such as cost of pharmacist’s time, phone calls, etc. In some studies [26, 27], 
the economic value of a PI is estimated through cost savings plus cost avoidance less cost of 
implementation of a PI.  
Regarding to the content of tools, after combination of the above 4 models which are 
possible to be applied to assess IPs, we determined and classified indicators used in existing 
tools into 5 main types of indicators: indicators related to economic, clinical, and humanistic 
outcomes, process and probability of the impact. 
 
 
 
 
Clinical Economic Humanistic 
Kozma et al.’s Evaluation Model (1993) 
Structure Process Outcome 
Donabedian’s Evaluation Model (1978) 
Quality of pharmacist interventions 
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Fig. 3 Economic model for estimation of a pharmacist intervention 
 
2.3.2. Structure of tools  
Regarding to the structure of tools, it was classified as mono-dimensional or 
multidimensional. One dimension was defined as an independent rating to answer one 
question related to impacts of a PI. Each dimension was also classified as nominal (two or 
more categories, but there is no intrinsic ordering to the categories, for example, rating PIs 
into 2 categories: technical or clinical problems [28]) or ordinal (there is a clear ordering of 
the dimension, for example, ordering clinical impacts of PIs into three categories as minor, 
moderate, major significance [29]). Each aspect of impact of a PI (e.g., clinical, economic 
aspect) was evaluated independently in one dimension or combinedly within “significance” 
dimension with other aspects. For example, clinical impact was evaluated independently into 
6-category dimension (adverse significance, no significance, somewhat significant, very 
significant, extremely significant) and drug cost saving of a PI was evaluated independently in 
3-category dimension (drug cost reduction, drug cost increase, no change), respectively in the 
tool of Briceland et al. [30]. In contrary, drug cost savings was integrated with clinical impact 
into a 4-category dimension (low, mild, moderate, high significance) in the tool of Williams et 
al. [31]. 
 
 
Inputs 1 
Inputs 2 
Original drug therapy  
(without a PI) 
Recommended drug therapy 
(with a PI) 
Outputs 
1 
Outputs 
2 
Inputs (resources 
consumed) 
 Drug 
 Monitoring  
 Pharmacist’s time 
 Phone… 
Output (consequences)  
 Process-related 
consequences  
 Clinical 
consequences  
 Humanistic 
consequences 
Value of a PI = (Inputs 1 – Inputs 2) + (Outputs 2 – Outputs 1)  
Economic value of a PI = cost savings + cost avoidance related to adverse 
drug events – cost of the implement of a PI 
Cost of the 
implement of 
a PI 
Cost 
savings 
Cost 
avoidance 
Where 
Cost savings = cost of recommended drug therapy less cost of previous drug 
therapy 
Cost avoidance = probability (most likely harmful outcome would have occurred) X 
the cost of medical care associate with that outcome 
Costs of the implement of a PI = cost of pharmacist’s time + cost of phone calls… 
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2.3.3. Psychometric parameters of tools  
Regarding to the psychometric parameters of tools, validity aims to check if the tool is 
measuring what it is supposed to measure; inter-rater reliability measures whether, when the 
same test is applied to the same scenarios by different raters, the same results are produced; 
intra-rater reliability measures whether, when the same test is applied to the same scenarios 
by the same rater on two different occasions, the same results are produced [32]. We assessed 
risk of bias in studies which reported results of validity and/or reliability according to the 
Cochrane Handbook for Systematic Reviews of Interventions [33]. We addressed main 
components: selection bias, performance bias, detection bias, and others biases. For each 
study, we placed judgments of low, high, or unclear/unknown risk of bias (see Electronic 
Supplementary Material (ESM) 1).  
 
2.3.3. Assessment of quality of tools  
We assessed quality of each tool used in included studies using the criteria outlined in 
the ESM 2.  One point is awarded when a criterion is clearly satisfied. The sum of scores 
presents the quality of a tool for assessing significance of PIs in an included study.   
 We designed two forms to extract data. The articles were evaluated and summarized by 
(1) authors, published year, country; (2) structure of tools; (3) approach of assessment; (4) 
content of tools; (5) notes (see ESM 3); and by (6) setting, number of sample, sampling; (7) 
qualification and number of raters; (8) rating methods; (9) definitions of consensus; (10) 
validation; (11) inter-rater reliability; (12) intra-rater reliability, (13) risk of bias, and (14) 
score of quality of a tool (see ESM 4). For eligible studies, at least two review authors (THV 
and CC) independently extracted the data using these form. We resolved discrepancies 
through discussion until consensus was reached. When information regarding any of the 
above was unclear, we attempted to contact authors of the original reports to provide further 
details. We conducted this systematic review according to the PRISMA guidelines [34].  
 
3. RESULTS 
3.1. Studies identified 
A total of 873 articles were retrieved from Pubmed (646), PASCAL (96), PsycINFO 
(33) and CINAHL with full-text (98). Of these, 833 articles were removed because of 
repetition or irrelevance and 93 articles were added from reference lists, the review by 
Quélennec [14], an independent search by the second reviewer, and other sources. Finally, 
133 articles [3, 12, 20-24, 28-30, 35-157] were selected and comprised the reviewed data-set 
(see ESM 3, 4). Some studies used a tool or multiple tools which were described in previous 
studies, there were, therefore, only 82 distinct tools in 133 selected articles. Fig. 4 presents the 
systematic review flowchart. 
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Fig. 4 Systematic review inclusion, exclusion flowchart 
Tools were created by research teams in USA (43 studies), UK (19 studies), Canada 
(16 studies), Australia (15 studies), France (7 studies), Netherlands (5 studies), Sweden (4 
studies), Norway (4 studies), Spain (4 studies), Germany (3 studies), Switzerland (3 studies), 
Belgium (2 studies), Denmark (1 study), Iran (1 study), Israel (1 study), Taiwan (1 study), 
Ethiopia (1 study), India (1 study), Malaysia (1 study), UK and Saudi Arabia (1 study). 
 
 
303 unique articles 
PASCAL (96 citations) 
Equation (ADRs + PIs) 
1997- February, 2013 
Abstract available 
English and French language  
 
Pubmed (646 citations) 
Equation (ADRs + PIs) 
1986 - February, 2013 
Abstract available 
English and French language 
 
CINAHL with full-text (98 
citations) 
Equation (ADRs + PIs) 
1993 - February 2013 
Abstract available 
English and French language  
PsyINFO (33 citations) 
Equation (ADRs + PIs) 
1999 - February 2013 
Peer-review journal 
English and French 
language 
873 citations 
  156 articles excluded (based on review of abstract) 
2 No abstracts 
41 neither in English nor in French 
23 review articles  
5 non-accessible articles  
85 No tools  
691 unique articles 
147 full-text articles 
  107 articles excluded (based on review of full-text article) 
61 no tools  
2 no definitions or descriptions of an tool 
3 PI intercepted by other persons 
7 assessing actual consequences of DRPs  
9 assessing actual consequences of a PI 
10 one specific type of DRPs/PIs 
15 assessing only economic impacts  
40 included articles 
   93 additional articles from 
67 reference lists  
11 review of Quélennec 
7 independent search by the second reviewer 
8 hand search  
  182 repeated articles excluded (146 duplicates, 29 triplicates or 7 quadruplicates) 
  388 articles excluded (based on review of title) 
133 included articles 
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3.2. Content of tools  
3.2.1. Main approaches for assessment of significance of PIs  
Of 82 distinct tools identified, 30 tools assessed the potential consequences of DRPs 
(approach 3A in Fig. 1) while 46 tools assessed the potential significance of a PI (approach 
3B). Six tools applied the multiple-approaches [3, 12, 56, 86, 100, 120]. For example, the tool 
of Overhage et Lukes assessed both the potential consequences of DRPs (approach 3A) and 
the potential significance of a PI (approach 3B) [12].  
 
3.2.2. Indicators used in the content of existing tools 
The tools can covered only one aspect or a range of aspects of impacts simultaneously. 
Indicators (not exhaustive) used in existing tools for assessment of potential significance of 
PIs are summarized (see ESM 5).   
 
Clinical impact 
All tools reported clinical aspect as an indispensable aspect of rating the significance 
of a PI. Ranking clinical significance of PI was realized by assessing effects of DRPs/PIs on 
safety (e.g., adverse health consequence [48], toxicity [44, 55], morbidity [21, 29, 86, 106, 
113]); effectiveness (e.g., response to medication [87], disease control [53]); and necessity of 
drug therapy [134]; or characteristics of effects (e.g., short-term/long-term [106], 
permanent/temporary [23, 105, 113]), etc.  
Humanistic impact 
Humanistic outcomes, also called patient-reported outcomes, are the consequences of 
the disease and/or its treatment as expressed by the patient. Humanistic outcome are now 
more commonly used in clinical practice [158]. In this review, distinct tools clearly stated 
some indicators of humanistic outcomes which were patient’s knowledge, compliance, 
patient’s satisfaction, inability to work, and quality of life. Humanistic aspect was often 
evaluated combinedly with clinical aspect into “significance” dimension and classified as 
“low significance” [31, 59, 71, 77, 79, 82, 108, 130] while some distinct tools evaluated 
independently certain indicators of humanistic impact of a PI [55, 87, 111, 120, 150]. 
Economic impact  
Different studies on the economic impact of a PI employ different terminologies, 
leading to some confusion in the perspective and components of costs, making the 
comparison of studies difficult. Cost savings and/or cost avoidance were rated independently 
in some tools [20, 30, 38, 41, 43, 48, 50, 53, 55, 56, 61, 65, 68, 73, 87, 93, 111, 123, 134]. In 
some studies, independent rating the economic impact of a PI was used as the first step to 
determine the monetary value of a PI program [38, 41, 43, 48, 50, 68, 73, 80, 94, 123]. Cost 
avoidance was estimated through the types of health care resources avoided (e.g., readmission 
[102, 105, 113] or a scheduled visit to the physician [31, 48]); while cost savings were 
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evaluated through costs related to drug therapy [20, 38, 43, 61, 66, 109, 111], drug therapy 
monitoring [38, 61], treatment cost [29], patient cost [43] or reimbursement [66].  
Process-related impact 
Like humanistic impacts, the process-related impact of a PI was often ignored, 
incomplete, ambiguous or were mentioned arbitrarily in some tools. They may be grouped 
into resolving technical problems [28, 57, 82, 91], informational intervention [31, 38, 53, 57, 
71, 75, 82, 94], physician’s satisfaction [120], facilitation of continuity of care  [55], 
teamwork support [82], adherence to evidence-based therapy [104, 135], and others  [93].  
Structure-related impact 
No structured-related indicator (e.g., a comprehensive inventory, record-keeping 
amenities such as a computer database, a designated area of the pharmacy, trained 
pharmacists/technicians [159]) was found in the reviewed tools.  
Probability 
The determination of probability of a consequence for each DRP/PI was used in 20 out 
of 82 distinct tools [3, 20-24, 48, 56, 70, 86, 89, 109, 112, 113, 115, 116, 121, 132, 135, 138]. 
The definitions of each level of probability were based on concrete terms with or without a 
range of numeric probabilities or a Likert score. The number of levels was from 2 to 11. 
Evaluation of the probability of a consequence of a DRP was useful to evaluate the confidence 
of judgment [70, 116, 135]; classify the risk of an adverse heath consequence by combining 
the severity and the probability of occurrence  [20-24]; and/or clarify the estimation of cost 
avoidance of a PI by combining the type of health care resources required to treat an adverse 
health consequence and its probability [48, 56]. 
 
3.3. Structure of tools 
The tools were multidimensional (one dimension with 2-20 categories, 39/82) or 
mono-dimensional (2-9 dimensions, 43/82), ordinal or nominal (see ESM 3). The majority 
were presented as classification systems with associated definitions but other tools were based 
on a visual analog scale[69, 132] or ordinal Likert scales[127].   
 
 
3.4. Validation process  
The validation process was heterogeneous in terms of qualification and number of 
raters, rating methods, determination of psychometric parameters etc. (see ESM 4).  
3.4.1. Raters and rating methods  
The profile of raters was different: internal or external, blinded or not, junior or senior, 
generalists or specialists; and with various qualification (e.g., pharmacist, physician, nurse, or 
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pharmacologist). Rating methods varied: some studies were simply based on a single 
professional’s view (individual-based rating) while others used an inter-disciplinary group 
(group-based rating) with up to 30 raters and up to 5 different specialties. 
There were a few instances in which a clear definition was presented outlining 
precisely what constituted consensus. For example, asking a panel of experts to independently 
judge an event and then combining their opinions using various mathematical approaches 
(e.g., mode [38, 39, 41, 56, 81, 100, 101, 119]; median [24, 100, 130]; mean [39, 41, 53, 56, 
60, 69, 81, 83, 89, 100, 122, 136]; sum [59]). Alternatively, a conservative approach was used 
taking the lower category of significance [138, 139] or an hierarchical approach in which a 
more senior expert was consulted when there was a disagreement among the clinical panel) 
[37, 48, 49, 54, 55, 65, 68, 77, 91, 99, 103, 108, 113, 116, 124, 125, 128, 144, 151-153, 156]. 
In most studies, the consensus may have been arbitrarily determined; in other words, it was 
defined simply as a consensus-based approach (reached through discussion) [3, 22, 37, 38, 
43, 44, 46, 48, 49, 54, 62, 68, 72, 77, 80, 82, 84, 91, 92, 97, 103, 104, 107, 108, 110, 113, 
115-118, 120, 121, 123, 124, 132, 134, 135, 150, 152, 153, 160, 161].  
3.4.2. Psychometric parameters of tools 
Validity was only reported in eight studies (8/133, 6%) [23, 45, 61, 69, 83, 106, 127, 
131]. These explored face validity [127] or criteria-based validity (the results of coding by 
raters were compared to known outcomes in the literature [69, 83] or evidence in patients' 
medical records [61], to those of other skilled people or consensus of an expert panel [23, 45, 
106, 131]. Dean and Barber [69] and Taxis et al. [83] found that there was a clear relationship 
between potential harm as assessed using their tools and actual harm. Eadon et al. [45] found 
that there was no significant difference between a pharmacist's scores and three physicians' 
score (Mann Whiteney U test, U = 933.5, z = 0.034). Elliott et al. [23] found 93-100% 
agreement between 2 pharmacists and 1 geriatrician while Knez at al.[131] found 46% 
agreement between a panel of 3 pharmacists and a physician. In three studies [61, 106, 127] 
descriptive information was given but no statistical information presented.  
Measures of inter- and intra-rater reliability were established in 49 studies (36.8%) 
(see ESM 4). High inter-rater reliability was found in 24 studies: Lesar et al. [63], Rupp at al. 
[48], Overhage and Lakes [12], Caleo et al. [56], Lewinski et al. [24], Gleason et al. [128], 
Kwan et al. [110], Wong et al. [118], Chua et al. [146], Midlov et al. [115], Pippins et al. 
[116], Granas et al. [120], Lee et al. [132] with kappa ≥ 0.7; Chedru et al. [59] with signma x, 
y ≥ 0.7; Goarin at al. [129] with t-test p < 0.05;  Hawkey at al. [20] with Spearman's rank 
correlation p < 0.05; Bayliff et al. [41], Strong et al. [50] and Virani et al. [87] with 
coefficient of agreement ≥ 0.7; Khalili et al. [151], Hick et al. [81], and Bobb et al. [88] with 
agreement ≥ 80%; Gisev et al. [127] with W ≥ 0.3; Coffey et al. [119] with AC1 = 0.69, p < 
0.01. Intra-rater reliability was only reported in 2 studies (1.5%) with a poor agreement in a 
study of Cousins et al. [61] and a good agreement in a study of Dean et al. [69].  
While many studies showed that reliability was not affected by the profession of the 
rater [45, 69, 102, 124, 129], others found that physicians rated DRPs/PIs with lower 
severity/value than did pharmacists [12, 23, 38, 98]; or on the contrary, pharmacists tended to 
score PIs as being less clinically significant than physicians [53, 79]. A study by Lee et al. 
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[100] found that ratings were more consistent between pharmacists than between physicians 
and pharmacists. However, even within the same profession, reliability was difficult to obtain. 
A study by Fernandez et al. [149] demonstrated that senior pharmacists rated more 
consistently than junior pharmacists.  
 
3.5. Assessment of quality of tools 
The scores of quality of tools for assessing significance of PIs in 133 included studies 
were presented in Table 1. 
Table 1. Scores of quality of tools for assessing significance 
of PIs in 133 included studies   
Sum of scores of quality of 
each tool  
Number of tools  
0 5 (3.8%) 
1 18 (13.5%) 
2 26 (19.5%) 
3 22 (16.5%) 
4 24 (18.1%) 
5 30 (22.6%) 
6 6 (4.5%) 
7 2 (1.5%) 
8 0 
9 0 
   
4. DISCUSSION 
4.1. Limitation of this review 
It was difficult to identify all tools in the literature. We retrieved only four available 
databases. Tools were sometimes mentioned but not described in detail [162]. Tools only 
assessing the actual consequences of DRPs (Approach 1 in Fig. 1) or the actual consequences 
of a PI (Approach 2 in Fig. 1) were not used for this review because these cover different 
concepts. We used the outcome terminology proposed by Holdford and Smith [13]. However, 
identifying classifications of indicators mentioned in existing tools was complicated because 
of the different terminologies used by authors and institutions. For example, determining 
whether a tool evaluates humanistic impact of a PI is difficult. The reasons are (1) not all 
indicators of humanistic outcomes are theoretically well defined, (2) in some tools the 
terminology of humanistic indicators is confusing, (3) the complex relationships between 
humanistic, clinical and economic outcomes. An assessment of the significance of PIs is a key 
to justifying value of pharmacy services. However, between studies methods are 
heterogeneous which hinders their review and synthesis. Our review is a first attempt to (1) 
distinguish different approaches used to assess the significance of PIs, (2) evaluate the quality 
of tools based on theoretical models, and (3) discuss the strengths and weaknesses of existing 
tools and validation process. We suggest recommendations for an optimal method of 
evaluation of the significance of PIs. 
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4.2. Content of tools 
The principal indicators of the impact of a PI concern the process and clinical, 
humanistic and economic outcomes, and probability. These indicators are inconsistently 
mentioned in tools. Some tools cover many indicators, but a comprehensive tool is not 
available. One reason may be that few tools were constructed based on theoretical models, a 
systematic literature review, and input from healthcare professionals. 
Pharmacy practitioners and pharmacy managers need to demonstrate that for each PI 
the benefits outweigh the costs for a given patient, a health care system, and society. 
According to the economic model, the cost of implementing a PI, cost savings and cost 
avoidance should be evaluated. Tools should be constructed so as to capture the potential 
significance of a PI with an estimation of its economic impact (e.g., using the tool of Williams 
et al. [31], the potential significance had a fairly good correlation with the economic value) 
and is the first step to conducting a more sophisticated economic evaluation [38, 48, 73, 77, 
93, 123].   
Most tools focus on patient outcomes. PIs, however, also are useful for the health 
practitioner. Tools therefore should reflect the possible impacts on both. In order to assign a 
probability for a potential consequence, it is ideal to know how often it has been described in 
the literature as well as how often it occurs at the local healthcare facility. However, in most 
cases, the determination of this probability was difficult to estimate. This is primarily because 
such probabilities are rarely available in the literature and can vary based on patient risk, co-
morbidities or other factors [138]. Generally, in order to improve the consistency of judgment 
of probability between raters, studies only select and code the most likely harm prevented [19, 
23, 48, 56] and request opinion of staff most familiar with these events. A multidimensional 
matrix of risk which considers many aspects of impacts and the probability of each aspect, 
such as the matrix developed by National Patient Safety Agency [17] could be used as a 
framework to construct a new tool for assessing PIs. 
Assessing the potential significance of a PI is primarily based on the potential severity 
of consequences of DRPs that might have occurred if a pharmacist had not intervened. It 
makes sense to use the same definitions, terminology and grading systems for both the 
potential significance of a PI and the actual severity of consequence of MEs, ADEs, or ADR 
[19, 93, 163]. Indeed, the NCC MERP Index [164] for classification of severity of MEs has 
been used to design new tools for assessing PIs [84, 86, 88, 128]. Furthermore, most tools use 
a variety of similar terminologies without precise definitions which risks inconsistency of 
rating. 
 
4.3. Structure of tools  
One can argue that a tool for evaluation of impacts of a PI should be as simple as 
possible. However, a simple tool can hardly detect all possible impacts of PIs and would not 
provide enough information for practice and research. Therefore, a well-structured tool should 
provide the main dimensions and the main levels. A stepwise instruction should be developed 
to guide the use of tools in practice. Such that results of different studies can be compared.  
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An ordinal tool is preferred in order to prioritize the most significant PIs. Half of tools 
are mono-dimensional, and often concentrate on clinical impacts of PIs failing to detect other 
impacts. Multidimensional tools and the independence of evaluation of different impacts of a 
PI improve the sensitivity and flexibility of evaluation methods. For example, the separation 
of evaluation of economic impacts (cost savings) and clinical impacts in the tool of Lindblad 
et al. [111] facilitates estimation of the cost savings by the whole PI program. The numeric-
based levels facilitate interpretation of results.  
Although the multidimensional tools were used in many studies, the results of each 
dimension were separately interpreted. Only the study by Lindblad et al. [111] used the 
method of simultaneous interpretation of mean impacts of many dimensions for all PI. For all 
interventions, this study found a mean of 1.4 clinical, 0.8 humanistic, and 0.1 economic 
outcomes. This method of interpretation of results gives the added value of the whole PI 
program rather than the individual PI. There is no method for determining these 
multidimensional impacts of each PI.  
Many authors adapted existing tools in the literature to their study. In the ESM 3 and 
4, we grouped studies into sub-groups which used a same tool or a slightly modified tool. The 
tools which were the most commonly adapted one for use in other studies include: Folli et al. 
in 1987 [36] (8 studies), Hatoum et al. in 1988[38] (26 studies), Lesar et al. in 1990 [42]  (4 
studies), Western Australian Clinical Pharmacists Group in 1991 [44] (3 studies), Rupp et al. 
in 1992 [48] (3 studies), Chedru et al. in 1997 [59] (5 studies), Alderman et al. in 1997 [29] (3 
studies), Overhage and Lakes in 1999 [12] (11 studies), Deans et al. in 1999 [69] (6 studies), 
Hawksworth et al. in 1999 [70] (3 studies), NCC MERP Index in 2001 [164] (5 studies), 
Society of Hospital Pharmacists of Australia Guideline in 2005 [19] (4 studies), Cornish et al. 
in 2005 [22] (5 studies), Blix et al. in 2006 [97] (3 studies). The advantages of using existing 
structured measures are: their reliability and validity have already been undertaken and using 
measures that have been applied by others enables comparison between studies. However, 
limitations include difficulties in finding a suitable tool for local use, and the fact that 
reproducibility of the reliability of a specific tool is not always obvious. For example, 
Overhage and Lakes's tool [12] had a high inter-rater reliability in their study but this tool 
adapted by Bosma et al. [98], and Lee et al. [100] Fernandez-Llamazares et al. [149] and 
Somers et al. [157] showed a low inter-rater reliability.     
4.4. Validation process  
The criteria-based validity of any method measuring the potential significance of a PI 
is difficult to assess because there is no generally accepted standard with which to compare 
[12]. The comparison of the scores given to MEs with known outcomes has limitations 
because errors resulting in more-severe outcomes may be more likely to be reported in the 
literature [69]. Nonetheless, the comparison of the individual scores with the consensus 
results of a group of experts has other limitations. The existence of a consensus does not mean 
that the "correct" answer has been found [165]. The consensus method is just a means of 
identifying current medical opinion and areas of disagreement. It recommends that the results 
should, when possible, be matched to other data in the literature [102], to the actual outcomes 
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in the patient after following-up [61], to observable events [165] or to other systems of 
reporting such as MEs and ADEs [89].  
Measuring the inter- and intra-rater reliability of methods for assessment of impacts of 
PIs is a scientific and practical requirement. Indeed, this information provides useful data not 
only about the reliability of a subjective assessment but can also be used for teaching, peer 
review and audit purposes [65, 149]. However, this measure was not established for all tools. 
It is not possible to directly compare the reliability of tools as they used different methods of 
assessing reliability.  
Like the actual severity ratings of ADEs [166-168] or MEs [169, 170], literature 
shows many inter-rater and intra-rater inconsistencies, within and between healthcare 
professional groups. Such inconsistencies can be partly attributed to lack of clarity in the tools 
and scenarios used for validation, shortage of time for proper case reading and coding, and 
different points of view of the assessors.  
The inconsistency of coding between raters prevents individual evaluation. Many 
studies have used an expert panel. However, there are no strict criteria governing the selection 
of experts. With regard to medical research, Jones and Hunter [165] defined the term “expert” 
to be “clinicians practicing in the field under consideration”. According to this definition, 
suitable experts for studies such as those proposed in this paper include pharmacists and 
medical practitioners. It has been recommended that experts should be selected based on their 
appropriateness for the study in terms of experience in the therapeutic area, reputation, 
geographic representation, practice type and specialty, heterogeneity in treatment patterns and 
willingness to participate in the study [11, 171]. Wright et al. [172] demonstrated that 
community pharmacists, hospital pharmacists, general practitioners and specialist physicians 
attribute significantly different values when undertaking these assessments.  
4.5. Properties of ideal tools for assessing the potential significance of a PI 
Currently, there are no formal guidelines or any standardization of methodology 
concerning methods of assessment of the potential significance of PIs. Taking into account 
the results of this review, we suggest some desirable pragmatic, psychometric and theoretical 
properties:  
Theoretical properties 
1. Tools should be developed based on (1) comprehensive theoretical models, (2) a 
systematic literature review of available evidence that reflects the whole range of 
impacts of a PI and (3) an evaluation of existing tools, and (4) input from healthcare 
professionals. 
2. Tools should be able to demonstrate that the benefits outweigh the costs in a given 
patient, health care system, and society at the level of each PI. 
3. An evaluation from multi-impact perspective, rather than simply focusing on clinical 
impact, should be used to enhance understanding of the comprehensive effect of PIs. 
For example, a tool integrating clinical, humanistic, economic, process-related impacts 
and the probability of these impacts.  
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4. The views of patients, health care providers, institutions, payers, and society should be 
considered. 
Psychometric properties 
1. Tools should be validated prior to its use. 
2. Along with the information on clinical case, experts should be provided with a 
literature review, coding instructions, and examples. Indices for 
agreement/validity/reliability should be conform to the current guidelines [173].  
3. The guideline proposed for the use of experts in pharmacoeconomic studies [174] is 
suitable for this type of study: description of consensus techniques (e.g., Delphi 
process, Nominal Group Technique, expert panels); justification in using such 
methods;  and description of selection of experts; provision of a definition of 
consensus in advance of the execution of a study; information that is provided to 
panelists in advance must be as objective and as comprehensive as possible; and 
modification of tool as appropriate with the input from independent experts or pilot-
test; appropriate presentation and interpretation of findings. 
Pragmatic properties 
1. Tools must be brief and not time-consuming. Acceptability to evaluators is also 
required. 
2. Tools should be well defined. 
3. Tools must be well-structured as well as flexible to adapt to meet their specific needs 
(e.g., multidimensional tool, possibility of modification of terminology of economic 
impact is based on different perspectives or modification of number of levels; 
independence between dimensions).  
4. Tools should have an open, numeric, and hierarchical structure (with main 
dimensions, main levels of each dimensions, and an open structure to include the 
option “non-determinable”).
5. Same definitions, terminology and grading systems for both the potential significance 
of a PI and the actual severity of consequence of MEs/ADEs/ADRs. 
 
4.6. Assessment of quality of tools 
Researchers and clinicians may have different needs in relation to a tool for assessing 
potential significance of PIs. Due to the wide range of tools used in the literature, researchers 
need consider developing a basis of comparison between tools. Therefore, we tried to assess 
quality of each tool in included studies using 10 criteria to assist in comparing tools across 
studies (see ESM 4). According to these criteria, the tools with highest scores were: Caleo et 
al.'s [56] and Hick et al.'s [81] (7 scores), Eadon et al.'s [45], Overhage and Lakes' s[12], 
Kopp et al.'s [109], Virani et al.'s [87], Lee et al.[100] and  Lewinski et al.'s tool [24] (6 
scores). No tool could be found that met all of our above criteria. It appears that further 
research in this filed should be conducted.  
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5. CONCLUSION  
Various structures and contents of tools for evaluation of impacts of PIs were 
highlighted, as well as suggestions for an optimal evaluation method. Majority of tools 
focused primarily on assessing clinical aspect and failed to detect other impacts. Variation of 
tools and assessment process hindered their summarization. Limited and varied results for 
their validity and reliability questioned the level of evidence of the evaluation of potential 
significance of PIs for justification of added value of PIs. The development of tools with 
optimal theoretical, pragmatic and psychometric properties and their integration into daily 
pharmacists’ practice through rational assessment process (e.g., peer review) and standardized 
documentation systems (e.g., IT tools) are needed. 
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2. Some important tools for assessing potential significance 
of pharmacist interventions 
Due to the wide range of tools used in the literature, researchers need know a basis of 
comparison between typical tools before deciding to use or develop a new tool. Therefore, we 
tried to present here some important tools which were commonly used in many studies or had 
the high score of quality of a tool, or had typical features. We grouped important tools into 
sub-groups: severity-of-error tools, value-of-service tools, tools of risk assessment, tools of 
assessment of cost avoidance, and multidimensional tools.  
2.1. The severity-of-error tools 
The severity-of-tools focused to assess the potential severity of DRPs/MEs to patient avoided 
by the PI (Approach 3A presented in the Article 1).  
2.1.1. The tool of Folli et al.  developed in 1987 (USA) 
The first tool for assessing potential significance of PIs was created by Folli et al. in 1987 
(13). The authors classified degree of potential severity of a ME into 3 levels (potential lethal, 
serious, or significant) with detailed descriptions of definition/explicit examples. However, 
the authors did not evaluate validity and reliability of this tool. Several investigators adopted 
this tool, sometimes with minor modifications (Iafrate et al. (198), Blum et al. (199), Lesar et 
al. (200-202), Ho et al. (203), Overhage et al. (12)).  
Table 16. The tool of Folli et al. 
Severity 
of a ME 
Definition/Description 
Potentially 
lethal  
It could have one or more of the following consequences:  
(1) the serum level resulting from such a dose is likely to be in the “severe 
toxicity range” based on common dosage guidelines, e.g., serum theophylline 
concentrations >30 µg/mL, more than ten times the dose of a chemotherapy 
agent;  
(2) the drug being administered has a high potential to cause cardiopulmonary 
arrest in the dose ordered;  
(3) the drug being administered has a high potential to cause a life-threatening 
adverse reaction, such as anaphylaxis, in light of the patient’s medical history;  
(4) the dose of a potentially life-saving drug is too low for a patient having the 
disease being treated; and  
(5) the dose of a drug with a very low therapeutic index is too high (ten 
times the normal dose). 
Serious It could have one or more of the following results:  
(1) the route of drug administration ordered is inappropriate, with the potential 
of causing the patient to suffer a severe toxic reaction;  
(2) the dose of the drug prescribed is too low for a patient with serious disease 
who is in acute distress;  
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(3) the dose of a drug with low therapeutic index is too high-four to ten times 
the normal dose;  
(4) the dose of the drug would result in serum drug levels in the toxic range, 
e.g., serum theophylline levels 20 to 30 µg/mL;  
(5) the drug ordered could exacerbate the patient’s condition, e.g., drug-drug 
interaction or drug-disease interaction; and  
(6) the name of the drug is misspelled, creating a risk that the wrong drug 
might be dispensed. 
Significant An error could have one or more of the following results:  
(1) the dose of the drug with low therapeutic index is too high - 1/2 to four 
times the normal dose;  
(2) the dose is too low for a patient with the condition being treated;  
(3) the wrong laboratory studies to monitor a specific side effect of a drug are 
ordered, e.g., CBC and reticulocyte counts are ordered to monitor gentamicin 
toxicity;  
(4) the wrong route of administration for the condition being treated is 
ordered, e.g., the inadvertent change from IV to oral therapy for the treatment 
of bacterial meningitis; and  
(5) errors ordering IV fluids are made, e.g., specific additives needed for 
complete therapy are omitted, or incompatible fluids are ordered. 
Source: Reproduction from Folli HL, Poole RL, Benitz WE, Russo JC. Medication error prevention by clinical 
pharmacists in two children's hospitals. Pediatrics. 1987;79(5):718-22. 
 
2.1.2. The tool of Lesar et al. developed in 1990 (USA) 
Besides the modification of 3 levels of the tool of Folli et al. (13), Lesar et al. (200) added the 
fourth level - "problem orders" to develop a new tool in 1990 (Table 17).  In two later studies 
in 1997 (201, 202), the authors said that consistency and agreement of the tool has been 
previously reported in a study in 1990 (200). But in fact, this information was not found. 
However, consistency and agreement of the tool was determined by review of 500 
consecutive errors rated as only A, B, or C (not D) occurring in the last study year by a 
physician and 2 pharmacists in a study in 1997 (202). All reviewers agreed on the ratings in 
485 (97%). Two or more reviewers agreed on 497 (99.5%) of the assigned error severity 
ratings. Agreement between reviewers as determined by k statistic (0.96, P<.001) was 
excellent.  
Table 17. The tool of Lesar et al. 
Potential severity classification for order errors 
A. 
Potentially 
Fatal or 
Severe 
1. The dose ordered for a medication with a low therapeutic index was greater 
than 10 times the normal dose. 
2. A dose was ordered for a medication with a very low therapeutic index that 
would potentially result in pharmacologic effects or serum concentrations 
associated with severe or fatal toxic reactions. 
3. A drug was ordered that had the potential to produce a severe or life-
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threatening reaction in the patient (e.g., anaphylaxis). 
4. The dose of a lifesaving drug or drug being used for a severe illness was too 
low for the patient being treated. 
B. 
Potentially 
Serious 
 
1. The dose ordered for a medication with a low therapeutic index was 4 to 10 
times the normal dose. 
2. A dose was ordered for a medication with a very low therapeutic index that 
would potentially result in serious toxic reactions. 
3. The dose ordered for a drug used for a serious illness was too low for the 
patient. 
4. The wrong medication was ordered, with potential serious toxic reactions or 
inadequate therapy for a serious illness. 
5. A route was ordered for a medication that could potentially produce serious 
toxic reactions or inadequate therapy for a serious illness. 
6. A medication order was written illegibly or in such a manner as to result in 
an error that could produce serious toxic reactions or inadequate therapy for a 
serious illness. 
7. Duplicate therapy with potential for serious toxic reactions was prescribed. 
C. 
Potentially 
Significant 
1. The dose ordered of a medication with a low therapeutic index was 1.5 to 4 
times the normal dose, with potential toxic reactions because of the high dose. 
2. The dose ordered of any medication was five times or greater than normal, 
with potential for adverse effects because of the high dose. 
3. The dose ordered was inadequate to produce therapeutic effects. 
4. The wrong route of administration was ordered, with potential for increased 
adverse effects or inadequate therapy. 
5. The wrong medication was ordered for a non-severe illness and/or there was 
a potential for side effects from the drug. 
6. A medication order was written illegibly or in such a manner as to result in 
an error producing adverse effects or inadequate therapy. 
7. Duplicate therapy was prescribed with a potential for additive toxic 
reactions. 
D. 
Problem 
Orders 
 
1. Duplicate therapy was prescribed without potential for increased adverse 
effects. 
2. The order lacked specific drug, dose, dosage strength, formulation, route, or 
frequency information. 
3. The wrong route was ordered without potential for toxic reactions or 
therapeutic failure. 
4. The dose of medication was five times greater than normal but without toxic 
potential. 
5. An errant order was written that was unlikely to be carried out given the 
nature of drug, dosage forms, route ordered, missing information, etc. 
1. Errors were assigned to a specific error class if the error detected met any of the listed 
criteria for each class. 
Source: Lesar TS, Briceland LL, Delcoure K, Parmalee JC, Masta-Gornic V, Pohl H. Medication prescribing 
errors in a teaching hospital. JAMA. 1990;263(17):2329-34. 
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2.1.3. The tool of Deans et al. developed in 1999 (UK) 
Deans et al. (204) in UK developed a reliable, validated method of scoring the severity of 
MEs on the basis of potential patient outcomes in 1999. The raters were asked to score the 
error cases in terms of their potential clinical significance on a visual-analogue scale from 0 to 
10, where 0 represented an incident with no potential effect on the patient and 10 an incident 
that would result in death. These anchors were chosen to allow as wide a range of responses 
as possible and thus maximize the sensitivity of the scale.  
The 30 health care professionals (10 nurses, 10 physicians, 10 pharmacists) scored 
independently 50 MEs which were selected from literature with known outcomes. Validity 
and reliability of the tool was good (204). The Dean and al.'s tool may be better for research 
as it has been tested on a large sample size and the continuous scale potentially permits more 
powerful statistical analysis in comparative studies (205, 206). However, this tools may be 
more time consuming to use because it required at least 4 health care professionals to 
calculate a reliable mean score for each ME (197, 204).     
The tool of Dean et al. was re-validated by Taxis et al. in 2002 in the Germany context(207). 
However, it required at least 3 health care professionals (not 4) to calculate a reliable mean 
score for each ME.     
2.1.4. The tools inspired from NCC MERP Index developed in 2001 (USA) 
In 1995, the United States Pharmacopeia founded the National Coordinating Council for 
Medication Error Reporting and Prevention (NCC MERP). In 1996, the Council created an 
NCC MERP Index to standardize ME definitions and outcome severity categorization. The 
Index was revised to its current form in 2001 (208). The Index currently consists of 9 discrete 
categories (A–I) that are further combined into four categories: (1) no error, (2) error, no 
harm, (3) error, harm, and (4) error, death (Figure 13).  
Many studies adapted the NCC MERP Index for evaluating potential (and actual) severity of 
MEs such as studies by Van den Bemt et al. (6 categories) (209), Davydov et al. (10 
categories) (210), Bobb et al. (3 categories) (211), Gleason et al. (3 categories) (212), and 
Quélennec et al. (3 categories) (213). In three studies, results of inter-rater reliability was 
good: agreement = 75-84% (211), k = 0.61-0.84 (212, 213).   
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Figure 13. NCC MERP Index for Categorizing Medication Errors 
Source: Duplicated from National Coordinating Council for Medication Error Reporting and Prevention. NCC 
MERP index for categorizing medication errors. 2011. Available at http://www.nccmerp.org/types-medication-
errors.  
2.1.5. The tool of Cornish et al. developed in 2005 (Canada) 
For assessing unintended medication discrepancies detected during medication reconciliation, 
Cornish et al. (214) classified each discrepancy for its potential to cause harm as unlikely, 
possible, or probable to cause harm. There was fair inter-rater reliability for judging the 
potential severity of discrepancies (k = 0.26, 95% CI, 0.16-0.36). This tool has been widely 
adopted for use in other studies which evaluated unintended medication discrepancies such as 
Kwan et al. (215), Wong et al. (216), Coffey et al. (217), Villanyi et al. (218), and Lee et al. 
(206) with good inter-rater reliability (k = 0.63-0.84 or p < 0.01).  
 
Table 18. The tool of Cornish et al. 
Class Definitions/Examples 
1 Discrepancies were unlikely to cause patient discomfort or clinical deterioration.  
Example: a patient prescribed 20 mg/d of atorvastatin calcium on admission, 
despite reporting a dosage of 10 mg/d on interview.  
2 Discrepancies were those with the potential to cause moderate discomfort or 
clinical deterioration.  
Example: a patient prescribed 25mg of atenolol twice daily on admission, despite 
reporting a dosage of 25 mg/d on interview.  
3 Discrepancies had the potential to result in severe discomfort or clinical 
deterioration.   
Example: a patient admitted with gastrointestinal hemorrhage who was ordered 2.5 
mg/d of ramipril on admission but reported no prior use of ramipril during the 
interview. 
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Source: Cornish PL, Knowles SR, Marchesano R, Tam V, Shadowitz S, Juurlink DN, et al. Unintended 
medication discrepancies at the time of hospital admission. Arch Intern Med. 2005;165(4):424-9. 
 
2.2. The impact-of-intervention tools 
The impact-of-intervention tools focus on assessing the potential impact of the PI on patient 
care (Approach 3B presented in the Article 1).  
2.2.1. The tool of Hatoum et al. developed in 1988 (USA) 
The study of Hatoum et al. in 1988 (14) was one of the most important studies in an effort to 
evaluate the value of CPSs. The objectives of the study were: (1) to evaluate the clinical 
significance of PIs, (2) to develop a process evaluation of PIs, and (3) to evaluated these PIs 
in term of economic value.  
For the first objective, the authors ranked PIs into 6 levels according to values of service by 
assessing the potential impact of PIs on patient (Table 19).  
For the second objective, process evaluation was proposed as follows:  
 Initial self-review: all clinical pharmacist providing inpatient care were asked to 
report two of their daily PIs (one  having an impact on the quality of patient care and 
the other for its potential cost-avoidance) and categorized PIs according to their 
impact on quality of care or cost.   
 Follow-up and short-term outcomes: A follow-up concerning physician acceptance 
and patient's treatment progress was recorded within two working days.   
 Peer-review process and evaluation: Nine clinical pharmacists served on three peer 
groups, each consisting of three members. Independently, these reviewers ranked PIs 
according to their potential for clinical impact on patient therapy. When two or more 
reviewers gave identical ranks, the mode was the assigned rank. Interventions with 
inconsistent ranks were discussed until it reached a consensus.  
For third objective, based on the results of the process evaluation, a random sample of those 
interventions with cost impact was subjected to evaluation of economic value. Evaluation 
focused on five considerations:  
 Saving were calculated relative to the estimated reduction in the cost of drug 
therapy (D), e.g, use of less expensive drugs, discontinuance of a drug, conversion to 
a less expensive drugs (including change of dose, dose interval, route, duration, or 
form of medication).  
 Savings were calculated relative to a more cost-effective method for drug therapy 
monitoring (M), i.e., use of appropriate monitoring variables, cancellation of 
unnecessary laboratory orders, and identification of therapeutic agents requiring fewer 
monitoring and/or fewer costly laboratory tests. 
 Savings were calculated relative to avoiding costs attributable to complications of 
drug therapy (U), i.e., costs related to the detection and management of such 
untoward effects as toxic side effects, adverse drug reactions, and therapeutic failures.  
 Savings were calculated relative to a reduction in length of patient hospitalization 
(L), i.e., more effective drug therapy resulting in improved therapy and more efficient 
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management of patient care, thus reducing the length of stay and/or avoiding 
predictable complications that might increase the hospital stay (e.g.;, preventing an 
allergic reaction in a patient for whom a known allergy is documented).  
 C: Cost of clinical pharmacy services: personnel cost (salaries) + indirect personnel 
cost (fringe and other employer-paid benefits).   
Total economic value (EV) was calculated by a multivariable formula expressed as follows: 
EV = D + M + U + L - C 
In this formula, it is possible for any one the four first variables to be positive, negative, or 
zero.  
Table 19. The intervention ranking of Hatoum et al. 
Recommendations are ranked according to potential impact on patient care. 
1.Adverse 
significance  
Recommendation supplied by the clinical may lead to adverse outcome.  
Example - None reported 
2. No 
significance 
Recommendation is informational (not specifically related or meaningful to 
the patient in question.) 
Example - Chief surgeon asked the clinical pharmacist to explain why one of 
his patients became hypotensive in the operating room. After reviewing the 
case, the pharmacist noted the pharmacist noted that vancomycin was given 
over a period of less than 60 minutes. The pharmacist then provided to the 
surgery department the appropriate information on the administration 
techniques of vancomycin. A procedural policy on vancomycin 
administration was instituted. In this case, the intervention was considered 
informational because it was after the fact. However, it will most likely have 
an impact on future use of vancomycin.  
3. 
Somewhat 
significant  
Benefit of the recommendation to the patient could be neutral depending on 
professional interpretation (to be differentiated from rank 4 where a standard 
of practice would support the recommendation).  
Example - an order was placed for an aminophylline loading dose followed  
by maintenance infusion in two separate bags and tubing. Pharmacist 
intervention: change both orders to the same bag and adjust infusion rate for 
loading and maintenance doses.  
4. 
Significant  
Recommendation would bring care to a more acceptable and appropriate 
level (i.e., standard of practice).  
Example - Preoperative cultures on patients with stump infection with 
osteomyelitis were found resistant to cefoxitin. However, patient was placed 
on cefoxitin postoperatively. Pharmacist intervention: discountinue cefoxitin. 
Use of the drug was no longer indicated due to the surgical removal of 
infected tissue through an uncontaminated tissue plane.  
5. Very 
significant 
Recommendation qualified by a potential or existing major organ 
dysfunction. 
Example - Patient with documented previous episode of heparin-induced 
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thrombocytopenia associated with a thrombotic episode was placed on 
heparin. Pharmacist intervention: substitute dextran 40 for heparin to 
prevent possible recurrence of thrombocytopenia and/or thrombotic or 
embotic complications.  
6. 
Extremely 
significant 
Information qualified by life and death situation. 
Example - Patient transferred for surgery for intracranial aneurysm was 
receiving oral narcotic therapy for chronic pain prior to transfer. However, 
therapy was not reinstated after patient was transferred. Pharmacist 
intervention: reinstitute narcotic therapy. Perioperative procedure for 
vascular disease complicated by narcotic withdrawal could cause aneurysm 
to rupture, leading to fatal hemorrhage. Also, postoperative withdrawal 
would extent hospital stay.   
Source: Hatoum HT, Hutchinson RA, Witte KW, Newby GP. Evaluation of the contribution of clinical 
pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm. 1988;22(3):252-9. 
The original tool of Hatoum al. was not tested for validity and reliability. Only interventions 
judged as level 5 and 6 by the peer reviewers of 3 pharmacists were under review by a team of 
physicians to validate the review process (219).  
The tool was commonly adopted for use in 31 of 133 studies (23%) identified in the previous 
systematic review. The results of validity and reliability of Hatoum et al.'s modified tools 
varied widely. Almost studies adopted only the ranking of clinical significance of PIs. Only 
Cousins et al. (189) adopted both ranking of clinical significance of PIs and economic 
indicators to develop a new tool. But the capacity of pharmacists to reliably code indicators of 
PIs was poor.     
 
2.2.2. The tool of Chedru et al. developed in 1997 (France)  
Chedru et al. inspired from the Hatoum et al.'s tool and developed a 4-level tool in 1997 
(220), which was used in other studies in France (221-224). The inter-rater reliability of this 
tool was tested in two studies (220, 223) and was good.  
Table 20. The tool of Chedru et al. 
Tool for rating pharmacist intervention 
Score Significance 
0 No clinical impact for the patient 
The intervention is present an objective, financial or informational exclusively 
or was proposed after the event; it is therefore without consequence for the 
patient. 
1 Significant impact 
The intervention increases the efficiency and/or safety and/or quality of life of 
the patient.  
2 Very significant impact 
The intervention prevents organ dysfunction, it avoids intensive medical 
surveillance or an irreversible consequence. 
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3 Vital impact 
The intervention avoids a potentially fatal accident. 
Source: Chedru V, Juste M. Medical evaluation of the clinical impact of pharmacist interventions [Evaluation 
médicale de l’impact clinique des interventions pharmaceutiques]. J Pharm Clin. 1997;16(4):254-8. 
 
2.3. The multidimensional tools 
Some studies combined many previous tools and used at the same time to evaluate impacts of 
PIs.    
2.3.1. The tool of Overhage and Lakes developed in 1999 (USA) 
After literature review of articles in a database for the years 1966-1997 and identified 10 
rating scale with an explicit description of definition (12). Overhage and Lake constructed a 
new tool including 2 dimensions: "severity of error" (inspired from the classification ranking 
scale of Folli et al. (13)) and "value of service" (based on the ranking system of Hatoum et al. 
(14)).  
Table 21. The tool of Overhage et Lakes 
Instrument for characterizing pharmacists’ clinical activities 
Severity of error in medication order 
Assess the inappropriateness of the order or its deviation from the standard of practice. 
A, Potentially 
lethal 
 
High potential for life-threatening adverse reactions 
Potentially lifesaving drug at a dosage too low for the disease being treated 
High dosage (>10 times normal) of drug with low therapeutic index 
B, Serious 
 
Route of administration could lead to severe toxicity 
Low dosage of drug for serious disease in patient with acute distress 
High dosage (4–10 times normal) of drug with low therapeutic index 
Dosage resulted in serum drug concentration in potentially toxic range 
Drug could exacerbate the patient’s condition (related to warnings or 
contraindications) 
Misspelling or mix-up in medication order could lead to dispensing of 
wrong drug 
Documented allergy to drug 
High dosage (10 times normal) of drug without low therapeutic index 
Omission of pretest for drug hypersensitivity 
C, Significant 
 
High dosage (1.5–4 times normal) of drug with low therapeutic index 
Drug dosage too low for patient’s condition 
High dosage (1.5–10 times normal) of drug without low therapeutic index 
Errant dual-drug therapy for single condition 
Inappropriate dosage interval 
Omission from medication order 
D, Minor 
 
Incomplete information in medication order 
Unavailable or inappropriate dosage form 
Non-formulary drug 
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Noncompliance with standard formulations and hospital policies 
Illegible, ambiguous, or nonstandard abbreviation 
E, No error 
 
Information or clarification requested by physician or other health care 
professional from pharmacist 
Cost savings only 
 
Value of service 
Assess the potential impact of the pharmacist’s recommendation on patient care. 
1, Extremely 
significant 
Recommendation qualified by extremely serious consequences or potential 
life-and-death situation 
2, Very 
significant 
 
Recommendation qualified by a potential or existing dysfunction in a major 
organ 
Avoidance of serious adverse drug interaction or contraindication to use 
3, Significant 
 
Recommendation would bring patient care to a more acceptable, appropriate 
level (e.g., standard of practice), including quality-of-life issues with 
evidence from the patient or documentation elsewhere, as well as issues of 
cost and convenience. (Standard of practice is defined by institutional 
guidelines and protocols and supported by acceptable references to the 
literature.) 
4, Somewhat 
significant 
 
Patient’s benefit from the recommendation could be neutral depending on 
professional interpretation (to distinguish this rank from rank 3, where a 
standard of practice would support the recommendation) 
More information or a clarification must be obtained by the pharmacist from 
the physician, nurse, or other appropriate health care professional before an 
order can be processed 
5, No 
significance 
Information only 
Recommendation not patient specific 
6, Adverse 
significance 
Recommendation inappropriate; its implementation may lead to adverse 
outcomes 
Source: Overhage JM, Lukes A. Practical, reliable, comprehensive method for characterizing pharmacists' 
clinical activities. Am J Health Syst Pharm. 1999;56(23):2444-50. 
The inter-rater reliability between of 3 clinical pharmacists and 2 internists was substantial 
(kw = 0.69) for severity-of-error and value-of-service scales individually. The authors found 
that severity of error and value of service were clearly related but that the relationship was not 
linear. Value of service was high for high severity-of-error interventions but could also be 
high for low severity of error. Therefore, the value-of-service and severity-of-error scales 
measured different dimensions of pharmacist's services (12).   
Others adopted the Overhage and Lakes's tool such as Bosma et al.(225), Lee et al.(226), 
Climenté-Martin et al.(227), Abdel-Qader et al.(54), Fernandez-Llamazares et al.(228, 229), 
and Somer et al.(230). Some studies (225, 226, 229), however, found poor agreement of 
ratings. There were some risks of bias which were likely to explain high agreement in the 
study of Overhage and Lakes but not repeatable in other studies (12). Bias concerning 
selection of raters included: (1) a single pharmacist who retrospectively reviewed and 
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adjusted the ratings assigned by the pharmacist who made the intervention, which improved 
the consistency of rating; (2) two internists having fellowship training in clinical 
pharmacology; and (3) one physician and one pharmacist participated in the refinement of the 
tools over a one-year period, therefore they understood well the tool. Bias concerning 
assessment process included: (1) examples and supplemental cues were developed to improve 
the consistency of ratings; (2) the two experiences raters oriented other raters who had not 
been involved in the development process.  
2.3.2.  The tool of Lee et al. developed in 2010 (Canada) 
Lee et al.(206) adopted the tool of Cornish et al. (214) and the tool of Deans et al.(204) to 
rank the clinical impact and severity of unintentional discrepancies detected during 
medication reconciliation. Each clinician categorized the clinical impact of each discrepancy 
as unlikely, possible, or probable to cause harm (214). These were then further categorized as 
having the potential to cause discomfort, clinical deterioration, or both and  were assessed for 
severity as mild, moderate, or severe using a 9-point scale (204). Pairwise k-scores of 2 
pharmacists, an internist, and an intensivist ranged from 0.637 to 0.769, indicating a 
substantial degree of agreement between assessors. 
2.3.3. The tool of Hick et al. developed in 2001 (UK)  
Hick et al. (205) used both the tool of Dean et al. (204) and the tool of Hatoum et al. (14) in 
their study.  
2.3.4. The tool of Lindblad et al. developed in 2007 (Canada) 
According to the tool of Lindblad et al. (231), anticipated health outcomes of PIs were defined 
according to the ECHO model (economic, clinical, and humanistic outcomes) (162). There 
were 5 clinical outcomes. Humanistic sub-outcomes were combined into a single category to 
simplify reporting. Economic sub-outcomes were also combined to focus specifically on drug 
costs that were quantifiable by the pharmacist (Table 22). Each PIs can be assessed to have 
one or many outcomes. During the study period, pharmacists anticipated that  2,645 PIs would 
lead to a total of 6,101 outcomes. Over 62% of the anticipated outcomes were clinical, 32.9% 
were humanistic, and 4.5% were economic. An average of 2.3 outcomes were associated with 
each PI. For every intervention, there were on average 1.4 clinical outcomes, 0.8 humanistic 
outcomes, and 0.1 economic outcomes (231). However, a disadvantage of the tool was that 5 
clinical outcomes were not hierarchical and were not mutually exclusive. Furthermore, it is 
difficult to base on categories of clinical outcomes to estimate cost avoidance of a PI.  
Table 22. The tool of Lindblad et al. 
Anticipated outcomes  Numeric code 
Clinical  
Cure a disease  1A 
Eliminate or reduce signs or symptoms  1B 
Arrest or slow a disease process 1C 
Prevent a disease or symptom 1D 
Achieve desired alterations in physiologic processes 1E 
Humanistic 
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Improve physical, mental, or social function or satisfaction with care 
(feeling better) 
2A 
Economic 
Drug cost savings of $1 or more/day 3A 
Drug cost increase of $1 or more/day 3B 
Source: Lindblad A, Alleyne A, Howorko J. Development and Initial Evaluation of a Software-Based Clinical 
Workload Measurement System for Pharmacists. Can J  Hosp Pharm. 2007;60(5):295-301. 
 
2.4. The tools of risk assessment 
These tools are based on standards for risk management, where risk is based on an estimate of 
the likelihood and consequences of an adverse outcome from a DRP, if no IP had made.  
2.4.1. The tool of the Society of Hospital Pharmacists of Australia in 2005 (Australia) 
The Society of Hospital Pharmacists of Australia’s (SHPA) Standards of Practice for Clinical 
Pharmacy provide a risk-classification system for PIs in hospital inpatients (10). A special 
feature of the SHPA's tool was that 5 levels of financial loss was integrated into the 
"consequence" dimension (Table 23). Struck at al. (123) evaluated inter-rater reliability of a 
modified tool and found that agreement between 2 pharmacists was moderate for the 
"consequence" dimension (kw = 0.51), slight for the "likelihood" dimension (kw = 0.14), and 
fair for the "economic benefit" dimension (kw = 0.39). Elliott et al. (232, 233) adapted the 
SHPA's tool to develop a new risk-classification system for use in geriatric ambulatory care. 
Results of validity was good (agreement = 93-100%) but inter-rater reliability of risk 
classification was fair (k = 0.24)(233).   
 Table 23. The tool of the Society of Hospital Pharmacists of Australia's tool 
Level/Descriptor Consequence or impact  
1. Insignificant No harm or injuries, low financial loss. 
2. Minor Minor injuries, minor treatment required, no increased length of stay or 
re-admission, minor financial loss.  
3. Moderate Major temporary injury, increased length of stay or re-admission, 
cancellation or delay in planned treatment/procedure. Potential for 
financial loss. 
4. Major Major permanent injury, increased length of stay or re-admission, 
morbidity at discharge, potential for significant financial loss. 
5. Catastrophic Death, large financial loss and/or threat to goodwill/good name.  
Level/Descriptor Likelihood of occurrence  
A. Almost certain Is expected to occur in most circumstances 
B. Likely Will probably occur in most circumstances 
C. Possible Might occur at some time 
D. Unlikely Could occur at some time 
E. Rare May occur only on exceptional circumstances 
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Risk (consequence x likelihood) 
Likelihood  Insignificant Minor Moderate Major Catastrophic 
A (almost certain)  H H E E E 
B (likely) M H H E E 
C (possible) L M H E E 
D (unlikely) L L M H E 
E (rare) L L M H H 
E = extreme risk; H = high risk; M = moderate risk; L = low risk 
Source: Society of Hospital Pharmacists of Australia. SHPA Standards of Practice for Clinical Pharmacy. J 
Pharm Pract Res. 2005;35(2):122-46. 
2.4.2. The tool of Lewinski et al. developed in 2010 in Germany 
Lewinski et al. (234) constructed a 3x3 matrix of risk assessment of DRPs. Inter-rater 
reliability in risk assessment was high (k = 0.78, 0.83 and 0.87 for three possible rater 
pairings).  
Table 24. The tool of Lewinski et al. 
 Severity 
1 2 3 
Probability 1 Low Significant High 
2 Low Significant Significant 
3 Low Low Significant 
Severity categories 
1 - Reversible, slight impairment of health compared to the best possible state of health 
(e.g. ineffective athlete's foot treatment). 
2 - Reversible, significant impairment of health compared to the best possible state of 
health (e.g. causation or prolongation of inability to work). 
3 - Irreversible or serious impairment of health (e.g. emergency, hospitalization), unwanted 
pregnancy 
Probability categories 
1 - p: existent - 0.02 (excl.) 
2 - p: 0.02-0.2 (excl.) 
3 - p: 0.2 and more, already occurred. 
Probability or severe rated 0: Exclusion, that is not safety-relevant, no intervention 
necessary. 
Assessment procedure 
First step: Listing and classifying for severity of all possible harms that can be induced by 
the drug-related problem (Harm can either be an acute event or a prolongation of an 
ameliorable condition.) 
Second step: Assessment of probability for harm occurrence for the harm(s) of the highest 
severity category 
Source: Lewinski D, Wind S, Belgardt C, Plate V. Prevalence and safety-relevance of drug-related problems in 
German community pharmacies. Pharmacoepidemiol Drug Saf. 2010;19(2):141-9. 
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2.5. The tools of assessment of cost avoidance  
The tools of assessment of cost avoidance of a PI were those that allowed to estimate the 
resources that would have been required to manage the patient as a result of the DRP. These 
tools were often used as the first step to conduct an economic study afterward.   
2.5.1. The tool of Rupp et al. developed in 1992 (USA) 
The purpose of the Rupp et al.'s tool was to estimate the cost avoidance of PIs in community 
pharmacies (196). The tool contained four questions (Figure 14). The cost avoidance was 
estimated from the cost of each level of care in question 4 multiplied by the probability rated 
from the question 3. The formula of cost avoidance was:  
 
The cost of each level of care was determined by using information from authoritative 
sources. For example, the cost of emergency medical attention followed by hospitalization of 
the patient was estimated to be $2001. The cost of the next three levels of care was estimated 
to be $110, $60, and $40. Finally, the study determined that the total value of PIs was 
$76,616, value per intervention $122.98 and value per prescription screened $2.32.    
Concerning the inter-rater reliability of a physician and 2 pharmacist, it was good agreement 
for the three first questions (k = 0.68-0.88, k = 0.79-0.82, t-test p > 0.05, respectively) but 
poor agreement for the last question (196, 235).   
Pharmacist intervention report evaluation 
1. Could this event have resulted in adverse health consequences to the patient if the 
pharmacist had not intervened ? (check one)  
 no (if no, stop here)      yes (if yes, please continue) 
2. What adverse health consequence do you consider most likely to have resulted from this 
event if the pharmacist had not intervened?  
 toxic or side effects of the drug(s) involved 
 inadequate control of the patient's condition 
 allergy/hypersensitivity reaction 
 other (specify) 
3. Based on the available information, what is your estimate of the probability that this event 
would have resulted in the adverse health consequence specified above? (circle one) 
 
 
 
4. What intensity of healthcare would be need to treat the adverse health consequence 
specified above, assuming that it did occur? (check one) 
 emergency medical attention (hospitalization likely) 
1.0 0.9 0.7 0.3  0.5 0.1 0 
very 
unlikely 
somewhat 
unlikely 
very 
likely 
somewhat 
likely 
neither 
likely 
nor 
unlikely 
[cost avoidance] = [probability of consequence] X [cost of level of care] 
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 emergency medical attention (hospitalization unlikely) 
 unscheduled physician contact (urgent care) 
 scheduled physician contact (office visit) 
 self-care (specify) 
Comments:  
Figure 14. The tool of Rupp et al. 
Source: Rupp MT. Value of community pharmacists' interventions to correct prescribing errors. Ann 
Pharmacother. 1992;26(12):1580-4. 
 
2.5.2. The tool of Caleo et al. developed in 1996 in Australia 
Caleo et al. (236) modified the first four questions of the tool of Rupp et al. (196) and added 
two questions to evaluate the quality of life of a patient and one for the overall outcome. 
Concerning the inter-rater reliability of 2 clinical pharmacologists, a clinical pharmacist, and a 
community pharmacist, it was moderate to good agreement for the question 2 (k = 0.50-0.76) 
and was poor to moderate agreement for the rest of questions.   
Pharmacist intervention report evaluation 
1. Could this event have resulted in adverse health consequences to the patient if the 
pharmacist had not intervened?  
 No (if no, stop here)      Yes (if yes, please continue) 
2. What adverse health consequence do you consider most likely to have resulted from this 
event if the pharmacist had not intervened?  
 Toxic or side effects of the drug(s) involved 
 Inadequate control of the patient's condition 
 Allergy/hypersensitivity reaction 
 Other (specify) 
3. Based on the available information, what is your estimate of the probability that this event 
would have resulted in the adverse health consequence specified above? (circle one) 
 
 
 
4. If the intervention had not occurred, what is your estimate concerning the extent of 
interference with the patient's everyday activity? (circle one) 
 
  
For how many days would this effect last?........(give a range if unsure)
1.0 0.9 0.7 0.3  0.5 0.1 0 
very 
unlikely 
somewhat 
unlikely 
very 
likely 
somewhat 
likely 
neither likely 
nor unlikely not at  
all 
definitely 
1.0 0.75 0.5 0.25 0 
slight  severe moderate no  interference 
no normal 
activity 
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5. Based on the available information, what is your estimate of the degree of patient 
discomfort? (circle one) 
 
  
 
For how many days would this discomfort last?........(give a range if unsure) 
 
6. What intensity of healthcare would be need to treat the adverse health consequence 
specified above, assuming that it did occur? (tick one) 
 Intensive care - hospital and no. of days........(give a range if unsure) 
 Standard ward - hospital and no. of days.........(give a range if unsure) 
 Accident and emergency (Casualty) - hospital 
 Urgent physician visit  
 Next regular physician visit  
 Self-care (specify) 
7. What is the overall outcome for the patient as a result of this intervention by the 
pharmacist? (tick one) 
 Negative 
 Neither 
 Positive 
Figure 15. The tool of Caleo et al. 
Source: Caleo SUE, Benrimoj S, Collins D, Lauchlan R, Stewart KAY. Clinical evaluation of community 
pharmacists' interventions. Int J Pharm Pract. 1996;4(4):221-7. 
2.5.3. The tool of Bayliff et al. developed in 1990 (Canada) 
Outcomes of PIs were labelled either detrimental, no effect, or beneficial to patient care (194). 
The inter-rater reliability of this rating between 4 physicians was good (coefficient of 
agreement = 0.76 (p>0.05), effective reliability = 0.93).  
The cost avoidance of PIs was estimated through a formula:  
 
Therefore, raters were required to answer whether the intervention averted a prolonged stay, 
and if prolonged, the extent of prolongation (1, 3, 5, or a week or more).  
The concordance between raters was lower for the two final question (coefficient of 
agreement 0.30-0.38 (p>0.05), effective reliability = 0.63-0.71). The study found that of 15 
PIs assessed, eight PIs were judged to have a prolonged hospital stay a mean of 3.7 days each 
or a total of 29.6 days. At the per diem rate of $600 per day this rendered a cost avoidance of 
$17,760. This method of estimation of cost avoidance of PIs were adopted to use in study of 
Chedru et al. in France (220).  
1.0 0.75 0.5 0.25 0 
slight  severe moderate no  discomfort 
extreme 
discomfort 
[cost avoidance] = [number of days of hospitalization avoided] X [cost per day] 
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Evaluation 
1. The intervention by the pharmacist resulted in a  
 detrimental effect 
 no effect 
 positive effect 
  minor effect on patient therapy 
  modest effect on patient therapy (Therapy would have been compromised or side 
effect may have occurred of the intervention did not take place.) 
  marked effect on patient therapy (Had the intervention not taken place, severe, life-
threatening events may have occurred.)  
2. If the intervention had no occurred, would hospitalization have been prolonged? 
 no   yes   don't know 
3. If yes, hospital stay may have been prolonged: 
 approximately 1 day 
 approximately 3 days 
 approximately 5 days 
 a week or more 
Figure 16. The tool of Bayliff et al. 
Source: Bayliff CD, Einarson TR. Physician assessment of pharmacists' interventions - a method of estimating 
cost avoidance and determining quality assurance. Can J Hosp Pharm. 1990;43(4):167-71, 95. 
Strong et al.(237) and Virani et al.(238) in Canada both inspired the Bayliff et al.'s tool to 
develop their own one. We presented here the tool of Varini et al. whose score of quality of a 
tool is 6 (see 1.  A  systematic  review  of  tools  for  assessing  potential  significance  of  pharmacist 
interventions .  
 The tool of Varani et al. in 2003 
Evaluation Form 
1. The intervention by the pharmacist resulted in a  
 detrimental effect 
 no effect 
 positive effect 
  minor effect on patient therapy 
  modest effect on patient therapy (Therapy would have been compromised or side 
effect may have occurred of the intervention did not take place.) 
  marked effect on patient therapy (Had the intervention not taken place, severe, life-
threatening events may have occurred.)  
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2. The above intervention would result in: 
      yes no    don't know 
increase quality of care      
avoidance of adverse effects      
decrease costs        
improve response to medication     
improve patient adherence to medication    
decrease length of hospital stay     
Comments:  
Figure 17. The tool of Varini et al. 
Source: Virani A, Crown N. The Impact of a Clinical Pharmacist on Patient and Economic Outcomes in a Child 
and Adolescent Mental Health Unit. Can J Hosp Pharm. 2003;56:158-62. 
Instead of assessment of cost avoidance in the study of Bayliff et al., Virani et al.(238) 
determined the financial impact of having a clinical pharmacist on the mental health unit. A 
retrospective cost analysis was conducted to determine prescription drug costs, ward stock 
drug costs, and total number of patient-days on the unit from pharmacy records for the year 
before and the year immediately after implementation of the position. From these data, the 
total drug cost per patient-day was calculated and compared for the two 1-year periods, using 
a matched-pair Student t-test. The study found that total drug cost per patient-day decreased 
by 14% in the 12 months after implementation of the pharmacy position.  
2.5.4. The tool of Buurma et al. developed in 2004 (Netherlands) 
 
 
 
 
 
 
 
 
 
 
Figure 18. Algorithm representing the low of questions for rating interventions 
ADR: adverse drug reaction. Source: Buurma H, De Smet PA, Leufkens HG, Egberts AC. Evaluation of the 
clinical value of pharmacists' modifications of prescription errors. Br J Clin Pharmacol. 2004;58:503-11. 
Probability: scale 1­5 
Importance: scale 1­5 
Both improvement of effectiveness 
and prevention of ADR 
Improvement of of 
effectiveness 
Prevention  
of ADR 
Other, like prevention of 
discomfort, etc. (stop)  
What is the contribution of this intervention to pharmacotherapy of this patient? 
None 
(stop) 
Positive:
What is the outcome of 
the intervention? 
Negative 
(stop) 
Probability: scale 1­5 
Seriousness: scale 1­5 
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The tool of Buurma et al. (239) was developed to use in community pharmacies. The 
algorithm used by raters for rating PIs is presented in Figure 18. According to the tool, 
assessment process included 3 steps:  
 Step 1: Raters had to rate the contribution of each PI proposed in community 
pharmacies on the pharmacotherapy of the patient as "positive", "negative" or 
"neutral".  
 Step 2: In the event of a "positive" rating, the rater had to decide whether the PI 
resulted in an improvement of effectiveness, prevention of an ADR or both.  
 Step 3: The judged improvement of effectiveness and/or prevention of ADR had to be 
rated on a five-point scale on two further points: probability and importance or 
seriousness.  
The inter-rater reliability of group including a community pharmacist, a hospital pharmacist, a 
general practitioner and a specialist was moderate (k = 0.40-0.49) for the two first steps. 
 
The impact of a PI can be described as "the product of the probability and seriousness of an 
ADR" OR as "the product of the probability and importance of effectiveness improvement" 
into 4 categories visualized in quadrant diagram: left upper quadrant A, right upper quadrant 
B, left lower quadrant C, or right lower quadrant D.  
 
Figure 19. Quadrant diagram 
Source: Buurma H, De Smet PA, Leufkens HG, Egberts AC. Evaluation of the clinical value of pharmacists' 
modifications of prescription errors. Br J Clin Pharmacol. 2004;58:503-11. 
 
 The tool of Westerlund et al. developed in 2009 
Westerlund et al. (195) inspired the algorithm of Buurma et al. to developed "an assessment 
model of clinical and economic outcomes of PIs" to evaluate PIs in community pharmacies in 
Sweden (Figure 20).  
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Figure 20. Model used for the assessment of clinical and economic outcomes of PIs 
Source: Westerlund T, Marklund B. Assessment of the clinical and economic outcomes of pharmacy 
interventions in drug-related problems. J Clin Pharm Ther. 2009;34(3):319-27. 
 
The assessment process included 2 steps: 
 Potential clinical outcomes of PIs was categorized as resulting in either an 
improvement of the therapeutic effect or a prevented/relieved ADR; or both.  
 Economic assessment of the PIs depended on type of health care resources needed to 
respond to the ADRs (e.g., cost for primary care visits and hospitalization) that were 
potentially avoided as a result of the interventions. "Primary care contact" was defined 
as a patient visit to a general practitioner, patient counselling by general practitioners 
over the phone, or a visit by a general practitioner to a patient's home.   
The formula was applied to calculate cost avoidance in the study: 
 
 
The authors did not include cost due to initiated primary care contacts, thus this cost was zero. 
The authors did not include indirect societal cost avoidance, such as that for sick leave 
expenditures and chose also not to use a multiplier to represent the idea that PI may have 
avoided more than one visit to the doctor in some patients. Finally, the authoer did not adjust 
for the possibility that some of the visits might have required a specialist, instead of a GP. 
 
The estimated pharmacy personnel costs for identifying, resolving and documenting the DRPs 
were calculated. Calculations were based on the average time spent per DRP in the study and 
an estimated average salary, according to the following formula:  
 
 
 
Extrapolation of the estimate to the national level, the authors found that the annual potential 
cost avoidance in Sweden was 357.9 million EUR (51.2 million EUR for avoided primary 
[cost avoidance] = [cost of avoided primary care visit] OR 
[number of avoided hospitalization days] X [cost per day] 
[cost of implementation] = [number of identified DRPs] x 
[time spent⁄DRP] x [personnel cost time] 
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care contacts and 306.7 million EUR for avoided hospitalizations). The annual pharmacy 
personnel costs for identifying, resolving and documenting DRPs was 9.6 million EUR. The 
ratio between the potential societal cost avoidance and the pharmacy personnel costs was thus 
37.3.  
2.5.5. The tool of Kopp et al. developed in 2007 (USA) 
The authors adopted the tool of Overhage and Lakes (12) to evaluate severity of potential MEs 
and significance of PIs and the method of Leape et al.(135) to estimate cost avoidance of PIs.   
Cost avoidance referred to potential money saved if the potential ADE was caught. To 
determine cost avoidance of potential ADE, each intervention was determined the probability 
of a potential ADE occurring in the absence of the intervention. Based on a previous 
investigation, the probability of an ADE was set at 0, 0.01, 0.1, 0.4, or 0.6. Each evaluator’s 
probability values were then multiplied by the estimated cost of a preventable ADE to 
calculate cost avoidance.  
 
In this study, cost savings refers to money saved, estimated by the evaluators based on 
differences in medication costs (e.g., intravenous-to oral conversions). 
 
 
 
 
 
 
 
 
 
[cost avoidance] = [probability of a potential ADE] X [cost of an estimated ADE] 
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PART 3.  
DEVELOPMENT AND VALIDATION OF A NEW 
TOOL FOR ASSESSMENT OF POTENTIAL IMPACTS 
OF PHARMACIST INTERVENTIONS 
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This part will introduce a national documentation system of PIs used commonly in hospitals 
in France - Act-IP®, a context in which the development of a new tool for assessment of 
potential impacts of PIs emerged. In the next section, the process of construction of the CLEO 
multidimensional tool will be presented. Finally, the results of two studies for testing the 
CLEO tool - one in general context and another in a specific clinical setting will be reported.  
1. The tool for documentation of PIs in France - Act-IP© 
In 2003, the French Society of Clinical Pharmacy (SFPC) drew attention to the lack of a 
validated tool for documentation of PIs performed in hospitals (130). Consequently, a special 
interest group (SIG) ‘‘Standardizing and demonstrating the value of clinical pharmacy 
activities’’ was formed by eight clinical pharmacists belonging to the SFPC working in six 
different hospitals. The SIG was charged with developing and validating an instrument for the 
documentation of clinical PIs (97). This instrument can be used in daily routine, including (1) 
the identification of DRPs, (2) the PI, (3) the type of drug involved (using ATC classification 
(Anatomical Therapeutic Chemical)), (4) the acceptance of the intervention by the prescriber. 
Ten main categories were determined for DRPs and seven for interventions (Figure 21). A 
detailed description of sub-domains for DRPs and interventions is given in Table 25 and 
Table 26.  
For the internal validity of the instrument (240), a panel of 12 French hospital pharmacists 
assessed 60 PIs which were randomly selected from daily practice in the six hospitals. Each 
case was composed of a brief description of the medical context and all relevant elements 
concerning the potential or identified DRP and the intervention suggested by the pharmacist. 
Of 12 pharmacists, a pair of one pharmacist from the SIG and an independent one was 
selected from six hospitals. For classification of DRPs, six pharmacists from SIG agreed in 
57% of cases with k = 0.77 while six independent ones agreed in 53% of cases with k = 0.75. 
For classification of PIs, the concordance between six pharmacists from SIG was 77% with k 
= 0.88 while the concordance between six independent pharmacists was 70% with k = 0.86.  
For the external validity of the instrument (97), a panel of 12 French speaking clinical 
pharmacists (six from France; six from foreign French speaking hospitals: two from Canada, 
two from Switzerland and two from Belgium) was asked to analyze a set of 60 PIs. Sixty 
cases of intervention were randomly selected from daily practice in the six hospitals 
participating in the SIG. The level of concordance observed in the validation was 0.76 for 
DRPs and 0.89 for the type of intervention. Concerning the coding of DRPs, the kappa 
coefficient for the six foreign experts was excellent (k = 0.82) and good for the six French 
experts (k = 0.73). Concerning the "type of intervention", kappa was excellent both for the 
foreign experts (k = 0.91) and for the French experts (k = 0.87). For the user-friendliness of 
the instrument, eleven experts out of 12 were "very satisfied" or "satisfied" and one "not 
satisfied" with the tool. Ten out of the 12 experts were ready to use it in daily practice. 
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Table 25. Description of drug related problems 
- Identification of DRP is based on the analysis of a drug prescription taking into account the 
available clinical and paraclinical data on the patient. 
- Only one problem intervention per form: If the patient’s drug regimen analysis reveals 
several problems, fill out as many intervention forms as there are problems. 
- Question(s) - Is this patient developing or is he susceptible to develop a symptom linked to a 
specific drug or is there a drug related problem requiring an intervention to avoid the 
unnecessary mobilization of resources? 
DRP Description 
1.1 Non conformity 
to guidelines 
or contra-
indication 
Non conformity of the drug choice compared to the Formulary: An equivalent is 
available on the formulary 
Non conformity of the drug choice compared to guidelines: Another drug has a better 
benefit/risk ratio or a better cost/efficacy ratio according to current guidelines 
There is a physio-pathologic contra-indication for the present drug: for example: the 
patient is asthmatic and was prescribed beta-blockers 
1.2 Untreated 
indication  
Valid indication without drug prescription 
A new symptom is not being treated 
A drug is missing after patient transfer 
The patient was not given any pre-medication or prophylactic treatment 
A synergic or corrective drug should be added to the ongoing treatment 
1.3 Subtherapeutic 
dosage  
Dose too low in this specific case (daily dose) 
Length of the treatment too short. (for example: antibiotic prescription for 5 days 
instead of 10 days) 
1.4 Supratherapeutic 
dosage  
Supratherapeutic dose: 
     Dose too high in this specific case 
     There is a risk for accumulation of the drug 
Duplicate prescription: a same active substance is prescribed several times (for 
example: oral acetaminophen and the oral association of 
dextropropoxyphen/acetaminophen) 
1.5 Drug without 
indication  
No justified indication for the drug 
The drug is prescribed for too long (for example: antibiotics prescribed for 15 days) 
Therapeutic redundancy: prescription of two different molecules from the same 
therapeutic class 
1.6 Drug interaction  A drug interferes with another drug and can lead to a non adapted pharmacological 
impact (over or under expressed) 
    Level according to the French ‘‘Red Book’’ Vidal© 
    Interaction reported but not documented in the Vidal© (specify bibliographic 
references) 
1.7 Adverse drug 
reaction  
The patient presents an adverse drug reaction with an adequate dosage (clinical, 
biological, or kinetic effect) 
1.8 Improper 
administration  
The drug is adequate but the mode of administration is not adapted 
    Another route may be more effective or less costly for the same effectiveness 
    The mode of administration is not adequate (reconstitution, dilution, length of 
administration) 
    Inappropriate drug form 
    Incomplete formulation (dosage missing, etc.) 
    Inappropriate timing of administration 
1.9 Failure to 
receive drug  
Physicochemical incompatibility between several injectable drugs: there is a risk of 
precipitation between drugs during infusion 
    Patient’s non-compliance 
1.10 Drug monitoring  The patient is not suitably or sufficiently followed-up: lab tests, kinetics, symptoms 
(glycemia, EKG, blood pressure, blood concentration of specific drugs, etc.) 
Source: Allenet B, Bedouch P, Rose FX, Escofier L, Roubille R, Charpiat B, et al. Validation of an instrument 
for the documentation of clinical pharmacists' interventions. Pharm World Sci. 2006 Aug;28(4):181-8. 
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Table 26. Description of the pharmacist’s interventions 
Only one choice per chart 
Intervention Description 
2.1 Addition of a new drug  Addition of a drug to the ongoing treatment
2.2 Drug discontinuation  Discontinuation of a drug without any substitution 
2.3 Drug switch  Switch from the currently administered drug to another drug 
Substitution for a generic drug or a therapeutic equivalent (according to 
the local formulary) 
Switch following a validated protocol 
Switch for another drug better adapted to the case 
2.4 Change of administration route 
 
Parenteral/oral switch 
    Alternative drug with equivalent effectiveness and possible oral 
administration 
    Alternative oral form of a parenteral drug with the same 
bioequivalence 
Choice of a route of administration better adapted to the case 
2.5 Drug monitoring  Drug monitoring: INR, kalemia, kinetics, symptoms, etc 
Discontinuation/Request for a new lab test 
Discontinuation/request for a new dosage of a specific drug 
2.6 Administration mode 
optimization 
 
Timing of administration 
    Distribution of doses according to food intake, to drug–food, drug–
drug interactions (without modification of the dose) 
    Information on the drug regimen (for example: take on an empty 
stomach, take during meals, take in the standing position, etc.) 
Data on administration procedure (for example: mode of 
reconstitution, of dilution, length of infusion, etc.) 
2.7 Dose adjustment  Dose adjustment for a drug with a narrow therapeutic index, according 
to its blood level, to renal and hepatic data, or other lab test 
Dose adjustment according to the patient’s weight, age, clinical status 
Prolongation of treatment 
Source: Allenet B, Bedouch P, Rose FX, Escofier L, Roubille R, Charpiat B, et al. Validation of an instrument 
for the documentation of clinical pharmacists' interventions. Pharm World Sci. 2006 Aug;28(4):181-8. 
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Figure 21. The pharmacist intervention form 
Source: Duplicated from Allenet B, Bedouch P, Rose FX, Escofier L, Roubille R, Charpiat B, et al. Validation of 
an instrument for the documentation of clinical pharmacists' interventions. Pharm World Sci. 2006 
Aug;28(4):181-8. 
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To extend the documentation of these interventions to every French speaking pharmacist, a 
website, Act-IP®, was put online September 2006 to gather DRPs detected by French hospital 
pharmacists and their subsequent interventions (241). This computerized documentation 
system is freely accessible to any pharmacist on the SFPC website. By registering with Act-
IP®, pharmacists can develop traceability and analysis of their clinical pharmacy activities 
using automated queries. The pooling of PIs on the website constitutes an observatory of 
clinical pharmacy practices (130). Many studies (129, 130, 242) on DRPs and PIs were 
conducted from this database.  
 
Figure 22. The documentation system of PIs in France - Act-IP® 
Source: Available at http://www.actip.sfpc.eu 
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2. Development of the CLEO tool 
Besides description of DRPs and PIs, the evaluation of potential impacts of PIs plays an 
important role to demonstrate the added value of pharmacists through PIs. In 2004, during the 
internal validity of the above instrument (240), the ratings of the clinical impact of the PI into 
three categories (potential, actual, or non-determined) could not be validated even after 
repeatedly revised the content of categories. The inter-rater reliability of the clinical impact 
remained be moderate, even in the final validation phase (k = 0.44 for pharmacists from SIG 
and k = 0.45 for independent pharmacists). Since 2012, we have started to develop and test a 
new tool for assessment of potential impacts of PIs, based on (1) theoretical models or 
frameworks of evaluations, (2) a systematic literature review of available tools for assessing 
impacts of PIs in literature, and (3) input from practice and healthcare professionals' view. 
The new tool was developed in order to answer to questions as following: 
1.1. What indicators does the new tool include?  
From the SP(ECH)O-P integrated model for assessment of impacts of PIs (see 3.7. The 
integrated model for evaluation of impacts of PIs), the impacts of PIs can be classified into 
6 sub-types as structure-related, process-related, clinical, economic and humanistic ones and 
probability of impacts. However, the systematic review of existing tools for assessment of 
potential impacts of PIs found that all sub-types existed, except of structure-related impacts. 
The reason may explain why the PI did not effect on the structure of a setting was: a PI was 
defined as any action by the pharmacist which changes therapy management at an individual 
patient. Therefore, the PI focuses on process of care of the particular patient, and never or 
rarely changes the stable features of structure of the setting. Therefore, we wanted to develop 
a new tool which consists of all 5 sub-types of impacts: process-related, clinical, economic 
and humanistic ones and probability of impacts.   
1.2. How can the new tool be used as first steps to conduct a calculation of value of the 
PI afterward? 
From the economic model of a PI, the value of each PI was estimated from cost savings, cost 
avoidance and cost of implementation of a PI in most studies. Many existing tools were used 
as first steps to conduct a calculation of the value of a PI afterward such as Rupp et al.'s (196), 
Bayliff et al.'s (194), and Westerlund et al.'s tool (195). We wanted to develop a new tool 
which is possible to be used as first steps to conduct a calculation of the value of a PI 
afterward. Furthermore, it is possible to evaluate cost savings, cost avoidance and cost of 
implementation independently using the new tool.  
"Cost-saving impact" was inspired from Hatoum et al.'s tool which took into consideration 
two variables: cost of drug therapy (positive, negative, zero) and drug therapy monitoring 
(increase, decrease, no change). But we wanted to simplify two variables into only "cost-
saving impact" (positive, negative, zero) and used a term "Economic impact" instead of "cost-
saving impact" (see Figure 23). Similar to some studies (14, 189), by choosing IPs which have 
positive or negative on economic impact, we can calculate the cost-savings of a sample of PIs.   
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"Cost avoidance" can be estimated through health care resources needed to treat harm which 
were prevented by the PI. Many tools used levels of health care as levels of severity of the 
DRP or importance of the PI. Therefore, we wanted to add different types of health care 
resources avoided by the PI into "Clinical impact" dimension. The types of health care 
resources were inspired from the NCC MERP index (243) and the SHPA's tool (233). Three 
main levels of care include treatment/monitoring, hospitalization and intensive care/death.    
"Cost of implementation of the PI" will be estimated mostly by the time pharmacists took to 
propose the PI plus other costs. Like most studies in literature, estimation of cost of 
implementation of the PI was not tested for validity and reliability. Therefore, we chose to not 
include it in the new tool.     
1.3. How many levels does the "Clinical impact" include? 
The 6-level structure of intervention ranking of Hatoum et al.’s tool (244) was used widely in 
the literature. Furthermore, this ranking included negative, null and positive ranking because 
although rarely, but it exists cases when a PI can cause harm to the patient (negative impact) 
(136). However, the Hatoum et al.'s intervention ranking did not include different types of 
health care resources avoided due to the PI. Instead of this, the authors separated intervention 
ranking with estimation of cost avoidance. Therefore, we chose a 6-level structure for the 
"clinical impact" dimension, including: negative (-1), null (0), minor (1), moderate (2), major 
(3), and vital (4). But we had to find new definitions of levels.  
1.4. How to define six levels of the "Clinical impact" dimension? 
In the systematic review of available tools for assessing impacts of PIs, important indicators 
of humanistic outcomes used were patient’s knowledge, medication compliance, satisfaction, 
inability to work, and quality of life. Humanistic outcomes was often evaluated combinedly 
with clinical outcomes into “significance” dimension and classified as “low significance” (96, 
220, 245-250). Some tools evaluated independently humanistic impacts of a PI (34, 231, 238, 
251, 252) with poor inter-rater reliability (236). It is likely that most consequences resulting 
from PIs will have relatively minor on humanistic outcomes (154). Therefore, we chose to 
define the level 1 of the "clinical impact" dimension by humanistic indicators (knowledge, 
satisfaction, medication compliance and/or quality of life of the patient) (Figure 23).   
The level 2, 3, and 4 are terminated by main avoidance indicators according to the NCC 
MERP index (243) and the SHPA's tool (233). The level 2 is equivalent to 
monitoring/treatment avoided while the level 3 is equivalent to an initiated or prolonged 
hospitalization avoided. The level 4 is equivalent to a potentially intensive care or death of 
the patient avoided. 
 
 
 
 
 
 124 
 
1. Clinical impact 
Score Impact Definition: The clinical impact is evaluated according to the most likely 
case expected, not the worst/best case 
-1C Nuisible The PI can lead to adverse outcomes on clinical status, knowledge, 
satisfaction, patient adherence and/or quality of life of the patient. 
0C Null The PI can have no influence on the patient regarding the clinical status, 
knowledge, satisfaction, patient adherence and or quality of life of the 
patient. 
1C Minor The PI can improve knowledge, satisfaction, medication adherence and/or 
quality of life OR the PI can prevent damage that does not require 
monitoring/treatment. 
2C Moderate The PI can prevent harm that requires further monitoring/treatment, but 
does not lead or do not extend a hospital stay of the patient. 
3C Major The PI can prevent harm which causes or lengthens a hospital stay OR 
causes permanent disability or handicap. 
4C Lethal The PI can prevent an accident that causes a potentially intensive care or 
death of the patient. 
ND Non-
determined 
The available information does not determine the clinical impact. 
 The clinical impact is evaluated for the patient's benefit.  
  Harm: alteration of the physical and mental capacities arising from an accident or illness.  
 Quality of life: physical function (autonomy, physical abilities, capacity to perform the tasks of 
daily life ...), psychological (anxiety, depression, emotion ...), social (relative to family 
environment, friendly or professional, engaging in personal relationships, participation in social 
and leisure activities ...) and somatic (symptoms related to the disease). 
  Monitoring: monitoring clinically relevant (physiological or psychological), biological.  
 Treatment: changing therapy or adding an additional medical / surgical treatment. 
 
2. Economic impact 
Score Impact Definition 
-1E Increase of cost The PI increases the cost of the drug treatment of the patient. 
0E No change The PI does not change the cost of drug treatment of the patient. 
1E Decrease of cost The PI saves the cost of drug treatment of the patient. 
ND Non-determined The available information does not allow determining the economic 
impact. 
 The cost of drug therapy contains two main elements: 
o The cost of drugs 
o The cost of monitoring of drug therapy (e.g., clinical, kinetic, biological monitoring ...).  
  The cost of drug therapy is based on the financial cost of the hospital. 
 
3. Organizational impact 
Score Impact Definition 
-1O Desfavorable The PI reduces the quality of care process. 
 0O Null The PI does not change the quality of the care process. 
 1O Favorable The PI increases the quality of the care process. 
ND Non-determined The available information does not identify the organizational impact. 
 The organizational impact is coded regarding the overall impact on the quality of the care 
process from the perspective of health care providers (eg, time savings, improved security, 
knowledge, job satisfaction of nursing staff; facilitating professional tasks or teamwork, 
continuity of care, etc.) 
Figure 23. The CLEO tool 
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1. Clinical impact 
Score Impact Example  
-1C Nuisible Description: Patient treated for ashme by Seretide (salmeterol, fluticasone) 
50/25mcg INHAL 3 times/day. DRP: surdose. PI: pharmacist proposed to reduce to 
the usual dose of 2 times/day. Physician's opinion: no reduction because it was a 
severe asthma. REFUSED. (Impact of IP was evaluated assuming that it will be 
accepted by the physician.)                                                         CL = -1, E = 1, O = 0 
0C Nul Description: patient treated for angina by ROVAMYCINE (spiramycin) 500mg 
morning and night for 10 days. PM: spiramycin dosage is measured in MUI and is 3 
MIU morning and night in case of angina. IP: dosage adjustment of ROVAMYCINE 
to 3 MIU morning and night.                                             CL = 0, E = 0, O = 1 
1C Minor Description: Patient treated for a skin infection (dermatophyte) by KETODERM 
(ketoconazole) 2% GEL SACHET 6G. PM: daily prescription of KETODERM. IP: 
conventional dosage is 2 times per week.                  CL = 1, E = 1, O = 1 
2C Moderate Description: respiratory infection in a child of 38 kg with AUGMENTIN 
(amoxicillin clavulanate) 100 mg/12.5mg oral suspension a weight based dosing 1 
time daily for 7 days. PM: risk of underdose. IP: change to 3 times per day.  
                                                                                                    CL = 2, E = -1, O = 0   
3C Major Description: Woman 85 years old treated by AUGMENTIN (amoxicillin + 
clavulanic acid) IV for sinusitis. PM: patient known to be allergic to beta-lactams 
(angioedema). IP: change to PYOSTACINE (pristinamycin) 500mg tablet. The daily 
cost of treatment is more expensive.                                          CL = 3, E = -1, O = 1 
4C Vital Prescription of COLCHIMAX (colchicine + opium) and PYOSTACINE 
(Spiramycin) 500MG tablet in a patient. PM: inadvisable association. Increased risk 
of adverse effects of colchicine with potentially fatal consequences. IP: Stopping 
COLCHIMAX.                                                                         CL = 4, E = 1, O = 0 
2. Economic impact 
Score Impact Exemple 
-1E Increase of 
cost 
Description: DIGOXINE NAT 0.25mg 1 tablet/ day prescribed in a patient for heart 
failure. PM: K + = 3.1mmol / L (normal range: 3.5 to 5 mmol / l). Hypokalemia 
increases the toxicity of DIGOXIN (risk of heart rhythm disturbances). IP: Adding 
Diffu 600MG K, 3 capsules/day and monitoring of serum potassium.  
                                                                                               CL = 2, E = -1, O = 0 
0E No change Description: prescription of ROCEPHINE (ceftriaxone) 1 g/day for a 75 year-old 
patient for pneumonia. PM: no details on injectable route (IV or IM or SC). IP: 
suggest IM route.                                                                  CL = 1, E = 0, O = 1 
1E Reduction 
of cost 
Description: LOVENOX 30000UI AXa/3ML INJ FL prescribed for a 78 year-old 
patient with curative dose. PM: scheduled Surgery required discontinuation of 
LOVENOX but the final date of treatment was unspecified. IP: Suggest a final date 
of LOVENOX.                                                                      CL = 2, E = 1, O = 1 
3. Organizational impact 
Score Impact Exemple 
-1O Disfavorable Description: prescription of HALDOL (haloperidol) 5MG/1ML SOL INJ 
AMP and TERCIAN (cyamemazine) 50MG/5ML injectable for an agitated 
patient. PM: Using the same syringe for mixing. IP: separation because of 
physicochemical incompatibility.                                  CL = 2, E = 0, O = -1      
0O Null Description: 60 year-old patient with prescription of Stilnox (zolpidem) 
10MG 2 tablets/day for insomnia. PM: maximum dosage 1tablet/day. IP: 
reduced to 1 tablet/day.                                                 CL = 2, E = 1, O = 0 
1O Favorable Description: Patient treated with FOSAVANCE (alendronic acid, 
cholecalciferol) 70mg/2800UI tablet in a patient at risk of osteoporotic hip 
fracture. PM: FOSAVANCE was not present in the drug formulary. IP: 
Suggest to replace by ADROVANCE (alendronic acid, cholecalciferol) 70 
mg/2800UI tablet. Price is equivalent.                           CL = 0, E = 0, O = 1 
Figure 24. Examples for assessment of impacts of PIs by using the CLEO tool 
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1.5. How was the probability of consequences of the PI? 
To simplify the new tool, we asked evaluators to rate according to the most likely 
consequence expected for the "clinical impact" dimension, not the worst/best one, and did not 
require determining the numerical probability. 
However, if researchers want to calculate the cost avoidance or risk assessment related to 
"clinical impacts", they can require raters to estimate the  level of probability of impacts after 
rating "clinical impacts", similar to the tool of Rupp et al. (196) or the tool of the SHPA (10), 
respectively. 
1.6. How was the "process-related impact" of the PI evaluated? 
Most tools focus on patient outcomes. PIs, however, also are useful for the health practitioners 
during care process. Tools therefore should reflect the possible impacts on both. For example, 
the majority of MEs were formalities regarding information about patient, prescriber and 
reimbursement. These formal errors and omissions have no direct consequences for the drug 
therapy and patient safety or cost savings, but they facilitate drug dispensing as the nurses 
doesn't have to contact the prescriber, patient or relatives to obtain the required information 
before the drug can be handed out (145). Therefore, we added the "Organizational impact" 
dimension which aims to detect any organizational effects of a PI from HCPs’ perspective, 
such as time savings, improvement of knowledge or safety for HCPs (Figure 23).  
 
We name this multidimensional tool as CLEO (CLinical, Economic, and Organizational) 
(Figure 23). Characteristics of CLEO tool are: terms/indicators are well defined; each 
dimension consists of 3-6 ordered, numeric levels; each dimension has both negative, zero, 
and positive levels, and an open level "non-determined" (Figure 23).  
 
1.7. How do people use the new tool and interpret the results of ratings? 
For each PI, the three dimensions were combined into a three-component code describing the 
entire impact of a PI (see examples in Figure 24). For example, a PI with (2C, -1E, 1O) 
means that the PI have moderate clinical impact (...) from the patient's perspective, negative 
economic impact (increase the cost of drug therapy and/or drug monitoring) from the 
hospital's perspective, and positive organizational impact on process of care from health care 
providers' perspective.  
For a sample of PIs, the results can be expressed as:  
 % PIs with -1C, 0C, 1C, 2C, 3C, 4C, ND-C; % PIs with -1E, 0E, 1E, ND-E, and %PIs 
with -1O, 0O, 1O, ND-O.  
 Average/Mean of numerical levels per PI. For example, 2.3 for clinical, 0.8 for 
economic, and 0.6 for organizational impact per intervention.   
 % PIs with different combinations described in Table 27.   
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Table 27. Matrix for combination of 3 dimensions of the CLEO tool 
CL E O  CL E O  CL E O 
-1 -1 -1 0 -1 -1 1 -1 -1 
-1 -1 0 0 -1 0 1 -1 0 
-1 -1 1 0 -1 1 1 -1 1 
-1 0 -1 0 0 -1 1 0 -1 
-1 0 0 0 0 0 1 0 0 
-1 0 1 0 0 1 1 0 1 
-1 1 -1 0 1 -1 1 1 -1 
-1 1 0 0 1 0 1 1 0 
-1 1 1 0 1 1 1 1 1 
 
2 -1 -1  3 -1 -1  4 -1 -1 
2 -1 0 3 -1 0 4 -1 0 
2 -1 1 3 -1 1 4 -1 1 
2 0 -1 3 0 -1 4 0 -1 
2 0 0 3 0 0 4 0 0 
2 0 1 3 0 1 4 0 1 
2 1 -1 3 1 -1 4 1 -1 
2 1 0 3 1 0 4 1 0 
2 1 1 3 1 1 4 1 1 
 
1.7. Which materials help to use the CLEO?  
A CLEO algorithm (Figure 25), similar to the NCC MERD algorithm (208), was created for 
guiding ratings. Some examples of results of rating by using the CLEO tool (Figure 24) were 
selected from validation process by an expert panel.  
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Figure 25. Algorithm for rating of significance of PIs according to the CLEO tool 
Harm: Impairment of the physical, psychological function or somatic function 
(structure of the body and/or pain resulting there from). 
Humanistic outcomes: knowledge, satisfaction, compliance, and quality of life 
of the patient. 
Quality of life: Physical function (independence, physical abilities, ability to 
perform daily activities...), psychological function (anxiety, depression, emotional 
...), and social function (environmental relationships with family, friends or 
professionals, involvement in personal relationships, participation in social and 
leisure activities ...), and somatic function (symptoms related to the disease). 
Monitoring: To observe or record relevant physiological or psychological signs. 
Treatment: May include change in therapy or active medical/surgical treatment. 
Permanent harm: irreversible harm (eg, unwanted pregnancy).  
Drug therapy cost: hospital charge of drug therapy, consisting of two main 
components: drug cost and drug monitoring cost (eg, laboratory tests). 
Process-related quality: indicators related to health care professionals’ 
perspective (time savings, safety, and knowledge, feasibility of professional 
tasks, continuity of care, job satisfaction, and adherence to guideline/evidence-
based medicine/process-related quality standards). 
*The most probable clinical impact, but not the most important clinical
impact of PI: 
Algorithm for Rating of  
Significance of  
Pharmacist Interventions  
According to the 
CLEO Multidimensional Tool 
PI may lead to 
adverse 
outcome? 
0C 
-1C 
NO 
YES 
PI may prevent a 
minor harm or
improve humanistic 
outcome?
1C 
NO 
YES 
Will a 
hospitalization or 
a readmission be 
required? 
2C 
3C 
NO 
YES 
Will the harm be 
permanent? 
3C 
YES 
PI may prevent  
a harm? 
Will an increased 
monitoring or a 
treatment be 
required?
PI may prevent a 
life-threatening 
situation? 
4C 
YES 
YES 
NO 
Process-related 
quality? 
1O 
0O 
-1O 
Drug therapy 
cost? 
 1E 
0E 
-1E 
IMPACTS OF PHARMACIST INTERVENTION 
CLINICAL IMPACT 
(Patient’s Perspective) 
ECONOMIC IMPACT 
(Hospital’s Financial 
Perspective) 
ORGANIZATIONAL IMPACT  
(Health Care Providers’ 
Perspective) 
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3. Validation of the CLEO tool 
An ideal tool for assessing the potential impacts of PIs should be comprehensive, relatively 
easy and not too time consuming to use, reliable and validated in different contexts. 
Therefore, we conducted two studies to test these properties of the CLEO tool. The first one 
aimed to test and refine the CLEO tool according to results of ratings of samples of PIs 
extracted from a variety of health care settings by seven expert pharmacists of the SIG. The 
final CLEO version obtained from the first study then was tested for daily use in a specific 
setting at the Grenoble University Hospital Center.   
3.1. Validation of the CLEO tool in a general practice by a SFPC 
expert group   
Ten years ago, the SIG failed to develop and validate a tool for assessing impacts of PIs. This 
project started again at the beginning of 2012 as a thesis work of a PhD student collaborated 
closely with seven pharmacists of the SIG who have worked in six French hospitals. In this 
first study, we decided to collect non-randomly a sample of PIs to balance types of PIs, scores 
and clinical specialty areas of practice because we want to assure the CLEO tool will be test 
in a general practice. PIs were selected from the Act-IP® database or practice of the six 
hospitals. During a period of 3 year, we asked seven pharmacists to discuss and validate the 
content of many versions of the CLEO (5 discussion meetings with 6 different versions of 
tools). Finally, the two versions of the CLEO were tested for inter-rater reliability between 
pharmacists, named the CLEO v.1 and the CLEO v.2. And the results of inter-rater reliability 
between pharmacists of the second version CLEO were improved in comparison with the first 
one. The percentage of agreement increased from 36% to 39% for "Clinical impact", from 
65% to 90% for "Economic impact", and from 57% to 62% for "Organizational impact". 
Similarly, weighted kappa score increased from 0.34 (fair) to 0.41 (moderate) for "Clinical 
impact", from 0.65 (moderate) to 0.95  (almost perfect) for "Economic impact", and 0.26 
(fair) to 0.39 (fair) for "Organizational impact". Intra-rater reliability was slight (agreement = 
33%, kw = 0.38) for "clinical impact" and moderate for "economic impact" (agreement = 
80%, kw = 0.70). Most pharmacists satisfied the whole tool, the structure of tool, definitions 
of keywords, the CLEO algorithm. However, pharmacists judged that CLEO algorithm isn't 
so useful for facilitating ratings, then we only used the CLEO v.2 with examples for ratings in 
and without providing the CLEO algorithm.    
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PURPOSE: This study aims to develop and validate a multidimensional tool for evaluating 
potential significance of pharmacist interventions (PIs) in general context. 
METHODS: Development of a new tool was based from a review of existing tools and 
evaluation models of health care interventions and inputs of PI practice. A group of 7 experts 
- 7 hospital clinical pharmacists of the French Society of Clinical Pharmacy coded 50 
scenarios extracted from the French national database of PIs by using the CLEO version 1 in 
order to calculate inter-rater reliability. Satisfaction on the content and structure of the CLEO 
version 1 by 4-level Likert (not satisfied = 0, somewhat satisfied = 2, satisfied = 4, very 
satisfied = 6) and suggestion for modification were questioned. Then, the pharmacists coded 
other 30PIs selected from six hospitals by using the CLEO v2 and recoded 10 cases 
(randomly select 30 IPs) the second time to calculate the intra-rater reliability. 
RESULTS: A first version of a multidimensional scale, named “CLEO”, includes 3 
dimensions: clinical (7 categories), economic (4 categories), and process-related dimension (4 
categories) with assessment supports (definitions of keywords, an assessment algorithm). The 
inter-rater reliability of the first ratings showed fair agreement for "clinical dimension" 
(agreement = 82%; kw = 0.34); moderate agreement for economic dimension (agreement = 
80%; kw = 0.53); and fair agreement for organizational dimension (agreement 76%; kw = 
0.27). The average scores of satisfaction on the whole tool, the structure of tool, definitions of 
keywords, the CLEO algorithm were 3.7; 4.9; 3.1; and 3.4, respectively. The CLEO version 1 
was modified into a version 2 according to many suggestions collected. The inter-rater 
reliability of the second rating was moderate for "clinical impact" (agreement = 39%; kw = 
0.41); almost perfect for "economic impact" (agreement = 90%; kw = 0.93); and fair for 
"organizational impact" (agreement = 62%; kw = 0.39). Intra-rater reliability was slight 
(agreement = 33%, kw= 0.38 ) for "clinical impact" and moderate for "economic impact" 
(agreement = 80%, kw = 0.70).  
CONCLUSIONS: A multidimensional scale CLEO for assessing the potential significance of 
PIs was developed and tested. The highest strength of reliability was found for "economic 
impact" of the CLEO classification, then "clinical impact". The lowest values were obtained 
for "organizational impact" dimension. Further study should be conducted to overcome some 
limitations of this study design, particularly the test for use in a local service is needed.   
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Introduction 
While the pharmaceutical care has undergone dramatic changes since 30 years, pharmacists 
still need to demonstrate the benefits or added value of services [1]. Pharmaceutical care has 
been described as a multi-facetted process that aims to result in positive outcomes for the 
patients. Associated with this process is the delivery of appropriate pharmaceutical services, 
which include obtaining patient medical history, evaluating laboratory data, reviewing patient 
records, and performing patient counseling, etc. These activities contribute to medication 
review of the patient with major outputs in form of PIs. PIs are defined as "any action by a 
pharmacist that directly resulted in a change in patient management or therapy" [2]. In times 
of limited resources allocation, it is important to evaluate the impacts and value of PIs 
proposed during medication review.  
 
A variety of methods [3-7] has been reported for recording of PIs. Most of methods are based 
on process-related indicators (e.g., patient-related information, drug-related information, 
causes, types of DRPs, action of pharmacists, acceptance by physicians).Some others tried to 
evaluate outcome-related indicators such as actual patient outcomes of DRPs [8], actual 
patient outcomes of PIs [9-12]; potential patient outcomes of PIs [13-18] or combinations of 
these [19-23]. Advantages and limitations of each method were described in another article 
[18, 24]. Of them, the assessment of potential impacts of a PI is frequently used because of its 
practicability when data of actual consequences are lacking, its usefulness in guidance for 
improving quality of  PIs (e.g., hierarchy of potential significance of a PI and target the most 
potential significant PIs) [24]. 
We conducted a systematic review [24] of existing tools for rating the potential impact of PIs. 
Detailed results of this review was reported in another article.  In brief, of 873 citations 
screened, 81 distinct tools were identified from 133 studies. However, the most 
comprehensive, valid, reliable and practical tool for rating the potential impacts of PIs is not 
available.  
In 2003, the French Society of Clinical Pharmacy (SFPC) drew attention to the lack of a 
validated tool for documentation of PIs performed in hospitals [25]. Consequently, a special 
interest group (SIG) ‘‘Standardizing and demonstrating the value of clinical pharmacy 
activities’’ was charged with developing and validating an instrument for the documentation 
of clinical PIs [26]. This instrument can be used in daily routine, including (1) the 
identification of DRPs (Ten main categories), (2) the PI (Ten main categories), (3) the type of 
drug involved (using ATC classification (Anatomical Therapeutic Chemical)), (4) the 
acceptance of the intervention by the prescriber. To extend the documentation of these 
interventions to every French speaking pharmacist, a website, Act-IP©, was put online 
September 2006 to gather DRPs detected by French hospital pharmacists and their subsequent 
interventions [27]. The objective of this study is to develop and validate a new tool for 
assessing potential impacts of PIs which then will be added into the next Act-IP system.  
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Method 
a. Development of a new tool 
Construction of a new tool is based from a review of models/frameworks of evaluation of 
health care interventions, a systematic review of existing tools, and inputs from experience of 
pharmacists' practice.  
Review of Models of Evaluation 
We synthetized five models: the SPO model, the ECHO model, the SEIPS model, the model of 
Martini, the economic model, and the risk assessment matrix into an integrated model for 
evaluation of impacts of PIs, named the SP(ECH)O-P.  
According to the SP(ECH)O-P model ( 
Figure 12), the PI can have impacts on structure, process of care and outcomes on the patient 
(similar to the SPO model). The outcomes can include economic, clinical, and humanistic 
outcomes (similar to the ECHO model). Not all impacts of the PI is obvious and certain but a 
potential to occur (probability). Therefore, it should combine probability of each impacts and 
severity/importance of each impacts into risk matrix (similar to the risk matrix). The value of 
each PI is the sum of differences of value of the scenario with and without the PI (similar to 
the economic model).        
According to the SP(ECH)O-P, there are six types of indicators which provide the 
comprehensive picture of impacts of PIs: structure-related, process-related impacts, clinical, 
humanistic, economic outcomes, and probability of each impact.  
Literature review of existing tools 
After analyzing and synthetizing results of the systematic search of tools for assessing 
potential impacts of PIs [24], some recommendations for development of new tools were 
suggested. We decided to develop a new tool to satisfy these recommendations. The tool 
consists of three dimensions. The Clinical dimension from patient’s perspective is scored 
from the 6-level structure of Hatoum’s tool [28]. Of which, the level 1 is defined by 
humanistic indicators and the level 2, 3, 4 are terminated according to the NCC MERP index 
[29] and the tool of the Society of Hospital Pharmacists of Australia [30]. The Economic 
dimension aims to detect whether a PI induces a cost savings or not from hospital’s 
perspective - a direct cost related to drug and monitoring. The Organizational dimension aims 
to detect any organizational effects of a PI from health care providers’ perspective, such as 
time savings, improvement of knowledge of health practitioners. We name this 
multidimensional tool CLEO (CLinical, Economic, and Organizational) (Figure 23). 
Characteristics of CLEO tool are: terms/indicators are well defined; each dimension consists 
of 3-6 ordered, numeric levels; each dimension has both negative, zero, positive levels and an 
open level "non-determined". The three dimensions were combined into a three-component 
code describing the entire impact of a PI (see example in Figure 24). A CLEO algorithm 
(Figure 25), similar to the NCC MERD algorithm, was created for guiding ratings.  
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b. Instrument testing 
The tool will be validated through three steps. In the first step, after content validation of the 
tool by a group of 7 clinical pharmacists from SIG in a direct meeting in June 2013, the 
pharmacists coded 50 scenarios extracted from the French national database of PIs “Act-IP©” 
in order to test the inter-rater reliability. Each scenarios consisted of a brief description of the 
medical context (patient information: age, sex, diagnostic) and data that were relevant to the 
potential or identified DRP (type of ADR, involved drugs), as well as the intervention made 
by the pharmacist, and acceptance by physicians. Seven clinical pharmacists have worked at 6 
different hospitals in France. The overall satisfaction and satisfaction on content and structure 
of CLEO, and usefulness of  the CLEO algorithm by 4-level Likert (not satisfied = 0, 
somewhat satisfied = 2, satisfied = 4, very satisfied = 6) and suggestion for modification of 
the tool were questioned. 
 
In the second step, from the experience of the first rating, clinical pharmacists discussed to 
modify the tool in a direct meeting in October 2013 and through a telephone conference in 
August 2014.  Clinical pharmacists found that lack of access to full clinical data of patients in 
scenarios extracted retrospectively from the database ACT-IP© may be a major barrier to 
effectiveness of PI assessment. Therefore, pharmacists were required to collect prospectively 
new scenarios from their practice and we chose PIs to ensure a balance of types DRPs and PIs 
and more complete patient's information. Each scenario was more precise regarding medical 
context: patient information, medical antecedents, medication history, diagnostic, results of 
examinations, treatment. Seven pharmacists were required to rate 30 PIs to calculate a new 
inter-rater reliability.  The mean time for scoring a PI also was recorded.  
 
In the third step, ten PIs were selected randomly from the same 30 PIs for second recoding by 
seven pharmacists two month later in order to calculate intra-rater reliability.  
 
The inter-rater reliability is calculated through percent of agreement and weighted kappa. The 
interpretation of results of weighted kappa is based on the Landis and Koch scale: k values of 
< 0 indicate poor agreement; 0.00-0.20, slight agreement, 0.21-0.40, fair; 0.41-0.60 moderate; 
0.61-0.80, substantial; 0.81-1.00, almost perfect [31]. We also determined which categories of 
the tool are main sources of disagreement between raters [32]. The statistical analysis was 
performed using the Stata statistical package, release 9.1 (StataCorp LP, College Station, TX, 
USA).  
 
Results 
Validation of the tool CLEO  
The first step 
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The inter-rater reliability for classification was as follows: fair agreement for "clinical 
impact" (agreement = 36%; kw = 0.34); moderate for "economic impact" (agreement = 65%; 
kw = 0.53); and fair agreement for "organizational impact" (agreement = 57%; k = 0.26).     
Because "clinical impact" dimension has 6 levels, consistency for rating this dimension may 
be more difficult than others. Therefore, we used weighted kappa to determine which 
categories of tool are the main sources of disagreement between raters. We found that great 
sources of disagreement were from ratings between 2C and 3C, then between 1C and 2C.  
The average score of satisfaction on the whole tool, structure of tool, definitions of keywords, 
algorithms was 3.7/6.0; 4.9/6.0; 3.1/6.0; and 3.4/6.0, respectively. Some suggestions for 
improvement of the first version of the tool were provided such as simplification of 
expression of 1C, 2C, 3C, 4C and clarification of terms in level 3C, and modification of 
definition of economic impact.  
The second rating 
The inter-rater reliability for classification was as follows: moderate agreement for clinical 
impact (agreement = 39%; kw = 0,41); almost perfect for economic impact (agreement = 
90%; kw = 0,93); and fair agreement for organizational impact (agreement = 62%; kw = 
0,39). The average time for rating per intervention using the CLEO was of 2.5 minutes.  
The third rating 
The intra-rater reliability was fair (agreement = 33%, kw = 0.38) for "clinical impact" and 
was substantial (agreement = 80% and kw=0.70) for "economic impact".  
Table 1: Inter-rater reliability of the CLEO instrument  
 Clinical Impact Economic Impact Organisational Impact 
1 st rating 2nd rating 1 st rating 2nd rating 1 st rating 2nd rating 
% kw % kw % kw % kw % kw % kw 
Mean 36 0,34 39 0,41 65 0,53 90 0,93 57 0,26 62 0,39 
Upper 95% 
limit  
32 0,29 34 0,37 57 0,42 86 0,91 53 0,20 56 0,30 
Lower 95% 
limit 
39 0,39 44 0,45 72 0,65 95 0,95 61 0,31 68 0,49 
Agreement fair moderate moderate almost perfect fair fair 
 
Discussion 
Construction of the CLEO tool  
Advantages of the CLEO tool are many. Firstly, it added humanistic indicators to level 1 of 
clinical dimension. Secondly, clinical dimension can detect also levels of cost avoidance (e.g., 
monitoring/treatment; prolongation of hospital stay; intensive care) while economic 
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dimension can detect if PI induces cost savings. Therefore, the CLEO can help to extract IPs 
to conduct economic study. Like some studies, independent rating the economic impact of a 
PI was used as the first step to determine the monetary value of a PI program [13, 16, 33-40]. 
A another study in a centralized preparation of cytotoxic drugs unit used the CLEO to extract 
IPs with -1E or 1E to calculate cost savings and cost increase due to PIs. Thirdly, most tools 
focus on patient outcomes and/or cost savings. PIs, however, also are useful for health 
practitioners. For example, there are some PIs which had neither clinical nor economic 
impact, but they are significant because they improve safety for nurses. Therefore, the 
organizational dimension of the CLEO aims to detect more sensitively effects of a PI. 
Fourthly, the CLEO also proposes a multidimensional, comprehensive framework which not 
only is useful for posterior assessment after implementation of a PI but also for pharmacists to 
take into consideration before they decide which PIs should be communicated to health care 
providers or patients. Fifthly, the numeric and independent dimensions help to facilitate the 
interpretation of results of ratings.  
In fact, each PI has many different consequences and each consequence has a probability of 
occurrence. Some tools allow estimating probability of consequences during rating process 
[15-17]. However, in most cases, the determination of this probability was difficult to estimate. 
Therefore, in order to improve consistency of judgment of probability between raters, the 
clinical impact of the CLEO is evaluated according to the most likely case expected and does 
not require to estimate probability of consequence. This strategy was applied similarly in 
other tools [16, 17, 30, 41]. However, estimation of probability of consequences can be added 
as a supplementary step to the first step - rating by the CLEO if required.   
Inter-rater and intra-rater reliability of the CLEO tool  
In the CLEO tool, the "clinical impact" dimension is scored from the 6-level structure of 
Hatoum’s [28]. Therefore, we extracted from the systematic review [24] only results of 
reliability of tools which derived from Hatoum's tool and have 5-7 levels to compare with our 
study's results (Table 2). The highest strength of inter-rater reliability was found  in the study 
of Overhage and Lake (kw=0.76) [19]. However, this good result did not repeat when other 
studies adopted this tool for use [21, 42, 43]. Our results showed moderate agreement for 
clinical impact (kw = 0.41) in the second rating, which is higher than results obtained by 
Cousin et al. (k=0.26)[44]; by Bosma et al. (kw=0.20)[42]; by Lee et al. (k=0.14-0.31)[21]; by 
Fernandez-Llamazarez et al. (k=0.24)[43]; and by Somers et al. (k=0.15-0.25)[45].  
 
Table 2: Reliability and validity of tools which derived from Hatoum's 
No Author(s), 
Year, 
Country 
Too
l 
N° of 
PIs 
Rater(s) Validity and/or Reliability 
1 Lucas et al.* 
[46] 
1997, 
Australia 
S61 
 
56 1 intervening 
pharmacist + 1 
internal physician 
+ 2 external 
physicians 
Internal inter-rater reliability (1 intervening 
pharmacist vs 1 internal physician):  
agreement = 83%,  t-test p>0.05: no different 
External inter-rater reliability  
(1 internal physician vs the first external physician) 
agreement = 48%, 63%; t-test  p>0.05 no different  
(1 internal physician vs the second external 
physician)  
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agreement = 63%; t-test p<0.05 different 
2 Cousins et 
al.* [44] 
1997, UK 
S61 
 
584a 
62b 
pharmacists  Intra-rater reliability (12 intervening 
pharmacists):  
Wilcoxon matched-pairs signed-rank test p=0.01-
0.69 
Inter-rater reliability (12 pharmacists): k=0.26 
3 Overhage et 
al.* [19] 
1999, USA 
S61 
 
300 3 pharmacists, 2 
physicians 
Inter-rater reliability 
kw=0.76 
4 Hick  et al. 
[47] 
2001, UK 
S61 
 
155 3 senior 
pharmacists 
Inter-rater reliability 
agreement = 85% of case: at least 2 out of 3 raters 
agreed on the rated grades.  
5 Bosma  et al. 
[42] 
2006, 
Netherland 
S72 
 
255 1 hospital 
pharmacist + 1 
internal medicine 
specialist 
Inter-rater reliability 
kw=0.20 
6 Lee et al.* 
[21] 
2006, USA 
S61 98 2 pharmacists + 1 
physician + 2 
principal 
investigators  
Inter-rater reliability of each pairs 
agreement = 63-80%, k=0.14-0.31 
7 Spinewine et 
al.* [48] 
2006, 
Belgium 
S53 700 2 Belgian 
geriatricians + 1 
Canadian clinical 
pharmacist 
Inter-rater reliability 
agreement = 33% 
8 Fernandez-
Llamazares  
et al. [43] 
2012, Spain 
S61 20 4 senior 
pharmacists + 5 
junior pharmacists  
Inter-rater reliability 
agreement=66%, k=0.24 (0.15-0.32) for all raters;  
agreement = 72%, k=0.27(0.16-0.38) for senior 
pharmacists;  
agreement = 64%, k=0.10 (0.00-0.20) for junior 
pharmacists 
9 Somers  et 
al. [45] 
2013, 
Belgium 
S61 304 2 clinical 
pharmacologists + 
2 clinical 
pharmacists 
Inter-rater reliability 
k = 0.15-0.25 
10 Vo et al., 
2015, France 
C74 
 
30-50 7 clinical 
pharmacists 
2nd rating 
Inter-rater reliability  
39% (95%CI 34-44); kw= 0,41 (95%CI 0,37-0,45) 
S6: Clinical impact consists of 6 levels: adverse significance, no significance, somewhat significant, 
significant, very significant, extremely significant 
S7: Clinical impact consists of 7 levels: no intervention, adverse significance, not significant, somewhat 
significant, significant, very significant, extremely significant 
S5: Clinical significance consists of 5 levels: deleterious, minor, moderate, major, extreme 
C7: Clinical impact consists of 7 levels: nuisible, null, minor, moderate, major, lethal, non-determined 
 
The highest strength of agreement was found for "economic impact" dimension (agreement = 
90% and kw = 0.93) in the second rating. In many cases, it is quite easy to determine 
"economic impact". For example, types of PIs such as adding a new drug, switching to more 
expensive drug have a 1E code while discontinuation of a drug or a monitoring test have a -1E 
code. In the literature, only the study of Cousin et al. [44] determined the inter-rater reliability 
of economic impact. However, its coding was different. In the study of Cousin et al., up to 
four of five economic codes could be assigned to each intervention: (i) savings in cost of drug 
therapy, (ii) increase in cost of drug therapy, (iii) savings in cost of laboratory tests, (iv) 
savings in cost of complications, and (v) savings in costs of hospitalization time. The study of 
Cousin et al. reported worse results for this variable with an overall kappa of 0.27 indicating 
fair agreement among panel members.  
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The "organizational impact" dimension aims to detect any beneficial effects of a PI on quality 
of process of care from point of view of health care providers. The lowest score of kappa were 
obtained for "organizational impact" (agreement = 62% and kw = 0.39). There are some 
reasons for explanation of this result. Firstly, the evaluators found that it was difficult to 
consider many different indicators  of process of care (e.g., time savings, improved security, 
knowledge, job satisfaction of nursing staff; facilitating professional tasks or teamwork, 
continuity of care...) and points of view of different health care providers (physicians, 
pharmacists, nurses) to make a global opinion of organizational impact. For example, some 
IPs such as adding a new medication may require nurses more time to administer drugs to 
patients but such IPs can improve job satisfaction from pharmacists and physicians' view. 
Another reason is that there was no precious definition and/or examples of the indicators of 
organizational impact (e.g., improve security of nursing staff; facilitating professional tasks or 
teamwork, continuity of care).  
 
Consistency between raters improves for all three dimensions in the second rating, 
particularly economic dimension. Modification of the CLEO tool, providing examples and 
more information of clinical cases for rating may be reasons for this improvement.  
 
Limitations 
The main threats to internal validity are confounding, maturation, testing, selection bias, and 
analytic methods.  
Concerning threat of confounding, results of agreement between raters in the two studies may 
be effected by perceptions of raters themselves rather than functionality of the tool itself. 
Threat of maturation is present when evaluators rate more consistently over time due to their 
experience/familiarity with the tool. The seven pharmacists have involved in process of 
development and the refinement of the tool over a two-year period, therefore they understood 
well the tool. This was a bias.   
Testing bias occurs when evaluators are aware of that their ratings will be compared to ones 
of their colleagues; then they are likely to rate based on what researchers expect rather than 
based on their true perceptions. To minimize this threat, we informed clearly all evaluators 
that the objective of studies aims to test the functionality of the tool and not achieve perfect 
concordance between raters. Such that, all evaluators were required to rate based on their true 
opinions.  
Selection bias of PIs could threaten the internal validity of a study when PIs are selected in a 
nonrandom fashion. In this study, we selected non-randomly PIs to balance sample size, 
variety of interventions, scores.  
Evaluating agreement or reliability is fundamental to the evaluation of research tools. 
Agreement is defined as the degree to which scores/ratings are identical, whereas reliability 
relates to the extent of variability and error inherent in a measurement [49]. Hence, we used 
both agreement and reliability but focused more in reliability. Although the kappa score was 
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commonly used to assess the reliability between raters in literature, the k statistic may be 
difficult to interpret. First, mathematically, a value of +1 is difficult to achieve and is only 
observed in extreme circumstances. Second, the k score depends on the number of categories 
[49]. The more categories there are, the more difficult it is to classify correctly and the lower 
the resulting k value. In our results, the strength of agreement and reliability of "clinical 
impact" (kw = 0.41) can be considered quite high given the large number of categories (seven 
categories) involved. However, the "organizational impact" dimension had similar kw score 
(kw = 0.39) but has fewer categories (four categories). Therefore, we thought that the inter-
rater reliability of "clinical impact" dimension of the CLEO tool is acceptable and reliable 
enough to use in practice but not "organizational impact". Third, kappa is sensitive to bias 
between raters and the overall prevalence of responses. In some instances, a relatively high 
proportion of observed agreement can result in a low kappa value and an unbalanced or biased 
distribution of responses can result in a higher kappa value than a more balanced distribution 
of responses. Hence, a low kappa value may not always be indicative of low agreement [49]. 
This event occurred in our studies for "organizational impact" dimension in which a high 
agreement (62%) existed with a low kappa (kw = 0.39).  
Conclusions 
A multidimensional scale CLEO for assessing the potential significance of PIs was developed 
and tested. The highest strength of reliability was found for "economic impact" of the CLEO 
classification, then "clinical impact". The lowest values were obtained for "organizational 
impact" dimension. Further study should be conducted to overcome some limitations of this 
study design; particularly the test for use in a local service is needed.   
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3.2. Validation process of the CLEO tool in clinical practice  
Results of validation of a method of assessment depend on many factors: scale (content, 
structure), process of assessment (quality of information of scenarios, retrospective or 
prospective rating, etc.), and profiles of evaluators (professional, number of experience years, 
etc.). Limitations of the previous study were only rating retrospectively PIs by external 
pharmacists, testing the reliability among pharmacists only, and rating PIs extracted from the 
general pharmacy practice. Therefore, this study aims to test prospectively both validity and 
reliability of the method of assessment of potential significance of PIs using the CLEO tool in 
a specific setting - a centralized preparation of cytotoxic drugs unit (CPU) at the Grenoble 
University Hospital Center. We choose the CPU for a practical reason rather than a 
methodological reason. When we finished the first study of validation of the CLEO tool with 
the SIG, there was an emergent requirement for assessing impacts of PIs conducted in the 
CPU. This unit has found since 20 years and there were many studies that measured the 
production of PIs and acceptance rate of PIs. However, no study measured potential outcomes 
of PIs. Therefore, we collaborated with clinical pharmacists and pharmacy residents in this 
unit to use and test the CLEO v.2. In this setting, there are two types of pharmacists, ones 
reviewed the patient's electronic medical record at the CPU before preparation of drugs and a 
full-time on-ward of clinical pharmacists who participated in medical teams. And we wanted 
to know how agreement of ratings between two types of pharmacists was. Another question 
was how agreement of ratings between pharmacists and opinions in consensus of 
multidisciplinary groups.    
All 237 PIs made by pharmacists in the CPU were recorded from July to September 2014 and 
then were divided into 4 specific therapeutic domains: hematology, oncology-radiotherapy, 
pneumology, hepato-gastroenterology (HGE). Four expert panels were constituted 
respectively. Each expert panel consists of 4 members: a medical specialist of the domain, a 
clinical pharmacy specialist, a pharmacist working in the CPU, a pharmacovigilance expert. 
The inter-rater reliability between two pharmacists was moderate agreement for clinical 
(agreement=51%; kw=0.48); substantial for economic (agreement=71%; kw=0.61); and fair 
agreement for organizational dimension (agreement=60%; kw=0.27). The validity when 
comparing ratings between a pharmacist in the CPU and panels was fair agreement for 
"Clinical impact" (agreement=41%; kw=0.32); substantial agreement for "Economic impact" 
(agreement=68%; kw=0.53); and slight agreement for "Organizational dimension" 
(agreement=57%; kw=0.17).  
 
Comparing to inter-rater reliability of the CLEO in the first study, the results of this study was 
better for "Clinical impact" (from kw=0.41 to 0.48), was worse (but was still substantial 
agreement) (from kw=0.93 to 0.61) for "Economic impact" but worse much for 
"Organizational impact" (from kw=0.39 to 0.27). The results of this study helped to confirm 
that it was difficult to achieve high kappa score (kw > 0.6) for "Clinical impact" and we 
considered a kw score in range of 0.4-0.6 as acceptable for "Clinical impact". In conclusion, 
the "Clinical impact" and "Economic impact" were valid and reliable enough to use. The 
explorations of reasons of low agreement concerning "Organization impact" in this study are 
useful to refine this dimension in further study.  
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Finally, reproducibility of validity and reliability of the CLEO in a local setting is not always 
obvious. Subgroup analyses used in this study to target the main source of disagreement 
(panel experts, pharmacists or types of PIs) were useful for further training of rating and peer-
review process to improve agreement afterward. 
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Background and Objective: The CLEO tool (including 3 independent dimensions: 7-
category clinical, 4-categogry economic, and 4-category organizational) for evaluation of 
potential significance of a pharmacist intervention (PI) was validated in general practice. This 
study aims to test the validity and reliability of CLEO tool for PIs from pharmacist analysis of 
prescriptions in a centralized chemotherapy preparation unit (CPU). 
Setting and Method: The inter-rater reliability is a concordance between intervening 
pharmacists (2 pharmacy residents and 3 senior pharmacists working in the CPU) and a peer 
reviewer pharmacist. The validity is a concordance between intervening pharmacists and 
consensus opinions of expert panels (ie: multidisciplinary expert committees). All 237 PIs 
recorded from July to September 2014 were divided into 4 specific therapeutic domains: 
hematology (43PIs), oncology-radiotherapy (146PIs), pneumology (33PIs), hepato-
gastroenterology (HGE) (15PIs). Four expert panels were constituted respectively. Each 
expert panel consists of 4 members: a medical specialist of the domain, a clinical pharmacy 
specialist, a pharmacist working in the CPU, a pharmacovigilance expert. Subgroup analyses 
were also conducted. 
Main outcome measures: Inter-rater reliability, validity, factors affecting agreement 
Results: The inter-rater reliability was moderate agreement for clinical (agreement=51%; 
kw=0.48); substantial for economic (agreement=71%; kw=0.61); and fair agreement for 
organizational dimension (agreement=60%; kw=0.27). The validity was fair agreement for 
clinical (agreement=41%; kw=0.32); substantial agreement for economic (agreement=68%; 
kw=0.53); and slight agreement for organizational dimension (agreement=57%; kw=0.17). 
The peer pharmacist rated more consistently with expert panels than pharmacists in the CPU; 
pharmacy residents rated more consistently than senior pharmacists. Ratings were less 
consistent with the expert panel of HGE. Validity of the CLEO was higher if evaluators rated 
accepted PIs than refused PIs. 
Conclusion: The highest strength of agreement was found for economic dimension of the 
CLEO classification, then clinical dimension. The lowest values were obtained for 
organizational dimension. Reproducibility of validity and reliability of the CLEO in a local 
setting is not always obvious. Subgroup analyses is useful to target the main source of 
disagreement (panel experts, pharmacists or types of PIs) and further training of rating and 
peer-review process is necessary to improve agreement. 
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INTRODUCTION 
The special interest group “Standardizing and demonstrating the value of clinical pharmacy 
activities” of the French Society of Clinical Pharmacy (SFPC) developed and validated a 
multidimensional tool for determining the impacts of pharmacist interventions (PIs), named 
the CLEO [1]. Construction of the CLEO was based on a review of models of evaluation of 
PIs, a systematic review of existing tools [2], selection and examination of impacts of 200 PIs. 
The CLEO includes three independent dimensions: clinical impact of a PI from the point of 
view of patient (C), economic impact of a PI from point of view of the hospital setting (E), 
and organizational impact of a PI from point of view of health care providers (O). Each 
dimension consists of many numeric levels; and has both negative, zero, positive values and 
an open level "non-determined" (Figure 23). The three dimensions were combined into a 
three-component code describing the whole impacts of PI (see examples in Figure 24).  
 
The scale was validated through three steps of rating by a group of 7 clinical pharmacists of 
SFPC. They coded retrospectively 30 or 50 scenarios extracted from the general pharmacy 
practice in order to estimate the reliability (% agreement and kw). The second rating showed 
moderate agreement for clinical dimension (agreement = 39% and kw = 0.41); almost perfect 
agreement for economic dimension (agreement = 90% and kw = 0.93); and fair agreement for 
organizational dimension (agreement = 62% and kw = 0.39). The information of validation 
process of the CLEO was presented in the another article [1].  
Results of validation of a method of assessment depends on many factors: scale (content, 
structure), process of assessment (quality of information of scenarios, retrospective or 
prospective rating, etc.), profiles of evaluators (professional, number of experience years, etc.) 
[2]. Limitations of the previous study were only rating retrospectively PIs by external 
pharmacists, testing the reliability among pharmacists only, and rating PIs extracted from the 
general pharmacy practice. Therefore, this study aims to test prospectively both validity and 
reliability of the method of assessment of potential significance of PIs using the CLEO tool in 
a specific setting - a centralized preparation of cytotoxic drugs unit (CPU). This study was 
designed to determine if the CLEO tool is reliable for daily use in a specific setting.  
Method 
Grenoble University Hospital is a 2000-bed, public hospital. Since late 1995, all of the 
injectable chemotherapy for all onco-hematology services are prepared at a CPU. Three 
pharmacists and 2 pharmacy residents work at CPU.  
 
In 1999, the hospital implemented an electronic medical record system covering all the 
aspects of patient care and a CPOE program for chemotherapy prescription (Cristal-link ©), 
which provides access to patient demographic information, laboratory results, drugs dispensed 
and medication administration records. Firstly, all anti-cancer medication are prescribed 
through predefined order sets which was validated by pharmacists and physicians. These 
order sets include drugs, doses, administration (route, infusion time, solvent used), and 
associated premedication. Once the prescription was signed electronically by the physician, 
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prescriptions automatically appear on the pharmacy computer screen. Then pharmacists in the 
CPU analyze the prescription and call physicians when a DRP is identified during the 
medication order validation process. PIs are daily recorded. A preparation sheet is then sent to 
pharmacy technicians.  
 
In the Hematology service, the hospital integrates a clinical pharmacy resident as a full-time 
staff member. The clinical pharmacy resident has completed 5-year pharmacy studies and has 
chosen to specialize, pursuing a hospital residency program lasting 4 years divided into 
rotations of 6 months in different services. Pharmacy residents work under the supervision of 
a clinical pharmacist. The main mission of clinical pharmacy residents is to assist physicians 
with drug therapy, by taking medication histories directly from patients at admission, 
participating in physicians’ ward rounds, validating medication orders (except validation of 
anti-cancer drugs was done by pharmacists in the CPU) and performing patient education 
before discharge.  
 
Data collection 
All consecutive PIs proposed by pharmacists in the CPU were recorded for the whole duration 
of the study. In fact, 237 PIs were recorded from 7 July to 14 September 2014. The clinical 
pharmacy resident on ward recorded prospectively PIs into a report form, including:  patient 
characteristics (sex, age, weight, height, body surface area); medical history; cancer drugs and 
cancer protocols used, the types of DRPs and PIs were classified according to the validated 
tool of the SFPC[3]; description of DRPs and PIs in detail; whether or not it was accepted by 
the physician. These forms were provided to expert panels at the end of the study for rating.   
 
Rating 
The study's objective is to determine inter-rater reliability (concordance between intervening 
pharmacists and second pharmacist as peer reviewer) and validity (concordance between 
intervening pharmacist and an expert panel) of the CLEO tool. Pharmacists in the CPU rated 
PIs as soon as they intervened while the clinical pharmacy resident on ward rated PIs after 
collecting data and filling in a report form. There are 2 pharmacy residents and 3 pharmacists 
in the CPU who participated to rate PIs. At the end of the study, all 237 PIs were devided into 
4 specific therapeutic domain: hematology (43PIs), oncology-radiotherapy (146PIs), 
pneumology (33PIs), hepato-gastroenterology (15PIs). Therefore, 4 panels of experts were 
formed respectively. Each expert panel consists of 4 members: a medical specialist, a 
pharmacy specialist, a pharmacist working in the CPU, a pharmacist working in a 
pharmacovigilance center. The CLEO version 3 and 12 examples for rating were sent to 
members of expert panels one week before the day of face-to-face direct meeting. During the 
meeting, after the clinical pharmacy resident on ward read each PI, each rater evaluated 
independently and then discussed until reaching the consensus (3 or more raters agree).  
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Statistical analysis 
The reliability and validity is calculated through percentage of agreement and weighted 
kappa. The interpretation of results of weighted kappa is based on the Landis and Koch scale 
(k values of < 0 indicate poor agreement; 0.00-0.20, slight agreement, 0.21-0.40, fair; 0.41-
0.60 moderate; 0.61-0.80, substantial; 0.81-1.00, almost perfect)[4]. Subgroup analyses were 
conducted for 5 pharmacists in the CPU, 4 specific therapeutic domains, and whether or not a 
PI was accepted by the physician. The statistical analysis was performed using the Stata 
statistical package, release 9.1 (StataCorp LP, College Station, TX, USA).  
 
Results 
Reliablity and validity of assessment method 
The inter-rater reliability between pharmacists for classification was as follows: moderate 
agreement for clinical impact (agreement = 51%; kw = 0.48); substantial for economic impact 
(agreement = 71%; kw = 0.61); and fair agreement for organizational impact (agreement = 
60%; kw = 0.27) (Table 1).   
The validity (concordance between pharmacists in the CPU and an expert panel) for 
classification was as follows: fair agreement for clinical impact (agreement = 41%; kw = 
0.32); substantial agreement for economic impact (agreement = 68%; kw = 0.53); and slight 
agreement for organizational impact (agreement = 57%; kw = 0.17).  
 
Subgroup analyses of validity  
Compare validity of CLEO between the clinical pharmacy resident on ward  and 
pharmacists in the CPU 
Ratings of the clinical pharmacy resident on ward was more consistent with those of expert 
panels than the pharmacists in the CPU in term of clinical and economic impact, but less 
consistent in term of organizational impact (Table 2). Validity of clinical impact was 
moderate (agreement = 54%; kw = 0.56) and fair (agreement = 41%; kw = 0.32), 
respectively. Validity of economic impact was substantial (agreement = 81%; kw = 0.75) and 
Table 1: Reliablity and validity of assessment method 
Type 
  
  
Cinical 
Impact 
Economic 
Impact Organizational Impact 
% kw % kw % kw 
General 
  R (P1-P2) 51 0.48 71 0.61 60 0.27 
 V (P1-C) 41 0.32 68 0.53 57 0.17 
R: reliability. V: validity. P1: pharmacist on ward. P2: pharmacist in the CPU 
 152 
 
moderate agreement (agreement = 68%; kw = 0.53), respectively. Validity of organizational 
impact was slight (agreement = 49% and 57%; kw = 0.11 and 0.17 respectively).  
Table 2. Subgroup analyses of validity of assessment method 
Sub-analysis  
  
 Validity 
Cinical 
Impact 
Economic 
Impact 
Organizational 
Impact 
% kw % kw % kw 
Which 
pharmacist 
Pharmacists in the 
CPU V(P1-C) 41 0.32 68 0.53 57 0.17 
Pharmacist on ward  V(P2-C) 54 0.56 81 0.75 49 0.11 
Which 
Expert 
panel 
Hepato-
gastroenterology  V (P1-C) 20 0.36 87 0.42 73 0.44 
Hematology V (P1-C) 60 0.48 84 0.80 40 -0.13 
Pneumology V (P1-C) 66 0.50 89 0.87 49 0.22 
Oncology-
Radiotherapy V (P1-C) 52 0.58 78 0.72 50 0.15 
Which type 
of PIs 
Accepted PI V(P1-C) 58 0.58 86 0.83 52 0.12 
Refused PI V(P1-C) 41 0.34 66 0.50  41 0.05 
Which 
pharmacists 
in the CPU 
If P1 is the Interne 1 V(P1-C) 44 0.37 79 0.70 50 0.15 
If P1 is the Interne 1 V(P1-C) 54 0.42 66 0.48 59 0.23 
If P1 is the  
Pharmacist 1 V(P1-C) 32 0.21 55 0.29 59 0.13 
If P1 is the  
Pharmacist 2 V(P1-C) 36 0.31 77 0.67 69 0.28 
If P1 is the  
Pharmacist 3 V(P1-C) 28 0.08 50 0.24 28 0.07 
V: validity. P1: pharmacist on ward. P2: pharmacist in the CPU. C: expert panel  
 
Compare validity of CLEO among groups of expert panels 
Ratings of pharmacists in the CPU were less consistent with those of expert panel of hepato-
gastroenterology than other expert panels in term of clinical impact and economic impact. But 
ratings of pharmacists in the CPU were less consistent with those of expert panel of 
hematology and oncology-radiotherapy in term of organizational impact.   
Compare validity of CLEO between accepted PIs and refused PIs 
Validity score of CLEO were higher if evaluators rated accepted PIs than refused PIs.   
Compare validity of CLEO between different pharmacists in the CPU 
Validity score of CLEO was higher if evaluators in the CPU were clinical pharmacy residents 
than clinical pharmacists. Particularly, the clinical pharmacist 1 and 3 rated the worst. 
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DISCUSSION 
We agreed with Hatoum et al. [5] that building consensus on the positive contribution of 
clinical pharmacy services to patient care mandates both inter- and intra-professional 
evaluation. Therefore, in this study each IP was evaluated independently by 2 practicing 
pharmacists and a multidisciplinary expert panel. Unlike the study of Hatoum et al., only PIs 
which have been considered clinically significant with ranks 5 and 6 by pharmacists, were 
subjected to the physician-review process; in our study all PI were evaluated by expert panels.  
Concerning inter-rater reliability of "clinical impact", our results showed moderate 
agreement for clinical impact (kw = 0.48), which is similar to the result when the CLEO tool 
was used in general pharmacy practice (kw = 0.41) in our previous study. Both are higher 
than other studies [6], [7], [8], [9], [10]. Therefore, we thought that the inter-rater reliability of 
clinical dimension of the CLEO tool is acceptable and reliable enough to use in practice.  
 
Concerning the validity of the tool, it is difficult to assess validity of any method measuring 
the potential significance of a PI because there is no generally accepted standard with which 
to compare [11]. The comparison of the scores given by evaluators with known outcomes in 
the literature as in the study of Dean et al.[12] and Taxis et al.[13] has limitations because 
errors resulting in more-severe outcomes may be more likely to be reported in the literature 
[12]. There were studies in which the validation was determined by comparing results of 
ranking of practicing pharmacists with a senior expert (e.g., a pharmacy manager [14], an 
academic pharmacist [15], an internal physician [16], an external physician [15, 16]. 
Nonetheless, no study aimed to compare results of ranking of practicing pharmacists with the 
consensus results of a group of experts like in our study. We found 4 specific panel experts 
and each panel expert consists of 4 members (a medical specialist, a pharmacy specialist, a 
pharmacist working in the CPU, a pharmacist working in the pharmacovigilance center), 
which aims to assure the validity of consensus opinions of panel experts. Our results showed 
slight agreement for clinical impact (agreement = 41%; kw = 0.32).  
 
The highest strength of agreement was found for "economic impact" dimension (agreement = 
71% and kw = 0.61 for inter-rater reliability; agreement = 68% and kw = 0.53 for validity). 
However, these results were lower when the CLEO was used in the previous study (agreement 
= 90%, kw = 0.93).   
 
The organizational dimension aims to detect any beneficial effects of a PI on quality of 
process of care from point of view of health care providers. The lowest values were obtained 
for organizational impact (agreement = 60% and kw = 0.27 for reliability; agreement = 57% 
and kw = 0.17 for validity). These results were lower than ones in the previous study 
(agreement = 62% , kw = 0.39).  The reasons for explanation of this low result were found as 
same as in the previous study. One difficulty is to choose the point of view. Because health 
care providers such as physicians, pharmacists, nurses are involved in process of care, we then 
choose to evaluate from the point of view of health care providers.  However, in many cases, 
the points of view were different between professional groups. For example, in meetings of 
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multidisciplinary groups in the second study, switching from intravenous (IV) to oral (PO) 
therapy as soon as patients are clinically stable sometimes were considered as having no 
effect on "organizational impact" by physicians while pharmacists judged the PI as having 
positive impact because it saved times for nurses. The CLEO tool did not specify which 
professional groups' view was used, which results in the ambiguity in ratings. Purpose of the 
CLEO tool is to be used independently by pharmacists in daily practice and pharmacists often 
have to consider potential impacts from different points of view before deciding to intervene 
or not. Therefore, one suggestion for refining "Organizational impact" may be that "The 
organizational impact is coded regarding the overall impact on process of care from 
pharmacists' judgement/perception".     
Second difficulty is to how to evaluate many organizational indicators in a simple way. We 
decided to combine many organizational indicators into a single global opinion to simplify 
reporting. However, impacts of a PI on different organizational indicators sometimes are not 
the same and then contributing a global impact on "Organizational impact" is difficult. For 
example, in the second study for cancer patients, many times pharmacists found that patients 
used cancer drugs whose dose needed to be adapted to patients' renal function without update 
information of creatinine levels of patients. Pharmacists reminded physicians to update. 
However, physicians responded that physicians already considered the update creatinine level 
into dosing adaption but physicians did not save this new information in patients' medical 
record. This type of PIs requires more times by both pharmacists and physicians (negative 
impact) but they are necessary tasks of teamwork (positive impact). One suggestion is to 
separate organizational indictors, to evaluate them independently, and to have just 3 choices 
(yes/no/don't know) instead of 4 choices (negative/no/positive/don't know). Further studies 
need to be conducted to refine "Organizational impact" dimension and retest its validity and 
reliability.  
 
Measuring the reliability and validity of methods for assessment of impacts of PIs not only 
provide an credibility/evidence of a subjective assessment but can also be used for training, 
peer review and audit purposes [9, 16].  Therefore, subgroup analyses can be conducted to 
target the main source of disagreement. Ratings of clinical pharmacy resident in ward was 
more much consistent with those of expert panels than the pharmacists in the CPU in term of 
clinical and economic impact (agreement = 54% and kw = 0.56 for clinical impact; agreement 
= 81% and kw = 0.75 for economic impact) (Table 2). The reason may be the clinical 
pharmacist on ward who practiced in the service, contacted directly with patients and health 
care team, and rated impacts of PIs only after collecting complete patient information while 
pharmacists in the CPU who only access to patient information in the computer and had to 
rate impacts of PIs as soon as they intervened. This result confirms the opinion of Hatoum et 
al. [5] that peer-review process added further credibility to results presented.  
 
Compare validity of CLEO among groups of expert panels, the worst results of consistency of 
clinical impact and economic impact is between pharmacists in the CPU and expert panel of 
hepato-gastroenterology. Therefore, it is necessary to extract PIs of hepato-gastroenterology 
in which it exists divergence to discuss further among members and then to provide more 
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examples of rating. Validity of CLEO was higher if evaluators rated accepted PIs than refused 
PIs. In the literature, there is no information about that. Sub-analysis of validity of CLEO 
between different pharmacists in the CPU found that pharmacy residents rated better than 
clinical pharmacists did. Particularly, the clinical pharmacist 1 and 3 rated the worst. This 
result is contrary to findings of study conducted by Fernandez-Llamazarez et al. [9] in which 
senior pharmacists rated more consistently than junior pharmacists.  
Limitations   
Inevitably, the evaluated studies suffered from some problems with external validity. The 
study sample may have included unique characteristics which make the results unique to the 
study. The tool was used by pharmacists and physicians in one CPU. And the specific 
characteristics of this service (e.g., types of DRPs and PIs) may be not representative for other 
services or settings. Other more broad-based, multicenter, and longitudinal studies are needed 
to validate the CLEO tool in a variety settings.  
In fact, reproducibility of reliability of a specific tool in a local setting is not always obvious 
because it depends on not only the structure and content of tools, but also process of 
assessment. Therefore, sub-analysis of validity is useful to target panel experts, pharmacists or 
types of PIs in which it exists great divergence in order to improve agreement.  
CONCLUSION 
The highest strength of agreement was found for economic dimension of the CLEO, then 
clinical dimension. The lowest values were obtained for organizational dimension. 
Reproducibility of validity and reliability of the CLEO in a local setting is not always 
obvious. Subgroup analyses is useful  to target the main source of disagreement (panel 
experts, pharmacists or types of PIs) and further training of rating and peer-review process is 
necessary to improve agreement.  
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More complex patient care resulting from new technology, higher acuity of illness or higher 
burden of chronic diseases are placing heavier demands on health care practitioners. These 
trends are reflected in the increasing number, types and cost of prescribed drugs. The optimal 
drug use may best be achieved by using an interdisciplinary approach. The direct involvement 
of a pharmacist throughout the medication-use process helps ensure continuity of care and has 
the potential to minimize risk, lower the cost, and improve the outcomes associated with drug 
therapy (175).        
While the pharmaceutical care has undergone dramatic changes since 30 years, pharmacists 
still need to demonstrate the benefits or added value of services because demonstration of 
value defines professional contribution (253). Pharmaceutical care has been described as a 
multi-faceted process that aims to result in positive outcomes for the patients. Associated with 
this process is the delivery of appropriate clinical pharmaceutical services, which include 
obtaining patient medical history, evaluating laboratory data, reviewing patient records, and 
performing patient counseling, etc. These activities contribute to medication reconciliation 
and medication review of the patient with major outputs in form of PIs. In times of limited 
resources allocation, it is important to evaluate the impacts and value of PIs proposed during 
medication review. The present work aimed to develop methodologies for assessment of 
impacts and value of PIs.  
1. Principal findings of this work 
When evaluating our work as a whole, several important and new findings can be identified.  
First, many theoretical models and frameworks can be applied to evaluate impacts of PIs. 
However, only a few studies measured more than one types of impacts. In order to obtain a 
comprehensive picture of the impact of PIs, we constructed an integrated model, named the 
SP(ECH)O-P model, which synthetized six types of impacts from many evaluation models in 
literature. All impacts of this model should be measured when possible. 
Second, a systematic review of existing tool for assessment of the potential significance of PIs 
was conducted with a rigor method1. This review helps to update a previous review of 
Overhage and Lakes in 1999 (12). A variety of tools and methodologies for estimate of value 
of PIs were found and analyzed. For the first time in the literature, an attempt to classification 
of these tools based on the 10-criteria scale of quality of tools was conducted, which will 
provide useful information for researchers who want to adopt or develop a new tool for local 
use. From the results of review, some recommendations on characteristics of optimal tools for 
assessing potential impacts of  PIs were suggested.   
Third, we developed a new multidimensional tool, named CLEO, which aimed to satisfy the 
above recommendations for optimal tools. The CLEO tool was a result from a review of 
theoretical models of evaluation, existing tools and inputs of clinical pharmacists' practice. 
The CLEO tool allows to evaluate CLinical and humanistic outcomes from the patient's 
                                                          
1 Thi Ha VO et al. A systematic review of tools for assessing potential significance of pharmacist interventions. 
Drug Safety (in press).  
 159 
 
perspective, Economic impacts (cost savings) from the hospital's perspective and 
Organizational impacts from HCPs' perspective. The original features of the CLEO tool is to 
include many humanistic outcomes integrated into "clinical impact" dimension. Furthermore, 
for the first time in the literature, an independent dimension for evaluating "organizational 
impacts" of PIs on process of care from HCPs' perspective was developed and tested. This 3-
dimension tool allows to interpret different impacts together in order to obtain a complete 
picture of impacts of PIs.  
The new tool was tested for validity and inter-rater and intra-rater reliability, and user-
friendliness in two studies2,3 In the first one2, a research group of 7 expert pharmacists from 
the SFPC was required to assess retrospectively PIs selected from the database Act-IP© or 
their practice. Many steps of refinement of the tools were conducted and the results of inter-
rater reliability were improved over time. After that, the final version of the CLEO tool was 
used prospectively in daily practice in a specific hospital service in the second study. We 
anticipated the condition/context in which the tool was used will influence profoundly results 
of ratings. Therefore, we designed a study which allowed practitioners to use the tool in 
realistic study conditions. An evaluation process included three steps: (i) an initial and 
immediate evaluation by the pharmacist who intervened, (ii) a peer-review evaluation by the 
ward-based pharmacist who can access to more complete patient information several days 
later, and (iii) an evaluation in consensus by multi-disciplinary panels two month later. By 
sub-analysis of results of concordance between raters/panels, these results of the second study 
not only allow to test validity and inter-rater reliability, but also supply useful information to 
improve concordance measure. Concerning inter-rater reliability, the results obtained were 
substantial for "economic impact" dimension (kw = 0.93 and 0.61, respectively); moderate 
for "clinical impact" dimension (kw = 0.41 and 0.48, respectively); and fair (kw = 0.39 and 
0.27, respectively) for "organizational impact" dimension in the two studies. Concerning 
intra-rater reliability, results were sligh (kw = 0.38) for clinical impact and were moderate 
(kw = 0.70) for economic impact. Concerning validity tested in the second study, ratings of 
the pharmacist on ward were more consistent with those of expert panels than the pharmacists 
in the centralized preparation unit in term of clinical and economic impact (kw = 0.56 and 
0.32 for clinical; kw = 0.75 and 0.53 for economic, respectively), but less consistent in terms 
of organizational impact (kw = 0.11 and 0.17, respectively). Comparing to results of other 
tools in literature, we found that clinical and economic dimension are likely to be reliable and 
valid enough to be able to use independently in daily practice by pharmacists. However, inter-
rater reliability of organizational dimension was better in the first study and worse in the 
second study, which requires further research. We will discuss this point in more detail in the 
next section.   
                                                          
2 Thi Ha VO et al. Validation of the CLEO tool for assessment of significance of pharmacist interventions in 
general context.  
 
3 Thi Ha VO et al. Validation process of the CLEO tool in clinical practice: oncology service.  
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2. Validity of findings  
The validity of research approach of this work need to be discussed to raise questions about 
the quality of the CLEO tool and the internal and external validity of findings of the studies, 
its advantages, limitations and further perspectives of research.   
2.1. Quality of the CLEO tool 
Currently, there are no formal guidelines or any recommendations concerning methods of 
assessing the potential impacts of PIs. Taking into account the results of our systematic 
review of existing tools in literature, we suggested 12 recommendations as follows: 
Table 28. Recommendations of methods of assessment of potential impacts of PIs 
Theoretical properties 
R1. Tools should be developed based on (1) comprehensive theoretical models, (2) a 
systematic literature review of available evidence that reflects the whole range of impacts of 
a PI and (3) an evaluation of existing tools, and (4) input from healthcare professionals. 
R2. Tools should be able to demonstrate that the benefits outweigh the costs in a given 
patient, health care system, and society at the level of each PI. 
R3. An evaluation from multi-impact perspective, rather than simply focusing on clinical 
impact, should be used to enhance understanding of the comprehensive effect of PIs. For 
example, a tool integrating clinical, humanistic, economic, process-related impacts and the 
probability of these impacts.  
R4. The views of patients, health care providers, institutions, payers, and society should be 
considered. 
Psychometric properties 
R5. Tools should be validated prior to its use. 
R6. Along with the information on clinical case, experts should be provided with a literature 
review, coding instructions, and examples. Indices for agreement/validity/reliability should 
be conform to the current guidelines.  
R7. The guideline proposed for the use of experts in pharmacoeconomic studies is suitable 
for this type of study including description of consensus techniques; justification in using 
such methods;  and description of selection of experts; provision of a definition of consensus 
in advance of the execution of a study; information that is provided to panelists in advance 
must be as objective and as comprehensive as possible; and modification of tool as 
appropriate with the input from independent experts or pilot-test; appropriate presentation 
and interpretation of findings. 
Pragmatic properties  
R8. Tools must be brief and not time-consuming. Acceptability to evaluators is also required. 
R9. Tools should be well defined. 
R10. Tools must be well-structured as well as flexible to adapt to meet their specific needs 
(e.g., multidimensional tool, possibility of modification of terminology of economic impact 
is based on different perspectives or modification of number of levels; independence 
between dimensions).  
R11. Tools should have an open, numeric, and hierarchical structure (with main dimensions, 
main levels of each dimensions, and an open structure to include the option “non-
determinable”). 
R12. Same definitions, terminology and grading systems for both the potential significance 
of a PI and the actual severity of consequence of MEs/ADEs/ADRs. 
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Researchers and clinicians may have different needs in relation to a tool for assessing 
potential significance of PIs. Due to the wide range of tools used in the literature, researchers 
need consider developing a basis of comparison between tools. Therefore, we tried to assess 
quality of each tool using 10 criteria to assist in comparing tools across studies.  
Table 29. Criteria of quality of a tool for assessing significance of PIs and the score of 
the CLEO tool  
A. Structure of a tool Score The 
CLEO 
A1. A tool has 2 or more dimensions 1 x 
A2. A tool has at least one dimension which has 4 or more categories 1 x 
B. Content of a tool   
B3. A tool applies 2 or more approaches of assessment  1 0 
B4. A tool consists of indicator(s) related to cost savings  1 x 
B5. A tool consists of indicator(s) related to cost avoidance 1 x 
B6. A tool consists of humanistic indicator(s) 1 x 
B7. A tool consists of process-related indicator(s) 1 x 
B8. A tool consists of indicator(s) related to probability of consequences 1 0 
C. Psychometric parameters of tools    
C9. A tool has at least one of psychometric parameters (validity, inter- or 
intra-rater reliability) which presented a moderate or good agreement.    
1 0 
C10. Risk of bias of a study which tested validity, inter- or intra-rater 
reliability of a tool was low.  
1 0 
Sum of scores: 10 6 
Comparing the CLEO to these recommendations and criteria, some questions were raised: 
How does the CLEO tool satisfy these recommendations and criteria? What are advantages 
and disadvantages of the CLEO tool? How to improve the CLEO tool?  
The CLEO tool was developed based on reviewing many theoretical models and existing tools 
in literature and inputs from expert pharmacists of the SFPC. Ideally, a tool should evaluate 
impact of PIs on structure, process of care, clinical, humanistic, economic outcomes with the 
probability of its impacts. We will discuss each type of impacts assessed in the CLEO tool 
below.  
2.1.1. Clinical impact 
There are some advantages of "clinical impact" of the CLEO. Firstly, "Clinical impact" 
includes the levels 2, 3, and 4 which are terminated by main cost-avoidance indicators (level 2 
= monitoring/treatment avoided; level 3 = an initiated or prolonged hospitalization avoided; 
and level 4 = a potentially intensive care or death avoided). Secondly, many definitions and 
terminology used in "clinical impact" are similar to the NCC MERP Index - a famous grading 
system for the actual severity of MEs. Thirdly, the six-level structure of "clinical impact" was 
inspired from the structure of a famous tool of Hatoum et al. used most widely in literature, 
which will facilitate better comparison of results across studies. 
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There are two perspectives for improvement of "clinical impact": (i) improvement of 
concordance of rating potential clinical impact and (ii) establishment of relationship between 
potential and actual clinical impacts of PIs. In our first study, for the first time in literature, we 
also determined which levels of "clinical impact" were main sources of disagreement between 
raters. Both the statistic method and opinions of expert pharmacists shown that great sources 
of disagreement were from ratings between level 2C and 3C. One limitation of "clinical 
impact" was that its weighted kappa score was moderate which were higher than many other 
tools' in literature.  However, it still needs to be improved. And a strategy is to give more 
examples, training and discussion on PIs having the 2C or 3C impact code.  
Potential clinical impacts of PIs are only intermediate (surrogate) outcomes for proving the 
benefits of PIs. The fact that a positive intermediate outcome may not lead to a positive end-
point outcome such as death and cure. However, the measurement of end-point outcomes is 
limited by measurement difficulties and design complications (11). Therefore, studies are 
needed to establish correlation between potential and actual clinical impacts of PIs. Such that, 
measures of potential impacts of PIs can be validly used as a measure of quality and value 
provided by pharmacists. 
2.1.2. Humanistic impact 
We decided to combine humanistic indicators into a single category (the level 1C) of "clinical 
impact" for simplifying reporting. Another reason is that this integration may be increase 
sensitivity to detect humanistic impacts. In fact, a majority of PIs such as undertaking 
monitoring, adding additional drugs, changing administration schedule or providing drug 
information to the patient, which have no remarked effect on symptoms or disease control. 
The impact of these on quality of life is likely to be minimal or event undetectable. 
Furthermore, some interventions may have a brief or delayed effect on quality of life and the 
timescale used in studies cannot detect benefits (40). However, PIs can improve the patient's 
satisfaction or knowledge which attributes a positive score (the level +1C).  
 
However, this integration is likely to fail to describe humanistic impacts of the PI in detail on 
the patient. Further studies should develop separate tools that incorporate drug-use-specific 
and disease-specific measures because MR tends to have small effects on QOL and generic 
measures of QOL are likely to be somewhat insensitive. Some tools related to drug use were 
developed. Several relate to medication compliance and belief of the patient such as Beliefs 
about Medicines Questionnaire (254), Brief Medication Questionnaire (255), Medication 
Adherence Scale (256). Others relate to the provision of information about medicines (for 
example the Satisfaction with Information about Medicines Scale (257), the Desire for 
Information Scale (258)). Another scales measure patients' satisfaction with pharmaceutical 
care service (259, 260). Although all these are important, they focused on one aspect of 
medicines use or pharmaceutical care. Other measures are more global, including the Drug 
Therapy Concerns Questionnaire (261) and the Medicines-Related Quality of Life 
Measure(262). Again the sensitive of such a measure to PI should be much greater than that of 
generic quality-of-life measure(40).  
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2.1.3. Economic impact 
The "Economic impact" dimension of the CLEO tool indeed evaluate just "cost saving" of PIs 
related to drug and monitoring costs. This strategy is used in other tools. A new advantage of 
the CLEO tool, as mentioned in arguments for development of the CLEO tool, is possible to 
use the first results of ratings impact of PIs in order to calculate the economic value of PIs 
afterward. The value of PIs can be estimated through 3 variables: cost of implementation, cost 
savings and cost avoidance of PIs. In the same study in the CPU at the Grenoble University 
Hospital, we selected PIs with positive or negative economic impact to estimate cost savings 
of PIs. Another study should calculate also cost avoidance, cost of providing medication 
review to estimate the benefit: cost ratio. It is possible to estimate the benefit: cost ratio for 
each PI or the whole medication review program in a setting. Each approach has different 
purposes. The estimate of the benefit: cost ratio for each PI is useful for pharmacists to target 
PIs which provide most value while the estimate of the benefit: cost for the whole medication 
review program in a setting helps directors of pharmacy or hospital to choose best investment 
among clinical pharmacy services.      
The estimated value of PIs was often limited in the analysis to the projected direct costs of 
medical care that was avoided as a result of the pharmacists' actions. Studies rarely included 
in this estimate indirect costs (costs attributable to losses in patient productivity or their 
families, and costs arising from possible litigation against physicians or pharmacists) and 
intangible costs (costs related to humanistic outcomes). Therefore, another perspective for 
economic research on MR is to develop methods for evaluating indirect and intangible costs 
that were always ignored in literature.   
2.1.4. Organizational impact 
The development and process of validation of the CLEO tool emerged a lot of reflections on 
"Organizational impact": What is definition? How will evaluation be operated? Is it valid and 
reliable?
From the Sructure-Process-Outcome model of Donabedian, we can confirm that the PI not 
only influence on patient outcomes but also on structure and process of care. To clarify 
elements and component of structure and process of care, it is necessary to look the broader 
picture as "pharmacy work systems" presented in the Systems Engineering Initiative for 
Patient Safety (SEIPS) model According to this model, PIs can influence on "work system or 
structure" (including Person, Organization, Technologies and tools, Tasks), Process and 
Outcomes (including Emloyee and organizational outcomes and Patient outcomes). However, 
in reality, a PI was defined as any action by the pharmacist, which changes therapy 
management at an individual patient. The PI then focuses on process of care of the particular 
patient, and never or rarely changes the stable features of structure of the setting. Therefore, 
the CLEO tried to capture process-related indicators but not structure-related ones. We also 
inspired from process-related indicators used in other tools to develop "Organizational 
impact" dimension such as time savings, improved security, knowledge, job satisfaction of 
staff; facilitation professional tasks, continuation of care, or teamwork.  
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One difficulty is to choose the point of view. Because health care providers such as 
physicians, pharmacists, nurses are involved in process of care, we then choose to evaluate 
from the point of view of HCPs.  However, in many cases, the points of view were different 
between professional groups. For example, in meetings of multidisciplinary groups in the 
second study, switching from intravenous (IV) to oral (PO) therapy as soon as patients are 
clinically stable sometimes were considered as having no effect on "organizational impact" by 
physicians while pharmacists judged the PI as having positive impact because it saved times 
for nurses. The CLEO tool did not specify which professional groups' view was used, which 
results in the ambiguity in ratings. Purpose of the CLEO tool is to be used independently by 
pharmacists in daily practice and pharmacists often have to consider potential impacts from 
different points of view before deciding to intervene or not. Therefore, one suggestion for 
refining "Organizational impact" may be that "The organizational impact is coded regarding 
the overall impact on process of care from pharmacists' judgement/perception".     
Second difficulty is how to evaluate many organizational indicators in a simple way. We 
decided to combine many organizational indicators into a single global opinion to simplify 
reporting. However, impacts of a PI on different organizational indicators sometimes are not 
the same and then contributing a global impact on "Organizational impact" is difficult. For 
example, in the second study for cancer patients, many times pharmacists found that patients 
used cancer drugs whose dose needed to be adapted to patients' renal function without update 
information of creatinine levels of patients. Pharmacists reminded physicians to update. 
However, physicians responded that physicians already considered the update creatinine level 
into dosing adaption but physicians did not save this new information in patients' medical 
record. This type of PIs requires more times by both pharmacists and physicians (negative 
impact) but they are necessary tasks of teamwork (positive impact). One suggestion is to 
separate organizational indicators, to evaluate them independently, and to have just 3 choices 
(yes/no/don't know) instead of 4 choices (negative/no/positive/don't know) like the tool of 
Lindblad et al. (231) or the tool of Virani et al. (238). An example of suggestions for 
modification of "Organizational impact" dimension:  
Organization impact 
The organizational impact is coded regarding the overall impact on process of care from 
pharmacists' judgement/perception.     
Indicators  yes no don't know 
Time savings    
Improved security of working    
Improved knowledge     
Facilitating professional tasks    
Facilitating teamwork    
Facilitating continuity of care    
 
With regard to the organizational impacts of PIs, it is clear that further study should aim to 
refine and clarify these impacts. Firstly, benefits of PIs from perceptions of different HCPs 
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including physicians, nurses can be exploited through qualitative studies. Then, these data can 
be useful to give clear definitions of the "organizational impact" dimension and examples for 
ratings.  
2.1.5. Probability 
As explained in the section "Development of the CLEO tool", in most cases, the 
determination of the probability of impacts of PIs was difficult to estimate. Generally, in order 
to improve the consistency of judgement of probability between raters, studies only select and 
code the most likely harm prevented, request opinion of experts most familiar with these 
events and review how often it occurred in the literature. To simplify the new tool, we asked 
evaluators to rate according to the most likely consequence expected for the "clinical impact" 
dimension, not the worst/best one, and did not require determining the numerical probability.  
However, if researchers want to calculate the cost avoidance related to "clinical impact", the 
estimate of probability is necessary to specify the cost avoidance as many methods presented 
in the section "Methods for estimation of cost avoidance related to pharmacist 
interventions". Furthermore, the probability can be used to classify risk levels as presented in 
the section "Tools of risk assessment".     
2.1.6. Use of the CLEO tool and interpretation of results of ratings 
Each dimension can be used independently. For examples, some studies prefer to use only 
"Clinical impact" dimension, others want to use both "Clinical impact" and "Economic 
impact" while others will use all three dimensions. When we can conduct an economic study 
with a rigor method to calculate the benefit: cost ratio of each PI as discussed above, it is easy 
to judge the value of the PI and compare it to other PIs. However, it is time consuming and 
difficult to conduct. Then, one question raised is that how to combine three codes of impacts 
for each PI into a single code when we don't conduct an economic study with a rigor method. 
Whether do we judge one impact (e.g. clinical impact) more important than other impacts 
(e.g. economic or organizational impact)? If yes, how is this distribution of importance and is 
it the same for all types PIs. There are 9 x 6 = 54 different combinations of three codes of the 
CLEO (page 133). It is obvious the PIs having the (4C, 1E, 1O) code is likely to provide more 
value than the PIs having the (-1C, -1E, -1O). However, other comparisons are not always 
easy. One factors need to be considered is the costs for providing the PI (e.g. time of 
pharmacists involved). Further studies need to be conducted to response to these questions.   
2.1.7. Modification of the CLEO tool for use in community pharmacies 
The CLEO tool which was constructed and tested to evaluate the impacts of PIs done in 
hospitals; therefore, without modification it is not suitable to be used in ambulatory care 
settings (such as community pharmacy). The context of practice by pharmacists between 
hospitals and community pharmacies is different. Firstly, hospital pharmacists are likely to 
expect that their PIs can prevent the inpatient from the initiated or lengthened hospitalization 
while community pharmacists are likely to expect that their PIs can prevent the outpatient 
from physician office visit. Secondly, community pharmacists often provide a majority of PIs 
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aiming to optimization of drug use such as change of drug form, administration schedule, 
drug equivalence or providing advice/information in health promotion while few PIs have a 
major impacts. Therefore, a tool used in community pharmacy need to be specific and 
sensitive enough to detect these minor impacts. Thirdly, medication adherence/compliance is 
one of major problems for outpatients who visited community pharmacy compared to higher 
medication compliance for inpatients in hospital. How a specific tool can not only evaluate 
the impact of PIs but also favor the role of community pharmacy in improvement in 
medication adherence need to be discussed. Concerning the "Economic impact", from which 
point of view, the cost savings related to drug/monitoring induced by the PI should be 
evaluated: the patient's, medical insurances', community pharmacy's or the society's? 
Concerning the "Organization impact", there are some raised questions. Is the "Organization 
impact" still necessary to keep in a tool? If we keep this dimension, how should we modify it? 
In hospital, pharmacists always work closely with physicians and nurses in big teams. In 
many cases, hospital pharmacists contact more frequently health care providers (HCPs) than 
patients. Therefore, HCPs become "major clients" of their services and PIs. Therefore, many 
PIs have organization impacts from the HCPs' point of view. However, in community 
pharmacy, pharmacists work in a small and simple organizational system, focus more in the 
patients and have a "weak" relationship with other HCPs. It is likely that the "Organizational 
impact" is not so essential.        
2.2. Validity of research methods  
2.2.1. Internal validity  
The main threats to internal validity are confounding, maturation, testing, selection bias, and 
analytic methods.  
Concerning threat of confounding, results of agreement between raters in the two studies may 
be effected by perceptions of raters themselves rather than functionality of the tool itself. 
Threat of maturation is present when evaluators rate more consistently over time due to their 
experience/familiarity with the tool. To minimize this threat, we chose a variety of raters with 
different profiles. In the first study, seven pharmacists who practice in six different French 
hospitals were included. These seven pharmacists were involved in process of development 
and the refinement of the tool over a two-year period; therefore, they understood well the tool. 
This was a bias. To overcome this bias, in the second study, we required pharmacists and 
physicians who did not belong to research group rated their PIs in daily practice. The 
pharmacists who intervened in the CPU, the ward-base pharmacist and four multi-disciplinary 
groups of expert (each consisting of a specialist, a pharmacist at the CPU, a clinical 
pharmacist, a pharmacist in pharmacovigilance center) were required to raise their opinions 
on impacts of PIs by using the CLEO tool. However, for intra-rater reliability in the first 
study, results of one rater were missing. Thus, the result may be biased.  
Testing bias occurs when evaluators are aware of that their ratings will be compared to ones 
of their colleagues; then they are likely to rate based on what researchers expect rather than 
based on their true perceptions. To minimize this threat, we informed clearly all evaluators 
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that the objective of studies aims to test the functionality of the tool and not achieve perfect 
concordance between raters. Such that, all evaluators were required to rate based on their true 
opinions.  
Selection bias of PIs could threaten the internal validity of a study when PIs are selected in a 
nonrandom fashion. In the first study, we selected non-randomly PIs to balance sample size, 
variety of interventions, scores. In the second study, we selected all PIs during a 10-week 
study period. Two different sampling strategies help to overcome the weakness and take the 
advantages of each one.   
Concerning analytic method, evaluating interrater agreement (IRA) or interrater reliability 
(IRR) is fundamental to the evaluation of research tools. However, many statistical tests exist 
and there is debate in the statistical literature about the appropriateness of the different 
statistical tests. IRA is defined as the degree to which scores/ratings are identical, whereas 
reliability relates to the extent of variability and error inherent in a measurement (263). 
Hence, we used both IRA and IRR but focused more in IRR. Although the kappa score was 
commonly used to assess the IRR between raters in literature, the k statistic may be difficult 
to interpret. First, mathematically, a value of +1 is difficult to achieve and is only observed in 
extreme circumstances. It has been suggested that this upper limit is unnecessarily high and 
realistically may not be achievable in the context of some research studies. Second, the k 
score depends on the number of categories (263). The more categories there are, the more 
difficult it is to classify correctly and the lower the resulting k value. In our results, the 
strength of agreement and reliability can be considered quite high given the large number of 
categories, raters and PIs involved. Third, kappa is sensitive to bias between raters and the 
overall prevalence of responses. In some instances, a relatively high proportion of observed 
agreement can result in a low kappa value and an unbalanced or biased distribution of 
responses can result in a higher kappa value than a more balanced distribution of responses. 
Hence, a low kappa value may not always be indicative of low agreement (263). This event 
occurred in our studies for "organizational impact" dimension in which a high agreement 
(62%) existed with a low kappa (kw = 0.39) in the first study of validation of the CLEO tool4. 
Further statistical analysis is needed to correct for any potential bias in the kappa value. 
Furthermore, we used the weighted kappa instead of kappa because it is more suitable for 
rating items that have between 3 and 10 ordinal categories, and as expected, weighted kappa 
values tend to be higher than unweighted kappa values. Therefore, comparison to other 
studies need to consider this point.  
2.2.2. External validity 
Inevitably, the evaluated studies suffered from some problems with external validity. The 
study sample may have included unique characteristics that make the results unique to the 
study.  
                                                          
4 Thi Ha VO et al. Validation of the CLEO tool for assessment of significance of pharmacist interventions in 
general context.  
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First, in the first study, seven raters were involved to develop another tool for assessing 
impacts of PIs in 2004. Their previous experience may influence research results of this work. 
However, it may be a minor concern because it occurred ten years ago.  
Second, in the first study, to improve the results obtained during the second rating, if the 
investigator found one evaluator rated differently with majority of raters, he/she could be 
required to rate again in blinding others' rating and his/her previous rating. The objective was 
to prevent cognitive or unintentional errors of evaluators. However, only few PIs were needed 
to do so. Therefore, this bias was minor.  
Third, in the second study, the tool was used by pharmacists and physicians in one CPU. And 
the specific characteristics of this service (e.g., types of DRPs and PIs) may be not 
representative for other services or settings. Other more broad-based, multicenter, and 
longitudinal studies are needed to assess the CLEO tool in a variety of settings. In the near 
future, the CLEO tool will be tested for use in a geriatric service at a hospital in Lyon, France.  
Fifth, the reproducibility of results of validation of the French-written CLEO tool needs to be 
tested in other languages and countries. The CLEO tool was originally constructed and 
written in French and was tested in two studies by French pharmacists and physicians for PIs 
conducted in hospitals. The translation and adaptation of the tool from one language and 
culture/country to another needs follow the International Test Commission guidelines on the 
adapting of tests (264). Four kinds of equivalence need to be considered: linguistic 
equivalence, conceptual equivalence, functional equivalence and metric equivalence. There 
are a variety of different approaches to test adaptation: one might develop a new tool to meet 
one's needs, others want to validate the same CLEO tool in their countries. Steps in the 
translation and adaptation process includes: translate and adapt the tool, review the translated 
of adapted version of the tool, adapt the draft tool on the basis of the comments of the 
reviewers, pilot-test the tool, field-test the tool, standardize the score, perform validation 
research as needed, develop a manual and other documents for users of the tool, train users, 
collect reactions from users (264). We are planning to cooperate with Swiss and Vietnamese 
colleagues for the translation and adaptation of the CLEO tool in these two countries.      
3. Perspectives 
The present work generates some perspectives. We presented some perspectives for further 
research on the above section "Validity of findings". Here we will discuss other approaches 
for research.   
3.1. Role of pharmacists in outcome research 
Outcome studies have emerged as a primary research focus for pharmacy and other medical 
disciplines as a result of demands by health care payers and the public for justification of the 
rising costs of care. The role of pharmacists in pharmaceutical outcomes research should be to 
determine the value of pharmaceutical services on the basis of their relative impact. To 
achieve this, research should be directed toward: 
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 Improving our knowledge of which pharmaceutical processes and structures improve 
specific patient outcomes, 
 Determining the degree to which these processes and structures improve outcomes, 
 Assessing the types of outcomes most affected by pharmaceutical services and 
programs, and 
 Improving methods of measuring outcomes. 
 
Some studies show promise of positive impacts of pharmaceutical services. However, it is 
possible that some of pharmacy’s high-profile, heavily promoted services and products do not 
provide significant improvement in outcomes. Some pharmacists may worry that pharmacy, 
as widely practiced, may not have as much of an effect on outcomes as once believed. 
Pharmacists must be sufficiently committed to improving outcomes to accept this possibility 
and the possibility that some services and products may need to be altered or discarded (11). 
 
Pharmacists promote their value best within their own professional journals. However, if 
pharmacist published more in non-pharmacy literature, this would allow other health care 
professionals the opportunity to see how pharmacists add value.   
3.2. Evaluation of impact of PIs 
3.2.1. Integration of the CLEO tool into the Act-IP© website for quality improvement 
The initial purpose of development of the CLEO tool is to integrate it into the Act-IP© 
website. The Act-IP© website was created 10 years ago. Before that time, practice of MR by 
French pharmacists in hospitals has just started and varied across hospital settings. The 
leading group "Standardizing and Demonstrating the value of clinical pharmacy activities" 
belonging to the SFPC had a good vision that developed a valid and standardized instrument 
for documentation of PIs. Diffusion of this instrument has created the first national trend of 
enhancement of MR in France through practice, collection and analysis of data and quality 
improvement (130). However, this instrument just describes characteristics of PIs, which 
means only process of PI practice collected. Furthermore, nowadays, in the period of 
economic crisis, the role of demonstration of value of PIs in term of both costs and potential 
outcomes is so important.  
 
In a review of studies published between 1995 and 2008 in French hospitals by Morice et al. 
(121), of 24 studies selected, almost all studies (83%) measure the production of PI and 58% 
measure acceptance rate of PI. Few studies (25%) assess the potential clinical impact of PI 
and a poor number of studies (17%) evaluate the homogeneity of PI production among 
pharmacists. The French 4-level tool of Chedru et al.(220) which was developed in 1997 by 
modification of the Hatoum's tool was widely used in other studies in France. The inter-rater 
reliability of this tool was good in two studies. However, this tool has some limitations 
including (i) the cost saving was combined into "clinical impact" and was considered as "null 
impact", (ii) the number of levels was only four and (iii) validation process was not rigor. 
With many advantages of the new CLEO tool as well as some limitations needed to be 
improved, we hoped that our work will trigger many studies adopt it widely for testing and 
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use. At present, only the "Clinical impact" and "Economic impact" of the CLEO tool were 
valid, reliable and practical enough to will be integrated into the Act-IP© in the near future. 
This integration is expected to create the second national trend of enhancement of MR in 
France through demonstration of outcomes of PIs. A variety of epidemiological studies of MR 
can be conducted more effectively with this complete observatory of MR. Some kinds of 
these studies will be discussed in the below section.            
   
3.2.2. Relationship between characteristics of medication review and their impacts 
The impacts of MR depends mainly on how MR is conducted. Therefore, exploration of the 
relationship between characteristics of MR (e.g., level of MR, skills of pharmacists for 
providing MR, type of pharmacists, hospitals or ambulatory settings, whether PIs were 
accepted or not) and their impacts are needed. These data allow to improve quality and value 
of MR. For example, the study of Denneboom et al., the authors developed a risk-model for 
detecting patients at risk of DRPs, considered the inclusion of clinical relevance (265). DRPs 
were classified into those with low and those with (potential) clinical relevance. Factors 
possibly associated with DRPs (both for all and relevant problems) were identified. When 
including clinical relevance a shift in main problem categories is observed. Furthermore, the 
risk model for problems with clinical relevance contains more factors than the model which 
considered all problems.  
 
It is also important that the intervention is reproducible, and this in turn depends upon a clear 
description of the intervention (37). There are different levels of MR, for example, from 
opportunistic review (level 0) to a clinical medication review involving the patient, the 
clinical records and the actual drugs (level 3) (46). Although the level 3 of MR may be seen as 
the golf standard, it is also the most expensive in time and other resources, and may not 
always be necessary (37). In contrary, a subgroup meta-analysis of 36 studies found that 
clinical MR but not adherence support review reduced hospitalization (9). Further studies 
should be conducted to determine when, where and how different types of MRs will be 
performed effectively.   
 
The training, skills and experience of the pharmacist conducting the review are also 
important. While a very prescriptive protocol-led review may reduce the need for training, it 
also limits the potential of the review which takes account of the patient's individual situation 
and needs (37). Pharmacists should possess uniformity in skills for providing medication 
review according to recommendations of Singhal et al. (38). This can be addressed through 
uniform training, with skills assessment. If uniform training cannot be achieved or skill cannot 
be assessed, an alternative is to measure the level of pharmaceutical care provision through 
scales such as the Behavioral Pharmaceutical Care scale (266), the Pharmacist 
Implementation of Pharmaceutical Care Scale (267), or the Purdue Pharmacist Directive 
Guidance Scale (268). Differences in pharmaceutical care provision could then be 
incorporated into study results through statistical techniques such as ANCOVA (38).  
Pharmacist-led medication review in community pharmacies or primary-care teams is 
expanding that is needed to evaluate.   
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3.2.3. Other methodologies of evaluation of impacts of PIs 
Researchers have measured the process and outcomes of MR in many ways. These have 
varied from the observational to the randomized controlled trial (RCT), prospective to 
retrospective. Benefits of PIs proven in randomized, controlled, multicenter trials are 
considered as "gold evidence". Thus, such studies are needed. Power in study design can be 
improved through using larger great sample size, designing more effective interventions, 
choosing valid and sensitive variables of impacts  and studying homogeneous high-risk 
populations, such as the elderly or AIDS patients who will likely benefits from 
pharmaceutical services.  
4. Conclusion 
The commitment to pharmaceutical care has given pharmacists new roles and responsibilities, 
namely to detect, resolve and prevent DRPs through PIs. The impacts and value of PIs to the 
patient, the health care system, healthcare providers and society are needed to be evaluated 
and documented in order to expand clinical pharmacy services.    
We addressed some issues in this thesis. The work of the thesis: 
1. Described a variety of theoretical models and frameworks which can be applied to evaluate 
impacts of PIs and synthetize them into an integrated model - the SP(ECH)O  model which 
can provide the comprehensive picture of impacts of PIs.  
2. Reviewed systematically existing tools for assessment potential significance of PIs. A 
variety of tools and methodologies for estimate of value of PIs were found and analyzed. An 
attempt to classification of these tools based on the 10-criteria scale of quality of tools was 
conducted, which will provide useful information for researchers who want to adopt or 
develop a new tool for local use. Some recommendations on characteristics of optimal tools 
for assessing potential impacts of  PIs were suggested. 
3. Developed and tested a new multidimensional tool, named the CLEO, for assessing 
potential impacts of PIs. The CLEO tool was a result from a review of theoretical models of 
evaluation, existing tools and inputs of clinical pharmacists' practice. The CLEO tool allows 
to evaluate CLinical and humanistic outcomes from the patient's perspective, Economic 
impacts (cost savings) from the hospital's perspective and Organizational impacts from HCPs' 
perspective. This 3-dimension tool allows interpreting different impacts together in order to 
obtain a complete picture of impacts of PIs.  
4. Tested the CLEO tool for validity and inter-rater and intra-rater reliability, and user-
friendliness in two studies. In the first study, a research group of 7 pharmacists was required 
to assess retrospectively PIs selected from the database Act-IP or their practice. The final 
version of the CLEO tool was used prospectively in daily practice in a specific service in the 
second study. An evaluation process included three steps: (i) an initial and immediate 
evaluation by the pharmacist who intervened, (ii) a peer-review evaluation by the ward-based 
pharmacist who can access to more complete patient information several days later, and (iii) 
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an evaluation in consensus by multi-disciplinary panels two month later. Concerning inter-
rater reliability, the results obtained were almost perfect or substantial for "economic impact" 
dimension (kw = 0.93 and 0.61, respectively); moderate for "clinical impact" dimension (kw 
= 0.41 and 0.48, respectively); and fair (kw = 0.39 and 0.27, respectively) for "organizational 
impact" dimension in the two studies. Concerning intra-rater reliability, results were slight 
(kw = 0.38) for "clinical impact" and were moderate (kw = 0.70) for "economic impact" in 
the first study. Concerning validity tested in the second study, ratings of the pharmacist on 
ward were more consistent with those of expert panels than the pharmacists in the CPU in 
terms of "clinical impact" and "economic impact" (kw = 0.56 and 0.32 for clinical; kw = 0.75 
and 0.53 for economic, respectively), but less consistent in term of "organizational impact" 
(kw = 0.11 and 0.17, respectively). Comparing to results of other tools in literature, we found 
that "clinical and economic impact" dimension are likely to be reliable and valid enough to be 
able to use independently in daily practice by pharmacists. However, inter-rater reliability of 
"organizational impact" dimension was better in the first study and worse in the second study, 
which requires further research.  
Outcome studies have emerged as a primary research focus for pharmacy and other medical 
disciplines as a result of demands by health care payers and the public for justification of the 
rising costs of care. The role of pharmacists should be to determine the value of PIs and target 
PIs which have most value. The CLEO tool will contribute as a new multidimensional tool to 
research and evaluate value of PIs. For application the CLEO tool in other settings, it is 
necessary to keep in mind that whether the results of ratings using the CLEO tool are valid 
and reliable which not only depend on the functionality of the tool itself but also depend on 
factors related to process of ratings and opinions of evaluators. Therefore, strategies such as 
providing examples, training of ratings, review by a peer or review by a multidisciplinary 
panel need to be conducted in order to improve continuously validity and reliability of results 
of independent ratings by pharmacists.   
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Electronic Supplementary Material  
ESM 1. Assessment of Risk of Bias in Studies 
Risk of Bias Score 
A. The rigor of the sampling methodology of DRPs/PIs/patients (checking for possible 
selection bias) 
1. Number of DRPs/PIs/patients was less than 5 times the maximum 
number of categories of a dimension of a tool 
1 
2. Sampling of DRPs/PIs/patients was selected non-randomly or non-
consecutively or from a setting which probably didn't cover all types of 
DRPs/PIs/patients 
1 
B. The profile of evaluators (checking for possible performance bias)  
3. Only 2 raters  1 
4. Raters from only one group of health care professionals 1 
5. Only internal or external raters 1 
6. More half of raters involved in tool construction/data collection 1 
C. The process of evaluation (checking for possible detection bias)  
7. Raters did not assess independently cases 1 
8. The method did not blind raters from knowledge of which PIs were 
accepted by physicians 
1 
9. The method did not blind raters from knowledge of actual outcome of 
following-up of patient  
1 
D. Other bias  1 
Total Score: 10 
Assessment of Risk of Bias (ROB)  
High (H):  ≥ 1 
Low (L): 0 
Unclear (U): not enough 
information 
reported to 
judge 
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ESM 2: Criteria of quality of a tool for assessing significance of PIs   
A. Structure of a tool Score 
1. A tool has 2 or more dimensions 1 
2. A tool has at least one dimension which has 4 or more categories 1 
B. Content of a tool  
3. A tool applies 2 or more approaches of assessment  1 
4. A tool consists of indicator(s) related to cost savings  1 
5. A tool consists of indicator(s) related to cost avoidance 1 
6. A tool consists of humanistic indicator(s) 1 
7. A tool consists of process-related indicator(s) 1 
8. A tool consists of indicator(s) related to probability of consequences 1 
C. Psychometric parameters of tools   
9. A tool has at least one of psychometric parameters (validity, inter- or intra-rater 
reliability) which presented a moderate or good agreement.    
1 
10. Risk of bias of a study which tested validity, inter- or intra-rater reliability of a 
tool was low.  
1 
Sum of scores: 10 
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ESM 3. Content and Structure of tools in 133 identified studies  
 Structure of each dimension of a tool is coded by 3 or 4-character code; of which: 
+ The final number indicates the number of categories of the dimension;  
+ The next final character (N or O, respectively) indicates a nominal or ordinal dimension, respectively;  
+ One or two first characters (S, E, E1, E2, C, H, Pc, Pb, or R, respectively) indicate aspect of impacts (significance, economic impact, cost savings, cost avoidance, 
clinical impact, humanistic impact, process-related impact, probability, or risk, respectively).  
 Approach of assessment: Approach 3 is the estimation of potential significance of a PI. The approach 3A – prediction of the potential consequences of DRPs in 
absence of a PI; approach 3B - prediction of the potential consequences of an implemented PI. 
 PI = pharmacist intervention. DRP = drug related problem. “_” = Not reported. “+” Reported. “±” Non-determined. "*" = Distinct tool 
 Author(s), 
Published Year, 
Country  
Structure of a tool Approa
ch of 
Assess
ment 
Content of a tool  Notes 
No. Econo
mic 
(E) 
Clinic
al 
(C)  
Huma
nistic 
(H)  
Process-
related 
(Pc)  
Probabilit
y 
(Pb)  
 
1.1 Folli et al.* [36] 
1987, USA  
CO3/Severity of error (significant, serious, 
potentially lethal) 
3A _ + _ _ _ The tool was adapted for use in 
many studies (Iafrate et al. [35], 
Blum et al. [37], Lesar et al. [42, 
63, 64], Ho et al. [46], Overhage et 
al. [12]) 
1.2 Iafrate et al. [35] 
1986, USA  
CO4/Severity of error (minor, significant, 
serious, potentially lethal) 
3A _ + _ _ _ Folli et al. [36]  
1.3 Blum  et al. [37] 
1988, USA  
CO4/Severity of error (minor, significant, 
serious, potential lethal) 
3A _ + _ _ _ Folli et al. [36] 
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1.4 
 
Lesar  et al. [42] 
1990, USA 
CO4/Severity of error (problem order errors, 
potentially significant, potentially serious, 
potentially fatal or severe) 
3A _ + _ _ _ Folli et al. [36] 
1.5 Lesar  et al. [63] 
1997, USA 
CO4/Severity of error (problem order errors, 
potentially significant, potentially serious, 
potentially fatal or severe) 
3A  _ +   _ _   _  Adaption from the tool of Folli et 
al. [36] 
1.6 Lesar  et al. [64]  
1997, USA 
CO4/Severity of error (problem order errors, 
potentially significant, potentially serious, 
potentially fatal or severe) 
3A            Adaption from the tool of Folli et 
al. [36] 
1.7 Ho  et al. [46] 
1992, Canada 
The tool of Folli et al. [36]  3A             
2.1 Hatoum et al.* 
[38] 
1988, USA  
(1) SO6/Impact on patient care (adverse 
significance, no significance, somewhat 
significant, very significant, extremely 
significant) 
(2) E1O3/Cost savings of drug therapy
(negative, zero, positive) 
(3) E1O3/Cost savings of drug therapy 
monitoring (negative, zero, positive) 
(4) E2O3/Savings attributable to complication 
of drug therapy (negative, zero, positive) 
(5) E2O3/Savings in length of patient 
hospitalization (negative, zero, positive) 
3B E1, 
E2 
+ ± + _  The first dimension of the tool is 
the most commonly adapted one 
for use in other studies (26 of 133 
studies) 
2.2 Hatoum  et al. 
[39] 
1988, USA 
The tool of Hatoum et al. [38]  3B             
2.3 Briceland et al. 
[30] 
1992, USA 
(1) SO6/Significance (Adverse significance, no 
significance, somewhat significant, significant, 
very significant, extremely significant)  
(2) E1O3/Cost savings (positive, no change, 
negative) 
3B E1 + ± ± _ Hatoum et al. [38] 
2.4 Eadon  et al. [45] 
1992, UK 
Adaption from the tool of Hatoum et al. [38] 3B       
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2.5 Chisholm  et al. 
[54] 
1995, USA 
Adaption from the tool of Hatoum et al. [38] 3B       
2.6 Wernick  et al. 
[58] 
1996, USA 
Adaption from the tool of Hatoum et al. [38]  3B             
2.7 Lucas et al. [65] 
1997, Australia 
(1) SO6/Clinical significance (adverse 
significance, no significance, somewhat 
significant, significant, very significant, 
extremely significant)  
(2) E1O2/Cost savings (yes/no)  
3B E1 + ± ± _ Hatoum et al. [38] 
Eadon et al. [45] 
2.8 Chisholm et al. 
[60] 
1997, USA 
Adaption from the tool of Hatoum et al. [38] 3B       
2.9 Grabe  et al. [62] 
1997, USA 
Adaption from the tool of Hatoum et al. [38]  3B             
2.10 Smythe  et al. [67] 
1998, USA 
Adaptation from the tool of Hatoum et al. [38] 3B       
2.11 Possidente  et al. 
[72] 
1999, USA 
Adaption from the tool of Hatoum et al. [38]  3B            
2.12 Reddick  et al.[76] 
1999 USA 
SO5/Significance (adverse significance, no 
significance, somewhat significant, significant, 
very significant) 
3B ± + ± ± _ Hatoum et al. [38] 
2.13 Nickerson et al. 
[95] 
2005, Canada 
Adaption from the tool of Hatoum et al. [38] 3B       
2.14 Wang  et al. [117] 
2008, Taiwan 
Adaption from the tool of Hatoum et al. [38] 3B       
2.15 Bondesson  et al. 
[144] 
2012, Sweden 
Adaption from the tool of Hatoum et al. [38] 3B       
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3 Mueller et al.* 
[43] 
1990, USA 
(1) SO6/Clinical impact (adverse significance, 
no significance, somewhat significant, 
significant, very significant, extremely 
significant) 
(2) E1O3/Influence on drug cost (increase, 
decrease, no change)  
(3) E1O3/Influence on patient cost (increase, 
decrease, no change) 
3B E1 + ± + _ Hatoum et al. [38] 
4.1 Chedru et al.* 
[59] 
1997, France 
SO4/Significance (no significance, significant, 
very significant, fatal) 
3B E1 + + _ _ Hatoum et al. [38] 
4.2 Guignon  et 
al.[80] 
2001, France 
Adaption from the tool of Chedru et al. [59] 3B       
4.3 Grangeasse et al. 
[99] 
2006, France 
Adaption from the tool of Chedru et al. [59] 
and of Hatoum et al. [38] 
 
 3B             
4.4 Goarin  et al. 
[129] 
2010, France 
The tool of Chedru et al. [59] 3B       
4.5 Nerich  et al. 
[133] 
2010, France 
The tool of Chedru et al. [59] 3B      x 
5 Cousins et al.* 
[61] 
1997, UK 
(1) SO6/Significance (adverse significance, no 
significance, somewhat significant, very 
significant, extremely significant)  
(2) EN5/Economic impact (Savings in cost of 
drug therapy, Increase in cost of drug therapy, 
Savings in cost of laboratory tests, Savings in 
cost of complications, Savings in costs of 
hospitalization time)  
3B E1, E2 + ± + _ Modified the tool of Hatoum et al. 
[38] 
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6.1 Overhage et al.* 
[12] 
1999, USA 
(1) CO5/Severity of error (no error, minor, 
significant, serious, potentially lethal)  
(2) SO6/Value of service (adverse significance, 
not significant, somewhat significant, 
significant, very significant, extremely 
significant)  
3A + 
3B 
E1 + ± + _ After reviewing literature, the two 
-dimension tool was constructed, 
tested and determined to be 
reliable. The tool was developed 
from the two famous tools: one of 
Hatoum et al. [38] et another of  
Folli et al. [36].  
6.2 Bosma  et al. [98] 
2006, Netherland 
Adaption from the tool of Overhage and Lukes 
[12] 
3A + 3 
B 
      
6.3 Lee et al. [100] 
2006, USA 
(1) CO5/Severity of drug related problems (not 
applicable, minor, significant, serious, 
potentially lethal)  
(2) SO6/Value of pharmacist intervention 
(adverse significance, not significant, 
somewhat significant, significant, very 
significant, extremely significant)  
      The tool was modified from the 
tool of  Overhage and Lukes [12] 
for home-based hospice care. 
6.4 Climenté-Marti  et 
al. [125] 
2010, Spain 
Severity scores were adapted from the tool of 
Overhage et Lukes [12] 
3A + 3B      x 
6.5 Abdel-Qader  et 
al. [124] 
2010, UK 
Adaption from the tool of Overhage and Lukes 
[12] 
 3A + 
3B 
           x 
6.6 Fernandez-
Llamazares  et al. 
[149] 
2012, Spain 
Adaption from the tool of Overhage and Lukes 
[12] 
(2) SO6/Value of service (adverse significance, 
not significant, somewhat significant, 
significant, very significant, extremely 
significant)  
3A + 3B       
6.7 Fernandez-
Llamazares  et al. 
[148] 
Impact of pharmacy service was modified 
slightly from the tool of Overhage and Lukes 
[12] 
3A + 3B       
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2012, Spain 
6.8 Somers  et al. 
[157] 
2013, Belgium 
Adaption from the tool of Overhage et al. [12] 3A + 3B       
7 Kopp et al.* [109] 
2007, USA 
(1) SO5/Severity of error (no error, minor, 
significant, serious, potentially lethal) 
(2) SO6/Value of service (adverse significance, 
not significant, somewhat significant, very 
significant, extremely significant) 
(3) CN4/Probability of Adverse Drug Events 
(none, potential, preventable-actual, 
nonpreventable-actual) 
(4) E1O2/Cost saving(yes/no) 
(5) PbO5/Probability of ADE occurring in the 
absence of the intervention (0; 0.01; 0.1; 0.4; 
0.6) 
3A + 
3B 
E1, 
E2 
+ _ _ + Leape et al.[163] and Overhage et 
al. [12] 
8 Spinewine et al.* 
[102] 
2006, Belgium 
SO5/Clinical significance ( deleterious, minor, 
moderate, major, extreme) 
3B E2 + ± ± _ Hatoum et al. [38] 
Dooley et al. [21] 
9 Neville et al.* 
[40] 
1989, UK 
SO4/Classification of error (potentially serious 
to patient, major nuisance, minor nuisance, 
trivial) 
3A _ + + +  _   
10 Hawkey et al.* 
[20] 
1990, UK 
(1) CO4/Degree of harm (unnoticed, noticed, 
harmful, lethal) 
(2) PbO3/Likelihood of occurrence (<5%, 5-
20%, >20%)  
(3) RO4/ Risk (none, minor, appreciable, 
major)  
(4) E1O5/Savings of drug cost (decrease of 
drug cost <50p, decrease of drug cost >50p, no 
change, increase of drug costs <50p, increase 
of drug costs >50p) 
3A E1 + _ _ +  
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11 Bayliff et al.* [41] 
1990, Canada 
(1) SO5/Effect (detrimental effect, no effect, 
minor positive effect, modest effect, marked 
effect) 
(2) E2O2/Avoided hospitalization (yes/no)  
(3) E2O4/Duration of prolonged 
hospitalization (1, 3, 5 days, a week or more)  
3B E2  + ± _ _   
12 Strong et al.* [50] 
1993, Canada 
(1) CO3/Effect (detrimental effect, no effect, 
positive effect) 
(2) CO2/Life- saving (yes/no)  
(3) SO2/Increased quality of care (yes/no)  
(4) CO2/Avoidance of adverse effects (yes/no)  
(5) E2O2/Reduction of hospital stay (yes/no)  
(6) E1O2/Cost saving (yes/no)  
(7) PcO3/Physician education (yes/no) 
3B E1, 
E2 
+ ± + _  
13 Virani et al.* [87] 
2003, Canada 
(1) SO5/Perceived impact on patient care 
(detrimental effect, no effect, minor positive 
effect, moderate positive effect, marked 
positive effect)  
(2) SO2/Increased quality of care (yes/no)  
(3) CO2/Avoidance of adverse effect (yes/no)  
(4) E1O2/Potential cost savings (yes/no)  
(5) CO2/Improved response to medication 
(yes/no)  
(6) HO2/Improved patient adherence to 
medication (yes/no)  
(7) E2O2/Decreased hospital length of stay 
(yes/no) 
3B E1, 
E2 
+ + ± _ Strong et al. [50] 
Bayliff et al. [41] 
14 Western 
Australian 
Clinical 
Pharmacists 
Group* [44] 
1991, Australia 
SO4/Clinical significance (minor, optimizing 
drug therapy, preventing major toxicity or end-
organ damage, potentially life-saving) 
3B _ + ± _ _   
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15.1 Krass et al.* [73] 
2000 Australia 
(1) SO6/Clinical significance (negative effect, 
no effect, minor significance, significant, very 
significant, potentially life savings)  
(2) E1O2/Cost savings (yes/no) 
3B E1 + ± ±  _ Western Australian Clinical 
Pharmacists’ Group [44] 
15.2 Lövgren et al. 
[121] 
2009, Australia 
SO6/Clinical impact (negative, none , minor, 
significant, very significant, potentially life-
saving) 
3B _ + + _ + Western Australian Clinical 
Pharmacists Group [44] 
16 Struck et al.* 
[113] 
2007, Australia 
(1) SO5/Severity (insignificant, minor, 
moderate, major, catastrophic)  
(2) PbO5/Possibility  
(3) E? 
3A E2, E? + _ _ + Society of Hospital Pharmacists of 
Australia's guideline [19] 
17.1 Elliott et al.* [23] 
2009, Australia 
(1) SO5/Severity of medication-related 
problem (insignificant, minor, moderate, major, 
catastrophic)  
(2) PbO5/Likelihood of consequence (rare, 
low, possible, likely, almost certain) 
(3) RO5 (no, low, moderate, high, extreme) 
3A E2 + _ _ + Society of Hospital Pharmacists of 
Australia's guideline [19]. This is a 
risk matrix 5x5. 
17.2 Elliott et al. [147] 
2012, Australia 
The tool of Elliott et al. 2009 [23] 3A       
18 Khalili et al.* 
[151] 
2012, Iran 
(1) SO5/Clinical significance (insignificant, 
minor, moderate, major, catastrophic)  
(2) EO4/Economic significance (insignificant, 
minor, moderate, major) 
3A + + ± _ _ Clinical significance was based on 
the Guideline of Society of 
Hospital Pharmacy of Australia 
[19]. Economic significance was 
adapted from the IMPROVE study.  
19.1 Lipton  et al.* 
[47] 
1992, USA 
SO3/Severity (0 = no problem, 1 = clinically 
significant but not life threatening, 2 = 
potentially life threatening or leading to serious 
injury or hospitalization, 9 = not enough 
information to make an assessment) 
3A E2 + _ _ _ Numeric tool 
19.2 Lalonde et al. 
[114] 
2008, Canada 
SO3/Significance (not clinically significant, 
clinically significant but not life-threatening, 
serious, not enough information to judge or not 
applicable) 
3A E2 + _ _ _ Adaption of the tool of Lipton et 
al. [47] 
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20.1 Rupp et al.* [48] 
1992, USA 
(1) CO2/Adverse health consequence (yes/no)  
(2) CN4/Type of adverse health consequence 
(toxic, side effects; inadequate control; 
allergy/hypersensitivity; others)  
(3) PbO7/Probability of adverse health 
consequence (not at all, very unlikely, 
somewhat unlikely, neither unlikely or likely, 
somewhat likely, very likely, definitely)  
(4) E2O5/Intensity of health care utilization 
(hospital admission, urgent or emergence care, 
scheduled physician visit, self-care, or other) 
3A E2 + _ _ +  A typical tool for estimating the 
cost avoidance of a PI 
20.2 Rupp  et al. [49] 
1992, USA 
CO2/Adverse health consequence (yes/no) 3A _ + _ _ _ The tool of Rupp et al. [48] 
21 Tang et al.* [51] 
1993, USA 
(1) SN3/Effect of PIs (improvement of quality 
of care, reduce of cost, both)  
(2) SO6/Clinical significance (detrimental to 
patient, general information, a choice among 
several equally acceptable actions, improve 
level of care to acceptable standards, preserve 
one or more major organs, life-saving)  
3B E1 + ± + _   
22 Mason et al.* [52] 
1994, USA 
SO4/Clinical importance (cost savings only, 
minimal, moderate, and high clinical 
importance) 
3A E1 + _ _ _  Lesar et al. [42] 
23 Slaughter et al.* 
[53] 
1994, Canada 
(1) PcN2/Type of intervention (intervention 
event, information event)  
(2) SO9/Quality of intervention (extreme 
adverse significance, very adverse significance, 
adverse significance, somewhat adverse 
significance, no significance, somewhat 
significant, significant, very significant, 
extremely significant)  
(3) E1O3/Cost savings (decrease, increase, no 
change) 
3B E1 + _ + _  
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24 Wang Chin et al.* 
[55] 
1995, USA 
(1) CO2/Decrease toxicity (yes/no)  
(2) CO2/Increase efficacy (yes/no)  
(3) CO2/Avoid drug interaction/allergy 
(yes/no)  
(4) E1O2/Decrease cost (yes/no)  
(5) HO2/Increase compliance (yes/no)  
(6) SO2/Others (yes/no)  
3B E1 + + _ _  
 Other piloted version:  
(1) CO2/Prevent toxicity/side effects (yes/no)  
(2) CO2/Prevent allergy/interaction (yes/no)  
(3) CO2/Improve efficacy (yes/no) 
(4) HO2/Improve compliance (yes/no) 
(5) PcO2/Facilitate continuity of care (yes/no) 
(6) SO3/Clinical significance (somewhat 
significant, significant, very significant)  
(7) E1O2/Financial significance (cost saving 
likely, cost saving unlikely)  
3B E1 + + + _   
25 Caleo et al.* [56] 
1996, Australia 
(1) CO2/Adverse health consequence (yes/no)  
(2) CN4/Type of adverse health consequence 
(toxic, side effects; inadequate control; 
allergy/hypersensitivity; others)  
(3) PbO7/ Probability of adverse health 
consequence (not at all, very unlikely, 
somewhat unlikely, neither unlikely or likely, 
somewhat likely, very likely, definitely)  
(4) HO5/Inference with the patient's everyday 
activity (no, slight, moderate, severe inference, 
no normal activity)  
(5) HO5/Degree of patient discomfort (no, 
slight, moderate, severe, extreme discomfort)  
(6) E2O6/Intensity of health care utilization 
(intensive care-hospital, standard ward-
hospital, accident and emergency-hospital, 
urgent physician visit, next regular physician 
3A + 3B E2 + + _ + The first four questions are similar 
with the tool of   Rupp et al. [48]. 
However, they added the three 
questions 5, 6, 7 to evaluate the 
quality of life of a patient and the 
overall outcome.  
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visit, self-care) 
(7) SO3/Overall outcome (negative, positive, 
neither)   
26 Kettle et al.* [57] 
1996, UK 
 
(1) SN7/Impact on therapy (problem identified, 
problem resolved, problem prevented, problem 
unresolved, improved drug therapy, improved 
drug supply, monitoring)  
(2) SO3/Intervention rating (not significant, 
useful, significant) 
3B _ + _ +  _   
27.1 Alderman et al.* 
[29] 
1997, Australia 
SO3/Significance (minor, moderate, major) 3B E1, 
E2 
+ ± ± _   
27.2 Alderman et al. 
[78] 
2001, Australia 
The tool of Alderman et al. [29]  3B             
27.3 Castelino et al. 
[137] 
2011, India 
Adaption from the tool of Alderman et al. [29] 3B       
28 Dennehy et al.* 
[66] 
1998, USA 
(1) SN5/Potential outcome (optimizing drug 
therapy, minimizing ADRs or drug toxicity, 
decreasing drug costs, increasing 
reimbursement, increasing patient satisfaction)  
(2) SO3/Significance (low, moderate, high) 
3B E1, 
E2 
+ + _ _  
29 Weidle et al.* 
[68] 
1998, USA 
(1) SO3/ Severity of intervention (low, typical, 
high)  
(2) E1O3/Cost savings (no cost saving, low 
cost saving, high cost saving) 
3B E1 + _ _ _   
30.1 Dean et al.* [69] 
1999, UK 
CO11/A visual-analogue tool from 0 to 10 3A _ + _ _ _  A visual-analogue tool. 
30.2 Taxis  et al. [83] 
2002, Germany 
The tool of Dean et al. [69] 3A       
30.3 Hick  et al. [81] 
2001, UK 
(1) The tool of Dean et al. [69]  
(2) Adaption from the tool of Hatoum et al. 
 3A + 
3B 
 E1, 
E2 
+   ±  +  _   
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[38] 
30.4 Bourne  et al. 
[136] 
2011, UK 
Adaption from the tool of Deans et al. [69] 3A       
31 Hawksworth et 
al.* [70] 
1999, UK 
(1) SN4/ Clinical impact (detrimental, 
improved the efficacy, prevented harm, 
prevented a hospital admission)  
(2) PbO11/Confidence (0="definitely not" to 
10 = "definitely") 
3B E2 + _ _ +   
32 Lewinski et al.* 
[24] 
2010, Germany 
(1) CO4/Severity (no impairment; reversible, 
slight impairment of health; reversible, 
significant impairment of health; irreversible or 
serious impairment of health compared to the 
best possible state of health)  
(2) PbO4/Probability (impossible; existent-
0.02; 0.02-0.2; 0.2 and more, already occurred)  
(3) RO4/Safety-relevance (no intervention 
necessary, low, significant, high) 
3A E2 + +  _ + Hawksworth et al. [70]. This is a 
risk matrix. 
33 Gisev et al.* [127] 
2010, Australia 
(1) SO5/Finding agreement (Five-point Likert-
type scale) 
(2) SO5/Recommendation appropriateness 
(Five-point Likert-type scale) 
(3) SO5/Implementation probability (Five-
point Likert-type scale) 
(4) SO5/Overall expected clinical outcome for 
each client (detrimental, improved the efficacy, 
prevented harm, prevented a hospital 
admission, no change in the management of the 
client) 
3B E2  + _ + _ Hawksworth et al. [70] 
34 Nathan et al.* 
[71] 
1999, UK 
SO4/Clinical significance (no clinical 
intervention necessary, patient's knowledge 
improved, improved outcome if therapy 
3B E2 + + _ _   
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changed, hospital admission prevented) 
35 Ewan et al.* [79]
2001, UK 
(1) SO2/Appropriateness of the intervention
(yes, no)  
(2) SO4/Clinical significance of the 
intervention (no clinical intervention necessary, 
patient's knowledge improved, improved 
outcome if therapy changed, hospital admission 
prevented) 
3B E2 + + _ _ Nathan et al. [71]
36 Lustig et al.* [74] 
2000 Israel 
SO3/Severity (non-clinically significant, 
clinically significant, potentially serious)   
3B E2 + _ _ _   
37 Price et al.* [75] 
2000, UK 
(1) SN4/Reasons for interventions 
(effectiveness, safety, patient care, value of 
money) 
(2) SN6/Results of interventions (prescription 
altered, information, prescription the same and 
advice taken, resolved without doctor, 
prescription the same and advice not taken, 
other)  
(3) SO4/Significance of interventions (no 
difference, minor, moderate, severe) 
3B E1 + ± + _   
38 Taylor et al.* [77] 
2000, USA 
SO3/Severity of intervention (low, medium, 
high) 
3B _ + + ± _   
39 Needham et al.* 
[82] 
2002, UK 
(1) SN4/Type of intervention 
(clinical/pharmaceutical support, teamwork or 
communication, medication supply related, 
other)  
(2) SO6/Impact of intervention (improve 
symptom control, prevent deterioration of the 
patient, improve patient compliance, 
worthwhile but effected no change, 
unnecessary or inappropriate, be detrimental to 
3B _ + + _ _   
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the patient's well-being)  
40 van den Bemt et 
al.* [84]  
2002, Netherlands 
SO6/Seriousness of prescribing error (not be 
misunderstood, nurse need gather additional 
information, no clinical consequences, need for 
an increased patient monitoring, damage, 
death) 
3A E2 + _ + _ a modified version of 
the National Coordinating Council 
for Medication 
Error Reporting and Prevention 
(NCC MERP) taxonomy 
of medication errors 
 [164] 
41 Davydov et al.* 
[86] 
2003, USA 
SO10/Errors that reached the patient (no 
harm, increased monitoring, need for treatment 
or intervention and temporary harm, initial or 
prolonged hospitalization and temporary harm, 
permanent harm, near-death event, death); & 
Errors that did not reach the patient (would 
have resulted in significant morbidity or 
mortality, could have resulted in significant 
morbidity or mortality, low potential for 
negative patient outcome)  
1 + 3A E2 + _ _ + A modified version of 
NCC MERP taxonomy [164]. 
The tool evaluates separately errors 
that "reached" and "did not reach 
the patient".  
42 Bobb et al.* [88] 
2004, USA 
SO3/Potential error severity (no harm, 
monitoring required, harmful) 
3A E2  + _ _ _ A modified version of 
NCC MERP taxonomy [164] 
43.1 Gleason et al.* 
[128] 
2010, USA 
SO3/Severity of medication error (no potential 
harm;  monitoring or intervention potentially 
required to preclude harm; potential harm) 
3A E2 + _ _ _ Adaption from the NCC MERP 
taxonomy [164] 
43.2 Quélennec et al. 
[156] 
2013, France 
Adaption from the tool of Gleason et al. [128] 3A       
44 Dooley et al.* 
[21] 
2003, Australia 
SO5/Clinical significance (no clinically 
significance, minor, moderate, major, life-
savings) 
3B E2 + ± ± +   
45 Dale et al.* [85] 
2003, UK 
SO6/Outcome (harmful, neutral, minor, major, 
life- saving, no code) 
3B E2 + _ _ _   
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46 Buurma et al.* 
[89] 
2004, Netherlands 
(1) SO3/Contribution to patient (negative, 
positive, none)  
(2) SN4/Type of positive impact (improvement 
of effectiveness, prevention of ADR, both, 
other)  
(3) PbO5/Probability of positive impact (1-5)  
(4) SO5/Importance of positive impact (1-5)  
3B _ + ± _ + An algorithm representing the flow 
of questions for rating 
interventions. 
47 Westerlund et al.* 
[123] 
2009, Sweden 
(1) CN3/Expected clinical patient outcomes 
(improved therapeutic effects, prevented or 
relieved ADRs, and both)  
(2) E2O4/Hypothesized expected patient 
outcomes (hospitalization avoided , primary 
care contact neither initiated nor avoided, a 
primary care contact initiated, a primary care 
contact avoided) 
3B E2  + _ _ _ Buurma et al. [89] 
48 Gray et al.* [90] 
2004, UK 
(1) SN4/Type of intervention (safety, quality of 
life, concordance, value for money)  
(2) SO4/Significance of intervention 
(potentially harmful, not significant, 
significant, very significant) 
3B + + + _ _  
49 Prowse et al.* 
[91] 
2004, UK 
SO4/Clinical significance (nil, minor, 
moderate, severe) 
3B E1, E2  + + + _ A specific tool for a transplant 
department 
50.1 Cornish et al.* 
[22] 
2005, Canada 
SO3/Significance (unlikely cause discomfort or 
clinical deterioration; potential to cause 
moderate discomfort or clinical deterioration; 
potential to cause severe discomfort or clinical 
deterioration) 
3A _ + + _ + The tool was used in some other 
studies related to medication 
conciliation such as studies by 
Kwan et al. [110], Wong et al. 
[118], Coffey et al. [119], and 
Villanyi et al. [142]  
50.2 Kwan  et al. [110] 
2007, Canada 
Adaption from the tool of Cornish et al. [22] 3A       
50.3 Wong  et al. [118] 
2008, Canada 
Adaption from the tool of Cornish et al. [22] 3A       
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50.4 Coffey et al. [119] 
2009, Canada 
Adaption from the tool of Cornish et al. [22]               
50.5 Villanyi et al. 
[142] 
2011, Canada 
Adaption from the tool of Cornish et al. [22] 3A       
51 Denneboom et 
al.* [92] 
2005, Netherlands 
CO2/Clinical relevance (low, potential or high) 3A _ + _ _ _   
52 Fertleman et al.* 
[93] 
2005, UK 
(1) RO5/Risk matrix considered potential or 
actual impacts on patient, number of patients 
affected, impact on organization and has 5 
level of risk (no, minor, moderate, major, 
catastrophic)  
(2) E1O2/Actual medication cost savings 
between admission and discharge (yes/no) 
3A E1 + _ +  _ Adaption from the Nation Patient 
Safety risk matrix [17] 
53 Knudsen et al.* 
[108] 
2007, Denmark 
SO3/Potential seriousness score (minor 
potential inconvenience to the patient, 
potentially influence the treatment of the 
patient but correctable, potentially influence 
the treatment of the patient to the extent that 
intensive treatment would be necessary) 
3A E2 + + _ _ Safety Assessment Code score [17] 
54 Haavik et al.* 
[130] 
2010, Norway 
SO4/Seriousness of error (no influence on the 
patient’s treatment, minor potential 
inconvenience to the patient, potentially 
influence the treatment of the patient, but 
correctable, potentially influence the treatment 
of the patient to the extent that intensive 
treatment would be necessary, eg. admission to 
hospital) 
3A E2  + + _ _ Adaption from the Safety 
Assessment Code score [17] 
55 Serrano et al.* 
[96] 
2005, Spain 
SO9/Clinical significance (no medication error 
occurred; medication error without harm to 
patient and without necessitating change in 
medical treatment; change in treatment 
3B E2 + _ _ _  
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required without change in vital signs; 
increasing monitoring without change in vital 
signs; change in vital signs, or additional 
laboratory test/invasive procedures required; 
increased length of hospital stay with 
additional treatment; transfer to intensive care 
unit without permanent harm; permanent harm 
resulted; death) 
56 Ling et al.* [94] 
2005, USA 
SN20/20 subcategories belonging to 8 
categories of cost avoidance (no resource 
utilization; no medication-related problem; 
drug information; drug therapy modification; 
additional tests or treatments or noninvasive 
procedures; additional tests or treatments or 
noninvasive procedures and increased length of 
stay or drug-related admission; any resource 
utilization in level 4, long-term-care admission, 
or required transfer to intensive care unit; 
death) 
3B E1, 
E2 
+ _ + _ The tool was used for estimating 
cost avoidance.  
57.1 Blix et al.* [97] 
2006, Norway 
SO4/Clinical significance (minor, moderate, 
major, extremely important) 
3B _ + ± ± _  
57.2 Viktil  et al. [104] 
2006, Norway 
The tool of Blix et al. [97] 3B       
57.3 Schröder et al. 
[141] 
2011, Germany 
Adaption from the tool of Viktil et al. [104] 
 
3B       
58 Vira et al.* [105] 
2006, Canada 
SO2/Clinical significance (clinically important 
or not) 
3A E2 + _ _ _   
59.1 Stubbs et al.* 
[103] 
2006, UK 
CO4/Severity of error (doubtful or negligible 
importance, minor adverse effects or worsening 
condition, serious effects or relapse, fatality) 
3A _ + _ _ _   
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59.2 Chua  et al. [146] 
2012, Malaysia 
Adaption from the tool of Stubbs et al. [103] 3A       
60 Pham et al.* [101] 
2006, USA 
SO3/Significance (high, medium, low) 3B E2 + +  + _  
61 Estellat et al.* 
[107] 
2007, France 
CO3/Potential severity of prescription error 
(none, purely preventive; significant or serious; 
life-threatening) 
3A _ + _ _ _   
62.1 Lindblad et al.* 
[111] 
2007, Canada 
(1) CO2/Cure a disease = 1A (yes/no) 
(2) CO2/Eliminate or reduce signs or 
symptoms = 1B (yes/no) 
(3) CO2/Arrest or slow a disease process = 1C 
(yes/no) 
(4) CO2/Prevent a disease or symptom = 1D 
(yes/no)  
(5) CO2/Achieve desired alterations in 
physiologic processes = 1E (yes/no)  
(6) HO2/Improve physical, mental, or social 
function or satisfaction with care = 2A (yes/no)  
(7) E1O2/Drug cost savings of $1 or more/day 
= 3A(yes/no)  
(8) E1O2/Drug cost increases of $1 or 
more/day = 3B (yes/no) 
3B E1 + + + _  The coding system was developed 
according to the ECHO model 
(economic, clinical and humanistic 
outcome)[16]. An average of 
outcomes was calculated for each 
PI.  
62.2 Harrison et al. 
[150] 
2012, Canada 
(1) SO6/Potential clinical significance (adverse 
significance, insignificant, somewhat 
significant, significant, very significant, 
extremely significant) 
Anticipated clinical outcome  
(2) CO2/Cure a disease (yes/no)  
(3) CO2/Eliminate or reduce signs or 
symptoms (yes/no);  
(4) CO2/Arrest or slow a disease process 
(yes/no)  
3B _ + + + _ Used the tool of Hatoum et al. and 
[38] and the tool of Lindblad et al. 
[111] 
 209 
 
(5) CO2/Prevent a disease or symptom 
(yes/no) 
(6) CO2/Achieve desired alterations in 
physiologic processes (yes/no)  
(7) PcO2/Prevent a potential drug therapy 
problem (yes/no)  
(8) HO2/Anticipated humanistic outcome 
(improve physical, mental, or social function or 
satisfaction with care) 
63 Nguyen et al.* 
[112] 
2007, Australia 
SO6/Clinical impact of issues (negative 
impact, no impact, minor impact, significant 
impact, very significant impact, potentially 
lifesaving) 
3B _ + ± ± + Numeric tool from -1 to 4. 
64 Bayley et al.* 
[106] 
2007, USA 
(1) SO4/Importance of intervention (cost and 
product selection, prevented potential ADE or 
standard of practice, prevent serious morbidity, 
prevent mortality)  
(2) SN4/Expected time-frame of impact (short-
term, long-term, both, not rated) 
3B E1 + ± + _  
65.1 Midlov et al.* 
[115] 
2008, Sweden 
SO3/Clinical risk (no/low, moderate, high) 3A _ + _ _ +  
65.2 Midlov  et al. 
[153] 
2012, Sweden 
 The tool of Midlov et al. [115] 3A       
66 Krahenbuhl et al.* 
[28] 
2008, Switzerland 
(1) CN2/Type of problems (technical, clinical 
problem)  
(2) CN6/Types of potential negative outcome 
(not indicated, indication not treated, 
quantitative ineffectiveness, non-quantitative 
ineffectiveness, non-quantitative safety, 
quantitative safety) 
3A _ + _ _ _   
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67 Pippins et al.* 
[116] 
2008, USA 
(1) SO3 Significance (significant, serious, life-
threatening)  
(2) PbO6/Confidence (little or no confidence,  
slight to modest confidence, less than 50–50 
but close call, more than 50–50 but close call, 
strong confidence, virtually certain confidence) 
3A _ + + _ + Bates et al. [166] 
68 Rothschild et al.* 
[3] 
2010, USA  
(1) CN3/Type of recovered medication error 
(intercepted potential adverse drug event; 
mitigated adverse drug event; ameliorated 
adverse drug event)  
(2) PbO5/Presence of a recovered medication 
error (definitely, probable, probably not, 
definitely not, unsure)  
(3) CO4/Potential severity of harm 
(insignificant, significant, serious, life-
threatening, unable to determine) 
1 + 3A _ + _ _ + Bates et al.  [166] 
69 Abu-Ramaileh et 
al.* [135] 
2011, USA 
(1) SN2/Quality intervention (yes/no)  
(2) PbO5/Confidence of judgment (little or no 
confidence, modest confidence, medium 
confidence, strong confidence, virtually certain 
confidence)  
(3) SN4/Type of quality intervention (avoid 
overuse of medication, underuse of medication, 
and misuse of medication, improve adherence 
with current evidence based 
medicine/nationally adopted quality standards) 
3B _ + _ + + PIs were classified into PIs prevent 
medication errors (rated by the tool 
of Rothschild et al. [3]) and 
Quality Interventions (rated by the 
tool of Abu-Ramaileh et al. [135]) 
70.1 Patanwala et al.* 
[138] 
2011, USA  
(1) CO4/Severity (minor, significant, serious, 
potentially lethal)  
(2) PbO5/Probability of harm (no harm 
expected 0, very low 0.01, low 0.1, medium 
0.4, high 0.6) 
3A _ + _ _ + Adopted the tool of Overhage et al. 
[12] 
and the tool of Rothschild et al. [3] 
70.2 Patanwala et al. 
[139] 
2011, USA 
The tool of Patanwala et al. [138] 
 
 3A _ + _ _ _   
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71 Granas et al.* 
[120] 
2009, Norway 
(1) SO3/Clinical relevance of DRP (low, 
medium, high);  
(2) HO3/Quality of the PI with the patient 
(good, satisfaction, not satisfaction)  
(3) PcO3/Quality of the PI with the physician 
(good, satisfaction, not satisfaction) 
3A + 3B _ + + + _   
72 Vasileff et al.* 
[122] 
2009, Australia 
SO5/Clinical significance (nil, minor, 
significant, very significant, life-savings) 
3B _ + ± _ _   
73 Lee et al.* [132] 
2010, Canada 
(1) PbO3/Potential of patient harm (unlikely, 
possible, probable) 
(2) SN3/Type of patient harm (discomfort, 
clinical deterioration, or both) 
(3) SO3/Severity of patient harm (minor, 
moderate and severe by 9-point tool of Deans 
et al. [69]) 
3A _ + + _ + Deans et al. [69] 
74 Rashed et al.* 
[154]  
2012, UK and 
Saudi Arabia  
CO3/Severity (minor outcome, moderate 
outcome, severe outcome) 
3A _ + _ _ _ Adopted the tool of Dean et al. 
[69] 
75 Niquille et al.* 
[134] 
2010, Switzerland 
(1) SN3/Type of possible negative clinical 
outcome (necessity, effectiveness, safety)  
(2) SO4/Clinical problem (harmful;  interesting 
in theory, but not applicable in the case of the 
patient;  revaluated at the next visit;  
implemented as soon as possible)  
(3) E1O2/Expense problem (yes/no) 
3A E1 + _ _ _   
76 Eichenberger et 
al.*  
2010, Switzerland 
PcO4/Outcome (outcome unknown, problem 
solved, problem partially solved, problem not 
solved) 
3B _ _ _ + _ Adaptation from the PCNE V.5.01. 
77 Knez et al.* [131] 
2010, UK 
CO5/Clinical significance (insignificant, minor 
significant, significant, very significant, 
potentially life-savings) 
3B _ + _ _ _   
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78 Williams et al.* 
[31] 
2011, Australia 
SO4/Clinical significance (low, mild, 
moderate, high) 
3B E2 + +  + _  
79 Cesarz et al.* 
[145] 
2012, USA 
SN2/Type of intervention (error prevention, 
optimization of medication therapy) 
3B _ + ± ±    
80 Perera et al.* 
[140] 
2010, USA 
SN3/Intervention category (cost savings, 
safety, guideline adherence) 
3B E1 + _ + _  
81 Kwint et al.* 
[152] 
2012, Netherlands 
Three parameters of clinical relevance of DRP 
consists  
(1) SO3/High priority to be discussed with the 
physician (low, medium, high)  
(2) SN2/Recommendation for drug change 
(yes/no)  
(3) SN2/Implemented recommendation for 
drug change (yes/no) 
_ _ + _ + _   
82 Mekonnen  et al.* 
[155] 
2012, Ethiopia 
(1) SO4/Clinical importance of intervention 
(mild, moderate, major, extreme) 
3B _ + _ + _  
 213 
 
 
ESM 4. Process of validation of tools in 133 identified studies 
Note: "IN" = individual-based rating. "GR" = group-based rating. "ND" = non-determined. "_" = Not reported.  "*" = Distinct tool. "ME" = medication error. "PI" = pharmacist 
intervention. 1, 2 Number of PIs, sampling were presented and risk of bias/limits was assessed for only studies which reported validity or reliability results. "U" = unclear risk of bias. 
"H" = high risk of bias. "L" = low risk of bias 
No. Author(s), 
Published 
year, Country 
Setting, 
Number of 
PIs,  
Sampling1 
Quality and Number 
of Raters 
Rating 
Method 
Definitions 
of 
Consensus  
Validity Inter-rater 
Reliability 
Intra-rater 
Reliability 
Risk of 
Bias/Limits2 
Score of 
Quality of a 
Tool  
1.1 Folli et al. [36] 
1987, USA  
2 children's 
hospitals 
 
 
1 member of the 
pediatric faculty or 1 
attending physician + 
2 pediatric clinical 
pharmacist 
practitioners 
GR ND _ _ _ _ 0 
1.2 Iafrate et al. 
[35] 
1986, USA  
a hospital  
 
1 clinical supervisor + 
1 clinical resident 
GR ND _ _ _ _ 1 
1.3 Blum et al. 
[37] 
1988, USA  
a hospital  4 pharmacists + 1 
physician  
GR consensus + 
hierarchical 
approach 
_  _  _ _ 1 
1.4 Lesar et al. 
[42] 
1990, USA 
a hospital investigators  ND ND _ _ _ _ 1 
1.5 Lesar et al. 
[63] 
1997, USA 
a hospital, 
500 MEs, 
consecutive 
sampling 
1 physician + 2 
pharmacists  
IN 
 
IN _ agreement = 
97%, Cohen k = 
0.96, p < 0.001: 
excellent 
agreement 
_ U 2 
1.6 Lesar et al. 
[64]  
1997, USA 
 a hospital  investigators  ND ND _ _ _ _ 1 
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1.7 Ho et al. [46] 
1992, Canada 
a hospital  1 practicing 
pharmacist + 1 
practicing physician 
GR consensus _ _ _ _ 1 
2.1 Hatoum et al.* 
[38] 
1988, USA  
a hospital  3 physicians GR mode and 
mean 
_ _ _ _ 5 
2.2 Hatoum et al. 
[39] 
1988, USA 
a hospital  practicing clinical 
pharmacists + peer-
review process ( 9 
practicing clinical 
pharmacists served on 
3 reviewing teams) 
GR mode + 
consensus  
_ _ _ _ 5 
2.3 Briceland et 
al. [30] 
1992, USA 
a hospital 1 clinical pharmacy 
preceptor  
IN IN _ _ _ _ 5 
2.4 Eadon et al. 
[45] 
1992, UK 
a hospital, 25 
PIs, random 
sampling 
1 pharmacist + 3 
physicians (1 
transplant registrar + 1 
research registrar + 1 
senior registrar) 
IN IN Mann Whitney 
U = 933.5, 
z=0.034: no 
significant 
difference 
_ _ - sampling of 
few PIs from 
one hospital 
- no results of 
agreement 
between 
pharmacists 
(H) 
6 
2.5 Chisholm et al. 
[54] 
1995, USA 
a hospital  1 pharmacy resident + 
2 pharmacy 
practitioners + 1 fourth 
pharmacy practitioner 
served as arbitrator 
GR consensus + 
hierarchical 
approach 
_ _ _ _ 5 
2.6 Wernick et al. 
[58] 
1996, USA 
 a hospital  1 practicing 
pharmacist + a panel 
of 3 clinical 
pharmacists  
GR ND _ _ _ _ 5 
2.7 Lucas et al. an inpatient 1 pharmacist (P1) + 1 IN hierarchical  P1 vs P2: _ - sampling of 5 
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[65] 
1997, 
Australia 
palliative care 
unit, 
62 PIs, 
consecutive 
sampling 
internal physician (P2) 
+ 2 external physicians 
(P3, P4) 
 
 approach agreement = 
83%,  t-test p = 
0.495 > 0.05: no 
significant 
difference  
P2 vs P3: 
agreement = 48% 
P2 vs P4: 
agreement =  
63% 
P1 vs P3: t-test p 
= 0.983 > 0.05: 
no significant 
difference  
P1 vs P4: t-test p 
= 0.02 < 0.05: 
significant 
difference  
PIs from only 
one unit 
- no result of 
agreement 
between 2 
pharmacists  
(H) 
 
2.8 Chisholm et al. 
[60] 
1997, USA 
a hospital  1 preceptor + 1 
practicing pharmacist 
GR mean _ _ _ _ 5 
2.9 Grabe et al. 
[62] 
1997, USA 
a hospital  4 investigators  GR consensus _ _ _ _ 5 
2.10 Smythe et al. 
[67] 
1998, USA 
a step-down 
unit for the 
medical ICU, 
235 PIs, 
consecutive 
sampling 
2 intensivists + 2 
internists blinded to as 
to whether 
recommendations were 
accepted 
 
IN IN _ weighted kappa 
= 0.342 for 
intensivists;  
weighted kappa 
= 0.258 for 
internists 
_ - sampling of 
only one unit  
- there were no 
pharmacists as 
raters  
(H) 
5 
2.11 Possidente et 
al. [72] 
1999, USA 
a hospital  2 pharmacists + 1 
nephrologist 
GR consensus     _ _ _ _ 5 
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2.12 Reddick et al. 
[76] 
1999 USA 
27 clerkship 
sites of 
pharmacy 
students 
pharmacy students IN IN _ _ _ _ 5 
2.13 Nickerson et 
al. [95] 
2005, Canada 
2 general 
medicine units 
1 seamless care 
pharmacist + 1 clinical 
pharmacist  
GR ND _ _ _ _ 5 
2.14 Wang et al. 
[117] 
2008, Taiwan 
a medical 
center 
1 practicing 
pharmacist + 1 other 
physician 
GR consensus _ _ _ _ 5 
2.15 Bondesson et 
al. [144] 
2012, Sweden 
a hospital  Two pairs of 
evaluators (each 
including 1 clinical 
pharmacist + 1 
geriatrician or 1 
general physician with 
special interest in 
geriatrics); the third 
clinical pharmacist 
served as a tiebreaker 
GR hierarchical 
approach 
_ _ _ _ 5 
3 Mueller et al.* 
[43] 
1990, USA 
a hospital investigators GR consensus _ _ _ _ 4 
4.1 Chedru et al.* 
[59] 
1997, France 
 2 departments 
of a hospital, 
18 PIs, non-
random 
sampling 
 
2  external physicians  
 
IN 
 
sum _ signmax 0.8, 
signmay 0.7 
_ - sampling of 
few PIs 
- non-random 
sampling 
- there were no 
pharmacists as 
raters 
(H) 
4 
4.2 Guignon et al. 
[80] 
a hospital  1 external hospital 
pharmacist + 1 
GR consensus _ _ _ _ 3 
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2001, France physician of the 
regional center of 
pharmacovigilance 
4.3 Grangeasse et 
al. [99] 
2006, France 
a hospital  a center of clinical 
pharmacy of oncology 
+ 1 physician 
reviewed 
GR hierarchical 
approach 
_ _ _ _ 3 
4.4 Goarin et al. 
[129] 
2010, France 
an oncology 
and 
haematology 
ward in a 
hospital, 188 
PIs, 
consecutive 
sampling 
1 physician from a 
pharmacovigilance 
center + 1 pharmacist 
of a centralized 
cytotoxic service  
IN One 
parameter 
of the 
relevance of 
a PI is that 
score of a 
PI is > 0 by 
at least one 
assessors 
_ t-test p < 0.05: no 
significant 
difference 
_ - only 2 raters  
- PIs from only 
a ward 
(H) 
4 
4.5 Nerich et al. 
[133] 
2010, France 
a hospital  6 medical oncologists 
+ 3 pneumologists + 3 
hematologists 
GR ND _ _ _ _ 3 
5 Cousins et al.* 
[61] 
1997, UK 
a hospital, 
584 PIs for 
  intra-
reliability test; 
62 PIs for 
inter-reliability 
test 
 
12 pharmacists 
 
IN 
 
IN patients’ 
medical records 
of  
62 PIs were 
inspected for 
evidence of the 
interventions 
(1) kappa = 0.26 
(2) kappa = 0.27 
(1) Wilcoxon 
matched-pairs 
signed-rank test 
p = 0.01, 0.03 , 
0.13, 0.18, 0.32, 
0.37, 0.38, 0.46, 
0.55, 0.58, 0.60, 
0.69  
(2) agreement = 
48%; kappa < 0  
- there were no 
physicians as 
raters  
- raters 
involved in 
practice of 
medication 
review and data 
collection 
(H) 
5 
6.1 Overhage et 
al.* [12] 
1999, USA 
a hospital, 
300 PIs, 
sampling 
strategy to 
balance 
1 pharmacist 
retrospectively viewed 
+ an expert panel of 2 
clinical pharmacists 
and 2 internists with 
IN 
 
IN _ (1) kw = 0.69 
(2) kw = 0.69 
_ - non-random 
sampling of 
only one 
hospital  
- 2 internists 
6 
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sample size, 
variety of 
interventions 
 
fellowship training in 
clinical pharmacology 
with fellowship 
training in 
clinical 
pharmacology 
- 2 raters 
participated in 
the refinement 
of the 
instrument 
(H) 
6.2 Bosma et al. 
[98] 
2006, 
Netherland 
a hospital, 
255 PIs, 
consecutive 
sampling 
1 hospital pharmacist 
+ 1 internal medicine 
specialist - clinical 
pharmacologist  
IN IN _ (1) kw = 0.30  
(2) kw = 0.20 
_ - sampling of 
only one 
hospital 
- only 2 raters 
(H) 
5 
6.3 Lee et al. [100] 
2006, USA 
three hospice 
programs, 
98 DRPs 
87 PIs, 
consecutive 
sampling 
3 hospice experts (2 
pharmacists + 1 
physician) + 2 
principal investigators  
IN mean, mode 
and median  
_ (1) agreement = 
60-70%, k = 
0.19-0.47 
(2) agreement = 
63-80%, k = 
0.14-0.31 
  (L) 6 
6.4 Climenté-
Marti et al. 
[125] 
2010, Spain 
a hospital  1 pharmacist + 1 
physician + another 
physician or 
pharmacist (sometimes 
a third internist) 
GR hierarchical _ _ _ _ 5 
6.5 Abdel-Qader 
et al. [124] 
2010, UK 
a hospital  practicing pharmacists 
+ meetings among the 
research team 
GR consensus, 
hierarchical 
_ _ _ _ 5 
6.6 Fernandez-
Llamazares et 
al. [149] 
2012, Spain 
a hospital, 20 
PIs, random 
sampling 
4 senior pharmacists + 
5 junior pharmacists  
IN IN _ (2) agreement = 
66%, k = 0.24 
(95% CI 0.15-
0.32) for all 
raters; agreement 
_ - few PIs tested  
- PIs were not 
evaluated by 
physicians  
(H) 
5 
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= 72%, k = 
0.27(95% CI 
0.16-0.38) for 
senior 
pharmacists; 
agreement = 
64%, k = 0.10 
(95% CI 0.00-
0.20) for junior 
pharmacists 
6.7 Fernandez-
Llamazares et 
al. [148] 
2012, Spain 
a hospital  clinical pharmacists  IN IN _ _ _ _ 5 
6.8 Somers et al. 
[157] 
2013, Belgium  
a geriatric ward 
of a hospital, 
304 PIs, 
consecutive 
sampling 
2 clinical 
pharmacologists + 2 
clinical pharmacists 
IN IN _ k = 0.15-0.25: 
poor agreement 
_ - only one ward 
- PIs done by 
only one 
clinical 
pharmacist 
(H) 
5 
7 Kopp et al.* 
[109] 
2007, USA 
a surgical 
intensive care 
unit of a 
hospital, 129 
PIs, 
consecutive 
sampling 
2 pharmacists not 
involved in data 
collection   
IN consensus _ (1) agreement = 
62.8%; kappa = 
0.25;  
(5) agreement = 
69.8%; kappa = 
0.41 
(prevalence-
adjusted and 
bias-adjusted 
kappa) 
_ - PIs from only 
a surgical 
intensive care 
unit 
- there were no 
physicians as 
raters 
(H) 
6 
8 Spinewine et 
al.* [102] 
2006, Belgium 
a geriatric unit 
of a hospital, 
700 PIs 
2 geriatricians + 1 
clinical pharmacist 
 
IN consensus _ (1) agreement = 
33% 
_ - sampling of 
PIs of only a 
geriatric unit  
- raters did not 
2 
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blind to as to 
whether  PIs 
were accepted 
by physicians 
(H) 
9 Neville et al.* 
[40] 
1989, UK 
a health center  ND ND ND _ _ _ _ 3 
10 Hawkey et al.* 
[20] 
1990, UK 
6 hospitals, 
103 PIs, 
non-random 
sampling 
2 physicians  
 
IN 
 
IN _ (3) Spearman's 
rank correlation 
coefficient R = 
0.83, p<0.001: 
a significant 
correlation 
_ - only 2 raters 
- there were no 
pharmacists as 
raters 
(H) 
5 
11 Bayliff et al.* 
[41] 
1990, Canada 
a hospital, 15 
PIs, non-
random 
sampling 
4 physicians (2 clinical 
pharmacologists + 2 
chief residents in 
medicine) 
GR mean, mode _ (1) coefficient of 
agreement = 0.76 
(p>0.05), 
effective 
reliability = 0.93: 
"reasonably 
good" agreement 
(2) coefficient of 
agreement 0.38 
(p>0.05), 
effective 
reliability = 0.71  
(3) coefficient of 
agreement 0.30 
(p>0.05), 
effective 
reliability = 0.63 
_ - sampling of 
few PIs from 
only one 
hospital 
- there were no 
pharmacists as 
raters  
(H) 
4 
12 Strong et al.* 
[50] 
1993, Canada 
a hospital, each 
rater received 
11 identical 
7 physicians with 
clinical pharmacology 
experience 
IN IN _ (1) Coefficient of 
agreement = 
0.86: good 
_ - non-random 
sampling of 
few PIs from 
5 
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cases, non-
random 
sampling 
agreement only one 
hospital 
- no results of 
agreement 
between 
pharmacist 
(H) 
13 Virani et al.* 
[87] 
2003, Canada 
a mental health 
unit, 
8 PIs, 
consecutive 
sampling 
2 internal clinical 
pharmacists + 1 child 
and adolescent 
psychiatrist 
IN ND  _ coefficient of 
agreement = 0.7: 
reasonably good 
agreement 
_ - sampling of 
few PIs 
(H) 
6 
14 Western 
Australian 
Clinical 
Pharmacists 
Group* [44] 
1991, 
Australia 
12 hospitals 6 clinical pharmacists GR consensus _ _ _ _ 1 
15.1 Krass et al.* 
[73] 
2000 Australia 
community 
pharmacies   
1 clinical pharmacist + 
1 clinical 
pharmacologist + 1 
general medical 
practitioner + 1 
consultant physician  
ND ND _ _ _ _ 3 
15.2 Lövgren et al. 
[121] 
2009, 
Australia 
a hospital  1 consultant 
pharmacologist + 1 
academic pharmacist  
GR consensus     _ _ _ _ 3 
16 Struck et al.* 
[113] 
2007, 
Australia 
a hospital, 656 
PIs, 
consecutive 
sampling 
2 clinical pharmacists 
(1 third clinical 
pharmacist as needed)  
IN consensus + 
hierarchical 
approach 
_ (1) agreement = 
65% (95% CI 61-
68%), kw = 0.51 
(95% CI 0.46-
0.56): moderate 
_ - there were no 
physicians as 
raters 
- raters did not 
blind to as to 
4 
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agreement 
(2) agreement = 
37% (95% CI 33-
40), kw = 0.14 
(95%CI 0.09-
0.18): very poor 
agreement 
(3) agreement = 
68% (95% CI 65-
72), kw = 0.39 
(95% CI 0.34-
0.45): poor 
agreement 
whether PIs 
were accepted 
by physicians 
(H) 
17.1 Elliott et al.* 
[23] 
2009, 
Australia 
aged care and 
memory clinics 
at a hospital, 
113 DRPs 
2 clinical pharmacist + 
2 physician 
IN IN Face validity 
reviewed 30 
DRPs by 2 
pharmacists + 1 
senior 
geriatrician 
(agreement = 
93-100%) 
(3) k = 0.24 for 
all raters, k = 
0.55 for 
pharmacists, k = 
0.20 for 
physicians 
_ - PIs proposed 
by one 
pharmacist 
from aged care 
and memory 
clinics 
- only external 
raters  
- some raters 
were not 
provided with 
the risk table 
(H) 
4 
17.2 Elliott et al. 
[147] 
Aged Care 
Assessment 
Teams 
1 geriatrician + 1 
pharmacist 
GR consensus _ _ _ _ 4 
18 Khalili et al.* 
[151] 
2012, Iran 
an infectious 
diseases ward 
of a hospital, 
231 PIs, 
consecutive 
1 clinical pharmacist + 
1 physician  
IN hierarchical 
approach 
(physician's 
opinions) 
_ (1) agreement = 
93.6%: good 
agreement 
_ - raters 
probably did 
not blinded to 
as to whether 
PIs were 
4 
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sampling  accepted by 
physicians 
- PIs of only 
one ward 
(H) 
19.1 Lipton  et al.* 
[47] 
1992, USA 
a hospital  a principal investigator 
and a panel of 5 
physicians, 2 clinical 
pharmacists 
GR mean + 
hierarchical 
approach 
_ _ _ _ 1 
19.2 Lalonde et al. 
[114] 
2008, Canada 
a hospital and 
pharmacies 
1 clinical pharmacist + 
1 family-medicine 
physician 
GR ND _ _ _ _ 1 
20.1 Rupp et al.* 
[48] 
1992, USA 
89 community 
pharmacies, 
176 PIs, 
consecutive 
sampling 
1 physician + 1 
pharmacist  + 1 third 
pharmacist served as a 
tiebreaker 
IN consensus + 
hierarchical 
approach 
_ (1) agreement = 
87-95%; kappa = 
0.68-0.88: 
moderately 
strong agreement 
(2) agreement = 
87-88%; kappa = 
0.79-0.82: 
(3) p > 0.05  
(4) low 
agreement 
_ - the tool was 
tested in 
community 
pharmacies, not 
in hospitals  
- raters did not 
blind to the 
outcomes of 
PIs 
(H) 
5 
20.2 Rupp et al. 
[49] 
1992, USA 
89 community 
pharmacies, 
623 DRPs, 
consecutive 
sampling 
1 physician + 1 
pharmacist + 1 third 
pharmacist served as a 
tiebreaker) 
 
IN consensus + 
hierarchical 
approach 
_ agreement = 
87%, kappa = 
0.68: moderately 
strong agreement 
_ - the tool was 
tested in 
community 
pharmacies, not 
in hospitals  
- raters did not 
blind to the 
outcomes of 
PIs 
(H) 
5 
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21 Tang et al.* 
[51] 
1993, USA 
a hospital 2 clinical pharmacists ND ND _ _ _ _ 4 
22 Mason et al.* 
[52] 
1994, USA 
a medical 
center 
practicing pharmacists IN IN _ _ _ _ 2 
23 Slaughter et 
al.* [53] 
1994, Canada 
hospitals and 
an ambulatory 
care site 
1 physician (clinical 
preceptor) + 1 
pharmacist (internal 
medicine faculty 
preceptor) 
GR mean _ _ _ _ 4 
24 Wang Chin et 
al.* [55] 
1995, USA 
a cancer center practicing pharmacists 
+ 1 investigator  
GR hierarchical 
approach 
_ _ _ _ 3 
25 Caleo et al.* 
[56] 
1996, 
Australia 
30 community 
pharmacies, 
50 PIs, 
random 
sampling 
2 clinical 
pharmacologists + 1 
clinical pharmacist + 1 
community pharmacist 
GR 
 
mean, mode _ (1) weighted 
kappa (kw) < 0 
(2) kw = 0.50-
0.76: moderate to 
good agreement  
(4) kw with poor 
agreement 
(5) kw with poor 
agreement 
(6) kw with poor 
to moderate 
agreement 
(7) kw with poor 
to moderate 
agreement  
_ - there were no 
physicians 
raters  
- the tool was 
tested in 
community 
pharmacies, not 
in hospitals 
(H) 
7 
26 Kettle et al.* 
[57] 
1996, UK 
 
a hospital-
based 
community 
mental health 
team  
1 trust pharmacy 
manager + 1 
consultant psychiatrist  
GR ND _ _ _ _ 3 
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27.1 Alderman et 
al.* [29] 
1997, 
Australia 
a hospital ND ND ND _ _ _ _ 2 
27.2 Alderman et 
al. [78] 
2001, 
Australia 
a hospital  ND ND ND _ _ _ _ 2 
27.3 Castelino et al. 
[137] 
2011, India 
a hospital  ND ND ND _ _ _ _ 2 
28 Dennehy et 
al.* [66] 
1998, USA 
hospital(s) intervening student + 2 
pharmacists + 
committee of 8 
pharmacists 
GR consensus + 
hierarchical 
approach 
_ _ _ _ 5 
29 Weidle et al.* 
[68] 
1998, USA 
a hospital  recording pharmacist + 
Pharmaceutical 
Council 
(Pharmaceutical Care 
Team leaders + 
Associate Director of 
Pharmacy) 
GR consensus + 
hierarchical 
approach 
_ _ _ _ 2 
30.1 Dean et al.* 
[69] 
1999, USA 
_ 
50 MEs, non- 
random 
sampling 
 
10 physicians + 10 
pharmacists + 10 
nurses 
 
IN 
 
mean (a 
mean  score 
was reliable 
if it was 
calculated 
from scores 
given by 4 
health 
professional
s) 
clear 
relationship 
between patient 
outcomes and 
severity scores 
Generalizability 
coefficient = 
0.587 
(A 
generalizability 
coefficient of 0.8 
or more was 
considered to 
represent an 
acceptable level 
of reliability).  
Generalizability 
coefficient = 
0.780 
- only external 
raters 
(H) 
2 
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30.2 Taxis et al. 
[83] 
2002, 
Germany 
_ 
50 MEs, non -
random 
sampling 
10 physicians + 10 
pharmacists + 10 
nurses 
GR mean (a 
mean  score 
was reliable 
if it was 
calculated 
from scores 
given by 3 
health 
professional
s) 
Clear 
relationship 
between 
severity scores 
with known 
outcomes 
not reported not reported - only external 
raters 
2 
30.3 Hick et al. [81] 
2001, UK 
an pre-
admission 
clinic, 
155 PIs, 
consecutive 
sampling 
4 senior pharmacists 
for each tool  
IN (1) mean 
score  
(2) mode + 
fourth rater 
as a casting 
vote 
_ (1) ANOVA p < 
0.001: no 
significant 
agreement 
(2) agreement = 
85% of cases two 
out of 3 assessors 
agreed  
_ - sampling of 
PIs from only 
one clinic  
- there were no 
physicians as 
raters  
(H) 
7 
30.4 Bourne et al. 
[136] 
2011, UK 
a critical 
care unit 
3 clinical pharmacists 
+ 1 specialist nurse + 1 
intensive care 
consultant 
GR mean _ _ _ _ 1 
31 Hawksworth 
et al.* [70] 
1999, UK 
14 community 
pharmacies 
ND GR ND _ _ _ _ 4 
32 Lewinski et 
al.* [24] 
2010, 
Germany 
69 community 
pharmacies, 
638 patients, 
consecutive 
sampling 
2 pharmacists + 1 
physician 
IN median _ (1) Cohen k = 
0.78: substantial 
agreement  
(2) Cohen k = 
0.83: almost 
perfect 
agreement 
(3) Cohen k = 
0.87: almost 
_ - uncompleted 
or deficient 
cases was 
excluded from 
the 
analysis 
- no internal 
raters 
(H) 
6 
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perfect 
agreement 
33 Gisev et al.* 
[127] 
2010, 
Australia 
5 community 
mental health 
teams, 208 PIs, 
consecutive 
sampling  
1 consultant 
psychiatrist + 1 
general medical 
practitioner + 1 
specialist psychiatric 
pharmacist + 1 
medication review 
accredited pharmacist  
IN IN Face validity 
by an 
independent 
pharmacist 
(1) moderately 
consistent  
(2) W = 0.41: 
moderately 
consistent
(3) W = 0.40: 
moderately 
consistent
(4) ND  
(W = Kendall 
coefficient of 
concordance) 
_ - criteria-based 
validity was not 
tested 
- sampling of 
only patients 
with mental 
illness  
(H) 
5 
34 Nathan et al.* 
[71] 
1999, UK 
23 pharmacies  1 geriatrician + 1 
physician + 1 hospital 
clinical pharmacist + 1 
community pharmacist 
GR ND _ _ _ _ 3 
35 Ewan et 
al.*[79] 
2001, UK 
community 
pharmacies, 94 
DRPs, 
consecutive 
sampling 
 
2 pharmacists (R1 and 
R2) + 1 consultant 
psychiatrist (R3) 
 
IN 
 
IN    _ (1) R1 vs R3: 
agreement = 86, 
k = 0.31 
R1 vs R2: 
agreement = 90, 
k = 0.20 
R2 vs R3: 
agreement = 90, 
k=0.26 
(2) R1 vs R3: k = 
0.33 
R1 vs R2: k = 
0.25 
R2 vs R3: k = 
0.28 
_ - the tool was 
tested in 
community 
pharmacies, not 
in hospitals 
- sampling of 
only mentally 
ill patients (H) 
4 
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36 Lustig et al.* 
[74] 
2000 Israel 
a hospital ND ND ND _ _ _ _ 1 
37 Price et al.* 
[75] 
2000, UK 
a hospital  2 pharmacists + 
pharmacy services 
managers 
GR ND _ _ _ _ 4 
38 Taylor et al.* 
[77] 
2000, USA 
a hospital  pharmacy residents + 
pharmacy patient care 
leaders + 1 pharmacy 
manager 
GR consensus + 
hierarchical 
approach 
_ _ _ _ 1 
39 Needham et 
al.* [82] 
2002, UK 
14 community 
palliative care 
teams 
1 nurse + 1 consultant 
in palliative care  + 1 
hospital pharmacist 
GR consensus  _ _ _ _ 3 
40 van den Bemt 
et al.* [84]  
2002, 
Netherlands 
2 hospitals 2 hospital pharmacists GR consensus _ _ _ _ 3 
41 Davydov et 
al.* [86] 
2003, USA 
a hospital  ND IN IN _ _ _   4 
42 Bobb et al.* 
[88] 
2004, USA 
a medical 
center, 
56 MEs, 
random 
sampling 
3 pharmacists IN IN _ agreement = 
75.0-83.6% 
(effect strength = 
57.1-68.5): 
excellent  
agreement 
_ - sampling of 
one medical 
center 
- there were no 
physicians as 
raters 
(H) 
2 
43.1 Gleason et al.* 
[128] 
2010, USA 
a hospital, 309 
MEs, random 
sampling 
2 pharmacists + 1 
internist (the second 
physician as needed) 
IN hierarchical _ Cohen's k= 0.84: 
high agreement 
_ - no external 
raters  
- raters 
involved in 
medication 
review and data 
2 
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collection 
(H) 
43.2 Quélennec et 
al. [156] 
2013, France 
an internal 
medicine 
department, 
173 
unintentional 
discrepancies, 
consecutive 
sampling  
2 pharmacists + 2 
internists  
IN hierarchical 
approach  
_ Cohen's k= 0.61: 
substantial 
agreement  
_ - sampling of 
only patients ≥ 
65 years in 
only one 
department 
(H) 
 
2 
44 Dooley et al.* 
[21] 
2003, 
Australia 
8 hospitals ND GR ND _ _ _ _ 3 
45 Dale et al.* 
[85] 
2003, UK 
2 medical 
wards of a 
hospital, 
740 MEs, 
consecutive 
sampling 
1 consultant physician 
+ 1 pharmacist 
IN IN _ agreement = 41% 
for the 
intervention 
group and 46% 
for the control 
group 
_ - only 2 raters  
(H) 
2 
46 Buurma et al.* 
[89] 
2004, 
Netherlands 
141 
community 
pharmacies, 
72 PIs, random 
sampling 
5 groups and each 
group including  1 
community pharmacist 
+ 1 hospital 
pharmacist + 1 general 
practitioner + 1 
specialist or other non-
practicing 
medical/pharmaceutica
l experts)  
IN mean _ (1,2) kappa = 
0.40 
(2) kappa = 0.49 
for all raters, 
0.35 for 
physicians, 0.58 
for pharmacists;  
 
_ - the tool was 
tested in 
community 
pharmacies, not 
in hospitals 
(H) 
3 
47 Westerlund et 
al.* [123] 
2009, Sweden 
89 pharmacies 1 pharmacist + 1 
physician 
GR consensus _ _ _ _ 3 
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48 Gray et al.* 
[90] 
2004, UK 
21 pharmacies 2 pharmacists GR ND _ _ _ _ 4 
49 Prowse et al.* 
[91] 
2004, UK 
 1 clinical pharmacist + 
a multidisciplinary 
panel (1 consultant 
nephrologist + 1 
transplant nurse 
practitioner + 1 
specialist pharmacist 
in transplantation + 1 
pharmacist) 
GR consensus + 
hierarchical 
approach 
_ _ _ _ 5 
50.1 Cornish et al.* 
[22] 
2005, Canada 
a hospital, 
140 unintended 
discrepancies, 
consecutive 
sampling 
3 general internal 
medicine hospitalists  
IN consensus _ Fleiss's k = 0.26 
(95% CI 0.16-
0.36) 
_ - sampling of 
unintended 
discrepancies 
from only one 
hospital 
- there were no 
pharmacists as 
raters 
(H) 
2 
50.2 Kwan et al. 
[110] 
2007, Canada 
a surgical 
preadmission 
clinic, 46 
medication 
discrepancies , 
unclear  
3 pharmacists  GR consensus  _ mean Cohen k= 
0.84: 
substantial 
agreement  
_ - sampling of 
only PI of only 
one clinic 
- there were no 
physicians as 
raters 
(H) 
3 
50.3 Wong et al. 
[118] 
2008, Canada 
a hospital, 105 
actual 
unintentional 
discharge 
discrepancies, 
consecutive 
1 general internist + 2 
pharmacists not 
involved in the 
direct care 
 
GR consensus  _ mean Fleiss's k = 
0.76 
(pairwise k = 
0.72 - 0.80) 
_ - only actual 
unintentional 
discrepancies 
were assessed 
for clinical 
impact 
3 
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sampling - only external 
raters 
(H) 
50.4 Coffey et al. 
[119] 
2009, Canada 
general 
pediatric 
unit, 
59 patients 
with at least 
one 
unintentional 
discrepancy, 
non-
consecutive 
sampling 
3 physicians 
 
IN mode _ AC1 = 0.69, 
p<0.01: good 
agreement 
_ - non-
representative 
sampling 
- only external 
raters 
- no 
pharmacists as 
raters 
(H) 
3 
50.5 Villanyi et al. 
[142] 
2011, Canada 
a hospital  1 external pharmacist IN IN _ _ _ _ 2 
51 Denneboom et 
al.* [92] 
2005, 
Netherlands 
9 pharmacies 1 pharmacist + 1 
general practitioner 
GR consensus _ _ _ _ 0 
52 Fertleman et 
al.* [93] 
2005, UK 
a hospital  ND GR ND _ _ _ _ 4 
53 Knudsen et 
al.* [108] 
2007, 
Denmark 
40 community 
pharmacies  
3 pharmacists + 1 
chief researcher  
GR consensus + 
hierarchical 
approach 
_ _ _ _ 2 
54 Haavik et al.* 
[130] 
2010, Norway 
12 pharmacies, 
124 MEs, non-
random 
sampling   
3 hospital pharmacists 
+ 5  community 
pharmacists + 6 
hospital physicians + 2 
emergency care 
IN median, a 
clinically 
relevant 
error was 
defined as 
_ k = 0.093-0.115 _ - non-random 
sampling 
- information of 
clinical cases 
was probably 
3 
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physicians median 
score > =1 
insufficient 
- no pilot phase 
of assessment  
(H) 
55 Serrano et al.* 
[96] 
2005, Spain 
a hospital  ND ND ND _ _ _ _ 2 
56 Ling et al.* 
[94] 
2005, USA 
a hospital  practicing pharmacists IN IN _ _ _ _ 4 
57.1 Blix et al.* [97] 
2006, Norway 
5 hospitals 1 professor in 
pharmacotherapeutics 
+ 2 specialists in 
hospital pharmacy 
GR consensus _ _ _ _ 1 
57.2 Viktil et al. 
[104] 
2006, Norway 
4 hospitals  1 professor in 
pharmacotherapeutics, 
who is also a specialist 
in internal medicine + 
2 specialists 
GR consensus _ _ _ _ 1 
57.3 Schröder et al. 
[141] 
2011, 
Germany 
community 
pharmacies 
4 physicians + 1 
pharmacist 
GR consensus _ _ _ _ 1 
58 Vira et al.* 
[105] 
2006, Canada 
a hospital  1 internist IN IN _ _ _ _ 1 
59.1 Stubbs et al.* 
[103] 
2006, UK 
mental health 
units 
2 pharmacists + a 
panel of 5 
psychopharmacists  
GR hierarchical 
approach + 
consensus  
_ _ _ _ 1 
59.2 Chua et al. 
[146] 
2012, Malaysia 
44 primary 
care clinics, 
706 DRPs, 
consecutive 
1 clinician + 1 
pharmacist who were 
not involved in 
the study 
IN hierarchical 
approach 
_ Cohen's k = 
0.729: good 
agreement  
_ - only 2 raters  
- classification 
of the clinical 
significance of 
2 
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sampling DRPs was not 
re-tested 
(H) 
60 Pham et al.* 
[101] 
2006, USA 
a hospital  2 faculty members + 
10 external 
pharmacists 
GR mode _ _ _ _ 3 
61 Estellat et al.* 
[107] 
2007, France 
hospital 3 physicians + 1 
pharmacist 
GR consensus _ _ _ _ 0 
62.1 Lindblad et 
al.* [111] 
2007, Canada 
a hospital  practicing pharmacists IN IN _ _ _ _ 4 
62.2 Harrison et al. 
[150] 
2012, Canada 
an outpatient 
lung transplant 
clinic 
1 respirologist + 1 
advanced practice 
nurse + 1 transplant 
nurse coordinator + 1 
transplant pharmacist 
GR consensus _ _ _ _ 4 
63 Nguyen et al.* 
[112] 
2007, 
Australia 
a hospital  1 liaison pharmacist IN IN _ _ _ _ 2 
64 Bayley et al.* 
[106] 
2007, USA 
a hospital, 927 
PIs 
1 intervening 
pharmacist + 1 
pharmacy manager + 1 
pharmacist 
IN IN Few different 
between an 
intervening 
pharmacist and 
a pharmacy 
manager and a 
study author 
_ _ - result of 
validity was not 
reported in 
detail 
- no physicians 
as raters 
(H) 
5 
65.1 Midlov et al.* 
[115] 
2008, Sweden 
three 
departments of 
a hospital, 
197 patients 
with at least 
2 physicians   IN consensus _ Cohen's k = 0.85 
(95% CI 0.78-
0.92) 
_ - sampling of 
patients of 65 
years or older  
- only 2 raters  
- there were no 
2 
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one medication 
error  
pharmacists as 
raters 
(H) 
65.2 Midlov et al. 
[153] 
2012, Sweden 
a hospital  3 persons GR consensus + 
hierarchical 
approach 
_ _ _ _ 1 
66 Krahenbuhl et 
al.* [28] 
2008, 
Switzerland 
20 community 
pharmacies 
intervening 
pharmacists 
IN IN _ _ _ _ 2 
67 Pippins et al.* 
[116] 
2008, USA 
2 hospitals, 
939 
unintentional 
discrepancies 
2 physicians from a 
pool of six (the third 
judicator as needed) 
GR consensus + 
hierarchical 
approach 
_ (1) k = 0.95  
(2) k = 0.94 
_ - sampling of 
only 
unintentional 
discrepancies 
- only external 
raters 
- there were no 
pharmacists as 
raters 
- only two 
raters 
(H) 
5 
68 Rothschild et 
al.* [3] 
2010, USA  
4 emergency 
departments, 
504 MEs, 
consecutive 
sampling 
Pairs of physician and 
pharmacist  
IN consensus _ (1-2) k = 0.23  
(3) k = 0.22 
_ - MEs from 
only 
emergency 
departments 
- only 2 raters 
evaluated each 
ME 
(H) 
4 
69 Abu-Ramaileh 
et al.* [135] 
2011, USA 
an emergency 
department of 
4 medical 
centers, 130 
pairs of a physician 
and a pharmacist  
GR consensus _ (1) k = 0.21  
(3) k = 0.30 
_ - only 2 raters 
evaluated a PI 
- non-random 
sampling of PIs 
4 
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PIs, non-
random 
sampling 
- PIs from only 
emergency 
departments  
(H) 
70.1 Patanwala et 
al.* [138] 
2011, USA  
an emergency 
departments, 
237 MEs, 
consecutive 
sampling 
2 pharmacists + 1 
physician investigator 
not involved in the 
data collection process 
IN conservativ
e  
_ (1) agreement = 
76%, kw =0.35  
(2) agreement = 
77%, kw = 0.42 
after 
"dichotomization 
of severity scale 
and probability 
scale" 
  - PIs done by 
only a 
pharmacist in 
an emergency 
department 
- MEs did not 
consists of 
name 
misspellings or 
other 
inconsequential 
events 
(H) 
3 
70.2 Patanwala et 
al. [139] 
2011, USA 
4 emergency 
departments,  
401 MEs, 
consecutive 
sampling 
1 pharmacist + 1 
physician not involved 
in the data collection 
process and blinded to 
the study site 
IN conservativ
e approach  
_ (1) agreement 
83%, kw = 0.3 
 
_ - only 2 raters 
- PIs from only 
emergency 
departments 
(H) 
3 
71 Granas et al.* 
[120] 
2009, Norway 
23 community 
pharmacies, 88 
DRPs, 
consecutive 
sampling 
1 physician + 2 
hospital-based clinical 
pharmacists + 1 
community pharmacist 
GR consensus _ (1) k' = 0.5  
(2) k' = 0.64; (3) 
k' = 0.81 
(modified Fleiss' 
kappa)   
_ - patient notes 
from physician 
was not 
available  
- a meeting 
organized for 
understanding 
of the concept 
of 
categorisation 
of 
DRPs 
4 
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(H) 
72 Vasileff et al.* 
[122] 
2009, 
Australia 
an emergency 
department of a 
hospital, 111 
unintentional 
discrepancies, 
consecutive 
sampling  
3 hospital pharmacists 
+ 3 physicians + 1 
academic pharmacist + 
1 pharmacy researcher  
GR mean and 
rounded to 
the nearest 
clinical 
significance 
category 
_ Of the 15 
possible pairings 
of raters, 11 
gamma statistics 
indicated 
moderate 
agreement, 3 
indicated weak 
agreement and 1 
indicated strong 
agreement 
_ - sampling of 
only 
unintentional 
discrepancies 
of an 
emergency 
department  
- assumptions 
made 
when assessing 
the clinical 
significance of 
discrepancies 
(H) 
2 
73 Lee et al.* 
[132] 
2010, Canada 
10 inpatient 
units at 2 
tertiary care 
hospitals, 250 
unintentional 
discrepancies 
2 pharmacists + 1 
internist + 1 intensivist 
not involved in the 
direct care of the 
patient 
IN consensus _ (1-3) k =  0.637-
0.769 
_ - sampling of 
only 
medication 
discrepancies 
- a series of 
assumptions 
applied before 
assessment 
(H) 
4 
74 Rashed et al.* 
[154] 
2012, UK and 
Saudi Arabia 
2 hospitals 1 consultant 
pediatrician + 1 
clinical pharmacist + 1 
researcher 
GR consensus _ _ _ _ 0 
75 Niquille et al.* 
[134] 
2010, 
Switzerland 
community 
pharmacies  
General practitioners + 
2 pharmacists  
IN and 
GR 
IN and 
consensus 
_ _ _ _ 3 
76 Eichenberger 64 community Pharmacy students IN IN _ _ _ _ 2 
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et al.* [126] 
2010, 
Switzerland 
pharmacies  
77 Knez et al.* 
[131] 
2010, UK 
a 
chemotherapy 
preparation 
unit at a cancer 
center, 13 PIs, 
random 
sampling 
a consultant in medical 
oncology  and a panel 
of 1 head of 
preparation service + 2 
clinical oncology 
pharmacists + 1 
specialist in drug 
manufacture and drug 
stability 
GR Modified 
nominal 
group 
consensus 
method 
 Validated the 
panel’s 
decisions by a 
consultant in 
medical 
oncology 
(agreement = 
46%) 
_ _ - few PIs  
- PIs from on a 
chemotherapy 
preparation unit 
- the study did 
not test inter- 
and intra-
reliability 
(H) 
 
1 
78 Williams et 
al.* [31] 
2011, 
Australia 
community 
pharmacies  
intervening 
pharmacists 
IN IN _ _ _ _ 4 
79 Cesarz et al.* 
[145] 
2011, USA 
a medical 
center 
4 intervening 
pharmacists  
IN IN _ _ _ _ 0 
80 Perera et al.* 
[140] 
2011, USA 
Medication 
Therapy 
Management 
Program 
pharmacists IN IN _ _ _ _ 2 
81 Kwint et al.* 
[152] 
2012, 
Netherlands 
10 community 
pharmacies 
3 pharmacists  ND consensus + 
hierarchical 
approach 
_ _ _ _ 2 
82 Mekonnen et 
al.* [155] 
2013, Ethiopia 
a hospital  1 internist + 1 clinical 
pharmacologist + 1 
clinical pharmacist  
GR hierarchical 
approach 
_ _ _  2 
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ESM 5. Indicators used in existing tools for assessment of potential 
significance of PIs 
Impact Indicators used 
Clinical Safety [28, 75, 134, 140, 158], adverse health consequence [48], adverse effect 
[50, 77, 87, 101, 103], ADE [3, 102, 106], harmful effect [21], ADR [66, 89, 
123], detrimental effect [104], clinical deterioration [22, 132], toxicity [44, 55, 
66], side effects/allergy/interaction [55, 66], damage [84, 91], harm/injury [3, 
23, 47, 96, 113, 128], relapse [103], graft loss [91], organ loss [66], impairment 
of health [24], morbidity [21, 29, 86, 106, 113];  change in vital signs [96], 
mortality/life-threatening/lethal effect  [3, 12, 20, 23, 30, 38, 43, 44, 47, 51, 59, 
61, 65, 66, 76, 77, 84-86, 94, 96, 100-103, 106, 107, 112, 116, 122, 138, 150]   
Effectiveness of drug therapy [21, 28, 29, 75, 89, 134], efficacy [55], response 
to medication [87], efficacy of the patient’s therapeutic management[70], 
therapy effect [57, 123],  disease control [53], treatment failure [66], curing a 
disease, slowing a disease process [111, 150], disease-related complication [91], 
signs or symptom control [3, 82, 100, 111, 116, 150], major organ dysfunction 
[3, 12, 30, 38, 43, 44, 51, 59, 61, 65, 76, 100, 102, 150], alteration in 
physiological process [111, 150], alteration of life functions [3, 116], treatment 
failure [77, 101] 
Necessity [134]  
Characteristics of effects: short-term/long-term [106]; (ir)reversible [24, 59, 
99, 104, 129, 133]; permanent/temporary [23, 96, 105, 113], 
theoretical/(un)detectable/(un)noticed [20, 21]; trivial/minor/major/serious [40]; 
doubtful or negligible [103] 
Others: clinical relevance [92, 120],  examples of groups of similar MEs [12, 
35-37, 42], preventability [154] 
Humanistic Patient’s knowledge [71, 79]  
Compliance [31, 53, 55, 66, 71, 77, 82, 158], adherence [87, 101]   
Patient’s satisfaction [66, 120], (in)convenience [91, 100, 108, 159], distress 
[100], (dis)comfort to patient [22, 56, 66, 132] 
Inability to work [24, 105], inference with the patient’s everyday activity [56] 
Quality of life of patient [59, 100, 158], patient’s well-being [66, 82], standard 
of patient health [112, 121], state of health [24],  physical, mental or social 
function or satisfaction with care (feeling better) [111, 150], lifetime disability 
[66]  
Economic Cost savings [30, 31, 50, 51, 53, 55, 65, 68, 73, 87, 106, 140], expense problem 
[134], value for money [75, 158], cost of drug therapy [20, 38, 43, 61, 66, 109, 
111], savings from drug therapy monitoring [38, 61], influence on patient cost 
[43], reduction in treatment cost [29], increasing reimbursement [66]. 
Cost avoidance: Health care resources avoided such as a reduction in hospital 
stay [21, 29, 38, 41, 47, 50, 61, 66, 77, 85, 87, 94, 96, 101, 105, 113], hospital 
admission [21, 23, 24, 31, 48, 70, 71, 74, 79, 85, 94, 101, 105, 113, 123, 127, 
159], readmission [66, 102, 105, 113], schedule physician visit [31, 48, 66],  
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long-term-care admission [94], regular nurse visit or residential care [31],  
transfer to intensive care unit [94, 96, 159],  urgent or emergency care  [24, 48, 
66], primary care contact [123],  self-care [48], monitoring [59, 74, 84, 86, 88, 
91, 96, 105, 128], additional laboratory test/invasive procedures [96], treatment 
or change in therapy [23, 74, 75, 86, 91, 94, 96, 105, 108, 113, 152, 159], 
additional investigation/intervention/tests, noninvasive procedures [85, 94, 
128]. 
Process-
related 
Resolving technical problems: medication supply [57, 82], legally or technical 
problems/formulary [28, 91] 
Informational intervention [31, 38, 53, 57, 71, 75, 82, 94], physician 
education [50],  nurse need gather additional information [84] 
Physician’s satisfaction [120],  inconvenience to physician and pharmacist [40, 
91, 100], 
Facilitation of continuity of care [55],  cancellation or delay in planned 
treatment/procedure [40, 113], service closure [93]   
Teamwork, pharmaceutical support, or communication [82]  
Adherence to  evidence-based therapy, nationally adopted quality standards 
[104, 135], guideline adherence [140], adherence to unit protocols [91]  
Others: loss of confidence in the organization, litigation [93] 
Structure-
related 
No indicator 
Probability Probability/ chance/ likelihood of adverse health consequence [3, 20, 23, 48, 
56, 109, 113, 132] Confidence of judgment [70, 116, 135]. 
Probability as an intermediate indicator in order to classify risk [20-24] 
Probability as an intermediate indicator in order to calculate cost avoidance 
[48, 56, 109]
Significance Quality of care [50, 51, 87], bringing care to a more acceptable and appropriate 
level [38, 51, 102],  overall care of patient [77, 101], patient care [75, 87], 
standard of practice [38, 51, 102, 106] 
Improved patient outcome [71, 91], health outcome [122] 
Being neutral depending on professional interpretation [38, 53, 102], a choice 
among several equally acceptable actions [51]  
Priority to be discussed with the physician [152], priority into implementation 
[134]  
Effect: negative, no, positive effect [41, 50, 56, 87], significant/useful [57] 
Optimizing drug therapy [21, 44, 66, 160], rationalization of medication to 
reduce medication burden [91], adjustments [21, 29]  
Problem identified/resolved/unresolved/prevented [57, 111, 126, 150, 160] 
Appropriateness [79] 
PI: pharmacist intervention, ME: medication error  
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ESM 6. The French-written CLEO tool 
 
TITRE en français : Évaluation de l'impact potentiel des interventions pharmaceutiques : 
développement et validation de l'outil multidimensionel CLEO 
RESUME en francais : 
Dans le contexte de ressources limitées actuelles, il est nécessaire pour les pharmaciens de 
justifier la valeur ajoutée de leurs interventions pharmaceutiques (IP) formulées lors de 
l'analyse pharmaceutique (AP). L’objectif de ce travail de thèse est de mener une recherche 
sur les méthodes d'évaluation de la pertinence des IPs et développer un nouvel outil pour 
l’évaluation de l‘impact potentiel des IPs. Le travail se décompose en 3 grandes parties : (i) 
contexte de l’AP, et méthodes d'évaluation de l’impact des IPs, (ii) revue systématique des 
outils pour évaluer la pertinence potentielle des IPs, (iii) processus de développement et de 
validation du nouvel outil multidimensionnel - nommé CLEO pour évaluer l’impact potentiel 
des IPs. Les résultats de cette recherche apportent des éléments nouveaux pour l’évaluation et 
la démonstration de la valeur des IPs dans un objectif global de déploiement  des services de 
pharmacie clinique.  
TITRE en anglais : Evaluation of the potential impact of pharmacist interventions : 
development and validation of the CLEO multidimensional tool 
RESUME en anglais :  
In times of limited resources allocation, it is necessary for pharmacists to justify the added 
value of their pharmacist interventions (PIs) made during medication review (MR). The 
purpose of this thesis work is to research on methodologies of evaluation of value of PIs as 
well as development and validation of a new tool for assessing potential impacts of PIs. The 
work consists of 3 major parties: (i) context in which MR locates, characteristics of practice 
of MR, and methodologies of evaluation of impacts of PIs, (ii) systematic review of tools for 
assessing the potential significance of PIs in literature , (iii) process of development and 
validation of the new multidimensional tool - named CLEO for assessing potential impacts of 
PIs. The whole results of this research are useful to evaluate and demonstrate the value of PIs 
in efforts to expand clinical pharmacy services.   
MOTS-CLES : interventions pharmaceutiques, évaluation, outil, impacts 
MOT-CLES en anglais: pharmacist interventions, evaluation, tool, impacts 
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